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RNA Interference (RNAi) allows specific and potent knockdown of target genes and interest now 
lies beyond its use as a molecular biology tool and in its potential as a therapeutic to mediate 
gene silencing in diseased cells. Targeted local delivery of small interfering RNA (siRNA) to the 
lungs via inhalation offers a unique opportunity to treat a range of previously unbeatable or 
poorly controlled respiratory conditions. Alveolar macrophages are the first line of defence 
against inhaled toxins and pathogens and are essential for the initiation of the inflammatory 
response. Targeting these cells provides a means of manipulating the immune response of the 
lungs for the treatment of diseases such as chronic obstructive pulmonary disease (COPD), 
cystic fibrosis (CF) and asthma. However, macrophages are a difficult cell type to transfect. 
Consequently a delivery system that will enhance uptake as well as specifically target alveolar 
macrophages would be beneficial for the treatment of respiratory inflammatory conditions and 
has received notable attention in recent years. Herein we have developed targeted liposomes 
and microparticles (MP) suitable for inhalation for optimal siRNA delivery to alveolar 
macrophages.
Anionic and mannosylated liposomes and uncoated and gelatin coated poly(lactic-co-glycolic 
acid) (PLGA) microparticles targeted macrophages via scavenger receptors (SRs), mannose 
receptors (MRs) and size and charge related phagocytosis, respectively. Mannosylated 
cholesterol analogues Mann-C2-Chol, Mann-C4-Chol and Mann-C6-Chol, differing in linker 
lengths, were synthesised and incorporated into neutral liposomes. Formulations of liposomes 
and microparticles were optimised for efficient siRNA encapsulation and screened for uptake, 
toxicity and immunogenicity in vitro using high content cell analysis (HCA) methods that were 
specifically developed. HCA determined uptake of targeted anionic 1,2-dioleoyl-sn-glycero-3- 
phospho-L-serine (DOPS) and mannosylated (Mann-C6-Chol) composed liposomes between 
200 and 400nm and uncoated PLGA microparticles to be optimal in macrophage cells.
Significant knockdown of tumour necrosis factor-alpha (TNFa) in lipopolysaccharide (LPS) 
stimulated cells was mediated via DOPS liposomes and uncoated PLGA microparticles. 
Additionally, mannosylated liposomes appeared to activate macrophage mannose receptors in 
a concentration and linker dependent manner and reduce inflammation. In general liposomes 
and microparticles were non-toxic and non-immunogenic compared to positive controls. 
However exceptions included high doses of DOPS liposomes which significantly reduced cell 
viability in RAW 264.7 cells, significantly increased nuclear factor kappa B (NFkB) activity and 
induced pro-inflammatory cytokines in differentiated THP-1 cells after 24 hours. However, 
mannosylated liposomes induced a potent inflammatory response in vivo but effects were 
localised to the lungs, in vivo reductions of TNFa in bronchoalveolar lavage fluid (BALF) 
following LPS challenge were observed in mice treated with TNFa targeted naked siRNA and 
encapsulated in mannosylated liposomes.
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Chapter 1
General Introduction
1.1 Introduction
Inhalation therapy has a long history stretching back thousands of years. Treatments for 
respiratory diseases such as asthma delivering drugs directly to the lungs via inhalation have 
been routinely used for decades. Systemic delivery of therapeutics via the lungs such as insulin 
has also achieved some success. However many conditions remain untreatable or difficult to 
treat such as inflammatory lung diseases. Gene therapy began with the development of 
recombinant DNA technology [1] and over the past few decades has been an area of intense 
research. This form of therapy sets out to insert genetic material into tissue with wide ranging 
applications including vaccination, gene replacement and gene silencing to treat numerous 
conditions such as genetic disorders, cancers and viral infections. In recent years the discovery 
of RNA interference (RNAi) has lead to a surge in interest into the use of small interfering RNA 
(siRNA) to mediate gene silencing. Above all, this could prove a useful therapeutic approach 
for previously difficult to treat conditions such as respiratory conditions including chronic 
obstructive pulmonary disease (COPD) and cystic fibrosis (CF).
1.2 Lung Anatomy and Physiology
The respiratory system can be divided into the upper and lower respiratory systems 
anatomically consisting of the nose, nasal cavity, paranasal sinuses and pharynx and larynx, 
trachea, bronchi, bronchioles and alveoli of the lungs, respectively [2] (Figure 1.1 A). The 
complex architecture and interplay of specialised airway cells constitute the functional 
respiratory system which carries out a number of dedicated functions such as gaseous 
exchange at the alveolar level between the air and vascular system, the movement of air to and 
from the alveoli and the protection of pulmonary tissue against airborne pathogens and foreign 
particulates.
Air enters through the nose and mouth and continues through the conducting section of the 
respiratory system where it is filtered, warmed and humidified, through the trachea, bronchi, 
bronchioles and finally reaching the respiratory section, the alveoli, where gas exchange occurs 
[2] (Figure 1.1 A and B). Morphometry of the human lung was first described in the Weibel 
Model [3] in the 1960s in which dichotomous branching of the airways were termed as 
generations initiating at generation 0, the trachea and terminating at generation 23, the alveoli 
(Figure 1.1C). Pulmonary branching is extensive and with each generation the airway 
dimensions narrow and particle deposition in these regions will occur either due to impaction, 
sedimentation or Brownian diffusion with decreasing channel diameter [4, 5].
The trachea branches to form the two primary bronchi which supply air to the right and left lung. 
Both the trachea and bronchi are supported with cartilaginous C-shaped rings [2]. From there 
the bronchi divide repeatedly to give rise to the bronchial tree of primary, secondary and tertiary 
bronchi. The amount of cartilage present in the bronchial walls decreases with subsequent 
branching and the relative amount of smooth muscle increases. Consequently smooth muscle
2
begins to play a more influential role in airway diameter and resistance to airflow. Further 
branching of tertiary bronchi leads to the formation of bronchioles, the walls of which no longer 
contain cartilage but are instead predominantly smooth muscle [2]. Bronchoconstriction of 
these airways leads to reduced airflow which can occur in allergic reactions and asthma. 
Alveolar ducts connect the bronchioles to alveolar sacs. Each alveolus is surrounded by an 
extensive network of capillaries and the basement membranes between the alveolar and 
endothelial capillary cells are fused to promote efficient gas exchange of oxygen (0 2) and 
carbon dioxide (C02) (Figure 1.3). During inflammation however the diffusion distance is 
increased and gas exchange is negatively affected [2],
Upper [ Masai cavity 
respiratory \ 
system [Sphenoidal sinus
Internal nares
Cartilage rings
Cartilage plates
Terminal bronchiol 
Respiratory bronchi
Alveolus
Figure 1.1: Illustration of (A) the anatomical structure and components of the respiratory system, 
(B) representation of bronchial branching and (C) the Weibel model of lung morphology showing 
generations 1 - 2 3  and corresponding particle sedimentation mechanisms (taken from [2] and 
[4])
The airway epithelium structure relates closely to function and varies in diameter and cell 
composition along the pulmonary system (Figure 1.2B). For instance the nasal cavity and 
bronchial epithelium is pseudostratified, ciliated and columnar containing secretory cells (such
3
as clara, goblet and serous cells), ciliated cells and brush cells [4, 6]. The respiratory 
epithelium is also supported by connective tissue known as the lamina propria which also varies 
depending on the respiratory region. Mucus glands are present in the lamina propria of the 
trachea and bronchi which secrete mucus onto the epithelium surface and can be increased in 
volume and consistency in certain diseases such as CF and COPD. This is also the location of 
smooth muscle for the conducting airways.
Aside from air conductance and gas exchange a major function of the pulmonary system is 
defensive. Secretory cells release mucins and molecules that are antimicrobrial, 
immunomodulatory and protective in nature such as lysozymes, cytokines and heregulin 
respectively [6], By a process referred to as the mucociliary escalator, mucus and any insoluble 
particles deposited in the airways are propelled out of the lung towards the pharynx by ciliary 
beating at a velocity of 1mm per minute (fast phase removal, Figure 1.2A) [2, 4, 6], Although 
particles deposited in the deep lung, non-ciliated regions, can remain for up to 24 hours (slow 
phase removal) [7] and are more likely cleared by macrophages [4],
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Figure 1.2: Structure of the human pulmonary epithelium. (A) shows the mucocilliary escalator 
action of the large airways and (B) the structure and relative sizes of the bronchial, brionchiole 
and alveolar epithelia (taken from [2] and [4]).
The epithelium of the alveolus is very different form the rest of the airways, no longer consisting 
of pseudostratified columnar cells but instead of a thin squamous monolayered epithelium 
consisting of alveolar Type I cells (Figure 1.2B and 1.3) covered in lung surfactant that is 
produced by alveolar Type II cells (Figure 1.3). Surfactant contains phospholipids and proteins 
which is important in reducing surface tension thereby preventing alveolar collapse [2]. There 
are approximately 5 x 108 alveoli in the human lung, each of which is patrolled by 12 to 14 
alveolar macrophages [4] in the interstitium which phagocytose particles that have evaded the 
preceding defence mechanisms.
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Figure 1.3: The structure of the alveoli consisting of a thin eptithelial monolayer of Type I cells, 
Type II surfactant cells and patrolling alveolar macrophages. The distance between the alveolar 
epithelium and capillary endothelia is very small promoting efficient gas exchange [2].
1.3 Drug Delivery to the Lungs
The anatomy and physiology of the lungs are designed for the efficient removal of inhaled 
particulates and consequently pulmonary drug delivery can be challenging. Apart from 
mucociliary clearance the action of delivered drugs can be impeded by the protective lung 
barriers including airway epithelium, alveolar epithelial tight junctions, surfactant, macrophages 
and enzymatic action [8]. In addition cilia, mucus and the complex architecture of the 
respiratory tree filters particles from inhaled air before they can even reach sites of action such 
as the alveoli. In order to effectively deliver aerosol therapeutics to the respirable regions of the 
lungs a number of interdependent factors must be taken into account including aerosol/particle 
characteristics such as size, size distribution, charge, shape, density and hygroscopicity, patient 
factors such as inspiratory flow rate, age or disease state and inhaler devices [9, 10]. Therefore 
targeting specific lung regions requires optimised particle/aerosol properties and modes of 
inhalation [10]. The fate of inhaled particles depends on many factors and can include removal 
by mucocilliary clearance, phagocytosis by macrophages or gaining access to the pulmonary 
epithelium and being locally or systemically absorbed [7].
Size has a critical effect on particle deposition in the lungs which can occur via various 
mechanisms including inertial impaction, sedimentation, diffusion, interception and electrostatic 
precipitation [9] (Figure 1.4). Large particles (>5pm) travelling at high velocity will generally 
impact in the upper airways where airflow direction changes rapidly. This is due to inertial 
impaction whereby aerosolised particles gain enough momentum to maintain their trajectory
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rather than follow the path of airflow and collide with airway structures [7, 9], Deposition of 
particles >10pm generally occurs in the oropharyngeal region. Sedimentation is the settling of 
particles in lungs due to gravity. It requires the slowing down of air velocity and usually occurs in 
the bronchioles and alveoli with particles <3pm in diameter. Aerosolised small particles <1pm 
undergo Brownian motion and tend to be deposited by diffusion but are more likely to be 
exhaled [9]. Slow deep inspiration followed by a breath hold may promote submicron particle 
diffusion [11]. Therefore, deep lung deposition is optimal in the 1 -  5pm size range [7]. 
Suspensions of hydrophobic drugs or nanoparticles can also be delivered by inhalation and 
deposition relies on aerosol droplet size rather than particle size (or aerodynamic size which 
also accounts for particle density) and can offer many advantages over dry powder inhalation 
such as higher bioavailability, increased lung retention, faster dissolution rates and better 
particulate homogeneity [11].
Particle size (|im)
Figure 1.4: Deposition patterns of aerosolized monodisperse particles in the lungs related to 
particle size following a slow inhalation and short breath hold. Small particles (<1|-im) can be 
exhaled, particles ranging from 1 -  5 pm can reach the alveolar region and large particles 
(>5pm) impact the mouth, throat and upper airways [4].
1.4 Inflammatory Lung Diseases and Current Therapies
Diseases associated with airway inflammation include COPD, asthma and CF [12-14], which 
involve a huge array of immune cells including mast cells, neutrophils, macrophages, 
eosinophils as well as epithelial cells [15-18]. The inflammatory process is a key driver of both 
disease progression as well as pathogenesis [19]. Features of these diseases include chronic 
inflammation, smooth muscle hyper-responsiveness and airway remodelling resulting in 
reduced airflow and lung function (Figure 1.5) [2, 20], Pro-inflammatory cytokines such as 
TNFa and interleukin 1-beta (IL-1P) can lead to mucin production either indirectly or directly [6] 
and consequently chronic inflammation in the lung can lead to hypersecretion of mucus and is 
also associated with pulmonary lesions. Under normal healthy conditions mucus contains about
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3% solids but hypersecretion can increase solid content up to 15% making the mucus more 
elastic and viscous [6], Dehydrated viscous mucus is more difficult to clear from the lungs and 
is more adherent to the airway walls [6]. Characteristics of mucus vary between pulmonary 
diseases and can contain increased levels of mucin, plasma proteins, inflammatory cells, DNA 
and bacteria compared to the healthy state [6]. Mucus clearance is further hindered in CF due 
to mucociliary clearance dysfunction.
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Figure 1.5 Characteristics of a Chronic Obstructive Pulmonary Disease (COPD) small airway 
obstruction [19, 21]
COPD is the fifth leading cause of death worldwide with a prevalence of 9 -  10% in adults over 
40 years of age [22]. Drug development costs for COPD are high [22], The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) defined COPD as “a preventable and treatable 
disease with some significant extrapulmonary effects that may contribute to the severity in 
individual patients. Its pulmonary component is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases” [23]. Risk factors associated 
with the disease include a genetic predisposition, exposure to inhaled noxious stimuli such as 
cigarette smoke (Figure 1.7), socioeconomic status, infection and gender [23]. COPD disease 
pathological changes include fibrosis and airway narrowing in the bronchi as well as fibrosis and
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damage to the alveolar walls (emphysema) [19, 22] (Figure 1.5). Airway remodelling can occur 
due to repeated injury and repair [23]. COPD patients experience dyspnoea, cough, exercise 
intolerance and a lower quality of life in terms of health [22], The roles of current therapeutic 
strategies are to prevent and control disease symptoms, decrease both the frequency and 
severity of exacerbations and improve quality of health but do not improve long term impaired 
lung function [23] and most commonly include inhaled bronchodilators and glucocorticosteroids 
(Table 1.1).
Table 1.1: Common Medications for Chronic Obstructive Pulmonary Disease [23]
Solution for Weis lor Duration oi
Medical ion Inhaler (jl<j) Nebulizer (mg/mt) Oral Injection (mg) Action (h)
ßj-Agonärti
Short-acting
Fcnotcro) 100-200 (MDI) 1 0_5% (syrup) 4 -6
Salbutamof (albuterol) 100, 200 (MDI and DPI) 5 5 mg (pilQ 0.24% (syrup) 0.1. 0.5 4 -6
Terbutaline 400, 500 (DPI) 0.2, 0.25 4-6
Lon g- acting
formoic ro! 4.5-12 (MDI and DPI) 12+
Salmctcrd 25-50 (MDI end DPI) 12+
Anlicliolincrgiti
Short-acting
I pair opium bromide 20, 40 (MDI) 0.25-0.5 6-8
Oxitropium bromide 100 (MDI) 1.5 7-9
Lon (^acting
Tioiropium 18 (DPI)] 24 +
Combination short-ACting
fb-Agorusti
plus anticholinergic in
one inhaler
Fcnotorol/ipratropium 200/80 (MDI) 1.25/0.5 6-4
SaJbutamol/ipratropium 75/15 (MDI) 0.75/4.5 6-4
MclhytxanUiincs
Aminophytfnc 200-600 mg (p8l) 240 Variable, up to 24
ThcophyHinft (SR) 100-600 mg (pill) Variable, up to 24
Inhaled glucocorlico steroids
Bo do meth asonc 50-400 (MDI and DPI) 0.2-0.4
Budesonide 100, 200, 400 (DPI) 0.20, 0.25, 0.5
Fluticasone 50-500 (MDI and DPI)
Triamcinolone 100 (MDI) 40 40
Combination long-acting
ßj-agonisli pha
glucocorticosteroids
in one In h a lt
Foi m otc rol/b udes onidc 4.5/160, 9/320 (DPI)
Sal mete n> [/flutica sane 50/100, 250, 500 (DPI) 25/50, 
125, 250 (MDI)
Systemic ghjcocorticostcroirfs
Prednisone 5-60 mg (piB)
Mcthyiprcdrajolonc 4, 8. 16 mg (p il)
Definition of abbreviation-, DPI = d iy  powder inhaler; MCX = m rtcrod-doic inhaler; SR = slow release.
Ireland has the highest incidence of CF in the world at 1 in 1353 [24]. CF is a genetic disease 
caused by mutations in a 175kD glycoprotein the cystic fibrosis transmembrane conductance 
regulator (CFTR) and mostly affects epithelial cells especially in exocrine glands [13]. The 
disease is associated with pancreatic insufficiency, high levels of sodium chloride in the sweat 
and COPD, the later being the main cause of morbidity and mortality [13]. The CF lung is 
associated with airway obstruction and maintains chronic bacterial infections and inflammation. 
Infections are usually caused by a number of bacteria including S.aureus, H. influenzae, and P. 
aeruginosa [13], hence antibiotics are an important part of CF therapy. Changes in the airway 
epithelium also occur including ciiia loss and squamous metaplasia [13]. Aside from antibiotics, 
an anti-inflammatory approach to CF therapy has been the main focus to date via systemic and* 
inhaled corticosteroids and non-steroidal anti-inflammatory drugs (NSAID) [13] such as 
ibuprofen. However, effects in terms of lung function improvement or reduction in inflammatory 
markers in the lungs have not been very successful using inhaled corticosteroids [13]. NSAIDs
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on the other hand have shown positive results in CF patients but there are concerns over 
complications associated with NSAID therapy [13] such as venous thrombosis, pulmonary 
embolism, renal dysfunction, hypertension and damage to the gastrointestinal mucosa [25].
It is estimated that there are 300 million asthma sufferers globally and consequently asthma is a 
substantial economic burden [14]. Chronic inflammation of the airways, episodic and reversible 
airway obstruction, bronchial hyper-responsiveness and tissue remodelling are pathological 
hallmarks of asthma while clinical presentation includes breathlessness, wheeze and 
obstruction of airflow [14, 26]. A number of risk factors such as genetic predisposition, infection 
and inhaled allergen exposure are associated with asthma [14, 26]. Asthma is a heterogenous 
disorder with various distinct phenotypes, based on differences in drug responsiveness, long 
term outcomes such as lung tissue remodelling or irreversible loss of lung function, 
exacerbation frequency, severity and triggers which include allergens, exercise and aspirin and 
therefore targeted therapeutics are important [16, 26]. Asthma involves acute inflammatory 
episodes along with underlying chronic inflammation [14]. There is no cure for asthma, 
therapies simply provide symptomatic relief and again the gold standard therapeutics include 
bronchodialators and inhaled corticosteroids [14] alone or in combination with long acting 13- 
agonists [27]. Inhaled corticosteroids fail to improve lung function in 30 - 45% of asthma 
sufferers [26] and steroid therapies are associated with many side effects and consequently 
poor patient compliance [14].
1.4.1 Macrophages and Inflammatory Lung Disease
Macrophages play a central role in the development, progression and resolution of inflammation 
in the lung [28]. Under inflammatory conditions circulating monocytes can be recruited to the 
site of infection or injury and once there, differentiate into macrophages. Monocytes 
differentiate from hematopoietic stem cells, specifically granulocyte/macrophage progenitors in 
the bone marrow; enter the periphery as circulating monocytes and various micro-environmental 
cues determine their fate which can lead to differentiation into macrophage and dendritic cells 
[29]. However under steady state conditions local proliferation maintains resident macrophages 
in the lungs.
The majority of lung macrophages are interstitial macrophages which are localised within the 
airway and alveolar walls. These cells may represent a stage in alveolar macrophage 
maturation of recruited peripheral monocytes [30]. Alveolar macrophages are found in the 
alveolar spaces and can secrete a wide variety of inflammatory mediators such as lipid 
mediators (e.g. leukotrienes and prostaglandins), chemokines (e.g. IL-8 for recruitment of 
monocytes, neutrophils and T-lymphocytes), cytokines (e.g. TNFa and IL-10), growth factors 
(e.g. transforming growth factor-(31 (TGF-(31)), proteases (such as matrixmetallo proteases) and 
reactive oxygen and nitrogen species [30]. Transcription factors such as NFkB are important in 
the enhanced expression of TNFa, IL-8 and monocyte chemotactic protein-1 (MCP-1) [30].
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Following activation, macrophages become polarized into either classic (M1) or alternative (M2) 
macrophages [31-33], M1 macrophage activation is induced mainly by microbial products such 
as LPS or cytokines like interferon-gamma (IFN-y) and TNFa. M1 cells in a polarized response 
produce increased proinflammatory cytokines such as TNF-a, IL-12, IL-23, and proinflammatory 
mediators like nitric oxide (NO) and reactive oxygen intermediates (ROI). While, M2 
macrophages are promoted by various signals such as IL-4, IL-13, glucocorticoids and 1L-10. 
M2 cells function in inflammation resolution and tissue remodelling.
COPD patients experience poor lung function and eventual respiratory failure. A 5 -  10-fold 
increase in macrophage counts in the airways, lung parenchyma, bronchoalveolar lavage fluid 
(BALF) and sputum are found in COPD patients [30]. Furthermore, severity of COPD has been 
associated with the level of airway macrophage presence which may occur due to increased 
recruitment to the lung of peripheral monocytes represented by high levels of monocyte 
selective chemokine MCP-1 in COPD bronchoalveolar lavage (BAL) and expression by alveolar 
macrophages, prolonged macrophage survival and proliferation in the lung or an impaired 
macrophage clearance from the respiratory tract [30], Macrophage secretory proteins such as 
TNFa, IL-8, IL-10 and TGF-pi as well as activation of transcription factors such as NFkB are 
increased in COPD patients [30]. Traditional COPD treatments include anti-inflammatory 
agents such as corticosteroids and bronchodilators such as (3-adrenergic receptor (P-AR) 
agonists which only treat immediate symptoms [19]. However, COPD macrophages have 
shown some resistance to corticosteroids [30]. Other potential therapeutics for inflammatory 
lung diseases include protease inhibitors such as secretory leukocyte protease inhibitor (SLPI), 
immunosuppressants, mucoregulators, NFkB inhibitors and inhibitors of specific inflammatory 
mediators such as TNFa.
The genetic defect in CF may have a direct link to IL-8 and other inflammatory mediator 
dysregulation leading to the large neutrophil influx found in BAL of CF patients [13]. IL-8 is 
produced by stimulated macrophages, neutrophils and epithelial cells in the CF lung and IL-ip, 
IL-6 and TNFa are also found in high concentrations in CF BALF [13]. The large presence of 
neutrophils which generally outnumber macrophages in the CF lung is associated with 
increased protease concentrations which may inhibit macrophage phagocytosis of apoptotic 
cells [13]. Asthma and COPD are becoming more prevalent mainly due to environmental 
changes such as increased exposure to cigarette smoke and particulates in the air [12] and 
alveolar macrophages play a central role in the inflammatory pathogenesis of these diseases. 
Thus strategies aimed at targeting alveolar macrophages and specifically inflammation are 
highly attractive. Due to its pivotal role in inflammation, the mononuclear phagocytic system 
(MPS) is an important target for drug delivery to treat disease. In general however these cells 
are reputed to be difficult targets [34] particularly where intracellular delivery of the active is 
required such as for gene delivery [35]. Therefore the development of delivery systems that can 
target monocytes/macrophages intracellularly is crucial and could potentially open up new 
treatment paradigms for a range of diseases.
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1.4.2 Macrophage Mannose Receptor
The mannose receptor (MR, CD206) is a 180kDa type-l membrane protein and member of the 
MR family which forms part of the C-type lectin superfamily [36]. DEC-205, Endo-180 and the 
phospholipase A2 receptor are also members of the MR family [37, 38]. The MR is highly 
expressed by macrophages and was first identified in rabbit alveolar macrophages in the late 
1970s [36, 37], Since then expression has also been identified in other cell types including 
monocyte-derived dendritic cells and lymphatic endothelial cells [36], The MRs three 
extracellular domains include an /V-terminal cysteine-rich (CR) domain involved in qCa2+- 
independent binding to S04-3-Gal or S 04-3/4-GalNAc terminating sulphated sugars [36], a 
fibronectin type II (FN II) domain capable of collagen binding [36, 37] and finally eight C-type 
lectin-like domains (CTLD) involved in Ca2+-dependent binding to non-reducing sugars such as 
fucose, mannose, glucose and A/-acetylglucosamine [36, 37] (Figure 1.6). MR also has a single 
transmembrane domain and a short cytoplasmic tail which mediates receptor internalisation and 
recycling [36, 37].
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Figure 1.6: Structure of the mannose receptor (MR) (taken from [37]). The MR consists of an N- 
terminal cysteine-rich (CR) domain, fibronectin type II (FN II) domain, eight C-type lectin-like 
domains (CTLD), a transmembrane domain and a cytoplasmic domain. The extracellular 
domains are capable of binding sugar residues and collagen.
This receptor is involved in a range of processes including the recognition and internalisation of 
both foreign and self materials, antigen presentation and intracellular signalling [36]. MR
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recognises and binds sugar residues found on gram negative and positive bacteria, fungi, 
parasites, virus infected cells, mycobacteria and yeasts [39, 40], Additionally, MR is involved in 
the clearance of endogenous materials such as lysosomal hydrolases, pituitary hormones and 
tissue plasminogen activator [41, 42], many of which are secreted during inflammation. 
Therefore MR plays important roles in innate and adaptive immunity, homeostasis and the 
resolution of inflammation [36, 37, 43, 44]. Under steady state conditions only 10 -  30% of the 
MR is localised at the cell surface [36] and functions as an endocytic and/or phagocytic receptor 
[36]. The functional state and expression levels of MR are modulated by cytokines, pathogens 
and immunoglobulin receptors [40, 43], for instance IL-4 can enhance cell surface MR 
expression and MR endocytosis [40],
Internalisation of the receptor occurs via clathrin mediated endocytosis, MR enters endocytic 
pathways and is recycled back to the cell surface [36]. This mechanism is important for antigen 
presentation by both class I and class II major histocompatibility complex (MHC) molecules [36], 
Additionally, the involvement of MR in phagocytic uptake of pathogens such as Mycobacterium 
tuberculosis has been shown [36, 43]. Phagocytosis is a type of endocytosis whereby a 
phagocytic cell will extend projections (or pseudopodia) around foreign material, the projections 
fuse surrounding the material and form a vesicle known as a phagosome and this vesicle can 
then enter the endocytic pathway [36].
1.4.3 Tumour Necrosis Factor-a (TNFa)
TNFa is a 17-kDa pro-inflammatory cytokine of the TNF super family [45, 46] secreted by a 
variety of cells but primarily by macrophages and other monocytic cells and is central to the 
innate immune system [27, 47], The TNFa gene is found on human chromosome 6 and 
expression is regulated by the transcription factor NFkB [47]. It is expressed as a 27-kDa 
protein which anchors to the cell membrane and is proteolytically cleaved by a metalloprotease 
TNFa-converting enzyme (TACE) to produce the soluble 17-kDa TNFa (Figure 1.7) [47]. TNFa 
receptors (TNFR1 and TNFR2) bind TNFa with high affinity, leading to receptor activation, 
signal transduction through various pathways and induction of inflammatory mediators including 
TNFa, mainly via TNFR1 (Figure 1.7) [47]. The NFkB pathway can be activated via toll-like 
receptors (TLRs) as well as via TNFa-TNFR activation. Upon TNFa binding, the inhibitory 
protein silence of death domains (SODD) is released from the TNFR1 intracellular domain and 
an adaptor protein TNF receptor-associated death domain (TRADD) binds and recruits other 
adaptor proteins including receptor interacting protein-1 (RIP-1) and TNFR-associated factor 2 
(TRAF2) [45, 47]. The TRADD-RIP-1-TRAF2 complex is released from TNFR1 and further 
proteins are recruited [47]. Inhibitor of kB kinase (IKK) complex is activated which 
phosphorylates IkB proteins leading to their ubiquintination and degradation and the release of 
NFkB subunits [47]. NFkB can then translocate to the nucleus and promote transcription of 
inflammatory genes. TRAF2 can also activate NFkB pathways [47],
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Figure 1.7: TNFa receptor signalling pathways (taken from [48]).
TNFa functions both directly and indirectly in the inflammatory response inducing a host of 
inflammatory mediators including IL-1, TNFa, IL-6, matrix metallopeptidase-9 (MMP-9) and -12, 
MCP-1 and p-selectin in a wide range of cells (Figure 1.8) [12]. In the lungs TNFa has also 
been associated with mucus hypersecretion, cytotoxicity and IFNy receptor activation [12]. This 
potent cytokine is also involved in neutrophil recruitment leading to protease and reactive 
oxygen species (ROS) release.
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Figure 1.8: TNFa function in the inflamed lung [27]
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Macrophages are the predominant cell type found in BALF recovered from COPD patients and 
unsurprisingly COPD patients show raised TNFa expression [12]. In CF TNFa induces changes 
in lipoprotein metabolism, increases neutrophil oxidative and secretory responses and may be 
involved in CF associated cachexia [13]. Increased TNFa has also been reported in asthmatic 
airways at both the protein and mRNA levels [27]. Additionally, inhalation of recombinant TNFa 
by normal subjects has resulted in airway hyper responsiveness and neutrophilia both features 
of asthmatic pathology [27]. TNFa is the key player in chronic inflammation and is associated 
with disease progression and pathogenesis (Figure 1.9). For instance overexpression of TNFa 
in mice can mediate increases in airspace, chest and lung cavity volume and collagen as well 
as small airspace loss [46]. Hence, TNFa poses a potential target for anti-inflammatory 
therapies and clinical trials have investigated this cytokine as a target for the treatment of 
asthma using strategies such as adalimumab (human antibody) and infliximab (chimeric 
mouse/humanized monoclonal antibody); with some positive results [27]
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Figure 1.9: The central role of TNF-a in asthma and COPD pathogenesis [49].
1.5 New Treatments fo r Inflammatory Lung Disease
The ability to suppress chronic inflammation associated with lung diseases such as CF, asthma 
and COPD by the application of targeted siRNA presents an attractive therapeutic approach. 
Present therapies target inflammation such as glucocorticoids and smooth muscle such as 
bronchodilators and can be associated with many unwanted side effects [19].
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1.5.1 RNA Interference
The term RNA interference was coined by Fire and Mello just over a decade ago to describe an 
endogenous cellular mechanism involved in gene regulation [50]. They discovered that specific 
down-regulation of gene expression could be achieved by the exogenous introduction of double 
stranded RNAs (dsRNA) into C. elegans (a nematode) [50] and were subsequently awarded the 
Nobel Prize for Physiology or Medicine in 2006. Initially similar observations were made in 
insects and plants but not in mammalian cells lines. Also in higher eukaryotes dsRNA greater 
than 30 base pairs (30bp) can potently induce an interferon response. It was not until 2001 that 
dsRNA 21 nucleotides in length (and therefore similar in length to the dicer processed dsRNA, 
siRNA) were found to silence genes in mammalian cells [51] and a new branch of gene therapy 
emerged.
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Endogenously the process of RNAi is very complex and is primarily guided by small RNAs such 
as microRNAs (miRNA), siRNA as well as the less elucidated piwi-interacting RNAs (piRNA) 
[53], In general miRNA arises when long primary micro-RNAs (pri-mRNA) expressed in the 
nucleus are cleaved by the nuclear microprocessor Drosha (RNase Ill-like endoribonuclease) 
into shorter precursor miRNA (pre-miRNA) and transported to the cytoplasm via karyopherin
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Exportin-5 (exp5) [54], Once in the cytoplasm the pre-miRNA is processed along the microRNA 
pathway represented in Figure 1.10 in which translation of the target mRNA is prevented by the 
miRNA-RNA induced silencing complex (miRNA-RISC). Imperfect base-pairing exists between 
the miRNA and its target nucleic acid. The specificity of miRNA relies on a 6-7 base “seed 
region”.
The origins of siRNA however can vary greatly but once present in cytoplasm, long, linear 
dsRNA is cleaved by Dicer, a ribonuclease III, into double stranded fragments of 21-23 perfectly 
paired nucleotides, known as siRNA. The siRNA complexes with a multi-protein complex that 
includes Argonaute-2 (Ago2) and RISC. The complex remains inactive while the siRNA duplex 
is unwound by RISC-mediated heticase activity [55], specifically by the protein Ago2 at its Piwi- 
Argonaute-Zwille (PA2) domain [56]. The guide (antisense) strand is selected, the sense strand 
lost, and the RISC activated. Through RISC activation, the guide strand is hybridized to a 
perfect or near perfect complementary mRNA. Subsequently, the mRNA is cleaved by Ago2 
between the complementary nucleotides of the guide strand nucleotides 10 and 11 (from the 5’- 
end) [52, 53]. Further degradation of these cleavage products by exonucleases has been 
observed in drosophila [57], The guide strand disassociates from the RISC complex which can 
then complex with other siRNA.
It was believed that the role of miRNA was endogenous gene regulation while siRNA was 
defence of the genome against foreign or invasive nucleic acids such as viral nucleic acid or 
transposons (“jumping genes"). Following on from these roles miRNA appeared to be 
endogenous while siRNA chiefly exogenous possibly derived straight from a transposon, 
transgene or virus activator. However a range of other sources have since been observed 
including numerous endogenous genomic origins [53] indicating more diverse functions for 
these short RNA duplexes.
The potency and specificity of siRNA immediately attracted interest for its therapeutic potential. 
In short, plasmids or viral vectors expressing short hairpin RNA (shRNA) or synthetic siRNA 
duplexes can be introduced into cells to knockdown specific genes. In the case of shRNA, gene 
silencing can be longer lasting as expression of the shRNA persists within the cell while siRNA 
effects will only last a few days usually due to degradation [58]. However many concerns were 
raised over possible risks of introducing siRNA in vivo as well as difficulties in delivery. For 
instance, siRNA can target mRNA sequences of imperfect complementary likely causing 
undesired gene silencing or off-target effects [53] and so enter the miRNA pathway. A similar 
effect can be seen due to strand selection. The guide strand is selected based on the 
thermodynamic stability of its 5’- end, with the less stable (AU rich) terminus being preferred [53, 
54], While, thermodynamic symmetry grants each strand an equal opportunity of being selected 
[53] and therefore has a less predictable outcome. In addition, high concentrations of siRNA 
can induce an interferon response by the activation of protein kinase R (PKR; also triggered by 
dsRNA >30bp) as well as activating TLRs in particular TLR7 which recognizes dsRNA [52].
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Another issue is associated with the stability of siRNA in vivo. In human plasma naked siRNA is 
degraded within minutes [52],
1.5.2 siRNA Delivery
1.5.2.1 Naked Nucleic Acid
in vivo transfections with naked DNA have previously shown success using methods such as 
direct injection to muscle [59], electroporation to skin, muscle [60] and lungs [61], ultrasound 
and intravascular injection. However gene transfer of naked DNA is associated with low 
efficiency, variability [62] and has a serum half life of 10 minutes [63]. In addition mammalian 
DNA has methylated CpG sequences unlike bacterial DNA and plasmid vectors. Consequently 
immune activation occurs via TLR9 by the presence of unmethylated plasmid DNA (pDNA) [64]. 
Naked nucleic acids also lack cell target specificity [63].
Similarly siRNA is associated with many problems including toxicity, off-target effects and 
immune activation. In order to avoid these problems and to improve stability and potency 
modified siRNA duplexes are being developed. Synthetic siRNA typically is produced using 
phosphoramidite to form single-stranded oligonucleotides which are annealed into duplexes and 
can then be further modified. It is important that siRNA design also include bioinformatic and in 
vitro screening [52] for example “seed region” homology screening, however, this is not always 
effective and chemical alterations are also necessary [65], To minimise off-target gene 
silencing (via the miRNA pathway) chemical modifications such as a single 2’-0-methyl (2’OMe) 
modification at nucleotide 2 [52] and substitution o f DNA into “seed regions" have been 
successful. Immune activation can also be minimised by 2’-OMe modifications with ribose (r) U 
and rG modifications the most efficient [66]. siRNA modifications as simple as strand length 
changes can have substantial impact, for instance longer duplexes (up to 29bp) can be more 
potent and will be processed by Dicer while still avoiding the innate immune response [54]. 
Additionally to prevent TLR7 activation (an event that is sequence specific) GU-rich sequences 
should be avoided [52]. Other modifications include the synthesis of asymmetric siRNA with 3’ 
2-nt overhangs, small internally segmented interfering RNA (sisiRNA) with a guide strand and' 
two shorter passenger strands and asymmetric interfering RNA (aiRNA) with minimally sized 
passenger strands (15bp) (Figure 1.11). A recent study by Bramsen et al. assessed the activity, 
stability and toxicity of 2160 different siRNA duplexes (with 21 types of chemical modifications) 
and found that 134 siRNA duplexes were more potent than standard siRNA [67],
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Figure 1.11: Some of the chemical modifications of siRNA duplexes to reduce unwanted effects 
while retaining functionality.[54]
Chemical modifications can lower these risks, however, a major obstacle still remains; inefficient 
transport across the cell membrane. The structure of siRNA, with a large molecular weight of 
over 13kDa and a polyanionic structure (almost 40 negative phosphate charges) [56] is not 
suitable for transfer across cellular membrane. Moreover naked siRNA has a half-life of 
minutes in human serum [68] as a result of degradation by serum nucleases [69]. The 
development of a pharmaceutical vehicle that can effectively deliver siRNA to the intracellular 
target, while also enhancing stability, is essential for the advancement of siRNA to a useful 
therapeutic. However modification of siRNA is still important particularly if the delivery system 
(such as cationic lipids) brings the siRNA into direct contact with various TLRs which are 
present in endosomes. A recent study by Gao et al. (2009) compared the stability, blood 
clearance and biodistribution of a range of chemically modified siRNA and siRNA nanoparticles 
in mice [70]. It was found that modifications to siRNA increased in vivo stability nevertheless 
nanoparticle formulations such as siRNA complexes with cationic polymers and polyethylene 
glycolated (PEGylated) liposomes improved blood stability and biodistribution compared to 
naked siRNA.
1.5.2.2 siRNA Vectors
In order to overcome the numerous barriers to siRNA delivery such as off-target effects, 
nuclease siRNA degradation, non-specific accumulation, toxicity, cell internalisation and poor 
endosomal escape [71] vectors or carriers can be developed. These vectors are generally 
categorised as viral or non-viral. Viruses such as lentiviruses and adenoviruses can be 
harnessed for efficient delivery of siRNA in the form of a viral genome but their use has been
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limited by the difficulties associated with large-scale manufacture and possible mutagenic and 
immunogenic effects [71]. The need for an alternative to viral based delivery systems arose 
from the serious adverse effects associated with the use of viruses [1], The most frequently 
used non-viral vectors are polymers and liposomes which are very versatile carriers allowing 
modification to improve cell specific targeting, overcoming many of the previously mentioned 
barriers.
Cationic polymers and lipids are usually ionically complexed with negatively charged nucleic 
acids to form polyplexes and lipoplexes respectively [72]. While not as efficient as virally based 
delivery systems these vectors are somewhat safer. Also non-viral vectors can be synthesised 
in larger quantities to be more readily prepared and chemical improvements e.g. PEGylation 
targeting more easily incorporated. Commonly used polymers include poly(ethyleneimine) (PEI), 
poly-(l-lysine) (PLL), chitosan, gelatin, poly(dimethylaminoethylmethacrylate) (PDMAEMA) and 
poly(trimethylaminoethyl-methacrylate) (PTMAEMA) [72]. Many polymers can offer various 
advantages for nucleic acid delivery including biocompatibility, protection of siRNA against 
nucleases [73] and can be biodegradable. Many polymers are also strongly cationic. This 
characteristic helps in the formation of polyplexes with a net positive charge but can have 
biological consequence in vivo.
Non-viral vectors such as liposomes have been shown to enhance pharmacokinetics and 
decrease toxicity associated with siRNA therapy [74, 75]. Liposomes are versatile delivery 
systems that can incorporate components to enhance cell fusion, targeting and control the 
pharmacokinetics of the siRNA in vivo. Cationic liposomes tend to be toxic and have lower 
transfection efficiency in vivo. To address these shortcomings neutral targeted liposomes are 
being explored which encapsulate rather than bind with RNA [75, 76].
1.5.2.3 siRNA Delivery to the Lungs
Inhalation offers the means of direct delivery of siRNA to the target organ, the lungs, it also 
offers many advantages over systemic delivery such as decreased systemic toxicity, immediate 
availability, local and non-invasive delivery [75]. In vivo studies have administered siRNA naked 
[77-81], complexed with polymers or lipids [82, 83] or encapsulated in liposomes [84, 85] but to 
date there are no siRNA based therapeutics available as commercial products for lung disease. 
Clinical studies are currently underway for treatment of diseases including of wet neovascular 
age-related macular degeneration and respiratory syncytial virus (RSV) currently at clinical trial 
phase III and lib respectively [75, 76]. Delivery of siRNA to the lungs must overcome the 
pulmonary barriers discussed in 1.3 as well as maintain stability following formulation and 
inhalation and in the respiratory environment which can be achieved through siRNA 
modification and/or the use of carriers [75]. Therefore both formulation and the inhaler device 
used are very important for successful siRNA delivery to the lungs [75].
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1.6 Overall Aims
• To prepare and develop biocompatible siRNA liposomal and polymeric particles 
targeted to alveolar macrophages
• To develop high content screening methods to enable comprehensive, high throughput 
methods to compare cellular delivery and toxicity of siRNA carriers
• To determine siRNA-carrier ability to faciltate TNFa knockdown in LPS-stimulated 
macrophages in vitro and in LPS stimulated mice in vivo
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Chapter 2
Alveolar Macrophage Targeted siRNA Liposomes for Inhalation
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2.1 Introduction
Alveolar macrophages reside in the alveolar region of the lung and rapidly phagocytose foreign 
particles. Targeting of alveolar macrophages via inhalation avoids many of the barriers 
associated with delivery to other pulmonary targets such as the epithelium and vasculature 
including mucus and enzymatic degradation. One strategy to target siRNA to alveolar 
macrophages via inhalation is liposome delivery. Lipid based formulations form a major branch 
of non-viral gene therapy. A variety of lipid based formulations have been described including 
micelle structures, solid lipid nanoparticles (SLN) and nano-structure lipid carriers (NLC) but the 
most extensively investigated for gene delivery are liposomes and cationic lipid nucleic acid 
complexes (lipoplexes) [86], Liposomes have been evaluated for decades as drug carriers due 
in part to their versatility. They boast a great number of benefits over other drug carrier systems 
such as the capability of entrapping a wide range of drugs, biocompatibility and low toxicity 
[87]. Furthermore, phospholipids have a long history in relation to pulmonary drug delivery, 
being used in the treatment of respiratory distress syndrome (RDS) in newborns for over 40 
years [87],
2.1.1 Liposomes
A liposome is a lipid vesicle in which natural or synthetic lipids are arranged in one or more 
concentric lipid bilayers with an inner aqueous volume [88]. First described to entrap solutes as 
early as 1965, liposomes have since established themselves as extremely versatile drug carrier 
systems with the added advantage for inhalation that their composition can utilize lipids 
endogenous to the lungs such as those found in the lung surfactant [89, 90] potentially 
bestowing biocompatibility. Consequently liposomes will undergo uptake, processing and 
recycling by alveolar type II cells similar to endogenous surfactant [90]. Phospholipids consist 
of polar or hydrophobic head groups and hydrophilic fatty acid tails which in aqueous solution 
will spontaneously rearrange to form structures such as lipid bilayers or micelles (Figure 2.2). 
The variation in lipid properties (Figure 2.1) including self assembly characteristics lends itself to 
preparation of liposomes with diverse qualities. Depending on the target (such as tumour, 
specific organ or cell type), the drug to be incorporated and method of delivery, liposome 
composition can be tailored, using a vast array of lipids and the incorporation of ligands and/or 
chemical modifications. Liposome physicochemical properties include variations in size, surface 
charge, encapsulation efficiency, drug release profiles and bilayer fluidity [90] optimised for their 
therapeutic end goal.
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Figure 2.1: Structure of commonly used synthetic lipids (A) 1,2-dioleoyl-sn-glycero-3-phospho-L- 
serine (DOPS), (B) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), (C) 1,2-distearoyl-sn- 
glycero-3-phosphocholine (DSPC), (D) ,2-Dioleoyl-3-trimethylammonium-propane (DOTAP), (E) 
cholesterol and (F) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
sulfonyl) (PE-rhodamine) (Avanti Polar Lipids Inc.)
Using various techiques liposomes are formed normally as large multi lamellar vesicles (MLV) 
and re-sized to unilamellar vesicles (UV) of a predetermined diameter via sonication, extrusion, 
reverse-phase evaporation or solvent injection [86]. Liposomes by virtue of their structure can 
entrap hydrophobic, hydrophilic and amphiphilic drugs within the lipid bilayer, the aqueous 
compartment and at the bilayer interface respectively [90] and encapsulation efficiencies can be 
maximised using a number of strategies. Release of drug can also .be controlled by the 
formulation with the capability of internal or external triggers such as pH, enzymes, light, heat or 
a magnetic field [86].
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Figure 2.2: Lipid and liposome structures. Lipids are amphiphiles with a polar head and non­
polar tail. Lipid structure dictates resulting self-assembly such as micelle or lipid bilayer 
formation. Liposomes formed are usually large multilamellar vesicles (MLV) or can be resized 
via sonication or extrusion to form small or large unilamellar vesicles (SUV or LUV respectively). 
[91]
2.1.2 Liposomes as siRNA Carriers in Gene Therapy
The encapsulation of nucleic acids into liposomes of neutral naturally occurring lipids was first 
described in the late 1970s [92]. Nucleic acids including pDNA and siRNA are highly negatively 
charged which is one of many barriers to cell internalisation and hence the need for a carrier 
system. This feature however allows nucleic acids to be complexed through electrostatic 
interactions to cationic lipids such as 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) and
1,2-di-0-octadecenyl-3-trimethylammonium propane (DOTMA) to form lipoplexes. Although 
cationic lipoplexes enable efficient nucleic acid encapsulation and in vitro cell uptake and 
transfection they are associated with cytotoxicity most likely due to interaction with enzymes 
such as protein kinase C (PKC) [93] and proteoglycans on the cell surface (Chapter 3) that 
often results in toxicity and poor transfection efficiencies in vivo [92], Consequently, interest has 
turned to the use of more biocompatible neutral and anionic lipids sometimes with ligands for 
intracellular targeting. However efficient encapsulation of siRNA is a major obstacle in neutral 
and anionic liposome preparations.
Various strategies have been developed to encapsulate nucleic acids in non-cationic liposomes 
including passive, ethanol drop method, ethanol destabilisation, ethanol dilution, reverse phase 
evaporation and hydration of freeze-dried matrix (HFDM) [92, 94, 95]. A summary of the 
methods for the encapsulation of nucleic acids into liposomes composed of neutral and/or 
anionic lipids in the absence of cationic lipids is shown in Table 2.1. The most commonly used 
method for liposome preparation is dry film hydration where lipids are dissolved and mixed in a 
solvent such as chloroform. The solvent is removed leaving a dry lipid film which is then 
hydrated with an aqueous buffer. Passive encapsulation of siRNA simply involves the 
rehydration of the lipid film with an aqueous siRNA solution. This generally leads to poor 
encapsulation efficiency particularly if cationic lipids are completely absent from the formulation. 
To improve loading of siRNA one strategy has been used most frequently, the pre-complexation
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of siRNA with cationic reagents such as protamine, octa-arginine (R8) and PLL achieving 
encapsulation efficiencies greater than 80% [96-98], Nakamura et a/. (2007) condensed siRNA 
using PLL, stearylated R8 (STR-R8) and protamine for encapsulation into anionic 1,2-dioleoyl- 
sn-glycero-3-phosphoethanolamine:cholesteryl hemisuccinate (DOPE:CHEMS) liposomes [98]. 
STR-R8 siRNA complexes showed the most efficient condensation (with particle sizes less than 
100nm) and were encapsulated in liposomes at an efficiency of 87.8 ± 8%. Additionally, 
luciferase activity in HeLa cells was knocked down by 80% 24 hours following transfection with 
these liposomes.
Table 2.1 Strategies for Nucleic Acid Encapsulation in Liposomes Composed Anionic 
and/or Neutral Lipids
Lipid
Components
Preparation
Method
Nucleic
Acid
Encapsulation Method EE% Ref.
POPC:DDAB, DSPE- 
PEG, DSPE-PEG-MAL
thin film hydration siRNA Freeze thaw 6x in liquid ntirogen 3 [99]
EPC, DMPG.DSPE-PEG thin film hydration ODN ODN pre-complexed with PEI (N/P 
ratio 8)
80 [100]
DOPE,Choi, PS, PC thin film hydration pDNA DNA complexed with protamine - [101]
DOPE:DOPA:Chol - siRNA siRNA pre-complexed with protamine 
and calf thymus DNA
- [96]
PC:DPPE:Chol thin film hydration siRNA siRNA pre-complexed with protamine - [97]
PE:Chol:CHEMS
reverse phase 
method siRNA Via liposome preparation method 10-12 [102]
POPC:POPG:Chol:DSPE-
PEG
thin film hydration ODN ODN pre-complexed with PEI (N/P 6) 95 [103]
EPC:DSPE-PEG thin film and reverse 
phase
ODN ODN pre-complexed with DOTAP 
mixed with PC lipids in ethanol
up to 97 [104]
DOPC, DAP thin film hydration siRNA 7 freeze thaw cycles 19 [105]
DOPE:CHEMS thin film hydration siRNA siRNA pre-complexed with STR-R8 88 [98]
PE:CHEMS:Chol reverse phase siRNA Via liposome preparation method 10-14 [106]
DOPC freeze-dried matrix siRNA Via liposome preparation method 65 [94]
hydration
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2.1.3 Liposomes for Macrophage Targeting
Targeting of liposomes to specific locations or cell type can be determined to some extent by 
the liposome physicochemical properties including size, surface charge and the incorporation 
of ligands such as proteins, peptides, antibodies, polysaccharides, glycolipids, glycoproteins 
and lectins. Macrophages are notoriously difficult to transfect and although their location and 
phagocytotic nature are advantages in terms of alveolar macrophage targeting and pulmonary 
delivery, strategies that enhance cellular uptake are important. A number of strategies have 
been developed to target liposomes to macrophages/monocytes (Figure 2.3 and Table 2.2).
Uptake of small liposomes (< 100nm) by phagocytic cells has been reported [107] however 
many other studies have shown liposome uptake to be improved with increased size [108-110]. 
Surface charge may also promote macrophage targeting. Negatively charged lipids such as 
phosphatidylserine (PS) and phosphatidylglycerol (PG) are preferentially recognised by 
macrophages [107]. Chono et al (2006) evaluated the uptake of anionic liposomes loaded with 
ciprofloxacin (CPFX), composed of hydrogenated soybean phosphatidylcholine (HSPC), 
cholesterol (chol) and the anionic lipid dicetylphosphate (DCP) at five different sizes 100, 200, 
400, 1000 and 2000 nm by rat alveolar macrophages [108]. Following pulmonary administration 
efficiency of CPFX delivery to alveolar macrophages was improved with increasing liposome 
size from 100 -  1000nm and became constant over 1000nm. PS and phosphatidylethanolamine 
(PE) are located in the inner membrane leaflet of eukaryotic cells [111-113] which is exposed on 
the outer cell surface during apoptosis. It is believed that PS targets scavenger receptors (SRs) 
on macrophages.
In addition to controlling the physicochemical properties of liposomes, ligands such as lectins, 
antibodies and peptides can be incorporated into liposome formulations for improved 
macrophage targeting and uptake via lectin recpectors, Fc receptors and integrins respectively. 
The MR, a C-type lectin receptor [43, 114], is constitutively highly expressed by immune cells 
including alveolar macrophages, peritoneal macrophages, monocyte-derived dendritic cells and 
Kupffer cells. Ligands of the MR can be incorporated into liposome formulations for 
macrophage targeting such as mannosylated cholesterol (Mann-C4-Chol) [115]. MRs are 
involved in antigenic recognition, endocytosis and presentation as well as in homeostatic 
maintenance, inflammation and immune responses [36, 116]. Consequently MR can identify 
and engulf pathogens such as Mycobacterium turberculosis and Leishmania donovani via 
surface sugar antigens.
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Figure 2.3: Summary of liposomal targeting strategies to
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Table 2.2 Summary of Ligand Based strategies for Monocyte/Macrophage Liposomal 
Targeting
Ligand Active Disease Reference
Anionic Lipids Dexamethasone Atherosclerosis [118]
SLPI Inflammatory Lung Disease [119]
Bisphosphonates Restinosis [120]
Rifampicin Tuberculosis [121]
Dideoxycytidine-5’-triphosphate HIV [122]
Clarithromycin Mycobacterium avium infection [123]
Peptides
Muramyl tripeptide (MTP) MTP-phosphotidylethanolamine Osteosarcoma (124]
Arg-Gly-Asp (RGD) diclofenac sodium (model drug) Cerebrovascular disease [125]
Antibodies
Anti-VCAM-1 Prostaglandins Atherosclerosis [126]
Anti-CC52 - Colon Cancer [127]
anti-CC531 - Colon Adenocarcinoma [128]
Anti-CD11 c/DEC-205 tumour antigen (OVA) Cancer [129]
Lectins
Mann-C4-Chol dexamethasone palmitate Inflammatory Lung Disease [130]
Man2DOG - - [131]
Aminophenyl-a-D-mannopyranoside doxorubicin experimental visceral leishmaniasis [132]
Ciprofloxacin respiratory infection [133]
Man3-DPPE OVA [134]
Gastric cancer [135]
Other Ligands
Maleylated bovine serum albumin (MBSA) [121]
O-steroly amylopectin (O-SAP) [121]
Fibronectin [107]
Galactosyl [107]
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2.1.4 Liposome Nébulisation
A means of effective in vivo targeting is critical. Liposomes have been used in the pulmonary 
delivery of antioxidants, anti-microbial compounds, proteins, peptides and DNA in animals and 
humans [89] but there are no products on the market. For effective pulmonary delivery it is 
necessary to attain a high respirable fraction (i.e. the amount of drug reaching the deep lungs). 
In order to achieve this, various device technologies are available including metered dose 
inhalers (MDI), dry powder inhalers (DPI) and nebulisers. Other factors affecting deep lung 
deposition include particle size (or aerodynamic diameter), patient inhalation pattern, oral or 
nasal inhalation, airflow obstruction and patient disease severity [136].
Pressurized MDIs (pMDIs) contain drug in suspension or solution in a liquefied propellant such 
as hydrofluoroalkanes (HFAs) which forms a high velocity aerosol when actuated [136] and are 
the most widely used inhalers for asthma and COPD [136]. Phospholipids are poorly soluble in 
HFA propellants [89]. DPIs deliver a fine powder and can be breath actuated but liposome 
formulations must be prepared as dry powders [89] involving increased development time and 
manufacturing complexity. Nebulisers such as air-jet, ultrasonic and vibrating mesh nebulisers 
on the other hand, deliver liquid suspensions in the form of a mist or aerosol which can vary in 
droplet size suitable for liposome aerosolisation. The particulate aerodynamic diameter and 
droplet size are crucial for efficient deep lung deposition of powdered and liquid based 
formulations respectively. Ex vivo testing of aerosol delivery can be carried out in lung models 
including twin-impinger systems [89], cascade impactors [137] and mathematical [138, 139] 
models as in vivo predictors of drug deposition patterns, respirable doses, formulation stability 
and device efficiency. Table 2.3 summarises the main types of nebulisers currently available.
Although nébulisation appears to be the simplest method of liposome delivery to the lungs from 
a formulation perspective, damage to nucleic acids and liposome destabilisation has been 
reported [89]. To date nébulisation of liposomes encapsulating DNA [140-144], isoniazid [145], 
salbutamol sulphate [146, 147], rSLPI [119], peptides [148], insulin [149] and rifampicin [150] 
have been assessed for inhalation but as of yet, siRNA loaded liposomes have not been 
evaluated. However nébulisation of particles associated with siRNA including hexanediol 
diacrylate cross-linked oligoethylenimine (OEI-HD) [151], chitosan [152] and polyesters [153] 
have been assessed. Recently, Steele et ai. (2011) nebulized anti-luciferase siRNA complexed 
with OEI-HD at various weight ratios with an AeroNeb nebuliser and noted significant changes 
in polyplex size at certain weight ratios [151]. Furthermore in vitro knockdown via these 
polyplexes was used to determine siRNA functionality following nébulisation as nébulisation has 
the potential to cause siRNA nicking, polyplex re-organisation or splitting of the siRNA duplex 
post-nebulisation [151].
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Table 2.3: Comparison of the main types of nebulisers [136]
Jet Ultrasonic Vibrating mesh
Features
Compressed gas or Batteries or electrical
Power source electrical mains Electrical mains mains
Portability Restricted Restricted Portable
Treatment time Long Intermediate Short
Output rate Low Higher Highest
Residual
Volume 0 .8 - 2 .0  ml Variable but low < 0 .2  ml
Environmental contamination
Continuous use High High High
Breath-activated Low Low Low
Performance
variability High Intermediate Low
Formulation characteristics
Temperature Decreases Increases Minimum change
Concentration Increases Variable Minimum change
Suspensions Low efficiency Poor efficiency Variable efficiency
Dénaturation Possible Probable Possible
Required, after Required, after single
Cleaning Required, after single use multiple use use
Cost Very low High High
2.1.5 Chapter Aims
siRNA targeting to alveolar macrophages using liposomes provides both anatomical 
(nébulisation) and cellular targeting using DOPS and mannosylated liposomes. DOPS 
liposomes can target macrophage SRs. DOPS liposome targeting to alveolar macrophages has 
been previously shown in work by us [154]. Mannosylated liposomes provide alveolar 
macrophage targeting via the macrophage man nose receptor. Therefore, this chapter aims to:
• synthesise mannosylated cholesterols
• prepare and characterise a range of liposomes (anionic and mannosylated) for alveolar
macrophage targeting
• optimise encapsulation of siRNA by neutral, anionic and mannosylated liposomes
• determine siRNA-liposome suitability for inhalation using nebulisers
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2.2 Materials
1.2-Dioleoyl-3-trimethylammonium-propane (DOTAP), M.W. 698.542, Avanti Polar Lipids Inc.
1.2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), M.W. 786.15, Avanti Polar Lipids Inc.
1.2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (PE- 
rhodamine), M.W. 1319.753, Avanti Polar Lipids Inc.
1.2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), M.W. 810.025, Avanti Polar Lipids Inc.
1.2-distearoyl-sn-glycero-3-phosphocholine (DSPC), M.W. 790.145, Avanti Polar Lipids Inc. 
2% bisacrylamide, Sigma Aldrich
40% acrylamide, Sigma Aldrich 
Acetic anhydride, Sigma Aldrich 
Acetone, Sigma Aldrich 
AeroNeb® Pro, Aerogen
AllStar Negative Control siRNA, AlexaFluor 488 (Qiagen)
Ammonium persulfate (AP), Sigma Aldrich 
Anhydrous magnesium sulphate, Sigma Aldrich 
Avanti ®  Mini-Extruder, Avanti Polar Lipids Inc.
Blue/orange 6 x loading dye, Promega 
Celite, Sigma Aldrich
Centristart spin filters 100,000 MW, Sartorius
Charcoal, Sigma Aldrich
Chloroacetonitrile, Sigma Aldrich
Chloroform, Fisher Scientific
Cholesterol, M.W. 386.66, Avanti Polar Lipids Inc.
Dichloromethane (DCM), Sigma Aldrich
Disposable Capillary Cells, Malvern
D-Mannose, Sigma Aldrich
Drain disc polyethylene 10mm, Whatman
Ethylenediaminetetraacetic acid (EDTA), Sigma Aldrich
Filter circle nucleopore 0.1, 0.2, 0.4 and 1pm polycarbonate membrane 19mm, Whatman
Filter circle nucleopore 0.2pm polycarbonate membrane 25mm, Whatman
G:BOX, Syngene
GelStar, Lonza
GIBCO PBS, Invitrogen
Iodine, Sigma Aldrich
LabAssay (TM) Cholesterol, Wako Pure Chemical Industries, Ltd.
LabAssay (TM) Phopholipid C, Wako Pure Chemical Industries, Ltd.
Labconco Freeze Drier, Labconco
Lipex 10ml Thermo-barrel Extruder. Northern Lipids
Methanol, Fisher Scientific
Methanol, Sigma Aldrich
N.N.N'.N'-Tetramethylethylenediamine (TEMED), Fluka
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NanoDrop 1000 Spectrophotometer
PARI Air-Jet Nebuliser, PARI
Phosphate buffered saline (PBS), GIBCO
Polyethylenimine (PEI), average MW 25kDa, Sigma Aldrich
Potassium bicarbonate, Sigma Aldrich
Protamine sulphate, for biochemistry, Merck
Pyridine, Sigma Aldrich
Quant if  RiboGreen Assay, Invitrogen
Rotary Evaporator, Büchi Rotavapor R200
siRNA (siCONTROL non-targeting and siGLO RISC-free) Dharmacon
siRNA marker, New England Biolabs
siRNA, Dharmacon
Sodium bicarbonate, Sigma Aldrich
Sodium bisulfite, Sigma Aldrich
Sodium Chloride (NaCI), Sigma Aldrich
Sodium methoxide, Sigma Aldrich
Sodium sulphate, Sigma Aldrich
Sodium thiosulphate, Sigma Aldrich
Solid-glass beads borosilicate, diameter 1 mm, Sigma Aldrich
Sorvall Discovery M120SE Centrifuge, Sorvall
Tertiary-Butanol (t-Butanol), Fluka
Thiourea, Sigma Aldrich
Triethylamine, Sigma Aldrich
Trifluoroacetic acid, Sigma Aldrich
Triton X-100, Sigma Aldrich
Ultrapure TBE buffer, Invitrogen
Wallac Victor2 1420 Multilabel Counter (Perkin Life Sciences)
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Cholesten-5-y loxy-/V-(4-(( 1 -imino-2-a-thioglycosy lethyl)amino)butyl)formamide (Mann-C4-Chol) 
and its C2 and C 6  derivatives were synthesized in house by Colin Burke supervised by Dr. 
James Barlow. Briefly 2-imino-2-methoxyethyl-1-thio-a-D-mannopyrannoside was synthesized 
from man nose in a five step procedure (Figure 2.4) while cholesterol chloroformate was reacted 
with N-Boc spacers in a two-step reaction (Figure 2.5). Cholesterol chloroformate and 2-imino- 
2-methoxyethyl-1-thio-a-D-mannopyrannoside were then reacted to give Mann-Cn-Chol (Figure 
2.6). Melting points were obtained using a Stuart Scientific SMP10 apparatus, and are 
uncorrected. Infrared Spectroscopy (IR) of test samples was performed on a Bruker Tensor 27 
FTIR. Nuclear Magnetic Resonance (NMR) Spectroscopy was performed using a Bruker 
DPX400 instrument, at 400.13 MHz for proton (1 H) magnetic resonance and 100.61 MHz for 
carbon (13C). All NMR samples were prepared in deuterised chloroform (chloroform-d). High 
Resolution Mass Spectroscopy (HRMS) was performed using a Micromass LC T instrument 
(E S+ mode).
2.3 Methods
2.3.1 Synthesis of Mannosylated Cholesterol Derivatives
0
1
Ch3
Figure 2.4: Schematic of the 5 step synthesis of the methyl imidate 2-imino-2-methoxy ethyl-1 
thio-a-D-mannopyrannoside (compound 5).
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2.3.1.1 Synthesis of 2-imino-2-methoxyethyl-1-thio-a-D-mannopyrannoside
D-Mannose Penta-acetate (1)
D-Mannose (10g, 55 mmol) was dissolved in acetic anhydride (40ml, 423 mmol). Iodine (0.5g,
2 mmol) dissolved in acetic anhydride (2ml, 2 mmol) was added dropwise. The reaction was 
stirred under an argon atmosphere in an ice bath for 3.5 hours. Dichloromethane (DCM) was 
added and the mixture was washed twice with sodium thiosulphate (10% w/v). The organic 
layer was collected and washed twice with sodium bicarbonate (20% w/v). The organic layer 
was then collected, washed with saturated brine and dried with anhydrous magnesium sulphate. 
This was then concentrated in vacuo to D-mannose penta-acetate. Yield 83%; IR (potassium 
bromide (KBr), v) 3474, 2967, 2257 cm'1. 1H NMR: 6ppm = 6.11 (d, J=1.7Hz, 1H), 5.35 (m, 2H), 
5.28 (m, 1H), 4.30 (dd, J=4.8 and 12.3Hz, 1H), 4.12 (dd, J=2.5 and 12.4Hz, 1H), 4.07 (m, 1H), 
2.20 (s, 3H, OAc), 2.19 (s, 3H, OAc), 2.12 (s, 3H, OacCH3), 2.07 (s, 3H), 2.03 (s, 3H).
2,3,4,6-tetra-O-acetyl-a-D-mannopyranosyl Bromide (2)
Compound 1 (17.99g, 46 mmol) was dissolved in anhydrous DCM (40ml, 620 mmol) and 33% 
hydrogen bromide (HBr) in acetic acid (30ml, 167 mmol) was added. The reaction was stirred 
under an argon atmosphere at room temperature for 24 hours. The completed reaction was 
diluted with DCM (40ml) and washed with cold water, sodium bicarbonate 20% twice and cold 
water. The organic layer was dried with anhydrous magnesium sulphate and concentrated in 
vacuo to an oil. Yield 64%; 1H NMR: 5ppm = 6.23 (brs, H1), 5.65 (dd, J=3.5 and 10.1Hz, 1H), 
5.38 (dd, J= 3.5 and 1.5Hz, 1H), 5.31 (t, J= 10.3Hz, H-4, 1H) 4.27 (dd, J=12.5 and 4.7hz, 1H), 
4.16 (ddq, J=10.2, 4.8, 2.2Hz, 1H), 4.07 (dd, J= 12.2 and 2.1Hz, 1H), 2.11 (s, 3H), 2.05 (s, 3H),
2.01 (s, 3H), 1.95 (s, 3H).
2-S-(2,3,4,6-tetra-0-acetyl-a-D-mannopyranosyl)-2-thiopseudourea Hydrobromide (3)
Compound 2  (12.65g, 30 mmol) was dissolved in dry acetone (25ml) and mixed with 1.1 
equivalents of thiourea (2.48g, 30 mmol). The reaction was boiled and refluxed under an argon 
atmosphere for 2 hours. The resulting crude mixture was concentrated in vacuo.
Cyanomethyl 2,3,4,6~tetra-0-acetyl-1-thio-a-D-mannopyrannoside (4)
Compound 3 (13.65g, 27 mmol) was dissolved in a 1 : 1  (v/v) watenacetone mixture (25ml). To a 
stirred solution, chloroacetonitrile (6.83ml, 108 mmol, 4 equivalents) was added dropwise, then 
sodium bisulfite (4.37g, 42 mmol, 2 equivalents) and finally potassium bicarbonate (4.49g, 32.5 
mmol, 1.2 equivalents) were added. The solution was stirred at room temperature for 2 hours at 
which point 1 0 0 ml of ice water was added to the reaction mixture and stirred for a further 2  
hours. The resulting precipitate was suction filtered. The air-dried filtrate was dissolved in a 
minimum of boiling methanol. The methanolic solution was stored at 4°C overnight to promote
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crystallisation. The crystals formed were then filtered off and vacuum dried. In some instances 
little precipitate crystallised out of the methanolic solution and the following purification was 
performed. The methanolic solutions were mixed with water. The water methanol mix was 
washed with chloroform (60ml) three times. The chloroform layers were combined and washed 
with 1M NaCI twice. The chloroform layers were then dried with sodium suphate and 
decolourised with charcoal. The solution was then vacuum filtered through celite. The solution 
dried using rotary evaporation. The resulting solid was dissolved in boiling methanol. The 
resulting crystals were filtered off and dried by rotary evaporation. The cyanomethyl crystals 
were stored at -10°C. Yield: 44% to 27.4%. IR (KBr, v) 3454, 2970, 2931, 2852, 2257 cm'1. 1H 
NMR: Sppm = 5.40 (d, J= 1.2Hz, 1H), 5.27 -  5.32 (m, 2H, 2 x CH), 5.13 (dd, J= 10.0, 3.2Hz, 1H, 
CH), 4.24 -4.32 (m, 2H), 4.10 (dd, J=12.0Hz, 1.4Hz, 1H), 3.25 (d, ¿=17.1Hz, 1H, H of CH2), 3.41 
(d, J=17.1Hz, 1H, H of CH2)2.13 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H), 1.94 (s, 3H). 13C  NMR: 8ppm 
= 169.6, 169.7, 169.8, 170.6 (C=0), 115.6 (CN), 82.4, 70.0, 69.6, 69.3, 65.8, 62.0 (CH), 62.0 
(CH20), 20.83, 20.76, 20.69, 20.6 (CH3), 15.5 (SCH 2). Melting Point: 136°C.
2-imin o-2-methoxye thy I-1 -thio-a-D-mannopyrannoside (5)
Compound 4 (0.1M) was dissolved in anhydrous methanol and reacted with 0.01 M sodium 
methoxide solution under an argon atmosphere at room temperature. The mix was reacted for 
48 hours and then concentrated in vacuo and stored at -10°C. 1H NMR (400MHz, CDCI3, 25°C): 
Sppm = 5.35 (d, 1H, J=0.4Hz, OCHS), 5.18 (d, J=0.74Hz, OCHS).
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Figure 2.5: Schematic of A/-(n-aminobutyl)-(cholesten-5-yloxy)formamide synthesis (compound 
6 ). Cholesteryl chloroformate is reacted with /V-(n-aminobutyl)carbamic acid tertbutyl ester 
(where n = 2, 4 or 6 )
2.3.1.2 Synthesis of N-(4-aminobutyl)-(cholesten-5-yloxy)formamide, N-(2-aminobutyl)- 
(cholesten-5-yloxy)formamide and N-(6-aminobutyl)-(cholesten-5-yloxy)formamide
N-(4-aminobutyl)-(cholesten-5’yloxy)formamide (6a)
Cholesteryl chloroformate (2.64g, 5.8 mmol) was reacted with a 1.1 equivalent of A/-(4- 
aminobutyl)carbamic acid tertbutyl ester (6.4 mmol) in anhydrous chloroform (10ml) for 24 hours 
at room temperature under an argon atmosphere. This was then purified using column 
chromatography. The purified intermediate produced a 42.4% yield. IR (KBr, v) 3330, 2948, 
2853, 2719, 2356 cm'1. 1H NMR (400MHz, CDCI3, 25°C): 8ppm = 5.30 (m, H-1 C=CH), 4.61, 4.52 
(broad s, 1H, NH), 4.44 (m, 1H, OCH), 3.15 (m, 4H, 2xNCH2), cholesterol skeleton (2.34 -0.59). 
13C NMR (100.61 MHz, CDCI3) 5ppm = 156.1 (C=0), 156.0 (C=0), 122.5 (C), 74.5 (CH), 56.6 
(CH), 56.1 (CH), 49.8 (CH), 42.3 (C), 41.2 (C), 39.7 (CH2), 39.5 (CH2), 37.0 (CH2), 36.6 (C),
36.2 (C), 35.8 (CH), 31.9 (CH2), 31.8 (CH), 28.4 (CH3), 28.2 (CH2), 28.1 (NCH2), 28.0 (CH),
24.3 (CH2), 23.8 (CH2), 22.5 (CH3), 21.0 (CH2), 19.3 (CH3), 18.7 (CH3), 11.8 (CH3). Anal Calc, 
for C 37H64N20 9 C, 73.95. H, 10.73. N, 4.66. Found: C, 72.18, H, 10.56. N, 4.33. Melting point: 
112°C. The intermediate was deprotected using an excess of trifluoroacetic acid (1.6ml, 21.5 
mmol) in anhydrous chloroform for 24 hours at room temperature under an argon atmosphere 
and then concentrated in vacuo.
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N-(2-aminobutyl)-(cholesten-5’yloxy)formamide (6b)
Cholesteryl chloroformate (3.5g, 7.8 mmol) was reacted with A/-(2-aminobutyl)carbamic acid 
tertbutyl ester (8 .6  mmol). The intermediate was purified using column chromatography. The 
purified intermediate produced a 51.4% yield. 1H NMR (400MHz, CDCI3> 25°C): 5ppm = 5.31 (m, 
H-1 C=CH), 4.88, 4.77 (broad s, 1H, NH), 4.42 (m, 1H, OCH), 3.22 (m, 4H, 2xNCH2), 
cholesterol skeleton (2.32 >0.6). 13C  NMR (100.61 MHz, CDCI3) 5ppm = 122.5 (C), 74.1 (CH),
56.6 (CH), 56.1 (CH), 49.8 (CH), 42.3 (C), 41.2 (C), 39.7 (CH2), 39.5 (CH2), 37.0 (CH2), 36.6 
(C), 36.2 (C), 35.8 (CH), 31.9 (CH2), 31.8 (CH), 28.4 (CH3), 28.2 (CH2), 28.1 (NCH2), 28.0 (CH),
24.3 (CH2), 23.8 (CH2), 22.5 (CH3), 21.0 (CH2), 19.3 (CH3), 18.7 (CH3), 11.8 (CH3). Anal Calc, 
for C 35H6oN20 4 C, 73.38 H, 10.56. N, 4.89. Found: C, 73.74, H, 10.66. N, 4.92. Melting point: 
152°C.
The intermediate was deprotected using an excess of trifluoroacetic acid (1.6ml, 21.5 mmol) in 
anhydrous chloroform for 24 hours at room temperature under an argon atmosphere and then 
concentrated in vacuo.
N-(6-aminobutyl)-(cholesten-5-yloxy)formamide (6c)
Cholesteryl chloroformate (2g, 4.5 mmol) was reacted with A/-(6 -aminobutyl)carbamic acid 
tertbutyl ester (4.9 mmol) and this intermediate was then purified using column chromatography 
producing a 63.7% yield. 1H NMR (400MHz, CDCI3, 25°C): Sppm = 5.39 (m, H-1 C=CH), 4.65, 
4.54 (broad s, 1H, NH), 4.50 (m, 1H, OCH), 3.15 (m, 4H, 2xNCH2), cholesterol skeleton (2.4 - 
0.67). 13C NMR (100.61 MHz, CDCI3) 8ppm = 156.1 (C=0), 156.0 (C=0), 122.5 (C), 74.0 (CH),
56.7 (CH), 56.1 (CH), 42.3 (C), 40.7 (CH2), 39.7 (CH2), 39.6 (CH2), 36.9 (CH2), 36.5 (C), 36.2 
(C), 35.8 (CH), 31.9 (CH2), 31.8 (CH), 28.4 (CH3), 28.2 (CH2), 28.1 (NCH2), 28.0 (CH), 24.3 
(CH2), 23.8 (CH2), 22.5 (CH3), 21.0 (CH2), 19.3 (CH3), 18.7 (CH3), 11.8 (CH3). Anal Calc, for 
C ^ H e a N ^  C, 73.47. H, 10.90. N, 4.45. Found: C, 73.98, H, 10.92. N, 4.27. Melting point: 
63°C.
The intermediate was deprotected using an excess of trifluoroacetic acid (1.6ml, 21.5 mmol) in 
anhydrous chloroform for 24 hours at room temperature under an argon atmosphere and then 
concentrated in vacuo.
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Figure 2.6: Schematic of the reaction of /V-(n-aminobutyl)-(cholesten-5-yloxy)formamide 
(compound 6 ) and 2-imino-2-methoxyethyl-1-thio-a-D-mannopyrannoside (compound 5) to yield 
Mann-Cn-Chol (where n = 2, 4 or 6 )
2.3.1.3 Synthesis of Cholesten-5-yloxy-N-(4-((1-imino-2-a-thioglycosylethyl) amino) butyl) 
formamide (Mann-C4-Chol) (7a)
Compound 5 (0.75g, 3.7 mmol, 2.5 equivalents) was dissolved in pyridine containing 
triethylamine (1.5mmol). Compound 6 a (1 g, 2mmol) was added and the solution was reacted for 
24 hours at room temperature under an argon atmosphere. The reaction mixture was 
concentrated in vacuo. Mann-C2-Chol and Mann-C6 -Chol were synthesised in a similar 
manner with A/-(2-aminobutyl)-(cholesten-5-yloxy)formamide (compound 6 b) and A/-(6 - 
aminobutyl)-(cholesten-5-yloxy)formamide (compound 6 c) respectively replacing A/-(4- 
aminobutyl)-(cholesten-5-yloxy)formamide (compound 6 a) in the reaction.
2.3.1.4 Purification and Characterisation of Mannosylated Cholesterol Derivatives
Mann-C2-Chol (compound 7b), Mann-C4-Chol (compound 7a) and Mann-C6 -Chol (compound 
7c) were dialyzed for 48 hours. Briefly, dialysis tubing was prepared to remove glycerol and 
sulphur compounds by placing cut tubing in bicarbonate solution (2% w/v sodium bicarbonate 
(NaHC03) and 1mM ethylenediaminetetraacetic acid (EDTA), pH 8 .0 ) at 70°C for 10 minutes 
and rinsed with distilled water (dH20). The tubing was placed in 1mM EDTA (pH 8.0) at 70°C for 
10 minutes followed by rinsing in dH20. Mann-C2-Chol, Mann-C4-Chol and Mann-C6 -Chol were
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suspended in dH20 and dialyzed against dH20 for 48 hours. Water was replaced with fresh dH20 
after 24 hours. The compounds were then lyophilized for 48 hours and underwent analysis by 
IR spectroscopy, MS and NMR, to confirm synthesis and determine purity. IR spectra were 
recorded as KBr discs on a Mattson Genesis II CSI FTIR spectrometer in the 4000-400 cm' 1 
region. NMR spectra were acquired with a Bruker Advance DPX-400 instrument.
Mann-C2-Chol: IR (KBr, v): 3354, 2936, 2868 cm'1. 1 H-NMR (400 MHz, CDCI3): 0.6-1.9 (m, 
cholesteiyl skeleton), 2.2-2 3 (m, N-CH2), 3.2 (s, N-CH2). HR-ESI-MS m/z ([M-Hf): calculated 
for CmHbsNsOtS 708.00 found 708.4645. Mann-C4-Chol: IR (KBr, v): 3351, 2933, 2868 cm'\ 
1 H-NMR (400 MHz, CDCI3): 0.6-2.0 (m, cholesteryl skeleton), 3.0 (broad s, N-CH2). HR-ESI-MS 
m/z ([M-H]+): calculated for C 40H69N3O7S  736.49 found 736.5215. Mann-C6 -Chol: IR (KBr, v): 
3345, 2933, 2868 cm'1. 1 H-NMR (400 MHz, CDCI3): 0.6-1.9 (m, cholesteryl skeleton), 2.2 (s, N- 
CH2), 3.0 (broad s, N-CH2). HR-ESI-MS m/z ([M-H]+): calculated for C 42H73N30 7S  764.11 found 
764.5182.
2.3.2 siRNA Condensation and Complex Characterisation
siRNA was complexed with DOTAP, 25kDa PEI and protamine at various weight or 
nitrogen/phosphate (N/P) ratios in order to condense the siRNA prior to encapsulation and 
improve siRNA encapsulation efficiency by liposomes. N/P ratio is calculated using the formula 
in Table 2.4 with repeating units of 698.55g/mol and 43.1g/mol for DOTAP and PEI respectively. 
Each repeating unit corresponds to one mole of nitrogen. Protamine sulphate was of unknown 
molecular weight. Consequently weight ratios were used to prepare siRNA protamine 
complexes.
2.4: Table: N/P ratio calculation
TNI -  Number of moles of Nitrogen in D O TA P or PEI 
[P] Number of moles of Phosphate in siRN A
For optimisation of siRNA condensation, complexes were prepared by diluting 1pg siRNA in 
diethylpyrocarbonate (DEPC)-treated RNase free water up to a final volume of 25pl. The 
cationic component was prepared separately in 25|jl of RNase free water. Following a 5 minute 
incubation at room temperature siRNA and the cationic reagent were mixed by pipetting up and 
down at least 5 times and incubated at room temperature for 20 minutes.
For protamine and PEI, stock solutions of 1 mg/ml in DEPC-treated RNase free water was 
prepared and diluted appropriately in 25pl of RNase free water. DOTAP liposomes were 
prepared by dehydration rehydration with 10mg of DOTAP dissolved in Folch and rehydrated in 
1ml of RNase free water following solvent evaporation (Liposome Preparation 2.3.3). DOTAP
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suspensions were then passed 10 times through 100nm pore filters using an Avanti® syringe 
mini-extruder. DOTAP liposomes were then diluted appropriately in RNase free water.
An alternative method for siRNA-DOTAP complexation was also used. 1 mg/ml DOTAP 
solutions were prepared by dissolving the lipid in tertiary-butanol. A suitable amount of DOTAP 
was added to a fresh tube and brought up to 200|jl with tertiary-butanol (f-butanol). Separately 
1pg siRNA was diluted in RNase-free water and brought up to a final volume of 200^1. Diluted 
siRNA was added dropwise and mixed with DOTAP in f-butanol. Mixtures were frozen at -80°C 
and then lyophilized overnight. The lyophilised pellet was rehydrated in 50pl of RNase free 
water with vortexing.
2.3.2.1 Particle size and Zeta Potential
Complex size was determined by dynamic light scattering. Zeta potential was measured by 
laser Doppler electrophoresis (LDE) using the Smoluchowski theory. Complexes were diluted 
50 times in ultrapure water and 1ml was loaded into a disposable capillary cell. Sizes and zeta 
potentials were determined using a zetasizer (nanoseries, Malvern) with 5 measurements 
acquired per sample.
2.3.2.2 Gel Retardation Assay
Gel retardation assays were used to determine the minimum amount of cationic reagent 
necessary to form neutralised complexes. A 20% non-denaturing polyacrylamide (19:1 
acrylamide.bisacrylamide) Tris-borate-EDTA (TBE) gel was prepared with 30% polyacrylamide, 
TBE buffer, 10% ammonium persulfate (AP), deH20  and A/,A/,/\/,,A/,-Tetramethylethylenediamine 
(TEMED) with a 4% stacking gel using the recipe in Table 2.5. The stacking gel was prepared 
with 30% polyacrylamide, 10x TBE buffer, 10% AP, deH20  and TEMED. Blue/orange 6x 
loading dye (Promega) was used to track gel migration. Loading dye contains 0.4% orange G, 
0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10mM Tris-hydrochloride 
(HCI) (pH 7.5) and 50mM EDTA (pH 8). In a 20% polyacrylamide gel bromophenol blue 
migrates equivalent to 12bp double stranded DNA (dsDNA) while xylene cyanol migrates to the 
same point as 45bp dsDNA. Complexed siRNA is retarded in the wells and unable to enter the 
gel. 100ng of siRNA marker, free siRNA and complexed siRNA were mixed with loading dye 
and loaded onto 20% polyacrylamide TBE gels and run at 100V for 90 minutes. Gels were 
post-stained with GelStar and visualisation was obtained using a GBox.
40
Table 2.5: 20% Polyacrylamide TBE gel recipe
Ingredient 4% Stack Gel 20% Running Gel
Total volume 8 ml Total volume 20 ml
30% Polyacrylamide 800 pi 4.75ml
10x Ultrapure TBE buffer 800 pi 2 ml
10% Ammonium Persulfate 36 pi 200 Ml
Deonized Water 6 ml 7.8 ml
TEMED 8 M< 10 Ml
2.3.2.3 Fluorescence Quenching Assay
Standard curves were prepared by diluting fluorescent siRNA (AlexFluor488-siRNA) in TE buffer 
to give a curve from 0 to 50ng/ml. 1 OOjjI of fluorescein tagged siRNA (fl-siRNA) at 0, 2, 10, 50 
and 100ng/ml was added to wells of a black 96 well plate in triplicate. 5pl of complexes 
prepared in DEPC RNase free water with 1pg of siRNA and PEI were added to wells in triplicate 
in black 96 well plates and brought up to 100pl with TE buffer pH 7.5 or pH 12. Fluoresence 
was detected at 485nm excitation and 535nm emission wavelengths using a Wallac multiplate 
reader. Free siRNA was set as 100% fluorescence.
2.3.2.4 RNA Quantification
Ribogreen RNA quantitation uses a fluorescent RNA stain that can provide 200- and 1000-fold 
greater sensitivity than ethidium bromide and ultraviolet based detection. Ribogreen reagent 
binds to RNA and fluoresces with maximum excitation and emission wavelengths of 500nm and 
525nm respectively. Fluorescence can be detected at fluorescein wavelengths with detection 
as low as 1ng/ml RNA [155]. Briefly, 100pl of appropriately diluted samples and standards in 
TE buffer (10nM Tris-HCI, 1mM EDTA, pH 7.5) were added to wells of black 96 well plates in 
triplicate. Ribogreen reagent was diluted 1 in 2000 in TE buffer. 100pl of diluted ribogreen 
reagent was added to each well and protected from the light until read at fluorescein excitation 
and emission settings on a multiplate reader. Fluorescence of blank reagent was subtracted 
from sample and standard readings as recommended by the manufacturer.
Standard curves were prepared using ribosomal RNA (rRNA) standard supplied or siRNA of 
known concentration to give a curve from 0 to 50ng/ml. rRNA (16S and 23S rRNA from 
Escherichia coli (£. coli)) or siRNA was diluted in TE buffer and 100|jl at 0, 2, 10, 50 and 
100ng/ml was added to wells of a black 96 well plate in triplicate. 5pl of complexes prepared 
with 1 |jg of siRNA were added to wells in triplicate in black 96 well plates and brought up to 
100mI with TE buffer. Ribogreen reagent was diluted 1 in 2000 and 1QQyl was added to each 
well. Fluoresence was detected at 485nm excitation and 535nm emission wavelengths using a 
Wallac multiplate reader. Free siRNA was set as 100% fluorescence.
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TE buffer was adjusted to pH 12 and used to dilute ribogreen reagent in order to disrupt 
siRNA/PEI complexes [156-158] while 0.2% Triton-X100 and 1% sodium dodecyl sulfate (SDS) 
was added to wells after initial fluorescence detection and used to disrupt siRNA/DOTAP and 
siRNA/protamine complexes respectively [105, 159].
2.3.3 Liposome Preparation
Liposomes containing phospholipids, mannosylated cholesterol and cholesterol were formed by 
dehydration-rehydration. The liposome components (Table 2.11 and 2.12) were dissolved in a 
minimal volume of Folch (Chloroform:Methanol; 2:1 (v/v)) and mixed in a round bottomed flask. 
PE-Rhodamine (0.1% of mole ratio) was added to fluorescently label liposomes.
Solvents were evaporated at 40°C using a rotary evaporator (Büchi Rotavapor R200) and the 
lipid film was rehydrated in pH 7.4 Phosphate Buffered Saline (PBS; GIBCO). Following 
agitation or mixing with an equivalent mass of glass beads (1mm diameter) the system was 
allowed to hydrate overnight at 4°C resulting in large multi-lammellar liposome formation.
Passive encapsulation of siRNA was achieved by the rehydration of the thin lipid film with 
siRNA (0.5pM) or siRNA condensed with DOTAP, PEI or protamine (1 pM) in PBS. Size 
reduction of rehydrated lipids was achieved by extrusion using a LIPEX™  Thermobarrel 
Extruder or Avanti® Mini-Extruder 10 times through a polycarbonate membrane filter with 200nm 
or 400nm pores. Two polycarbonate membrane filters were used for thermobarrel extrusions 
and one membrane with 4 drain discs or filter supports were used in syringe extrusions. 
Extrusion was carried out at 60°C for D SPC containing formulations and a room temperature for 
all other formulations.
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2.3.4 Characterisation of Liposomes
2.3.4.1 Particle Size and Zeta Potential
Liposome particle size and zeta potential were measured as described in 2.3.2.1.
2.3.4.2 Transmission Electron Microscopy
For transmission electron microscopy (TEM) studies copper thin bar 200-mesh grids were 
coated with pioloform. Liposomes (2pl) were placed on the grid for 1 minute and blotted. The 
grid was negatively stained with a drop of (2% w/v) phosphotunstic acid (PTA) for 1 minute and 
again blotted followed by washing with deionized water. Thè grids were viewed the same day 
using a Hitachi H-7650 TEM.
2.3.4.3 Liposome Quantification
Liposome quantification was determined by cholesterol assay (WAKO) and/or phospholipid 
assay according to the manufacturers’ instructions, using a cholesterol oxidase and choline 
oxidase N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-domethoxyaniline (DAOS) method. A blue 
pigment is produced and absorbance measured. Standards and samples were prepared in 
triplicate using a clear 96-well plate.
2.3.4.3.1 Cholesterol Assay
A cholesterol standard curve was prepared by adding a diluted cholesterol standard to wells to 
give 0, 1, 2, 4, 8 and 12 pg/welL Fluorescent and unlabelled liposomes (8pl) were added to 
wells in triplicate. 300|jl of Chromagen reagent was added to each well. Chromagen reagent 
contains cholesterol esterase (1.6 units/mt), cholesterol oxidase (0.31 units/ml), peroxidise 
(HRP; 5.2 units/ml), DAOS (0.95 mmol/ml), 4-aminoantipyrin (0.19 mmol/ml) and ascorbate 
oxidase (4.4 units/ml). The plate was incubated at 37°C for 5 minutes. Cholesterol oxidase 
oxidises cholesterol producing hydrogen peroxide. In the presence of hydrogen peroxide 
oxidative condensation of DAOS and 4-aminoantipyrine occurs catalysed by peroxidise 
producing a blue pigment. Absorbance was read at 572nm using a Wallac multiplate reader.
2.3.4.3.2 Phospholipid Assay
A phospholipid standard curve was prepared by adding provided phosopholipid standard 
(choline chloride) to wells to give 0, 2, 3, 6, 12 and 24 jjg/well. Fluorescent and unlabelled 
DOPC containing liposomes (3pl) were added to wells in triplicate. 300|jl of Chromagen 
reagent was added to each well. Chromagen phospholipid reagent contains phospholipase D 
(0.47 units/ml), choline oxidase (250 units/ml), peroxidise (POD; 4.2 units/ml) DAOS (0.77 mM), 
4-aminoantipyrine (0.24 mM) and ascorbate oxidase (3.9 units/ml) in 50mM 2-(N-
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morpholino)ethanesulfonic acid (MES) buffer (pH 7.5). The plate was incubated at 37°C for 5 
minutes and absorbance read at 572nm using a Wallac multiplate reader.
2.3.4.4 Encapsulation Efficiency
To determine siRNA encapsulation efficiency a number of methods were applied. Firstly, siRNA 
was quantified in liposome preparations before and after liposome disruption by triton-X using a 
Ribogreen assay. Standard curves were prepared as described in 2.3.2.4. Liposomes were 
diluted to give a maximum of 100ng/ml siRNA. 10OpI of diluted liposomes was added to wells of 
a black 96-well plate in triplicate. lOOpI of a diluted ribogreen reagent was added to each well 
and fluorescence was detected as previously described. 4pl of 10% Triton-X100 was added to 
each well. Plates were incubated for 20 minutes at room temperature followed by repeated 
fluorescence detection. Secondly, unencapsulated free or condensed siRNA was removed by 
ultracentrifugation or by ultrafiltration. To determine siRNA encapsulation efficiencies in 
condensed siRNA liposome preparation unencapsulated free and condensed siRNA was 
quantified by Quant-iT ribogreen assay. Liposome preparations were centrifuged three times at 
45,000rpm for 40 minutes (DOPS liposomes) or 2 hours (DOPC and DSPC liposomes) under 
vacuum at 4°C using a Sorvall Discovery M120SE Centrifuge and S100 AT4 rotor. 
Supernatants were collected and pelleted liposomes gently resuspended in fresh PBS. Thirdly, 
using inverted centrifugal spin filters (Centrisart I, 100.000 MWCO), 500pl of liposome 
preparation was brought up to 2ml with PBS. Diluted siRNA-liposome preparations were placed 
in the spin filter outer tube and left to stand at room temperature for 5 minutes to wet the filters. 
Spin filters were centrifuged at 5000 rpm for 30 minutes at 4°C. Filtrate was collected from the 
inner chamber (Figure 2.7). Centrifugation was repeated until less than 500pl remained in the 
inner tube. siRNA complexes were disrupted using 0.2% TritonX, pH 12 TE buffer and 1% SDS 
for DOTAP, PEI and protamine respectively and siRNA quantified by Ribogreen assay.
Direction of 
ultrafiltration
Ultrafiltrate is 
collected in the 
floater insert 
tube, where it is 
readily accessible 
without removal 
of the tube.
t~ UltrafiltrateUltrafilter
Retentate
Centrifugal force
Figure 2.7: Centrisart I spin filters
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2.3.5 Aerosolisation of siRNA and Liposomes
Formulations of 10jjg/ml of siRNA in PBS were prepared. The formulations (10ml) were 
aerosolized into a glass twin stage impinger (TSI) (Figure 2.8A) at 60 liters per minute with 
either an AeroNeb® Pro nebulizer or PARI air jet nebulizer (pressure set to 2 bars) (Figure 2.8). 
PBS was added to the upper (3 ml) and lower (10 ml) stages. Washes were collected and 
concentrations were determined for each stage. Percentage respirable fraction and emitted 
doses were calculated (Table 2.6). Initially, 400nm liposomes at various concentrations 1, 2.5 
and 4.5mg/ml were nebulized with an AeroNeb® Pro nebulizer. Nebulized vapour was 
collected in a 15ml tube and percentage output of liposomes at each concentration was 
calculated. The amount of liposomes collected was determined by cholesterol and lipid assays 
described in 2.3.4.3 and output was calculated as a percentage of the liposome amount loaded 
onto the nebulizer. Similarly to siRNA nebulisation, 5ml of liposomes (4.5mg/ml) were 
aerosolised into the impinger.
Air-jet nebulisers such as PARI produce aerosols when compressed air enters the nebulizer unit 
at a high velocity breaking the liquid formulation into very small droplets. While the vibrating 
mesh or micropump nebulisers such as the AeroNeb® Pro nebulizer uses an OnQ technology 
(or electronic micropump) to produce an aerosol. This micropump consists of a vibrational 
element surrounding a domed aperture plate that contains as much as 1000 holes. When an 
electric current is applied to a vibrational element it contracts and expands therefore causing the 
mesh to move, vibrating about 100,000 times per second. The holes act as micropumps as the 
mesh vibrates bringing the liquid formulation through and generating an aerosol.
Table 2.6:
% Emitted Dose = UDDer ImDinqer Dose + Lower Imoinqer Dose x 100
Dose Loaded into the Nebuliser 1
% Respirable Fraction = Lower Imoinaer Dose x 100
Emitted Dose 1
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Figure 2.8: Set up of the (A) glass impinger apparatus with (B) AeroNeb® Pro vibrating-mesh 
and (C) PARI air jet nebulizer
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2.3.5.1 Aerosolised siRNA and Liposome Characterisation
siRNA concentration was determined using a NanoDrop 1000 Spectrophotometer. Initially, a 
series of dilutions was prepared giving siRNA concentrations of 266 (stock, 20pM), 100, 50, 25, 
12.5, 6.25, 3.125, 2 and 1 ng/pl to determine the limits of detection (LOD) of siRNA with a 
NanoDrop 1000 Spectrophotometer. 5 measurements were taken per dilution at 260nm. 
Liposome size and zeta potential were measured as described in 2.3.2.1. Liposome 
concentration was determined by cholesterol and phospholipid assays as described in 2.3.4.3.
2.3.5.2 Polyacrylamide Gel Electrophoresis
siRNA integrity post-nebulisation was assessed by gel electrophoresis. A 20% non-denaturing 
polyacrylimide (19:1 acrylamide:bisacrylamide) TBE gel was prepared as described in 2.3.2.2. 
Samples (30pl) and a siRNA marker (New England Biolabs) were loaded and the gels were run 
in 1x TBE buffer at 100V for 45 minutes followed by post-staining with GelStar (Lonza) for 30 
minutes. Visualization was obtained by UV transillumination (G:BOX, Syngene).
2.3.6 Statistics
Results are expressed as means ± standard deviation (SD). One way or two way analysis of 
variance (ANOVA) was used to test for differences between treatments with p-values < 0.05 
considered significant, < 0.01 very significant and < 0.001 highly significant.
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2.4 Results
Synthesis of intermediate products was confirmed by NMR, IR and elemental analysis and was 
carried out by Colin Burke under the supervision of Dr. James Barlow. The final Mann-C2-Chol, 
Mann-C4-Chol and Mann-C6-Chol products were dialysed and lyophilized. IR spectroscopy 
showed very similar spectra for each compound. Theoretical masses for Mann-C2-Chol, Mann- 
C4-Chol and Mann-C6-Chol are 708.5, 736.5 and 764.5 g/mol respectively. ESI-MS shows 
mass peaks at 708.5, 736.5 and 764.5 amu for Mann-C2-Chol (Figure 2.9A), Mann-C4-Chol 
(Figure 2.9B) and Mann-C6-Chol (Figure 2.9C) respectively.
A.
2.4.1 Characterisation of Man nosy lated Cholesterols
Figure 2.9 Structure of (A) Mann-C2-Chol, (B) Mann-C4-Chol and (C) Mann-C6-Chol
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2.4.2 siRNA Complexation
To improve encapsulation efficiency of siRNA in neutral liposomes siRNA was first condensed 
by complexation with DOTAP, protamine and PEI. Complexes were characterised by size and 
zeta potential. Additionally, complexes were electrophoresed to determine complexation 
efficiency. Only free or uncomplexed siRNA can run through the gel therefore a stronger band 
corresponds to a greater amount of free or uncomplexed siRNA and no band indicating 
complete complexation. Characterization was used to determine the optimal N/P or weight 
ratios to provide maximum siRNA encapsulation while attaining a small nano-scale size suitable 
for encapsulation by 20(M00nm liposomes and minimizing the positive charge introduced to the 
liposome preparations. Therefore the optimal ratios used the minimum amount of cationic 
reagent whilst achieving high encapsulation, low zeta potential and a particle size less that 
400nm.
DOTAP/siRNA complexes prepared with extruded DOTAP suspension (100% DOTAP 
liposomes) formed complexes less than 400nm with zeta potentials ranging from -39 ± 3 mV to
59 ± 11 mV (Table 2.7 and Figure 2.10A). However gel retardation assays showed low siRNA 
encapsulation even at N/P ratios up to 8 (Figure 2.11A). DOTAP-siRNA complexes prepared 
by lyophilisation of lipid and nucleic acid components in f-butanol showed improved siRNA 
complexation from N/P ratios of 5 and higher while sizes were more variable and polydisperse 
(Table 2.8). DOTAP siRNA complexes produced positive zeta potentials at N/P ratios above 3 
(Figure 2.1 OB). DOTAP siRNA complexes of N/P ratio 4 prepared by lyophilisation were 
selected for liposome encapsulation. Lyophilisation preparation showed improved siRNA 
condensation over DOTAP liposome complexation as well as lower zeta potentials. N/P ratio of 
5 gave a very positive zeta potential and therefore a ratio below this was chosen for liposome 
encapsulation.
Protamine siRNA complexes had sizes less than 400nm at weight ratios of 3 and 4 
(Protamine/siRNA (w/w)) (Table 2.9) and positive zeta potentials at and above a weight ratio of
3 (Figure 2.10C), Gel retardation assays repeatedly showed maximum complexation achieved 
at a weight ratio of 4 (Figure 2.11C). Consequently the weight ratio'of protamine:siRNA of 4 
was determined the optimum ratio for use in liposome encapsulation.
Negative zeta potentials of PEI-siRNA complexes were observed below N/P 7 (Figure 2.10D). 
At N/P 7 small sized (115.3nm and polydispersity index (PDI) 0.249) and positively charged 
(17.5 ± 5 mV) complexes were attained (Table 2.10 and Figure 2.10D). Gel retardation assay 
also confirmed optimal complexation of siRNA at N/P 7 (Figure 2.11D) and this ratio was used 
for liposome siRNA encapsulation.
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Table 2.7: Sizes of DOTAP liposome-siRNA complexes (means ± SD, n = 3)
Complex Ratio Average Diameter (nm) PDI
0:1 135.2 0.254
1:1 298.9 0.246
2:1 154.6 0.224
3:1 351.8 0.173
4:1 205.8 0.131
5:1 300.9 0.237
6:1 156.8 0.091
7:1 216.4 0.174
8:1 212.9 0.276
10:1 148.7 0.137
Table 2.8: Sizes of DOTAP-siRNA complexes prepared by lyophilisation. (means ± SD, n = 
3).
Complex Ratio Average Diameter (nm) PDI
1:1 4431.3 1
5:1 584.9 0.515
7.5:1 297.7 0.354
10:1 1473 0.709
12.5:1 721.5 0.618
15:1 339.5 0.627
.9: Sizes of Protamine-siRNA complexes (means ± SD, n = 3)
Complex Ratio Average Diameter (nm) PDI
1:1 491.7 0.267
2:1 415.4 0.376
3:1 272 0.297
4:1 386.9 0.401
6:1 550.7 0.365
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Table 2.10: Sizes of PEI complexes, (means ± SD, n = 3)
Complex Ratio Average Diameter (nm) PDI
VA 235.6 0414
3:1 146.5 0.23
5:1 356.1 0.189
7:1 115.3 0.249
10:1 721.1 0.216
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Figure 2.10: Zeta potentials of (A) DOTAP liposome siRNA complexes, (B) DOTAP-siRNA 
complexes prepared by lyophilisation, (C) protamine:siRNA complexes and (D) PELsiRNA 
complexes at a range of N/P or weight ratios.
Data expressed as means ± SD (n = 3)
51
A.
1 2 3 8 9 10
- - 6 7 ■ 8 9  ^ 10
B.
Figure 2.11: 20% non-denaturing polyacrylamide gels loaded with 100ng siRNA per well. Gel A 
shows the siRNA marker (Lane 1), siRNA stock (Lane 2) and DOTAP liposome siRNA 
complexes at N/P ratios of 1, 2, 3, 4, 5, 6, 7 and 8 (Lanes 3 -  10). Gel B shows the siRNA 
marker (Lane 1), siRNA stock (Lane 2) and DOTAP siRNA complexes rehydrated after 
lyophilisation at N/P ratios of 1, 2.5, 5, 7.5, 10, 12.5 and 15 (Lanes 3 -  9). Gel C  shows the 
siRNA marker (Lane 1), free siRNA stock (Lane 2) and Protamine siRNA complexes at N/P 
ratios of 2, 3, 3.75, 4, 4.25, 4.5, 4.75 and 5 (Lanes 3 - 1 0 ) .  Gel D shows the siRNA marker 
(Lane 1), siRNA stock (Lane 2) and PEI siRNA complexes at N/P ratios of 1, 2, 3, 4, 5, 6, 7 and 
10 (Lanes 3 -1 0 ).
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Free or uncomplexed siRNA was quantified using Ribogreen assay. This is an ultrasensitive 
assay, detecting RNA concentrations as low as 1ng/ml. Free siRNA was undetectable at all 
weight ratios of protamine-siRNA complexes (Figure 2.12A). Gel retardation assays as well as 
zeta potentials at low N/P ratios (below 4) indicate the presence of uncomplexed siRNA. 
Therefore protamine must be interfering with the assay resulting in fluorescence intensities just 
above background fluoresence in each sample.
As was observed by gel retardation assay PEI-siRNA complexes at and above N/P ratio of 7 
achieve maximum encapsulation of siRNA with little or no free siRNA detectable (Figure 2.12B - 
D). At pH 12 PEI-siRNA complexes should disassociate which has previously been reported by 
Merkel et af. (2009) [158]. Figure 2.12C shows little disruption of the complexes at pH 12 
compared to pH 7.5. Assays were preformed in triplicate three times. However samples using 
fluorescently tagged siRNA were diluted in pH 12 TE buffer and complete disassociation was 
observed (Figure 2.12D). Additionally as the N/P ratio increased above 5 the fluorescence 
intensity began to rise again. This has previously been observed in other studies [158, 160] and 
is attributed to a rearrangement of the nucleic acid within the complexes at higher N/P ratios.
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Figure 2.12: Fluorescent binding assays quantifying free siRNA following siRNA complexation. 
Quant iT ribogreen assay shows the percentage of free siRNA following complexation with (A) 
protamine (n =1 ) at a range of weight ratios and (B -  C) with PEI (n = 3) at various N/P ratios at 
pH 7.5 and pH 12. Fluorescently tagged siRNA (n = 1) complexed with PEI at various N/P ratios 
was also quantified at pH 7.5 and pH 12.
Data represented as means ± SD
2.4.3 Liposome Preparation and Characterisation
A range of non-mannosylated and mannosylated liposomes containing DOPS, DOTAP, DOPC, 
DSPC, Mann-C2-Chol, Mann-C4-Chol, Mann-C6-Chol and cholesterol in the molar ratios shown 
in Tables 2.11 and 2.12 were prepared. DOPS is an anionic lipid that could offer an advantage 
for targeting macrophages while DOPC or D SPC and DOTAP liposomes act as its neutral and 
cationic comparisons respectively. DOPC liposomes were used as a control for the 
mannosylated systems.
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Table 2.11: Non-mannosylated Liposomes Prepared
Liposome
Nomenclature DOPC
Molar Ratios of Constituent Lipids 
DOPS DSPC DOTAP Chol
DOPS
DSPC
DOPC
DOTAP
70
60
70
30 50
30
40
30
20
Table 2.12: Mannosylated Liposomes Prepared
Liposome Molar Ratios of Constituent Lipids
Nomenclature DSPC or DOPC Chol Mann-C2-Chol Mann-C4-Chol Mann-C6-Chol
MC2C-2.5 60 or 70 37.5 or 27.5 2.5 - -
MC2C-5 60 or 70 35 or 25 5 - -
MC2C-7.5 60 or 70 32.5 or 22.5 7.5 - -
MC4C-2.5 60 or 70 37.5 or 27.5 - 2.5 -
MC4C-5 60 or 70 35 or 25 - 5 -
MC4C-7.5 60 or 70 32.5 or 22.5 - 7.5 -
MC6C-2.5 60 or 70 37.5 or 27.5 - - 2.5
MC6C-5 60 or 70 35 or 25 - - 5
MC6C-7.5 60 or 70 32.5 or 22.5 - _ 7.5
Cholesterol quantification was used to determine total liposome concentration after extrusion. 
Total loss of liposomes due to extrusion was less than 50% and 15% by thermo-barrel extrusion 
and syringe extrusion respectively. In the case of DOPC containing liposomes a phospholipid 
assay for phosophatidylcholine was also used for quantification.
2.4.3.1 Encapsulation efficiency
Encapsulation efficiencies of free siRNA in neutral and mannosylated liposomes ranged from 0 
to 10%. With the incorporation of a small proportion of cationic lipid DOTAP into the liposome 
this encapsulation efficiency was improved to -30%  but was not reproducible. Additionally, as 
DOTAP is associated with toxicity the use of DOTAP in the liposome structure is undesirable. 
Consequently, condensation of siRNA was achieved by complexation with DOTAP, PEI and 
protamine prior to encapsulation in liposomes. To measure encapsulation efficiency 
unencapsulated (free and condensed) siRNA was separated from liposomes by 
ultracentrifugation or ultrafiltration. However, quantification of siRNA encapsulated was 
unsuccessful. Ultracentrifugation separated free and condensed siRNA from liposomes 
(determined by dynamic light scattering). Ultrafiltration separated free siRNA from condensed
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siRNA and siRNA encapsulated in liposomes. Formulations showed encapsulation efficiencies 
up to 98% however this did not take into account condensed siRNA that could not be detected 
by this technique. Various methods were used to disrupt complexes but either interfered with 
the RNA quantitation assay or complete disruption of the complexes could not be achieved. 
Both protamine and SD S interfered with the RiboGreen assay. Increased pH did not 
disassociate PEI-siRNA complexes (Figure 2.12C). And DOTAP condensation of siRNA 
produced very variable encapsulation results.
2.4.3.2 Particle Size and Zeta Potential
Particle size was recorded for each batch of liposomes prepared to assess the effectiveness of 
size reduction and liposome stability. Average sizes for non-man nosy lated liposomes extruded 
through 200nm pore filters were below 200 nm with PDI between 0.066 and 0.254 (Table 2.13).
Table 2.13: Non-mannosylated liposome particle sizes
Liposome Average Size Polydispersity
(d50 nm) Index (PDI)
DOPS 150 ± 2 0.101
DSPC 196 ±37 0.254
DOPC 168 ± 1 0.118
DOTAP 137 ± 5 0.066
Mannosylated liposomes showed higher average diameters and PDI compared to non- 
mannosylated liposomes (Table 2.14). Size reduction appeared to be less problematic using 
DO PC than DSPC.
56
Table 2.14: Mannosylated liposome particle sizes
Liposome Lipid Average Size Polydispersity
(dso nm) Index (PDI)
MC2C-2.5 D SPC 165 ± 6 0.16
DOPC 173 ± 3 0.119
MC2C-5 DSPC 203.6 0.351
DOPC 167 ± 2 0.126
MC2C-7.5 DSPC 266 ±14 0.39
DOPC 146 0.15
MC4C-2.5 DOPC 176 ± 3 0.139
MC4C-5 DSPC 2073.7 0.476
DOPC 173 ± 6 0.133
MC4C-7.5 DOPC 179 ±34 0.08
MC6C-2.5 DOPC 171 ± 3 0.126
MC6C-5 DOPC 169 ±1 0.124
MC6C-7.5 DOPC 164 ± 4 0.095
Size distribution showed single peaks for most extruded liposomes (Appendix). Multiple peaks 
were observed in D SPC composed mannosylated liposomes. Increasing the concentration of 
mannose incorporated corresponded with more variable size distribution [115]. However, 
DOPC based liposomes did not exhibit this problem. Consequently liposomes composed with 
DO PC were used in in vitro studies. Anionic, neutral and cationic liposomes stored at 4°C were 
stable for up to one month (see Appendix).
Optimum condensation of siRNA by the cationic reagents generally produced complexes 
greater than 200nm in size (with the exception of PE) siRNA complexes). Cell uptake studies 
(3.4.2) showed optimal size for liposome uptake to be between 200 and 400nm. Consequently 
following passive encapsulation of condensed siRNA, liposomes were extruded through 
polycarbonate filters with 400nm pores. Zeta potentials of liposomes composed of 50% cationic 
lipid DOTAP were recorded and ranged from 37.6 to 39.7 mV. Anionic liposomes had a surface 
charge of - 45mV and mannosylated liposomes incorporating 10% DOTAP had a zeta potential 
of 19mV.
Electron micrographs were also used to confirm liposome size. Figure 2.13 shows DOPS 
liposomes visualised by TEM using the negative stain PTA. Liposomes appear spherical and of 
about 200nm in diameter confirming sizes determined by dynamic light scattering. Alternative 
staining could be used such as uranyl acetate (2% w/v) to increase contrast. This stain is 
typically used for imaging liposomes. Some fusion can also be seen (Figure 2.13B).
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Figure 2.13: Transmission electron microscopy images of DOPS:Chol (7:3) liposomes at 100 kV 
high voltage and 50,000x magnification negatively stained with 2% phosphotunstic acid (PTA).
2.4.4 Aerodynamic Study of siRNA Aerosolised Using Nebulisers
For local siRNA delivery to the lung the siRNA must be aerosolised. In order to conserve stock 
siRNA, due to its expense, it was necessary to determine the lowest concentration that could be 
detected using the NanoDrop 1000 spectrophotometer and from this work out the minimum 
amount to be loaded into the impinger system (that could still be detected later after further 
dilutions). At this point a RiboGreen assay was not available. According to the NanoDrop 
manufacturer, detection of nucleic acids range from 2 to 10Ong/pl (± 2ng/pl) and siRNA as dilute 
as 2ng/[jl was detectable although accuracy became quite low below concentrations of 
6.25ng/pl (Appendix). The TSI was set up with a minimum volume of buffer in each of the 
stages. Washings were also collected with just 5ml of PBS to minimise further dilutions of the 
siRNA.
2.4.4.1 Twin Stage Impinger (TSI) Deposition of Aerosolised siRNA
Formulations of siRNA (100pg in 10ml) were aerosolised using a PARI air jet nebuliser or 
AeroNeb vibrating mesh nebuliser device into a glass impinger. The time taken to aerosolise 
the 10ml formulation for each device was 135 and 28 minutes for the PARI and AeroNeb 
devices respectively. The amount of siRNA deposited in the devices, “throat” section, stage A 
and stage B of the twin impinger was determined. The deposition patterns represented in 
Figure 2.14 show the percentage of deposited siRNA of total loaded siRNA detected.
The highest level of siRNA in the PARI impinger system remained in the device (79.7% ± 2.3) 
with low quantities detected in the throat (8.4% ± 0.4), stage A (3.9% ± 0.6) and stage B (8.1% ± 
2.1). The AeroNeb nebuliser shows the higher percentage of siRNA being deposited at stage B 
(64.2 % ± 5 .1 ) while stage A (12.2% ±1.1), throat (12.3%±1.2) and the device (12.3%±1.5) 
contain similar low levels of siRNA deposition.
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Respirable and emitted doses of siRNA with each nebuliser were calculated (Table 2.15). The 
AeroNeb nebuliser showed a higher respirable fraction (63.2% ± 3.4), respirable dose (50.7^/g ± 
4.8) and emitted dose (87.7% ± 1 .5  and 70.4pg ± 4.8) than the PARI nebuliser (8.1% ±2.1, 
10.1pg ± 2.8, 20.3% ± 2.3 and 25.4pg ± 3.2 respectively).
A. B.
T S I Stage T S I Stage
Figure 2.14: Deposition patterns of siRNA by the (A) PARI air jet and (B) AeroNeb vibrating 
mesh nebulisers. Data represented as mean percentages of total siRNA ± SD.
Table 2.15: Respirable and Emitted Doses of siRNA Data represented as means ± s d . (n = 3)
Device Respirable Fraction (%) Respirable Dose (pg) Emitted Dose (%) Emitted Dose (pg) 
PARI 8.1 ±2.1 10.1 ±2.8 20.3 ±2.3 25.4 ± 3.2
AeroNeb 63.2 ± 3.4 50.7 ±4.8 87.7 ± 1.5 70.4 ±4.8
2.4.4.2 Post-Aerosolisation Stability
To assess siRNA integrity after dilution in PBS and aerosolisation, samples from the impinger 
were electrophoresed on a 20% non-denaturing polyacrylamide gel [161-163]. A siRNA marker 
containing siRNA of 17, 21 and 25bps in length was loaded as a control. The level of the 
loaded samples corresponds to 21 bp the length of siRNA used. One band was visualised per 
lane (Figure 2.15). Relative band intensities are consistent with quantities detected by 
spectrophotometry with the AeroNeb Stage B and PARI device samples having the highest 
intensity (and highest % deposition). Smearing can be seen in lanes due to siRNA degradation 
particularly following nebulisation (Figure 2.15).
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Figure 2.15: siRNA integrity post-nebulisation assessed using 20% non-denaturing 
polyacrylamide gels. The gels show the siRNA marker (lane 1), PBS alone (lane 7), siRNA 
diluted and stored in PBS (lane 2) and siRNA collected after aerosolisation (lanes 3 - 6 )  by 
AeroNeb Nebuliser (Gel A) and by the PARI air-jet nebuliser (Gel B).
2.4.5 Aerodynamic Study of Liposomes Aerosolised Using Nebulisers
2.4.5.1 TSI Deposition of Aerosolised Liposomes
Liposomes were aerosolised using a PARI air jet nebuliser or AeroNeb vibrating mesh nebuliser 
device into a glass impinger. The time taken to aerosolise 1 ml of liposomes for each device 
was 7.98 ± 4 minutes and 2.05 ± 0.2 minutes for the PARI and AeroNeb devices respectively. 
The amount of liposomes deposited in the devices, “throat” section, stage A and stage B of the 
twin impinger was determined by assay. The deposition patterns represented in Figure 2.16 
show the percentage of deposited liposomes of total liposomes loaded. Overall liposomes 
nebulised via the air jet PARI nebuliser remained in the device or stage B of TSI whilst aerosols 
generated by the AeroNeb deposited predominantly in Stage B of TSI with minimal residual 
volume in the device. Furthermore little of the liposome preparation was lost during 
aerosolisation by the AeroNeb nebuliser with almost all loaded liposome being recovered from 
the system post-nebulisation (determined by assay). However, over 50% of loaded 
preparations escaped the twin impinger system during nebulisation by the PARI air jet
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nebuliser. This also highlights the efficiency of the vibrating mesh nebuliser over the air jet 
device for liposome lung delivery.
Nébulisation via the PARI nebuliser resulted in the highest proportion of DOPS liposome 
preparations remaining in the device (Figure 2.16A). The vibrating mesh nebuliser was more 
efficient delivering 35.7 ± 23.9 % DOPS liposomes to TSI Stage B (the deep lung) but also 
depositing 25.7 ± 17.1 % in TSI Stage (Figure 2.16B). Consequently, the emitted dose by the 
AeroNeb device was 89.3 ± 0.4 % with a respirable fraction of 46.4 ± 26.4 % (Table 2.16). 
Deposition patterns for DOPC and mannosylated MC6C liposomes were similar to DOPS 
liposome preparations but with greater respirable doses and reduced loss of liposome 
preparation from the system following PARI air jet nébulisation. Deposition (Figure 2.16C) of 
neutral DOPC liposomes was greatest in stage B with 18.3 ± 18.2 %. AeroNeb nébulisation 
lead to 56.3 ± 3.4 % deposition of DOPC liposome preparation in Stage B (Figure 2.16D). 
Emitted doses of 56.9 ± 22.4 % and 90.5 ± 2.1 % and respirable fractions of 45.8 ± 24.9 % and
69.2 ± 18.6 % were determined for DOPC liposome nébulisation via PARI and AeroNeb devices 
respectively (Table 2.16).
Mannoyslated liposomes composed with 7.5% Mann-C6-Chol were also aerosolized and 17.6 ±
4.7 %, 3.6 ± 1.7 % and 13.4 ± 9.1 % were deposited in the device, Stage A and Stage B via the 
PARI device respectively (Figure 2.16E and F). The AeroNeb nebulizer resulted in 2.8 ± 1.5 %,
13.7 ± 10.7 and 55.5 ± 20.4 % deposition of Mannosylated liposomes in the Throat stage, Stage 
A and Stage B respectively. 5.5 ± 1.1 % of mannosylated liposome preparations remained in 
the device. The liposome doses emitted from the PARI and AeroNeb devices were 48.7 ± 17.8 
% and 92.8 ± 2.1 % with 37.6 ± 22.9 % and 70.6 ± 19.8 % respirable respectively (Table 2.16).
Minimal liposome escape from the TSI system was obtained with AeroNeb device while over 
50% of liposome formulations were lost via PARI nébulisation. Additionally, the AeroNeb device 
was more efficient at delivering liposome formulations to TSI Stage B with least residual volume 
in the device. Deposition patterns of anionic, neutral and mannosylated liposomes also differed 
with mannosylated liposomes achieving the highest respirable fraction via the AeroNeb device.
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Figure 2.16: Twin Stage Impinger (TSI) Liposome Deposition Patterns by PARI air jet and 
AeroNeb nebulisers. DOPS liposome deposition by (A) PARI and (B) AeroNeb nebuliser, 
DOPC liposome deposition by (C) PARI and (D) AeroNeb nebuliser and MC6C liposome 
deposition by (E) PARI and (F) AeroNeb nebuliser represented as percentage of total loaded 
liposomes.
Table 2.16: Respirable and Emitted Doses of DOPS Liposomes
Liposome Device Respirable Fraction (%) Respirable Dose (jjg) Emitted Dose (%) Emitted Dose (pg)
DOPS PARI 23.8 ± 4 .3 2.6 ±2.1 31.6 ±1 5 .3 3.8 ± 3 .8
AeroNeb 46.4 ± 26.4 35.7 ± 23.9 89.3 ± 0 .4 66.3 ± 8.1
DOPC PARI 45.8 ± 24.9 18.3 ±18 .2 56.9 ± 22.4 21.8 ± 19.7
AeroNeb 69.2 ±1 8 .6 56.3 ± 3.4 90.5 ±2 .1 75.6 ± 14.2
MC6C PARI 37.6 ± 22.9 13.4 ±9 .1 48.7 ±1 7 .8 17.2 ± 7 .6
AeroNeb 70.6 ± 19.8 55.5 ± 20.4 92.8 ±2 .1 72.1 ± 8 .2
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2.4.5.2 Effect of Nébulisation of Liposome Properties
In studies following nébulisation liposomes are generally evaluated for changes in size, zeta 
potential and morphology through TEM and drug release. It is important that liposomes are not 
only delivered to the deep lung efficiently for alveolar macrophage targeting but also reach their 
destination intact to reduce drug loss. Consequently the characterisation of liposomes 
deposited in Stage B is most important. Nébulisation greatly affected size and surface charge 
of empty liposomes both of which are good indicators of particle stability. Changes were 
different for anionc, neutral and mannosylated liposomes and different for each device.
Anionic (DOPS) liposomes increased in size following deposition within the impinger system. 
Liposomes remaining in the device showed a marginal decrease in size. Nébulisation via the 
AerNeb device resulted in an increase in size almost two-fold from pre-nebulised DOPS 
liposomes reaching TSI Stage B (p < 0.001). The increase was higher than PARI aerosolised 
DOPS liposomes. Zeta potential of DOPS liposomes aerosolised by AeroNeb nebuliser 
remained unchanged (Figure 2.17).
DOPC liposomes showed altered mean diameter following PARI air-jet nébulisation with less 
dramatic effects brought on by AeroNeb nébulisation (Figure 2.17). Stage B deposited DOPC 
liposomes aerosolised by the AeroNeb device were equivalent to pre-nebulised liposomes while 
PARI aerosolisation increased size from 623.6 ± 301 nm to 893.4 ± 501.2 nm. Overall for 
DOPC liposomes sizes between batches and runs were variable. Zeta potentials were all 
negative but close to neutrality of 0 mV. PARI aerosolised liposomes recovered from the device 
and Stage B showed the greatest degree of difference in zeta potential to pre-nebulised 
liposomes (p < 0.001).
Mannosylated liposomes were most affected by nébulisation via the vibrating mesh AeroNeb 
device (Figure 2.17). Liposome size was increased in all stages whereas PARI aerosolised 
liposomes reaching Stage B showed little difference in size compared to pre-nebulised 
liposomes. More significantly nébulisation affected surface charge (p < 0.001). Mannoslyated 
liposomes were composed of neutral lipid DOPC (70%), cholesterol (22.5%) and Mann-C6-Chol 
(7.5%). The addition of the mannosylated cholesterol to the formulation changed the particle 
charge from neutral to positive. The decrease in zeta potential of the mannosylated liposomes 
particularly in Stage A and Stage B of the impinger system suggests alteration and perhaps loss 
of the liposome mannosylated coating.
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Figure 2.17: Size and zeta potentials of nebulised liposomes. Anionic (DOPS), neutral (DOPC) 
and mannosylated (MC6C) liposomes were nebulised using either an air-jet PARI ( B  ) or 
vibrating mesh AeroNeb ( ) nebulising device into a twin-stage impinger (TSI). Liposomes
were recovered from the devices and each stage of the impinger corresponding to “Throat”, 
upper lung (Stage A) and lower lung (Stage B) post-nebulisation and characterised by size (nm) 
and zeta potential (mV). A dashed line indicates the size or zeta potential of corresponding pre­
nebulised liposomes. Data represented as means ± SD. Statistical significance was determined 
by two-way ANOVA vs pre-nebulised liposomes (* p < 0.05, ** p < 0.01, *** p < 0.001)
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Liposomes encapsulating siRNA were also assessed but not coupled with the twin stage 
impinger. DOPS, DOPC and mannosylated liposomes encapsulating PEI/TNFa siRNA 
complexes were nebulised using an AeroNeb vibrating mesh nebuliser. These liposomes were 
selected as the siRNA-liposome model for nébulisation as they showed good in vitro 
transfection efficiencies (Chapter 3) and the effect of nébulisation would be more relevant. 
Liposomes encapsulating siRNA showed little change in size or zeta potential pre- and post- 
nebulisation particularly compared to empty liposomes (Figure 2.17). siRNA liposomes were 
not impinged due to limited size of volume preparation, difficulty in determining encapsulation 
efficiency and siRNA expense. Liposomes were nebulised using the AeroNeb nebuliser and 
immediately collected. Changes in size and surface charge were not significant. The mean 
diameter of anionic siRNA DOPS liposomes decreased from 403.7 ± 5.4 nm to 382.7 ± 3.6 nm 
with an increase in surface charge from -73.7 ±1.7  mV to -69.9 ±1.4  mV. DOPC liposomes 
encapsulating siRNA showed the least stability with an increase in size from 620.7 ± 13.3 nm to
792.5 ± 35.4 nm. Zeta potential of siRNA DOPC liposomes also increased 1.5 ± 0.3 mV to 4.5 
± 0.2 mV. Mannosylated liposomes encapsulating siRNA also showed an increase in size but 
not as substantial as uncoated DOPC liposomes. Mean diameter increased to 352 ± 2.2 nm 
from 310±3.7nm  while zeta potential decreased from 56.8 ± 0.9 mV to 54.1 ± 1.5 mV.
Previously, gel electrophoresis of nebulised naked siRNA showed signs of degradation (Figure 
2.15) with single yet smeared bands per lane following nébulisation by the PARI and AeroNeb 
devices. DOPS, DOPC and MC6C liposomes encapsulating PEI/siRNA complexes were also 
assessed by gel electrophoresis with the dual purposes of evaluating encapsulated siRNA 
integrity and to give an indication if nébulisation is associated with siRNA leakage or release 
from the liposomes. Before nébulisation a very faint band of 21 bp corresponding to siRNA can 
be visualised from the DOPS liposomes. siRNA is not detected following treatment with 1% 
SD S (or 0.3% Triton X, data not shown). The presence of siRNA in the pre-nebulised and post­
nebulised DOPS sample in Figure 2.18A could be due to liposome instability. Following 
nébulisation siRNA was detected only in lanes loaded with DOPS liposomes. This suggests 
DOPC and mannosylated liposomes are more stable formulations than the siRNA 
encapsulating DOPS liposomes and therefore more suitable for nébulisation.
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Figure 2.18: Polyacrylamide gels. DOPS, DOPC and mannosylated (MC6C) liposomes 
encapsulating siRNA complexed with PEI were nebulised using an AeroNeb Pro nebuliser. (A) 
show liposomes pre-nebulisation and (B) show formulations post-nebulisation. Liposomes were 
lysed using 1% SDS.
6 6
2.5 Discussion
Liposomes have been used to entrap molecules for almost half a century [86] and have since 
developed into carriers for drug delivery offering improved dosing, controlled release, targeting 
and biocompatibility over free drug and many other types of carriers. A carrier system for siRNA 
therapy is essential as siRNA can not cross the cell membrane due to its size and charge. 
Cationic liposomes have been the most extensively researched for siRNA and other nucleic 
acid delivery in the form of lipoplexes. However toxicity, immune activation and poor in vivo 
transfection have led to a need for alternative neutral and anionic lipid formulations for siRNA 
delivery to provide safe, non-toxic and biocompatible formulations. Inhalation as a therapeutic 
route allows rapid clinical response with minimal system side-effects as therapeutics can be 
delivered in low doses directly to the target organ [136].
A range of control (DOPC, D SPC and DOTAP) and targeted (DOPS and mannosylated) 
liposomes were prepared (Tables 2.11 and 2.12). Non-mannosylated liposomes particularly 
those composed of DOPC and DOPS were very reproducible to manufacture with each batch 
differing only by a few nm in mean diameter and having low PDI. A low PDI indicates 
uniformity. High PDI could signify aggregation, contamination or inefficient sizing [164].
Initially mannosylated liposomes included the lipid D SPC as a constituent. Use of this lipid has 
been applied in previous mannosylated liposome studies [115, 165]. DSPC is a neutral lipid 
with a high phase transition temperature (60°C). Characteristic phase transition temperatures 
(Tc) are reliant on both the length and saturation of the lipids fatty acid chains generally ranging 
from -20°C to 90°C [90]. Lipids tend to be rigid and ordered below their Tc (gel phase) and in a 
liquid crystalline state (fluid phase) above the Tc [90]. Therefore a benefit of a high Tc which is 
above physiological temperature (37°C) is reduced bilayer fluidity and consequently a less leaky 
liposome and higher stability in vivo [166]. As a result hydration and extrusion must be carried 
out above this temperature. Sizing of D SPC liposomes gave mean diameters less than 200nm 
with PDI as high as 0.254. In all cases more than one peak was present, typically a second 
peak over 1000nm.
Size reduction of mannosylated liposomes containing D SPC was difficult. Extrusions were 
increased but multiple peaks and high PDI were still recorded. In many cases, higher 
concentrations of mannosylated cholesterol in the preparation meant sizing measurements 
were more variable and the PDI higher. Mean sizes per reading ranged from 165nm to 2074nm 
with PDI from 0.16 to 0.467. This suggests aggregation is occurring and is most likely due to 
the presence of mannosylated cholesterol. The addition of Mann-C4-Chol and Mann-C2-Chol 
made uniform size reduction more difficult. Wijagkanalan, et al. (2008) reported PDI of similar 
mannosylated liposomes ranging from 0.14 to 0.35 [115]. It is possible the high temperatures 
required for D SPC may also be having an effect on the mannosylated cholesterol. Liposomes 
were subsequently prepared substituting DOPC [167] for D SPC to eliminate any problems 
caused by temperature. Reproducible formulations were prepared with sizes less than 200nm
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and low PDI using DOPC. Thus mannosylated DOPC based liposomes were assessed in vitro 
in Chapter 3. Although the Tc of DOPC is -20°C the incorporation of cholesterol, which greatly 
affects bilayer fluidity, at a molar percentage of 30% can compensate for a low phase transition 
to form liposomes with better stability and reduce leakiness [90] in vivo. High temperatures may 
also have negative effects on siRNA stability.
Liposomes were loaded with free siRNA and encapsulation efficiencies determined. Cationic 
formulations are generally used for nucleic acid delivery as high encapsulation can be achieved 
by the complexation of positively charged lipids and negatively charged nucleic acid [92]. 
Encapsulation of free siRNA was low and irreproducible. However the incorporation of a small 
percentage of (10%) DOTAP [168] into the liposome itself improved the encapsulation efficiency 
up to 30%. It would be preferable to avoid the use of a cationic surface charge on the 
liposomes therefore pre-complexation or condensation of siRNA with a cationic lipid or polymer 
was carried out to decrease possible toxicity and improve encapsulation efficiency in targeted 
liposomes.
Three different cationic reagents were evaluated for siRNA condensation; DOTAP, protamine 
and PEI. Through size, zeta-potential and electrophoresis analysis optimal condensation 
parameters were found and condensed siRNA was encapsulated into liposomes. Studies have 
used triton X-100 disruption in combination with ribogreen assay to determine encapsulation 
efficiencies of liposomes loaded with protamine siRNA complexes [169] reporting 90% 
encapsulation efficiency. Huang et ai. (2009) also incorporated calf thymus DNA into 
complexes with protamine:siRNA weight ratio of 1.2 [169]. However, repeated ribogreen 
assays of protamine siRNA complexes showed protamine interfered with the assay at all weight 
ratios. Additionally triton X-100 and SD S did not disassociate complexes. Other studies have 
used fluorescently tagged siRNA to determine encapsulation efficiencies by simply detecting 
fluorescence intensities in formulations before and after disruption by for example triton X-100 
or separated from liposomes by filtration, ultracentrifugation or size exclusion columns [98, 170, 
171]. Figure 2.12D shows fl-siRNA complexed with PEI disassociates at pH 12. Merkel et a/. 
(2009) found at higher N/P ratios that fluorescence intensity increased and was not 
representative of the amount of free or uncomplexed fl-siRNA present [158]. Consequently a 
method to determine encapsulation efficiency of siRNA by liposomes could not be optimised.
Targeting to alveolar macrophages involves both cellular and anatomical targeting by means of 
inhalation. Aerosolisation of formulations is required for local delivery to the lungs and was 
characterised in advance of in vivo testing. The nebulisers evaluated represent the early and 
more recent products available for aerosolisation. AeroNeb® Micropump nebulisers are 
claimed not to disrupt or damage the molecular integrity of formulations and can aerosolise a 
wide range of formulations (Aerogen Ltd.). Liposome nébulisation has frequently been 
assessed using the TSI system coupled with jet nebulisers such as PARI LC plus [140, 146], or 
ultrasonic/mesh/electronic nebulisers including AeroNebPro-4 and -8 [146,147], and Omron NE 
U07B [143]. To date, while mannosylated liposomes and siRNA liposomes have been
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aerosolised for direct delivery to animal models, no aerosolisation data has been published. 
AeroNeb Pro nebuliser has been used to evaluate aerosolisation of siRNA polyester 
nanoparticles [153]. Additionally, Vyas et al. (2003) characterized anionic (incorporating DCP) 
and mannosylated (MBSA coated) liposome aerosols using a pressurized packed system [121].
siRNA is expensive and labile and therefore an efficient means of delivering it is critical. Overall 
the AeroNeb nebuliser was shown to be more efficient than the PARI device for aerosolising 
naked siRNA and a range of liposomes. Over 50% of liposome preparations were not 
recovered from the TSI system following aerosolisation by the PARI Air-jet device. During set 
up of naked siRNA aerosolisation via PARI nebuliser one side of the T  -piece was attached to 
the “mouth” of the twin impinger and the other side sealed with parafilm to prevent escape of the 
aerosol. The omission of this step would explain the difference in the amount of loaded 
preparation recovered post nébulisation between naked siRNA and empty liposomes. 
Mannosylated liposomes deposited in TSI Stage B showed good stability in terms of size but a 
change in zeta-potential from positive to negative indicating damage to the mannosylated 
coating following nébulisation.
Gel electrophoresis showed slight leakage of siRNA from DOPS liposomes which was 
increased following AeroNeb nébulisation. Release of siRNA from DOPC or mannosylated 
liposomes was not detected pre- or post-nebulisation. This indicates DOPS liposome instability 
both pre- and post-nebulisation. Nebulised DNA encapsulating liposomes have been assessed 
in various studies and collected directly in glass tubes [140, 143], using a reflux reservoir [141], 
Anderson casade [143] or nebulised directly onto cells [144]. Nébulisation has previously been 
reported to damage naked DNA with liposomes affording some protection to maintain functional 
nucleic acids post-nebulisation. A comparison study between air-jet and ultrasonic nébulisation 
of PEGPEI-DNA complexes determined ultrasonic nébulisation to be a milder method for 
aerosolisation [172]. Nguyen et al. (2008) nebulised siRNA encapsulating polyester 
nanoparticles using an AeroNeb Pro nebuliser and noted changes in particle size and 
transfection efficiencies due to nebùlisation which was dependent on the formulation [153],
A range of liposomes designed to target alveolar macrophages were prepared including DOPS 
and mannosylated liposomes targeting macrophage scavenger and mannose receptors 
respectively. Mannosylated cholesterol derivatives Mann-C2-Chol, Mann-C4-Chol and Mann- 
C6-Chol, differing in the cholesterol mannose linker length, were synthesized and incorporated 
into liposomes composed of neutral (DOPC) lipid and cholesterol. Differences in linker length 
have previously been assessed and may influence interaction with the mannose receptor [173, 
174]. Various strategies for efficient encapsulation of siRNA into anionic and neutral liposomes 
were evaluated. Optimal siRNA liposomal systems were finally nebulised and assessed for 
Stability and deep lung delivery. Nébulisation of empty liposomes showed some instability 
perhaps due to liposome fusion and damage to mannosylated coating. In conclusion, targeted 
liposomes were manufactured and a means of encapsulating siRNA was developed. Targeted 
siRNA liposomes could be aerosolised effectively.
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Key Findings
• Synthesis of mannosylated cholesterols
• Preparation and characterisation of targeted liposomes
• Optimised method for maximal liposome encapsulation of siRNA
• Liposome formulation capable of nébulisation and therefore suitable for inhalation
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Chapter 3
Liposomes for Targeted siRNA Delivery to Alveolar 
Macrophages
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3.1 Introduction
Mononuclear phagocytes such as monocytes, macrophages and dendritic cells play a central 
role in innate immunity. The chief role of these cells is phagocytosis whereby cells will engulf 
and destroy apoptotic cells, pathogens and other targets generally by opsonin receptor- 
dependent mechanisms via complement- and Fc-receptors or opsonin receptor -independent 
mechanisms via lectin-receptors, SRs, stearylamine (SA) receptors or CD14 [111]. Liposomes 
are the most extensively explored delivery system for phagocyte-targeted therapies and offer 
many benefits such as low immunogenicity, biocompatibility, cell specificity and drug protection. 
However, liposomal drug carriers are also associated with poor scale-up and shelf-life, high cost 
and in some cases toxicity. The majority of studies have focused on the development of 
delivery formulations that avoid monocyte/macrophage clearance to enhance and prolong 
systemic circulation. Liposomal delivery systems targeting other cell types outside the MPS are 
modified to evade phagocytosis for instance “stealth liposomes” include poly-ethylene-glyco! 
(PEG) into their formulation to shield the liposomes from the MPS and increase their circulation 
times [175], Consequently there is now a greater understanding of the mechanisms of binding 
and uptake that can be harnessed for drug targeting to monocyte/macrophage cells.
3.1.1 Liposomal Targeting to Macrophages
Liposome drug delivery systems can be formulated to exploit the physiological role of 
macrophages to provide specific targeting and enhance drug efficacy. Mononuclear 
phagocytes have key roles in metabolism such as cholesterol and bilirubin metabolism and 
pathogen clearance [28]. For this reason, specialised cell surface receptors are expressed, for 
example SRs, which allow the identification and uptake of materials. These receptors can also 
be targeted for drug delivery. Targeting of liposomes to monocytes and macrophages can be 
achieved through various strategies including modification of lipid composition and 
physicochemical properties such as size and charge and by the inclusion of surface ligands 
including peptides such as Arg-Gly-Asp (RGD) [125], antibodies for example anti-CC531 
antibodies [128], polysaccharides such as O-stearyl amylopectin (O-SAP) [121], glycolipids 
such as Man3-DPPE [134, 135] and Mann-C4~Chol [130] and glycoproteins for example 
fibronectin [107]. Our strategies use anionic phosphatidylserine composed liposomes to target 
macrophage SR s and mannosylated liposomes composed of neutral lipids for macrophage MR 
targeting (Figure 3.1).
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Figure 3.1: Liposomal targeting strategies to alveolar macrophages
3.1.1.1 Anionic Liposomes
Cationic liposomes are associated with efficient cellular delivery of drug cargoes and routinely 
applied for in vitro gene delivery [176]. Electrostatic interactions between positively charged 
liposomes and the negatively charged cell membranes and cell surface proteoglycans [177] 
facilitates cell uptake. Unfortunately, cationic liposomes can cause cytotoxicity limiting their 
safety for clinical use [93]. In RAW264.7 macrophages cationic liposomes containing SA have 
previously been shown to induce apoptosis through mitochondrial pathways generating ROS, 
releasing cytochrome C, caspase-3 and -8 and more recently activating PKC5 possibly by cell 
surface proteoglycan interaction [178-181]. Consequently interest has turned to neutral and 
anionic liposomes for drug delivery applications. Currently there are several FDA approved 
liposomes available for the delivery of drugs such as amphotericin B (AmBisome®, ABELCET® 
and Amphocil) and doxorubicin (Doxil®) [86]. Although there are a number of amphotericin B 
liposome therapeutics available the liposome formulations of each differ considerably in terms 
of lipid composition, shape, size, stability, pharmacokinetics and toxicity [182], The lipid 
compositions do not include cationic lipids but consist of hydrogenated soy phosphatidylcholine, 
cholesterol and distearoyl-phophatidylglycerol (DSPG); dimyristoyl phosphatidylcholine and 
dimyristoyl phosphatidylglycerol and cholesteryl sulfate for AmBisome®, ABELCET® and 
Amphocil respectively [182],
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Anionic lipids such as PS and PG are preferentially recognised by macrophages [107]. 
Comparison studies between PC (neutral) and PS composed liposomes have long established 
the enhanced macrophage internalisation of negative liposome formulations [183]. Negative 
charge can also be achieved by the incorporation of DCP [109]. Vyas et al. (2004) showed a 
3.4-fold increase in rifampicin lung retention in rats when rifampicin was encapsulated in 
negatively charged DCP, PC and cholesterol composed liposomes compared to free drug after 
aerosol administration [121]. Furthermore work by us to deliver recombinant SLPI (rSLPI) 
encapsulated in DOPS:Chol (7:3 molar ratio) liposomes has shown enhanced 
monocyte/macrophage uptake of liposomes both in vitro and in vivo [154]. Detection of rSLPI 
in BALF was decreased when rSLPI was delivered encapsulated in anionic liposomes (Figure 
3.2A). Additionally BAL cell internalisation of the intratracheally instilled rSLPI was greater 
when rSLPI was encapsulated in anionic liposomes compared to free rSLPI in guinea pigs 48 
hours post-administration (Figure 3.2B) [154]. Monocytes were the most abundant cell type 
present in the BALF of these animals indicating monocyte targeting which was also confirmed in 
vitro [154].
Figure 3.2: (A) rSLPI concentration present in bronchoalveolar lavage fluid (BALF) of single 
prophylactic dose to guinea pigs. BALF was collected 48 hrs following a single 2.5 mg rSLPI/kg
dose by intratracheal instillation. (free-rSLPI n = 3; DOPS-rSLPI n=5; Control (DOPS-Empty or
PBS) n = 3). (B) rSLPI concentration in BALF cells taken from single prophylactic dosed guinea 
pigs. Cell lysates were collected 48 hrs following a single 2.5 mg rSLPI/kg dose by intratracheal 
administration. (free-rSLPI n = 3; DOPS-rSLPI n=5; Control [DOPS-Empty or PBS] n=9; ± S.D.) 
Data represented as means ± SD. [154]
The composition of the inner membrane leaflet of eukaryotic cells [111] consists of PS and 
phosotidylethanolamine (PE) with an outer layer of PC and sphingomyelin (SM) [112, 113]. 
Apoptosis results in PS being exposed on the outer cell surface and the induction of monocytic 
phagocytosis. It is believed that PS target SR s on macrophages. What is more, PS can 
activate complement and associate with plasma apolipoproteins such as ApoE and therefore 
promote phagocytosis by macrophages [184]. There are six classes of SR s with A, B and D as 
the most likely participants in liposome recognition [184]. Previously, liposomes composed of 
DOPS, DOPE and cholesterol at a molar ratio 1:1:1 have been mixed with siRNA pre- 
complexed with PEI to form artificial virus-like particles (AVPs) [185]. These AVPs were shown
A,
Control
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to mediate gene silencing in vitro in primary neurons with a reduction in cytotoxicity compared to 
commercial cationic transfection reagent Lipofectamine 2000™ [185].
3.1.1.2 Mannosylated Liposomes
A multitude of ligands are currently being assessed which make use of mononuclear 
phagocytes characteristic receptor expression and phagocytic innate processes. Using a ligand 
targeting strategy for liposome drug delivery has many advantages including increasing target 
specificity and avoiding the need for cationic lipids to trigger intracellular delivery. Immune cells 
including alveolar macrophages, peritoneal macrophages, monocyte-derived dendritic cells and 
Kupffer cells constitutively express high levels of the MR. Macrophages can therefore be 
targeted via mannosylated nanoparticles (Figure 3.1). The MR is a C-type lectin type I 
transmembrane protein [43, 114] whose ligands possess a terminal non-reducing sugar such as 
mannose, glucose, /V-acetylglucosamine and fucose [186, 187], These receptors play 
numerous roles in immune function and inflammation [36, 116]. Moreover MR activation has 
been linked to the initiation of an anti-inflammatory immunosuppressive programme in cells 
[188] and impaired NFkB activation [189], Hence, MR has the potential to be exploited for 
targeted drug delivery to macrophages but also as a therapeutic target. Herein we aimed to 
explore mannosylated liposomes with an anti-inflammatory cargo such as anti-inflammatory 
siRNA as dual acting therapeutics.
Mannosylated liposomes have repeatedly been shown to preferentially target macrophages and 
DCs attaining enhanced cellular uptake both in vitro and in vivo with better in vitro/in vivo 
correlation than for non-ligand containing liposomes [110, 115, 116, 130-135, 165, 174, 183, 
190-193]. Mannosylation has been achieved by the incorporation of ligands such as alkyl 
mannosides [174], Cholesten-5-yloxy-A/-(4-((1 -imino-2-a-thioglycosylethyl)amino)butyl) 
formamide (Mann-C4-Chol) [130, 165, 193, 194], Mann-His-C4-Chol [194], Man2DOG [131], 4- 
aminophenyl-a-D-mannopyranoside [133, 190] and manntriose (Man3)-DPPE [134, 135, 191] 
into the liposome formulations or by liposome coating with p-aminophenyl-a-D- 
mannopyranoside [132].
Over the past decade Hasida and colleagues have led the way in the development of 
mannosylated liposomes targeted to macrophages and DCs for the delivery of anti-inflammatory 
agents such as dexamethasone palmitate (dex) [130] and NFkB decoy and anti-cancer agents 
including CpG oligonucleotides and DNA [195]. Intratracheally administered Man-C4-Chol 
liposomes were shown to be preferentially taken up by alveolar macrophages which was 
mediated via MR endocytosis as revealed by inhibition studies. Mannosylation and the extent 
of this mannosylation significantly improved liposome internalisation by macrophages [115]. 
The ability of these liposomes to efficiently deliver their load has been the focus of a more 
recent study in which the use of bubble liposomes and ultrasound in combination with 
mannosylated liposomes to deliver plasmid DNA to mouse peritoneal macrophages was 
assessed [192]. To date, mannosylated liposome delivery has not been applied to siRNA.
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3.1.2 Chapter Aims
The focus of this chapter is to evaluate a range of targeted liposomes in vitro in terms of uptake, 
cytotoxicity, immunogenicity and knockdown ability. In order to achieve this high throughput 
screening assays were developed.
• To assess targeted liposome uptake by macrophages
• To determine knockdown in LP S stimulated macrophages via targeted liposomes using 
anti-inflammatory siRNA
• To evaluate toxicity and immunogenicity of targeted liposomes in vitro
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3.2 Materials
10-Plex TH1/TH2 Human, Mesoscale Discovery 
12 well plate, Grenier Bio One
Alexa Fluor® 488 Goat anti-Rabbit IgG (H+L), Invitrogen 
BCA assay, Pierce
bisBenzimide H 33342 trihydrochloride (Hoescht), Sigma Aldrich
Bovine serum albumin (BSA), Sigma
Cellomics® Multi para meter Cytotoxicty 3 kit, Thermo
CELLSTAR® 96well plate, Grenier Bio One
Confocal Laser Scanning Microcope, Zeiss LSM 510
DAKO fluorescent mounting medium (DakoCytomation S3023), DAKO
EDTA, Amresco
FBS, BioSera
Ficoll-Paque Plus
Fluorescent Microscope, Nikon Eclipse 90i
Goat anti-rabbit secondary antibody Alexa Fluor® 488, Invitrogen
Hoechst 33342, Sigma
IN Cell Analyzer 1000, GE Healthcare
Lab-Tek™ Chamber Slides, Nunc
Lipofectamine 2000™, Invitrogen
LS 50B Fluorescence Spectrometer, Perkin Elmer
MACS Columns, Miltenyi Biotec
MACS MicroBead Kit, Miltenyi Biotec
MACS® Separator for MicroBeads, Miltenyi Biotec
Mannose Receptor Rabbit Polyclonal Antibody, Abeam
Micro BCA™ Protein Assay Kit, Thermo Scientific Pierce
PBS, GIBCO
Phalloidin-FITC, Sigma Aldrich 
Phalloidin-TRITC, Sigma Aldrich 
Phorbol myristate acetate (PMA), Sigma Aldrich 
Rabbit polyclonal mannose receptor antibody, Abeam 
RPMI 1640, BioSera
siGENOME Non-Targeting siRNA#2, Dharmacon 
siGLO Lamin A/C Control siRNA (Human), Dharmacon 
Silencer® Select Pre-designed TNFa siRNA, Ambion 
THP-1 cell line. ATCC 
THP1-XBIue cell line, Invivogen 
TNFa ELISA, Biolegend
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3.3 Methods
3.3.1 siRNA
siGENOME Non-Targeting siRNA #2 (Dharmacon) is designed to target firefly luciferase mRNA 
(U47296) with at least 4 mismatches to human, mouse or rat genes serving as a non-target 
negative control to provide a baseline cellular response to siRNA transfection. siGLO Lamin 
A/C Control siRNA (Human) is a fluorescent siRNA that targets Lamin A/C and is chemically 
modified with a DY-547 fluorophore. The sequences of siGENOME non-targeting #2 and 
siGLO siRNA were 5'-UAAGGCUAUGAAGAGAUAC-3’ and 5’ ACCAGGUGGAGCAGUAUAA 3' 
respectively. Three Silencer®  Select Pre-designed siRNA sequences, sequence 1 (siRNA ID # 
S14249) sense 5’-GCGUGGAGCUGAGAGAUAAtt-3’ and anti-sense 5'- 
UUAUCUCUCAGCUCCACGAca-3’, sequence 2 (siRNA ID # s14248) sense 5’- 
GACCUCACCUAGAAAUUGAtt-3’ and antisense 5’-UCAAUUUCUAGGUGAGGUCtt-3' and 
sequence 3 (TNFa 3; siRNA ID # s14247) sense 5’-AGGCGGUGCUUGUUCCUCAtt-3’ and 
anti-sense 5’-UGAGGAACAAGCACCGCCUgg-3’ targeted to TNFa (Ambion). siRNAs for in 
vitro studies were reconstituted with nuclease-free buffer (Dharmacon) or water (Ambion) to a 
concentration of 20pM (non-targeting and siGLO siRNA) or 100fjM (TNFa siRNA).
3.3.2 Cell Culture
3.3.2.1 THP-1 Cells
THP-1 cells a human acute monocytic leukemia cell line derived from a 1 year old male infant 
were maintained in RPMI 1640 (BioSera) supplemented with 10% heat inactivated fetal bovine 
serum (FBS, BioSera) from passage 4 -  20 in a humidified atmosphere at 37°C and 5% C 0 2. 
THP-1 cells were differentiated by the addition of 100nM phorbol myristate acetate (PMA) and 
incubated at 37°C for 72 hours.
3.3.2.2 Primary Blood Monocyte Isolation
Ethical approval was obtained from the Research Ethics Committee (REC), Royal College of 
Surgeons in Ireland (REC651). Human monocytes were isolated from blood collected from 
healthy donors using Ficoll-Paque Plus density gradient separation and MACs colloidal super- 
paramagnetic MicroBeads conjugated with monoclonal mouse anti-human CD14 antibodies. 
60ml of blood was collected with 10% Na citrate and transferred to 50 ml tubes. Blood was 
diluted 1:1 with PBS and carefully layered onto Ficoll-Paque Plus (volume ratio 
PBS:blood:Ficoll-Paque of 1:1:1). Tubes were centrifuged at 300xg for 30 minutes with no 
brake. Following centrifugation a distinct band is formed at the blood/Ficoll-Paque interface. 
This fraction was carefully aspirated using a sterile pasture pipette into fresh 50ml tubes. The 
volumes per tube were adjusted to 50ml with PBS and tubes were centrifuged at 400xg for 5 
minutes with the brake on to pellet cells. If red blood cells were present the pellet was
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resuspended in 5ml red cell lysis buffer, the volume per tube brought up to 50ml and 
centrifugation at 400xg for 5 minutes repeated. Supernatants were discarded and pellets 
resuspended in RPMI and combined. A cell count was taken using a haemocytometer. Cells 
were centrifuged at 300xg for 10 minutes and supernatants were discarded. The cell pellet was 
resuspended in buffer (0.5% FBS and 2mM EDTA in PBS pH 7.2) 80pl per 107 cells. MACS 
CD 14 magnetic microbeads were added (20pl per 107 cells), mixed and incubated for 15 
minutes at 4°C. Cells were washed with buffer by adding 10 times the labelling volume of 
buffer, centrifuging at 300xg for 10 minutes and resuspending in 500(jl of buffer. A MACS LS  
column was placed in the MACS Multistand magnetic separator and equilibrated by adding 3ml 
of buffer. Once buffer has eluted from the LS column cell suspension was loaded. CD14 
positive monocytes were retained on the column. The column was washed by loading 3ml of 
buffer on to the column and allowing buffer and negative cells to elute. Washes were repeated 
twice more. The column was removed from the magnetic separator. 5ml of buffer was loaded 
onto the column and monocytes were flushed using the supplied plunger. Cells were collected 
and counted.
3.3.2.3 THP1-XBIue™ cells
THP1-XBIue™ cells are stably transfected THP-1 cells expressing secreted embryonic alkaline 
phosphatase (SEAP) gene which is induced by the transcription factors NF-kB and activator 
protein-1 (AP-1). Cells were maintained in RPMI 1640 supplemented with 10% heat inactivated 
FBS and 200fjg/ml of selection marker Zeocin™. TLR  stimulation induces NFkB and AP-1 
production which in turn leads to expression of the reporter protein SEAP. THP1-XBIue™ cells 
were differentiated by the addition of 100nM PMA and incubated at 37°C for 72 hours.
3.3.3 Immunofluoresence Microscopy to Determine Man nose Receptor Expression
THP-1 cells were seeded at 1x105 cells/ml in 96-well plates, differentiated and fixed with 4% 
paraformaldehyde for 20 minutes. Cells were incubated in 1% bovine serum albumin (BSA) in 
PBS tween (PBST) for one hour and then for another hour at room temperature with 0, 1 or 2 
pg/ml rabbit polyclonal MR antibody (Abeam). Cells were then washed with PBS three times 
with 5 minute incubations per wash and were subsequently incubated with goat anti-rabbit 
secondary antibody Alexa Fluor® 488 (1/200, 1/500 and 1/1000 dilutions) for 1 hour and 
counterstained with Hoechst 33342 (5 minutes) and phalloidin-tetramethyl rhodamine 
isothiocyanate (TRITC) (45 minutes). Images were acquired using an INCELL 1000 cell 
analyser.
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THP-1 cells were differentiated at 1x10s cells/ml in 12 well plates and incubated for 2 hours with 
anionic, neutral and mannosylated liposomes at 0, 100 and 300pM (Table 3.1). Liposomes 
were either unlabelled or fluorescently tagged with rhodamine. Media was removed and cells 
were washed three times with warmed PBS. Cells were lysed with 200pl 0.1% Triton X-100 in 
PBS and centrifuged at 2000rpm for 5 minutes to remove cell debris. 150jjl of lysed cells were 
brought up to 500pl with PBS and fluorescence was measured using a fluorescence 
spectrometer (LS 50B) at 550nm excitation and 590nm emission wavelengths.
Table 3.1: Liposome composition for differentiated THP-1 cell uptake assessment by
3.3.4 In Vitro Uptake Studies
3.3.4.1 Fluorescence Spectroscopy
Spectrofluorimetry
Liposome
Nomenclature
Lipid Components Molar Raltio
DOPC DOPS Choi MC2C MC4C MC6C
DOPS - 70 30 - - -
DOPC 70 - 30 - - -
MC2C-2.5 70 - 27.5 2.5 - -
MC2C-5 70 - 25 5 - -
MC2C-7.5 70 - 22.5 7.5 - -
MC4C-2.5 70 - 27.5 - 2.5 -
MC4C-5 70 - 25 - 5 -
MC4C-7.5 70 - 22.5 - 7.5 -
MC6C-2.5 70 - 27.5 - - 2.5
MC6C-5 70 - 25 - - 5
MC6C-7.5 70 - 22.5 - - 7.5
Fluorescently labelled siRNA (siGLO) was encapsulated in MC4C-7.5 liposomes with or without 
the incorporation of 10% DOTAP into the liposome formulation. THP-1 cells differentiated at 
1x105 cells/ml in 12 well plates were incubated for 2 hours with naked siGlo or siGlo 
encapsulated in MC4C liposomes (Table 3.2). THP-1 cells were washed three times with 
warmed PBS, lysed with 200|jl 0.1% TritonX100 and centrifuged at 2000rpm for 5 minutes to 
remove cell debris. 1 50jjI of lysed cells were brought up to 500pl with PBS and fluorescence 
was measured using a fluorescence spectrometer (LS SOB) at 550nm excitation and 590nm 
emission wavelengths.
Table 3.2: siRNA-Liposome composition for differentiated THP-1 cell uptake assessment 
by Spectrofluorimetry
Liposome
Nomenclature siRNA
Liposome Components Molar ratio
DOPC DOTAP Choi MC4C
siGLO siGLO - - - -
MC4C siGLO siGLO 70 - 22.5 7.5
MC4C/DOTAP siGLO siGLO 60 10 22.5 7.5
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Total protein levels were determined using a bicinchoninic acid (BCA) assay and used to 
normalise the fluorescence levels per well. BCA assay was carried out as per the 
manufacturers instructions using a clear 96-well plate and Wallac mulitplate reader. Briefly, 
BSA standard curve was prepared ranging from Opg/ml to 100pg/ml. Diluted albumin standard 
(150pl) or 75pl of diluted cell lysates were added to a 96 well plate in triplicate. Volumes per 
well were brought up to 150|jl. Working reagent (150fjl) was added to each well. Plates were 
incubated for 2 hours at 37°C and absorbance was read at 562nm.
3.3.4.2 High Content Cell Analysis (HCA)
A HCA method was developed for analysis of uptake to enable high throughput studies. Cells 
were differentiated at a density of 1x105 cells/ml in 96-well plate. Anionic, neutral and 
man nosy lated liposomes were incubated with cells in triplicate according to Table 3.3. 
Additionally 200nm liposomes were incubated with cells for 2 hours at 4°C at 100, 200 and 
300|jM. Liposomes were either unlabelled or rhodamine-tagged. Cells were washed three 
times with warmed PBS, fixed with 4% paraformaldehyde and stained with phalloidin­
fluorescein isothiocyanate (FITC) and Hoescht 33342. 150pl of PBS was added to each well 
and plates were stored at 4°C in the dark until analysed.
Table 3.3: Liposome treatments for differentiated THP-1 cell uptake assessment by HCA
Size (nm) Concentration (uM) Time (hours)
Size Unextruded, 100, 
200, 400, 1000
200 2
Concentration 200 0, 50, 100, 200, 300, 
1000
2
Time 200 200 0.5, 1,2, 4, 24
HCA was carried out using INCELL 1000 analyser. Images were acquired in three channels, 5 
fields per well and analysed using INCELL1000 analyser software. Multi target analysis module 
was used with nuclei, cells and organelles inputted as objects to be measured and assigned 
wavelengths for nuclei, cells and liposomes respectively. Parameters for segmentation analysis 
were then inputted. Nuclei were identified using Top Hat. A minimum area was inputted based 
on the images required and sensitivity generally set to 80%. Multi-scale top hat was used to 
identify cells. A minimum area based on representative images acquired was inputted and 
sensitivity set to 70%. Organelles (or liposomes) were identified using mulit-target analysis 
method. A minimum and maximum size was specified and a scale number selected. Scales 
can be set from 1 to 10 depending on the range of sizes to be detected. Scale was set to 10. It 
was necessary to acquire images for liposome uptake at least at a magnification of 200x to 
identify liposomes at the minimum end of the size range. A sensitivity level of 30% was used.
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Detection of liposomes was specified in cells only. Input values and sensitivity settings were 
adjusted for each experiment until all parameters were correctly assigned and identified (Figure
3.3).
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Figure 3.3: INCELL cell analysis. Images acquired at 3 excitation/emission wavelengths 
360/480 blue (nuclei; hoescht), 480/535 green (cells; phalloidin-FITC) and 535/620 (red; 
liposomes). Minimum area of nuclei, average are of cells and minimum and maximum size of 
liposomes was inputted into software. Images of each wavelength was analysed and nuclei, 
cells and liposomes were segmented. Fused images show each component circled. The 
number of liposomes in cell regions only were counted.
3.3.5 Toxicity
Cellomics® Multiparameter Cytotoxicty 3 kit and an INCELL 1000 analyser were used to 
determine cytotoxicity following liposome treatment and optimised for differentiated THP-1 cells. 
THP-1 cells were differentiated at 1.5x10s cells/ml in a flat-blottomed 96-well plate (CellStar, 
Grenier) for 72 hours. Media was replaced with fresh media and cells were treated with 
liposomes at concentrations of 0, 100 or 300|jM in triplicate and incubated at 37°C for 23.5 
hours. Cells were also treated with valinomycin (120|jM) for 23.5 hours as a positive toxicity 
control. 50pl of Live Staining Solution (2.1 pi permeability dye and 21 pi mitochondrial 
membrane potential dye in 6ml complete RPMI) was added to each well and cells were 
incubated at 37°C for 30 minutes. Media and staining solution was removed and the wells were 
washed with PBS. To fix cells, 4% paraformaldehyde (100pl) was added to each well and 
incubated at room temperature for 20 minutes. The wells were washed twice with PBS and 
100ul Of permeablisation buffer (0,1% Triton X-100 in PBS) was added to each well and 
incubated for 10 minutes protected from the light. Washing was repeated and 100pl of blocking 
buffer was added to each well and incubated at room temperature for 15 minutes. Blocking 
buffer was aspirated and 50pl of primary antibody solution (15pl cytochrome c primary antibody
82
in 6ml of blocking buffer) was added to each well and incubated at room temperature for 60 
minutes protected from the light. Wells were washed three times with PBS followed by the 
addition of 50[jl of a secondary antibody/staining solution (0.6|jl Hoechst dye and 12|j| DyLlght 
649 Goat anti-mouse antibody in 6ml of blocking buffer) to the wells. Cells were incubated for
60 minutes at room temperature protected from the light followed by three washes with PBS. 
150|jl of PBS was added to each well and the plate was stored at 4°C protected from light until 
analysis.
Images were acquired by an INCELL 1000 analyser within 24 hours in 4 fields per well using 4 
wavelengths; excitation/emission wavelengths of 360/460nm (Hoechst dye), 480/535nm 
(Permeability dye), 535/600nm (Mitochondrial Membrane Potential dye) and 620/700nm 
(DyLight 649). Cell loss, nuclear area, nuclear intensity, cytochrome c release, mitochondrial 
membrane potential and cell permeability were determined using INCELL analysis software 
using multiparameter target analysis and the settings in Table 3.4. Region growing method was 
used to identify nuclei as nuclei size was more variable. Segmentation of cells was performed 
using the collar method. This sets up a ring-shaped region around the nucleus using a specified 
average cell radius value to assign this region as the cell. Mitrochondrial membrane potential, 
cytochrome c and cell permeability were set as references and measurements were detected in 
cells. Intensities of each reference in cells were compared between treatments. Images were 
acquired at 10x magnification to include a larger number of cells in the analysis. Input values 
and sensitivity settings were adjusted for each experiment until all parameters were correctly 
assigned.
Table 3.4: Representative Parameters for HCA Analysis of Liposome Toxicity in THP-1 
Cells
Parameters Wavelength 
(Ex/Em wavelengths, nm)
Analysis Settings
Nucleus 360/460 Region growing; min. area 33.2pm^
Cell - Collar; 11pm
Permeability 480/535 Reference; In Cell
Mitochondrial Membrane 
Potential
535/600 Reference; In Cell
Cytochrome c 620/700 Reference; In Cell
3.3.6 in  V itro  Knockdown Studies
3.3.6.1 Targeted Knockdown of TNFa Expression in Differentiated THP-1 Cells
THP-1 cells were seeded 2 x io 5 cells/well in a 96 well culture plate and differentiated. Cells 
were treated with an equal amount of siRNA complexed with lipofectamine 2000 or 
encapsulated in mannosylated (MC4C) liposomes for 3 hrs and media was replaced. Cells
were stimulated with 100ng/ml LPS and supernatants were collected 24 and 48 hours post­
transfection 3 hours following LPS stimulation. TNF-a production was estimated by enzyme 
linked immunosorbant assay (ELISA; 3.3.6.3).
3.3.6.2 Targeted Knockdown of TNFa Expression in Primary Monocytes
Isolated primary monocytes were seeded at 3x104 cells per well in 96 well plates and incubated 
at 37°C 5% C 0 2 overnight. Media was changed leaving adherent macrophages. siRNA 
transfections were mediated by a commercial transfection reagent Lipofectamine 2000 and 
various liposome formulations listed in Table 3.5. Non-target or three TNFa targeted siRNAs 
were diluted in serum free RPMI while 1pl of lipofectamine 2000 was diluted separately in 
serum free RPMI. Diluted siRNA and lipofectamine 2000 were mixed and incubated at room 
temperature for 20 minutes to allow complexation. siRNA lipofectamine 2000 complexes were 
added dropwise to wells in triplicate. 4.5pl of each liposome preparation (~50ng siRNA) was 
added to wells in triplicate. Cells were incubated with liposomes at 37°C. Cells were stimulated 
with 100ng/ml LPS for 3 hours prior to each media collection time point of 24 and 48 hours. 
TNFa expression levels were determined by ELISA (3.3.6.3).
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Table 3.5: Liposome Formulations for In Vitro Transfection of Primary Monocytes
siRNA Liposome Liposome N:P or Cationic Complexing siRNA
Nomenclature Weight Ratio Reagent
DOPS DOTAP/NT DOPS 4 DOTAP Non-Target
DOPS PEI/NT DOPS 7 PEI Non-Target
DOPS Protamine/NT DOPS 4 Protamine Non-Target
DOPS DOTAP/NT DOPS 4 DOTAP TNFa
DOPS PEI/NT DOPS 7 PEI TNFa
DOPS Protamine/NT DOPS 4 Protamine TNFa
DOPC DOTAP/NT DOPC 4 DOTAP Non-Target
DOPC PEI/NT DOPC 7 PEI Non-Target
DOPC Protamine/NT DOPC 4 Protamine Non-Target
DOPC DOTAP/NT DOPC 4 DOTAP TNFa
DOPC PEI/NT DOPC 7 PEI TNFa
DOPC Protamine/NT DOPC 4 Protamine TNFa
MC6C DOTAP/NT MC6C 4 DOTAP Non-Target
MC6C PEI/NT MC6C 7 PEI Non-Target
MC6C Protamine/NT MC6C 4 Protamine Non-Target
MC6C DOTAP/NT MC6C 4 DOTAP TNFa
MC6C PEI/NT MC6C 7 PEI TNFa
MC6C Protamine/NT MC6C 4 Protamine TNFa
3.3.6.3 TNFa Enzyme Linked Immunosorbant Assay (ELISA)
Media was collected from transfected cells 3 hours following LPS stimulation and frozen at - 
80°C until assayed. An ELISA was carried out as per manufacturer’s instructions. TNFa  
capture antibody was diluted 1/200 in provided coating buffer and 10OpI was added to each well 
of a NUNC Maxisorp™ 96 MicroWell plate. The plate was sealed and incubated at 4°C  
overnight. The plate was washed 4 times with wash buffer (PBS and 0.05% Tween-20, pH 7.4) 
and blotted dry. 200|jl of assay diluent was added to each well and plates were sealed and 
shaken for 1 hour at room temperature to block non-specific binding. Washing was repeated. 
Mouse TNFa standard curve was prepared from provided stock solution and diluted in assay 
diluent to give 500, 250, 125, 62.5, 31.3, 15.6 and 7.8 pg/ml of mouse recombinant TNFa. 
10OpI of standards and appropriately diluted samples were added to wells in duplicate and 
incubated for 2 hours at room temperature in sealed plates with shaking. Washing was 
repeated and 1 OOjjI of Avidin-horseradish peroxidise (HRP) was added to each well, the plated 
sealed and incubated at room temperature for 30 minutes with shaking. Washing was repeated 
allowing the wash buffer to soak for up to 1 minute for each wash to lower background readings.
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Finally 1 OOjjI of TMB substrate solution was added to each well and incubated for at least 10 
minutes in the dark. The reaction was stopped by the addition of 1 OOjjI 2N H2S04 stop solution 
per well. Absorbance was read at 450nm.
3.3.7 Liposome Immunogenicity Screening
3.3.7.1 NF-kB Induction in THP-1 Blue Cells
THP-1 Blue cells (NF-kB/AP-1 Reporter Monocytes) were differentiated for 72 hours at 1x106 
cells/ml in a 96 well plate. PMA free media (100pl) was replaced daily for a further 5 days to 
remove residual PMA. Liposomes were added to cells in fresh media at 0, 100, 200 and 300pM 
final concentration in triplicate. Cells were stimulated with 100ng/ml LPS as a positive control. 
After 24 hours 20pl of media was removed and was added to 180jjI of QUANTI-Blue™. After a
4 hour incubation absorbance measured at 630nm using a mulitplate reader to determine SEAP 
activity.
3.3.7.2 10-Plex TH1/TH2 Assay
MesoScale Discovery multiplex assays allow the detection and quantitation of multiple analytes 
simultaneously over a wide range of concentrations using as little as 10pl of sample. Human 
TH1/TH2 10-plex assay simultaneously detects IFNy, IL-1 p, IL-2, IL-4, IL-5, IL-8, IL-10, IL- 
12p40, IL-13 and TNFa key effectors in the TH1/TH2 inflammatory response. The surface of 
each well contains 10 discrete capture antibody coated electrodes or “spots”. Each spot is 
coated with a different capture antibody arranged in a characteristic pattern (Figure 3.4). 
Analytes in samples are bound to specific capture and detection antibodies. Detection 
antibodies are labelled with SULFO-TAG™, an electrochemiluminescent compound. When a 
voltage is applied to the plate using the SECTOR Imager instrument light is emitted by the 
SULFO-TAG™ label and the intensity detected.
SULFO-TAG™ labeled 
Detection Antibody
Analyte
Capture Antibody
—  Working Electrode
Figure 3.4: Meso Scale Discovery multiplex assay. MSD multiplex or multispot 96-well plates 
have a carbon electrode plate surface onto which each capture antibody is coated onto one of 
ten electrodes or spots. The assay works as a sandwich immunoassay where the analyte is 
bound to the capture and detection antibody. MSD detection antibodies are labelled with 
SULFO-TAG™, an electrochemiluminescent compound, which emits light when voltage is 
applied to the electrodes. The light intensity is measured by the analyser and allows 
quantification of each analyte. (Image taken from MSD Multispot manual)
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THP-1 cells were differentiated in 24 well plates at 1x105 cells/ml. Cells were incubated in fresh 
complete media (untreated), RPMI supplemented with 100ng/ml LP S or empty DOPS, DOPC, 
MC2C, MC4C or MC6C liposomes at 100pM or 300pM for 24 hours. Media was harvested and 
stored at -80°C until assayed.
MSD mutilplex assay was carried out according to the manufacturers’ instructions. Briefly, the 
plate was blocked for 1 hour at room temperature with 150pl of 1% (w/v) Blocker B solution 
(blocking was recommended to improve the sensitivity of IFNy and IL-12p40 detection). Wells 
were washed with wash buffer (0.05% Tween20 in PBS (PBST)) three times and blotted dry 
with absorbent paper. A 4-fold serial dilution of mouse TH1/TH2 9-Plex Calibrator (10ng/ml to 
2.4pg/ml) was prepared in Diluent 1 (RPMI supplemented with 10% FBS). Standards and cell 
supernatants (25pl) were added in triplicate to wells and the plate was sealed and incubated 
over night at 4°C. The plate was washed 3 times with PBS-T followed by the addition of 25pl of 
1X detection antibody solution (50X stock diluted in Diluent 100 containing monoclonal 
antibodies to each analyte). The plate was resealed and vigorously shaken at room 
temperature for 2 hours. Washing 3 times in PBS-T was repeated. 150pl of 2X Read Buffer T  
(4X Read Buffer T diluted in deH20) was added to each well and the plate was immediately 
analysed on a SECTO R  Imager. Read buffer provides a suitable chemical environment for 
electrochemiluminescence. Standard curves were produced and concentrations of analytes for 
each sample determined using the MSD DISCO VERY W ORKBENCH® software.
3.3.8 Statistics
In general results are expressed as means ± SD. One way or two way ANOVA was used to test 
for differences between treatments with p-values < 0.05 considered significant, < 0.01 very 
significant and < 0.001 highly significant.
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3.4 Results
THP-1 cells are differentiated into a macrophage-like cell [196]. To confirm use of this cell line 
as an appropriate in vitro model for mannosylated liposome targeting immunofluoresence was 
carried out to determine MR expression. Figure 3.5 shows MR expression in differentiated 
THP-1 cells.
3.4.1 THP-1 cells as a Macrophage Cell Model: Mannose Receptor Expression
Figure 3.5: Immunofluorescence to determine the expression of mannose receptor by 
differentiated THP-1 cells. Fixed cells were incubated 1% BSA for 1 hour followed by 
incubation with (A) 1% BSA or (B) polyclonal mannose receptor antibody (1 pg/ml) for 1 hour. 
Cells were then incubated with secondary Alexa Fluor 488 antibody (green) for 1 hour followed 
by staining with Hoechst (nuclei; blue) and phalloidin-TRITC (T-Actin; Red). Images were 
acquired using an INCELL 1000 analyser at 100x magnification.
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3.4.2 Cell Uptake Studies
Cell uptake is the first stage of transfection and can be difficult to achieve particularly with 
macrophages [35], The aim of this set of experiments was to optimise and compare cell uptake 
of anionic liposomes and mannosylated liposomes in differentiated THP-1 cells. To quantify 
liposome uptake by THP-1 cells fluorescently tagged anionic, neutral and mannosylated 
liposomes (composed of 0.1% PE-Rhodamine) at 100 and 300pM were incubated with 
differentiated THP-1 cells for 2 hours. The cells were then washed, lysed and fluorescence was 
measured using spectrofluorimetry and normalised to per mg protein. Significant increases in 
(p < 0.001) cell association of anionic DOPS (Figure 3.6A) and mannosylated (Figure 3.6B) 
liposomes was found in comparison with neutral uncoated (DOPC) liposomes. There was a 5.3 
fold increase in the association of negatively charged DOPS liposomes compared to neutral 
DOPC liposomes.
Liposome composition for this experiment is described in Table 3.1. Mannosylated liposomes 
were prepared using DOPC (70%), cholesterol (22.5, 25 and 27.5%) and either mann-C2-chol 
(MC2C), mann-C4-chol (MC4C) or mann-C6-chol (MC6C) (2.5, 5 and 7.5%). Hence, 
mannosylated liposomes ranged in their degree of mannosylation (from 0 to 7.5% of the 
liposome molar composition) and in the mannosylated cholesterols. Three mannosylated 
cholesterol analogs were used, differing on the linker length between the mannose and 
cholesterol. The greater the extent of mannosylation the higher the level of cell uptake 
observed (Figure 3.6B) with all 7.5% mannosylated liposome formulations showing significantly 
increased cell uptake compared to unmannosylated DOPC liposomes (p < 0.01, MC2C-7.5 and 
MC6C-7.5; p < 0.001, MC4C-7.5). Additionally uptake was increased with higher 
concentrations of liposomes. MC4C-7.5 liposomes exhibited the most significant level of uptake 
by THP-1 cells (p < 0.001). Therefore uptake appears to be dependent on liposome 
concentration, mannosylated cholesterol linker length and the extent of liposome mannosylation 
with MC4C-7.5 as the optimal formulation.
3.4.2.1 Spectrofluorimetric Assessment of Liposome Uptake
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Figure 3.6: Uptake of liposome formulations by differentiated THP-1 cells determined by 
spectrofluorimetry. Cells were incubated for 2 hours with 100jjM or 300pM rhodamine-labelled 
liposomes (A) anionic or (B) mannosylated, washed and lysed. DOPC liposomes were the 
neutral or uncoated controls for anionic DOPS liposomes or mannosylated liposomes 
respectively. Fluorescence intensities of cell lysates at 550nm excitation and 590nm emission 
were measured and normalised to total protein. Data represented as means ± SEM (n = 6). 
Statistical differences were determined by two-way ANOVA with Bonferrini’s post-hoc test (* p < 
0.05, ** p < 0.01, *** p < 0.001) vs. DOPC liposome treated counterparts.
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3.4.2.2 Spectrofluorimetric Assessment of siRNA-Liposome Uptake
Additionally, the spectrofluorimetric method was used to determine the effect of liposome 
encapsulation on siRNA uptake into differentiated THP-1 cells. Initial studies to enhance siRNA 
encapsulation incorporated low percentages of DOTAP into the liposome formulations which 
later was optimised by encapsulation of pre-complexed siRNA. As shown in chapter 2 
encapsulation efficiency of free siRNA was low, usually <10%. In order to compare and quantify 
uptake of naked siRNA and liposome encapsulated siRNA a fluorescent siRNA (siGlo) was 
used (excitation/emission 560nm/590nm). From the previous uptake studies mannosylated 
liposomes composed of 7.5% Mann-C4-Chol were optimal for cell internalisation and were used 
for siGlo encapsulation. Fluorescent siRNA (siGlo) encapsulated in mannosylated liposomes 
showed increased uptake by differentiated THP-1 cells compared to free siGlo (Figure 3.7). 
Enhancement of siGlo uptake was significant when encapsulated in mannosylated liposomes 
(7.5%MC4C) incorporating DOTAP compared to siGlo alone (p < 0.01) and to siGlo 
encapsulated in mannosylated liposomes (7.5%MC4C) without DOTAP (p < 0.05). 
Encapsulation efficiencies were low and therefore fluorescence intensities were low however it 
is clear that liposome encapsulation enhances uptake of siRNA.
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Figure 3.7: Uptake of liposome formulations by differentiated THP-1 cells determined by 
spectrofluorimetry. Cells were incubated for 2 hours with naked fluorescent siRNA (siGlo) or 
liposome encapsulated siGlo, washed and lysed. siGlo was encapsulated in 7.5% MC4C 
liposomes with or without DOTAP incorporated into the liposome formulation. Fluorescence 
intensities of cell lysates at 550nm excitation and 590nm emission were measured and 
normalised to total protein. Data represented as means ± SEM (n = 6).
Statistical differences were determined by one-way AN OVA with Bonferrini’s post-hoc test (* p < 
0.05, **p<0.01)
Following uptake assessment of liposomes and liposomes encapsulating siRNA (siGlo) by 
spectrofluorimetry MannC4Chol (7.5%) liposomes including 10% DOTAP in their formulation 
was selected to encapsulate TNFa targeted siRNA. MC4C liposomes empty and encapsulating 
non-target or TNFa siRNA were used to transfect differentiated THP-1 cells. TNFa expression 
by THP-1 cells was determined 48 and 72 hours post transfection following a 3 hour LPS  
stimulation (100ng/ml). TNFa targeted siRNA encapsulated in MC4C liposomes composed with
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10% DOTAP reduced TNFa expression by 20.8 ± 7% and 21.4 ± 4% 48 and 72 hours post 
transfection respectively compared to untransfected stimulated cells. Furthermore a 
commercial transfection reagent Lipofectamine 2000 was used as a positive transfection control 
but yielded negligible changes in TNFa gene expression in LP S stimulated THP-1 cells 
(Appendix). In order to further optimise formulations to enhance knockdown a HCA method 
was developed to quantify liposome uptake in a high throughput format.
3.4.2.3 High Content Cell Analysis (HCA) Assessment of Liposome Uptake
A method was developed to quantify liposome uptake in differentiated THP-1 cells using HCA  
technology. Previous approaches to quantify liposome cellular internalisation have included 
spectrofluorimetry [197] and flow cytometry [115], both of which rely on fluorescent intensity 
measurements as indications of the extent of liposome cell uptake and are usually coupled with 
microscopy to confirm liposome internalisation and localisation. HCA combines imaging and 
quantitative analysis in a high throughput format to determine liposome cell uptake 
consequently providing more detail and accuracy than former techniques. HCA permits a visual 
assessment of uptake and liposome per cell count which can be defined by a number of 
parameters including particle size exclusion and localisation. Further information can be 
extrapolated such as uptake distribution pattern (homogenous or heterogenous), localisation 
and cell viability. Additionally techniques such as flow cytometry require cells to be in 
suspension. This could be problematic with adherent ceils such as macrophages which cannot 
be trypsinised and cell detachment can potentially cause damage and bias the results [198].
Uptake of anionic DOPS, neutral DOPC and 7.5% mannosylated MC2C, MC4C and MC6 C  
liposomes by differentiated THP-1 cells was determined by HCA. This high throughput 
assessment also showed an improvement by anionic surface charge and mannosylation (Figure
3.8 -  3.11) as was found by spectrofluorimetry (Figure 3.6). However using HCA several 
conditions could be evaluated including a range of liposome sizes (1 0 0 nm to > 1 pm in diameter), 
concentrations (0 to 1mM), incubation times (0.5 to 24 hours) and temperatures (4 or 37°C).
Size can contribute greatly to liposome cell uptake efficiency. Liposomes were extruded to 
100nm, 200nm, 400nm or 1000nm or unextruded (>1000nm) and incubated with differentiated 
THP-1 cells for 2 hours at 200pM. With increasing size of anionic DOPS liposomes uptake 
increased (Figure 3.8G) while neutral DOPC and MC2C and MC4C mannosylated liposomes 
showed a similar pattern up to 2 0 0 nm but uptake decreased with liposomes > 400nm in 
diameter. DOPS and DOPC uptake was not significantly altered by size reduction when 
compared to unextruded counterparts. The most significant increase was of MC4C 200 and 
400nm (p < 0.001) and MC6 C 200nm (p < 0.001). Overall DOPS and MC6 C liposomes showed 
the greatest level of cell internalisation with DOPS uptake size dependent and MC6 C uptake 
size independent in the 100 - 1000nm range. Furthermore the longer the linker length of the 
mannosylated cholesterols used the greater the cell uptake.
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In general the higher the concentration of liposome treatments the greater the number of 
liposomes internalised by THP-1 cells after 2 hours. Significant increase in targeted liposome 
uptake was found compared to concentration matching non-target DOPC liposomes. DOPS 
liposomes showed significant enhanced uptake at 1 0 0 jjm (p < 0 .0 1 ), 2 0 0 j^M (p < 0 .0 0 1 ) and 
300|jM (p < 0.01) compared to DOPC liposomes. MC6 C liposomes also showed highly 
significant uptake at 100 and 200pM (p < 0.001) and very significant uptake at 300|jM and 1mM 
(p < 0.01) to compared to DOPC control. MC4C liposomes also showed significant increase in 
uptake over DOPC liposomes but not as enhanced as MC6 C liposomes.
Incubation time of liposomes with differentiated THP-1 cells was also assessed for 30 minutes 
to 24 hours. A trend of increasing uptake over time was observed but for DOPC, MC2C and 
MC4C liposomes major changes in uptake over time were not detected. DOPS liposomes 
showed significant increase in uptake after 0.5 hour (p < 0.01), 1 hour (p < 0.05) and 2 hours (p 
< 0.01) compared to corresponding DOPC liposomes and decreased at 24 hours. Uptake of 
MC6 C liposomes was very significant following treatment times of 0.5 and 1 hour (p < 0.01) and 
highly significant beyond 1 hour (p < 0.001) compared to DOPC liposome counterparts (Figure 
3.10G).
HCA assessment of liposome uptake in differentiated THP-1 cells showed overwhelming 
confirmation of DOPS and MC6 C liposomes as lead delivery platforms. Additionally uptake of 
DOPS, MC4C and MC6 C  liposomes was impeded at 4°C with high significance (p < 0.001) 
suggesting an active uptake process (Figure 3.11).
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Figure 3.8: Uptake analysis by INCELL HCA of rhodamine labelled liposomes ranging in size 
by differentiated THP-1 cells. Cells were incubated without liposomes (untreated) or with 
fluorescently tagged (rhodamine; red) anionic (DOPS), non-mannosylated neutral (DOPC) and 
mannosylated liposomes (7.5% MC2C, MC4C and MC6 C) unextruded or sized to 100nm, 
200nm, 400nm or 1000nm in diameter by extrusion at 200pM and 37°C for 2 hours. Cells were 
fixed and stained for nuclei (hoescht; blue) and F-Actin (phalloidin-FITC; green). 
Representative images show (A) untreated cells or uptake of MC6 C mannosylated liposomes 
sized to (B) 100nm, (C) 200nm, (D) 400nm, (E) 1000nm and (F) unextruded. Images were 
acquired by an INCELL 1000 cell analyser and (G) liposomes were counted per cell using 
INCELL 1000. Data represented as means ± SD (n = 6 )
Statistical differences were determined by two-way ANOVA with Bonferrini’s post-hoc test (* p < 
0.05, ** p < 0.01) vs. unextruded liposome treated counterparts
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Figure 3.9: Uptake analysis by INCELL HCA of rhodamine labelled liposomes over a range of 
concentrations by differentiated THP-1 cells. Cells were incubated without liposomes 
(untreated) or with 200nm fluorescently tagged (rhodamine; red) anionic (DOPS), neutral non- 
mannosylated (DOPC) and mannosylated (7.5% MC2C, MC4C and MC6 C) liposomes at 50, 
100, 200, 300 and 1000 pM for 2 hours at 37°C. THP-1 cells were fixed and stained for nuclei 
(hoescht; blue) and F-actin (phalloidin-FITC; green) and images were acquired at 20x 
magnification using an INCELL 1000 cell analyser. Representative images show (A) untreated 
cells and cells treated with 200nm DOPS liposomes at concentrations of (B) 50, (C) 100, (D) 
200, (E) 300 and (F) 1000pM for 2 hours. Images were analysed and liposomes counted per 
cell (G). Data represented as means ± SD (n = 6 )
Statistical differences were determined by two-way ANOVA with Bonferrini’s post-hoc test (* p < 
0.05, ** p < 0.01, *** p < 0.001) vs. neutral (DOPC) liposome treated counterparts
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Figure 3.10: Uptake analysis by INCELL HCA of rhodamine labelled liposomes by differentiated 
THP-1 cells at various time points. Cells were incubated without liposomes (untreated) and 
200nm fluorescently tagged (rhodamine; red) anionic (DOPS), neutral non-mannosylated 
(DOPC) and mannosylated (7.5% MC2C, MC4C and MC6 C) liposomes at 200 pM for 0.5, 1, 2, 
4 and 24 hours at 37°C. THP-1 cells were fixed and stained for nuclei (hoescht; blue) and F- 
actin (phalloidin-FITC; green) and images were acquired using an INCELL 1000 cell analyser. 
Representative images show (A) untreated cells and cells treated with 200pM of 200nm MC6 C  
liposomes for (B) 0.5, (C) 1, (D) 2, (E) 4 and (F) 24 hours. Images were analysed and 
liposomes counted per cell (G). Data represented as means ± SD (n = 6 )
Statistical differences were determined by two-way ANOVA with Bonferrini’s post-hoc test (* p < 
0.05, ** p < 0.01, *** p < 0.001) vs. DOPC liposome treated counterparts
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Figure 3.11: Uptake analysis by INCELL HCA of rhodamine labelled liposomes by differentiated 
THP-1 cells at 4°C and 37°C. Cells were incubated without liposomes (untreated) or with 
100fjM 200nm fluorescently tagged (rhodamine; red) anionic (DOPS), neutral non- 
mannosylated (DOPC) and mannosylated (7.5% MC2C, MC4C and MC6 C) liposomes at 4  and 
37°C for 2 hours. THP-1 cells were fixed and stained for nuclei (hoescht; blue) and F-actin 
(phalloidin-FITC; green) and images were acquired using an INCELL 1000 cell analyser. 
Representative images show (A) untreated cells and cells treated with 100pM of 200nm MC6 C  
liposomes at (B) 4°C and (C) 37°C for 2 hours. Images were analysed and liposomes counted 
per cell (G). Data represented as means ± SD (n = 6 )
Statistical differences were determined by two-way ANOVA with Bonferrini’s post-hoc test (* p < 
0.05, **p<0.01, ***p< 0.001)
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3.4.3 In vitro TNFa Knockdown
Transfection using lipofectamine 2000 targeting TNFa expression was carried out in LPS  
stimulated isolated primary human monocytes/macrophages (Figure 3.12). Primary 
monocytes/macrophages showed a better LPS response and so were used here for knockdown 
studies. Interestingly the commercially available transfection reagent induced high levels of 
TNFa after 24 hours returning to levels below untransfected LPS stimulated control cells after 
48 hours. There was no significant knockdown of target TNFa as seen in THP-1 cells 
(Appendix).
Commercial Transfection Reagent
600-
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Figure 3.12: TNFa modulation in primary blood derived monocytes by TNFa targeted siRNA 
complexed with commercially available transfection reagent. Cells were transfected using 
lipofectamine 2000 and non-target (NT) or TNFa siRNA and stimulated with LPS 3 hours prior 
to supernatant collection at 24 and 48 hours. TNFa secretion was determined by ELISA. Data 
represented as means ± SD vs non-target counterparts (n = 3)
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Optimal formulations based on HCA uptake were composed of DOPS:Cho1 (70:30), DOPC:Chol 
(70:30) and DOPC.Chol.MC6 C (70:22.5:7.5) for anionic, neutral and mannosylated liposomes. 
Non-target and TNFa targeted siRNA complexed with DOTAP, PEI and protamine was 
encapsulated into these liposome formulations (as described in 2.3.3) and knockdown via 
liposomal delivery was evaluated in primary cells. DOPC liposomes served as a neutral control 
for anionic DOPS liposomes and an unmannosylated control for mannosylated liposomes. 
Primary monocytes were transfected with 50ng of siRNA encapsulated in liposomes. Neutral 
DOPC liposomes encapsulating TNFa siRNA complexed with DOTAP or protamine did not 
result in TNFa suppression but induced TNFa expression was slightly reduced (not significantly) 
when PEI/TNFa siRNA complexes were transfected encapsulated in DOPC liposomes clearly 
showing that using targeted systems enhanced knockdown (Figure 3.13).
DOPS liposomes caused a slight increase in TNFa expression compared to untransfected 
controls. However relative to non-target counterparts all DOPS formulations delivering TNFa  
targeting siRNA mediated significant knockdown which was dependent on the siRNA 
complexation agent used and time (Figure 3.13A). Significant suppression of TNFa (p < 0.01) 
was mediated via DOPS liposomes encapsulating PEI/TNFa siRNA complexes by 8 8  ± 28.7 % 
and 100 ± 16.2 % after 24 and 48 hours respectively while DOPS liposomes encapsulating 
protamine/TNFa siRNA reduced expression by 95.9 ± 3.3 % after 24 hours (Figure 3.13A).
Mannosylated (MC6 C) liposomes encapsulating DOTAP/TNFa complexes reduced TNFa 
expression by 87.1 ± 46.6 % 24 hours post-transfection. PEI/TNFa siRNA and Protamine/TNFa 
siRNA complexes encapsulated in mannosylated liposomes 48 hours following transfection 
suppressed TNFa expression by 81.1 ± 16.4 % and 64 ± 45.3 %, respectively, compared to 
non-target siRNA counterparts (Figure 3.13C). Although knockdown was observed it was not 
significant.
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Figure 3.13: TNFa modulation in peripheral blood derived monocytes by TNFa targeted siRNA 
encapsulated in anionic, neutral or mannosylated liposomes. Isolated monocytes were 
transfected using non-target (NT) or TNFa targeted siRNA was complexed with DOTAP (N/P 
ratio 4), PEI (N/P ratio 7) or protamine (weight ratio 4) and encapsulated in (A) DOPS 
(anionic),(B) DOPC (neutral) or (C) mannosylated (MC6 C) liposomes. Primary cells were 
transfected with liposomes and stimulated with LPS 3 hours prior to supernatant collection at 24 
and 48 hours. TNFa secretion was determined by ELISA. Data represented as means ± SD vs 
non-target counterparts (n = 3) Statistical significance was determined by two-way ANOVA 
with Bonferini’s Post-hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001)
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3.4.4 Toxicity
Differentiated THP-1 cells were used to assess the affects of liposome treatment on cell 
viability. Drug carriers are not always inert and therefore monitoring of carriers alone in terms of 
toxicity and immunogenicity is an essential step in the development of successful and safe drug 
delivery systems. Anionic (DOPS), neutral (DOPC) and mannosylated (MC2C, MC4C and 
MC6 C) liposomes were incubated at 100pM and 300|jM with differentiated THP-1 cells for 24 
hours, fixed and stained. The concentrations required for transfection experiments generally fell 
between these concentrations.
As positive toxic controls cells were treated with 120pM valinomycin (Figure 3.14) or cationic 
(DOTAP) liposomes at 100pM or 300[j M. Negative controls were incubated under normal 
conditions and served as the healthy cell comparison for other treatments. HCA was used to 
acquire and analyse images based on staining for nuclei, cell permeability, mitochondrial 
membrane potential (MMP) and cytochrome c (Figures 3.14 -  3.16). Cell loss, nuclear size, 
total nuclear intensity, cell permeability, mitochondrial membrane potential and cytochrome c 
release were measured as the parameters of cytotoxicity.
Nuclei Cell Permeability MMP Cytochrome c
Figure 3.14: High content cell assessment of liposome associated cytotoxicity in differentiated 
THP-1 cells. Fluorescent images were acquired by an INCELL 1000 analyser in 4 channels and 
show control treatments with cells treated with complete media as a negative control or 120^M 
valinomycin as a positive control.
Overall cell counts between replicate assays were variable. Positive control valinomycin 
induced significant cell loss (p < 0.001) (Figure 3.13 and Figure 3.17A) as did DOTAP liposome 
treatments at 100pM and 300|j M (p < 0.05) (Figure 3.15, 3.16 and 3.17A). DOTAP liposomes 
were composed with 50% DOTAP and were used as a liposome positive toxic control. DOTAP 
is a cationic lipid that is regularly used in lipoplex formation for gene transfections but has been 
shown to cause toxicity in macrophages [199, 200]. Significant cell loss was also found 
following 300pM treatments of mannosylated liposomes (Figure 3.16 and 3.17A). Valinomycin
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showed the most toxic effect in differentiated THP-1 cells while DOTAP liposomes were the 
most toxic liposome formulation. DOTAP liposomes significantly reduced cell numbers (p <
0.05), increased cell permeability, reduced MMP and lead to significant cytochrome c release 
indicating the induction of both necrosis and apoptosis in these cells.
Chromatin condensation is associated with apoptosis which can be monitored by changes in 
nuclear size and intensity. No significant changes in nuclear size were found but valinomycin 
treatment did decrease the mean nuclear area. Valinomycin also increased the total nuclear 
intensity but not significantly. However, 300jjM MC2C liposomes significantly (p < 0.01) 
increased nuclear intensity (Figure 3.17C).
Increased cell permeability occurs during necrosis and therefore was determined in 
differentiated THP-1 cells following liposome treatment. DOTAP liposomes showed increased 
permeability at both 100[j M and 300|jM concentrations however no significant elevation in 
permeability was determined following any treatment (Figure 3.17D).
A fall in MMP in associated with apoptosis and is linked with cytochrome c release. No 
significant changes in MMP were observed following any treatments in differentiated THP-1 
cells. However mean MMP intensities do decrease from untreated healthy cell level most 
notably after treatment with 120pM valinomycin and 300[jM DOTAP, DOPS and MC2C 
liposomes. Cytochrome c intensity was significantly (p < 0.05) reduced compared to healthy 
control cells following 300|jM DOTAP liposome treatment indicative of cytochrome c release. A 
reduction was also found following valinomycin and 100pM DOTAP liposome treatments but 
was not significant.
Of the targeted liposomes MC2C liposomes at 300pM caused the most significant effect leading 
to apoptosis in THP-1 cells after 24 hours with a highly significant cell loss (p < 0.001), a 
significant increase in nuclear intensity (p < 0.01) and a decrease in MMP. Liposome 
concentrations required for transfection were <300pM.
102
MC
6C
 
MC
4C
 
MC
2C
 
DO
PC
 
DO
PS
 
D
O
TA
P
Nuclei Cell Permeability MMP Cytochrome c
Figure 3.15: High content cell assessment of liposome associated cytotoxicity in differentiated 
THP-1 cells. Fluorescent images were acquired in 4 channels by an INCELL 1000 analyser and 
show cells treated with 100pM liposomes in complete media for 24 hours.
103
100 
ljM
MC
6C
 
MC
4C
 
MC
2C
 
DO
PC
 
DO
PS
 
D
O
TA
P
Nuclei Cell Permeability MMP Cytochrome c
Figure 3.16: High content cell assessment of liposome associated cytotoxicity in differentiated 
THP - 1  cells. Fluorescent images were acquired in 4 channels by an INCELL 1000 analyser and 
show cells treated with 300pM liposomes in complete media for 24 hours.
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Figure 3.17: High content cell assessment of toxicity in differentiated THP-1 cells induced by 
liposomes. Differentiated THP-1 cells were treated with 100pM H  or 300 i^M H I  anionic 
(DOPS), neutral (DOPC) or mannosylated (MC2C, MC4C and MC6 C) liposomes. Positive 
controls were treated with 120pM valinomycin or 100 or 300 pM cationic (DOTAP) liposomes. 
Cells were treated for 24 hours, fixed and stained. Images were acquired and analysed using 
an INCELL 1000. Cell loss, nuclear size and intensity, MMP, cytochrome c release were 
measured (A-F). Data represented as means ± SD (n = 9). Statistical significance was 
determined by two-way ANOVA vs untreated controls (* p < 0.05, ** p < 0.01, *** p < 0.001)
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3.4.5 Liposome Immunogenic Effects in a Macrophage Cell Model
3.4.5.1 NFkB Activity Induction by Liposome Treatment
To develop a successful drug delivery system it must have low toxicity and not lead to immune 
activation. Liposomes were incubated with THP-1 Blue cells and NFkB activation was 
determined. NFkB is a transcription factor that is activated by various stimuli and has a central 
role in inflammation [201], A significant increase in NFkB activation compared to untreated cells 
was found following 24 hour treatment with the positive control LPS (p < 0.001) (Figure 3.18). 
NFkB activation by DOPS liposomes was concentration dependent and 300pM DOPS 
liposomes (p < 0.01) induced significant NFkB activation. NFkB was also significantly activated 
by 100|jM DOPC liposomes (p < 0.05).
However, mannosylated liposome treatment showed no significant difference in NFkB activation 
compared to untreated cells but in comparison to unmannosylated DOPC liposome treatment at 
equal concentrations NFkB activation was significantly lower following 200|jM MC4C (p < 0.01), 
300|jM MC4C (p < 0.05), 200pM MC6C (p < 0.05) and 300|jM MC6C (p < 0.05) liposome 
treatment. Activation of MR has previously been shown to have an anti-inflammatory effect with 
impaired NFkB activation [188, 189]. Mannosylated liposomes have reduced NFkB activation in 
differentiated THP-1 cells compared to unmannosylated DOPC liposomes in a concentration 
and mannosylated cholesterol linker dependent manner.
Figure 3.18: Liposome induced NFkB Activation in THP-1 Blue Cells. Data represented as 
means ± SD (n = 3)
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3.4.5.2 TH1/TH2 Cytokine Response
NFkB can induce transcription of many pro-inflammatory genes such as TNFa, IL-1 (3, IL-6 and 
IL-8 [201]. In order to assess these downstream effects the production of a range of cytokines 
were determined including cytokines associated with a TH1 response such as TNFa, IL-1 (3, IL- 
2, IL-12p70, IFNy and IL-8 (Figure 3.19) and a TH2 response such as IL-2, IL-4, IL-5, IL-10 and 
IL-13 (Figure 3.20).
As part of the TH1 response TNFa was significantly induced by LPS (p < 0.05), further 
validation of inflammatory macrophage cell model used for in vitro  transfections. DOPS 
liposomes at 300pM also induced TNFa production but not significantly. All other liposome 
treatments did not induce a TNFa response above untreated control cells. The pro- 
inflammatory cytokine IL-1 (3 was increased above baseline levels following LPS, DOTAP 
(100pM and 300pM) and DOPS (300pM) liposome treatments but was not significantly induced 
in differentiated THP-1 cells by any treatment. IL-2 was induced by LPS, DOPS (300pM) MC2C 
(100 and 300pM) and MC6C (lOOpM) liposomes but decreased following treatment with DOPC 
(100 and 300pM), MC4C (100 and 300|jM) and MC6C (300jjM) liposomes. IL-12p70 was only 
slightly elevated following LPS stimulation. Induction of IL-12p70 was brought about by DOPC 
(300pM) and MC2C (100|jM) liposomes but not significantly. No significant changes in IFNy 
expression were detected. However, elevated IFNy was measured following LPS, DOTAP 
(100pM), DOPS (300pM), MC2C (100pM) and MC4C (100pM) liposome treatments. DOPC 
(100 and 300pM), MC4C (300pM) and MC6C (100 and 300pM) decreased IFNy levels 
compared to untreated control cells. IL-8 is an important chemokine for neutrophil recruitment 
and therefore is upregulated during inflammation. Significant induction of IL-8 (p < 0.05) 
followed 24 hour treatment with 300pM DOPS liposomes. LPS also increased IL-8 production 
in THP-1 cells while mannosylated liposomes showed levels of IL-8 below untreated control 
cells.
The TH2 response is most reliant on IL-4 [202] which was increased in differentiated THP-1 
cells following treatment with LPS and 300pM DOPS liposomes. IL-5 levels were elevated 
above levels of untreated cells by LPS, DOPS (300jjM), MC2C (100pM) and MC6C (300pM) 
liposomes (Figure 3.20). IL-10 was also induced by LPS, DOPS (300pM), MC2C (100pM) and 
MC6C (100pM) liposomes. IL-13 was induced by all treatments except MC4C (100pM). 
Induction of IL-13 by 300pM MC6C liposomes was significant (p < 0.05).
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Figure 3.19: TH1 response in differentiated THP-1 cells following 24 hour liposome treatment. 
Differentiated THP-1 cells were incubated for 24 hours with complete media (negative control), 
100ng/ml LPS (positive control) or DOTAP (liposome positive control), DOPS (anionic), DOPC 
(neutral), mannosylated (MC2C, MC4C, MC6C) liposomes at IOOjjM ( ) or 300mM ( ■ ) .
Supernatants were analysed using a MSD 10-plex cytokine assay and TNFa, IL-1 p, IL-2, IL- 
12p70, IFNy and IL-8 concentrations were determined.
Data represented as means ± SD. (n = 3) Statistical significance was determined by two-way 
ANOVA with Bonferini’s Post-hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001)
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Figure 3.20: TH2 repsonse in differentiated THP-1 cells following 24 hour liposome treatment. 
Differentiated THP-1 cells were incubated for 24 hours with complete media (negative control), 
100ng/ml LPS (positive control) or DOTAP (liposome positive control), DOPS (anionic), DOPC
(neutral), mannosylated (MC2C, MC4C, MC6 C) liposomes at 100pM ( ) or 300pM ( ■ ) .
Supernatants were analysed using a MSD 10-plex cytokine assay and IL^4, IL-5, IL-10 and IL- 
13 concentrations were determined.
Data represented as means ± SD. (n = 3) Statistical significance was determined by two-way 
ANOVA with Bonferini’s Post-hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001)
109
3.5 Discussion
Previous strategies for liposomal gene delivery have centred on cationic formulations. However 
limitations due to toxicity have focused interest in alternative non-toxic biocompatible 
formulations. Neutral lipids have received FDA approval for use in liposome delivery of many 
drugs such as amphotericin B (Ambisome®) [182], Consequently neutral and anionic lipids are 
currently being explored for siRNA delivery. Here we have formulated a range of liposomes 
based on neutral and/or anionic lipids specifically to target alveolar macrophages. These 
liposomes were composed with phosphatidylserine to target macrophage SR s or mannosylated 
cholesterols to target the macrophage MR. Both of these strategies have previously been 
shown to provided specific macrophage targeting and enhance cell uptake but neither 
formulations have been harnessed for siRNA delivery.
An essential step in targeted delivery is internalization of the carrier system by the target cells. 
Cell uptake of liposomes has been studied using a range of techniques such as flow cytometry, 
confocal microscopy and spectrofluorimetry [115, 197, 198]. We have developed a more 
powerful method for uptake analysis using HCA to combine imaging and uptake quantification, 
from single cells to cell populations, in a high throughput format [198, 203]. From both 
spectrofluorimetry and HCA uptake data DOPS and mannosylated liposomes showed 
significantly better cellular uptake compared to untargeted DOPC controls. Spectrofluorimetry 
determined the greatest degree of cellular uptake by differentiated THP-1 cells of 7.5% MC4C 
liposomes while MC6 C liposomes were repeatedly the most significantly internalized liposome 
formulations determined by HCA. Spectrofluorimetry relies on the fluorescence intensities of 
lysed cells that have previously been treated with fluorescent liposomes. This technique does 
therefore not distinguish between liposomes associated with cells or the culture plate and those 
internalized. HCA can add further levels of precision. The protocol was established to count 
liposomes per cell. Cells could be identified and consequently liposomes counted in the cell 
only. This could explain the difference in the relative uptake levels of MC4C and MC6 C  
liposomes determined using spectrofluorimetry and HCA.
HCA also enabled multiple, parallel experiments to be carried out to optimize the liposome 
formulation for siRNA delivery to macrophages. Optimal sizes ranged from 200 to 400nm, 
concentrations were above 100pM and incubation times >2 hours for the leading DOPS and 
MC6 C liposomes. Uptake of mannosylated liposomes also appeared to be linker dependent 
with uptake of liposomes composed with mann-C6 -chol greater than those composed with 
mann-C4-chol which both facilitated higher uptake than MC2C liposomes. Engel et a\. (2003) 
investigated the influence of spacer length between alkyl mannosides and liposome surface, on 
liposome interaction with phagocytic cells [174]. Spacers were 0 to 8  ethyleneoxy units long 
(ManO - Man8 ) with longer spacers mannosylated liposome uptake by MR expressing cells was 
more enhanced [174]. Furthermore Gal-C6 -Chol composed liposomes were previously shown 
to mediate a higher DNA transfection efficiency than Gal-2-Chol and Gal-C4-Chol liposomes 
[173].
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Strategies to encapsulate siRNA included the incorporation of a small percentage of DOTAP 
into the liposome formulation [168] and the condensation of siRNA using various cationic 
reagents [98]. The first strategy yielded low and variable encapsulation and transfection 
efficiency in THP-1 cells. Whereas, encapsulation of DOTAP, PEI and protamine condensed 
siRNA in DOPS liposomes yielded significant knockdown in primary monocytes. PEI and 
protamine formulations were the most effective. Depending on the liposome and complexation 
agent knockdown was observed either at 24 or 48 hours. DOPS liposomes appeared to have a 
more rapid effect than MC6C liposomes with knockdown of TNFa detected after 24 hours using 
DOTAP, PEI and protamine as condensing agents. DOPS/PEI/TNFa liposomes also showed 
very significant (p < 0.01) knockdown after 48 hours. MC6C liposomes mediated TNFa gene 
suppression at 48 hours with PEI and protamine siRNA complexes while DOTAP/siRNA 
formulations decreased TNFa at 24 hours. Additionally, TNFa expression was increased by 
commercial reagent lipofectamine 2000 after 24 hours and failed to illicit knockdown. This 
highlights the importance of avoiding cationic liposomes in the treatment of inflammatory 
conditions. Previously, Jing et al. (2008) delivered TNFa targeted siRNA encapsulated in 
anionic liposomes composed of phosphatidyl ethanolamine (PE), CHEMS and cholesterol 
(PE:CHEMS:Chol 7:4:2) to primary rat kupffer cells (resident macrophages of the liver) [102], 
Significant knockdown of TNFa following LPS stimulation was found up to 4 days following 
transfection ranging from 50 to 70% relative to non-target siRNA liposome controls [102]. 
Furthermore, a study using cationic liposome formulations to deliver anti-TNFa siRNA reported 
27-32% TNFa suppression in J774.1 murine macrophages following LPS stimulation [204],
Drug delivery systems are not always inert and therefore toxicity screening is important 
particularly relating to nanotoxicology. Nanoparticle induced toxicity is connected to particle 
size and surface chemistry and especially important in the lungs [205]. Smaller liposomes can 
be more toxic than larger liposomes [206]. HCA and the Cellomics Multiparameter Cytotoxicity 
kit allowed the screening of multiple parameters in differentiated THP-1 cells following liposome 
treatment for 24 hours. For these assays the ionophor valinomycin served as a positive control 
and validated the assay in terms of detection of changes in cell number, nuclear morphology, 
cell permeability, MMP and cytochrome c release in a toxic event. Usually assays such as MTT 
are used to assess cell viability but this method enables more subtle changes in cell health to 
be detected with more detail. Aside from toxicity, drug delivery systems can also induce 
immune responses, the extremes of which have been witnessed in clinical trials and in some 
cases have been fatal [1]. To assess the effects of the liposome carriers on the immune 
response in differentiated THP-1 cells we looked at NFkB activation and at cytokine/chemokine 
induction following 24 hours treatment with liposomes. NFkB can be activated through various 
receptors including TLRs and TNF receptors. NFkB is a transcription factor that regulates the 
transcription of numerous genes including TNFa, IL-8 and IL-10 [201].
Cationic liposomes have previously exhibited cytotoxic effects, particularly in macrophages 
[200] and consequently were avoided in the formulation of our siRNA liposomes. Additionally a 
study compared thé toxicity of liposomes composed of cationic (SA and cardiolipin), anionic
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(phosphatidylglycerol and phosphatidylserine) or neutral (phosphatidylcholine or 
dipalmitoylphosphatidylcholine) lipids [206]. Toxicity was determined at 200|jM, 130-3000|jM 
and 3000-4000pM for cationic, anionic and neutral liposome formulations in a range of human 
cell lines [206]. Cationic DOTAP liposomes however were used as positive toxic liposome 
controls in toxicity and immunogenicity assays. DOTAP liposomes induced significant cell loss 
while increasing cell permeability, decreasing MMP and promoting cytochrome c release at 100 
and 300pM indicative of both apoptosis and necrosis. DOTAP liposomes also induced a more 
predominantly TH1 response in the macrophage-like cells with increases in IL-1P, IL-2 and IFN- 
Y and decreases in IL-4. DOTAP has been shown to suppress TNFa synthesis in activated 
macrophages [200] and therefore the lack of TNFa induction following DOTAP liposome 
treatment was expected.
Anionic liposomes were composed of DOPS which targets macrophage SR s by mimicking 
apoptotic cells. At the higher concentration of 300|j M DOPS liposomes were found to reduce 
cell number and MMP, a sign of induced apoptosis. Furthermore, NFkB activity was 
significantly induced (p < 0.001) at 300pM and related cytokines induced including TNFa, IL-1p 
and IL-8. IL-8 was significantly induced (p < 0.05). DOPS liposomes were the most potent 
inducer of cytokines and chemokines in THP-1 cells with all measured immune mediators 
induced except IL-12p70.
Neutral DOPC liposomes were not completely inert either. Cell loss resulted from 300mM 
treatments of DOPC liposomes in THP-1 cells however other signs of apoptosis or necrosis 
were not observed. Interestingly NFkB was significantly (p < 0.05) activated following 24 hour 
DOPC liposome treatment at 100pM and IL-12p70 was induced by a 300pM dose of DOPC 
liposomes. In general DOPC liposome treatment in THP-1 cells resulted in reduction of immune 
mediators compared to untreated control cells.
Activation of the MR can have immunosuppressive effects and inactivate NFkB [188, 189]. A 
decrease in NFkB activity was observed in differentiated THP-1 cells following 24 hour 
incubation with MC4C and MC6C liposomes in a concentration dependent manner. Inactivation 
of NFkB associated with mannosylated liposome treatments at 200|jM and 300pM was 
significant compared to DOPC unmannosylated liposome treatments. In general this non- 
immunogenic effect was corroborated in cytokine screens. MC2C liposomes which did not 
significantly alter NFkB activation induced increased synthesis of IL-12p70 (to a lesser extent 
than DOPC liposomes), IFNy (at 100pM, similar to MC4C) and IL-2 and IL-13, IL-5 and IL-10 in 
a TH2 response. MC2C liposomes at 300|j M induced significant cell loss (p < 0.001) and 
showed increased nuclear intensity (p < 0.01) and a drop in MMP all signs of apoptosis.
On the other hand MC6C liposomes composed of mannosylated cholesterols with longer linker 
length at 300|jM induced significant cell loss but all other measures of cell health were 
comparable with untreated control cells. A significant inactivation of NFkB was induced by 
MC6C liposomes at 200 and 300pM with induction of TH2 cytokines in cells including IL-5, IL-10
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and IL-13 (p < 0.05). MC6C liposomes were also lead to IFNy and IL-8 suppression compared 
to untreated control levels. Previously, TNFa, IL-ip  and cytokine-induced neutrophil 
chemoattractant-1 (CINC-1) levels have been monitored in vitro in alveolar macrophages and in 
vivo in rat lungs following mannosylated liposome delivery of dex [130]. However, the immune 
response to mannosylated liposomes alone has not been investigated.
Overall, a range of liposomes were prepared that successfully targeted macrophages with 
DOPS and mannosylated 7.5% MC6C liposomes as the leading formulations. A range of 
macrophage targeting liposomes were prepared and HCA was applied to study their uptake into 
macrophage cells. DOPS and MC6C liposomes showed the most significant cellular 
internalization. The ability of liposomes to mediate gene silencing of a therapeutic inflammatory 
target TNFa was also assessed. Anionic DOPS and mannosylated liposomes encapsulated 
siRNA and mediated significant knockdown of an inflammatory cytokine in primary monocytes. 
At the lower concentration range suitable for in vitro transfection liposomes were non-toxic 
however DOPS liposomes caused immune activation particularly an inflammatory response in 
differentiated THP-1 cells. Although knockdown via MC6C liposomes was not as significant as 
DOPS formulations MC6C liposomes showed immunosuppressive characteristics such as a 
hampering of NFkB activation and reduced IL-8 and IFNy production. Hence, MC6C liposomes 
have the potential of mediating a dual anti-inflammatory effect via MR activation and delivery of 
anti-TNFa siRNA.
Key Findings
• Targeting (via DOPS and mannosylated cholesterols) significantly enhanced 
liposome uptake by macrophages
• Targeted liposomes mediated significant TNFa knockdown via delivery of TNFa 
targeted siRNA in LPS stimulated macrophages
• At higher doses targeted liposomes induced some cytotoxicity
• DOPS liposomes induced an inflammatory response while mannosylated liposomes 
showed immunosuppressive characteristics in differentiated THP-1 cells
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Chapter 4
Microparticles for siRNA Delivery to Alveolar Macrophages
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4.1 Introduction
Gene transfer by non-viral vectors has also been investigated using naturally occurring or 
synthetic polymers such as poly(ethyleneimine) (PEI), chitosan, gelatin, silica, PLL, polylactic 
acid (PLA) and PLGA [207, 208]. PLA and PLGA are the most extensively studied for general 
polymeric drug delivery. Polymer-based particles of less than 1000nm in diameter are generally 
referred to as nanoparticles while microparticles have diameters ranging between 1 and 250pm 
[209]. However, these designations are not widely agreed upon. Polymers allow encapsulation 
of a wide variety of drug types both small molecules and a range of macromolecules including 
proteins, antigens, vaccines and nucleic acids and can be designed to promote cell uptake [209, 
210]. PLGA microparticles have been engineered by our group to specifically target 
macrophages and enhance uptake using HCA [198]. siRNA has previously been incorporated 
into PLGA particles with favourable in vitro efficacy (Table 4.1). Development of macrophage 
targeting PLGA microparticles loaded with TNFa targeted siRNA allows comparison between a 
lipid (Chapter 3) and polymer based non-viral delivery of siRNA in terms of stability, uptake, 
toxicity and im mu nogen icity in order to determine the most suitable delivery system for in vivo 
applications.
4.1.1 PLGA Microparticles
PLGA microparticles allow controlled release of the loaded drug over periods extending to days 
and months [209]. This offers the advantage of sustained delivery perhaps negating the need 
for repeated dosing. Other advantageous qualities of PLGA include biocompatibility, low 
immunogenicity, low toxicity and biodegradability. For nucleic acid application PLGA  
microparticles allow high loading capacity, improved formulation stability and macrophage 
targeting [198] however nucleic acid stability during particle preparation could be an issue. 
PLGA in vivo is hydrolysed to form lactic acid and glycolic acid which are removed through the 
citric acid cycle [211]. The rate of biodégradation is dependent on the PLGA composition [209] 
but is slow, consequently these biocompatible degradation products do not interfere with normal 
cell function [211]. It has also been reported that PLGA encapsulated drugs achieve sustained 
cytoplasmic delivery with rapid endo-lysosomal escape. This is due to their ability to change 
surface charge in the acidic endo-lysosomal environment, a property that makes PLGA  
microparticles suitable for gene delivery. PLGA has established use in humans [212] with 
numerous FDA approved PLGA-based microparticle therapies [209].
Figure 4.1: Structure of poly(D,L-lactide-co-glycolide) (PLGA). X represents the lactic acid 
component and Y represents the glycolic acid component
115
Polymeric microparticles contain uniformly distributed interstitial spaces between polymer 
chains. Hydrophobic drugs which are miscible with PLGA tend to fill these spaces [213]. 
Nucleic acids such as DNA and siRNA are generally encapsulated by polymeric particles using 
double emulsion methods. The double emulsion method provides improved encapsulation 
efficiency over single emulsion methods as the nucleic acids and polymer tend not to be soluble 
in the same solvents [213]. Consequently distribution of encapsulated nucleic acid is not evenly 
dispersed through the particle usually accommodating voids within the particle rather than 
interstitial spaces. This leads to large initial burst release. In order to reduce or control the 
initial burst, formulations can be altered to improve the miscibility of the drug and polymer such 
as complexation of the nucleic acid with a cationic reagent such as PEI, use of co-solvents or 
chemical modifications of the drug including esterification and PEGylation or of PLGA [211]. 
Alternatively nucleic acids can be complexed with PLGA particles rather than encapsulated by 
coating the PLGA particle in a cationic surfactant such as cetyltrimethylammonium bromide 
(CTAB) [214]. However CTAB preparation has been associated with decreased in vitro DNA 
release [215],
4.1.2 PLGA Microparticle Preparation
Difficulties can arise in efficiently encapsulating hydrophilic nucleic acids such as DNA and 
siRNA in hydrophobic polymeric microparticles. Therefore approaches such as double 
emulsion water-oil-water (w/o/w) solvent evaporation are used to encourage encapsulation 
[208]. Hydrophilic nucleic acids generally require double emulsion preparations as the drug is 
not soluble in the polymer solvent, usually an organic solvent such as DCM or ethyl acetate 
leading to poor encapsulation efficiency by single emulsion methods [213].
PLGA microparticles can be prepared using a diverse range of methods that have been 
optimised over the past few decades to produce particles with specific characteristics including 
size, morphology, surface charge, cell specific targeting, controlled release profiles and specific 
drug loading or encapsulation. In general polymers are dissolved in an appropriate solvent 
typically ethyl acetate or DCM and the drug solution such as an aqueous pDNA or siRNA 
solution is added. The organic and aqueous solutions are mixed by homogenisation to form an 
emulsion (water in oil (w/o)), in the case of double emulsion methods this is the primary 
emulsion. Emulsions are then transferred to an emulsifying solution mostly commonly a 
polyvinyl alcohol (PVA) solution and homogenized to form the secondary emulsion which is 
added to another emulsifying solution, solvent is removed and particles isolated and dried [215], 
Parameters required for preparation are polymer and cargo dependent. Alternatively polymeric- 
drug emulsions can be added to a hardening agent or spray dried to promote particle formation 
(Figure 4.2).
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Figure 4.2: Polymer-based microparticle preparation techniques for encapsulating
macromolecular drugs [209]
Each step in the preparation process will determine the characteristics of the particles formed. 
The properties and scale of the. drug being encapsulated determine the optimal method for 
encapsulation such as double emulsion for nucleic acids. Size can be determined by various 
means such as homogenisation speed and the percentage PVA used as an emulsifier [208, 
215]. Surface charge and targeting can be altered by modifications to PLGA or later coating of 
the particles [213]. Drug release from PLGA particles occurs by diffusion and/or particle erosion 
and usually involves an initial burst release followed by sustained release over days and months 
[213]. The initial burst refers to drug that is released prior to polymer erosion-related release 
[213]. To create more predictable and reproducible release profiles, modification of particle 
preparation methods are key. Drug release is dependent on various factors including drug 
solubility and distribution within the particle and the presence of channels or pores [213].
PVA is a non-toxic and non-mutagenic polymer and is the most commonly used emulsifying 
agent in PLGA microparticle formulation [215]. It is used to stabilize the emulsion as it is 
associated with the formation of relatively small particles with uniform size distribution [216] but 
is also a limiting factor in PLGA based gene delivery [207]. PVA is used up to 10% (w/v) in 
aqueous solution and the greater the percentage PVA the smaller the particles. Residual PVA 
remains following aqueous washes during particle preparation as it forms an interconnected 
network with the polymer at the interface [217]. The amount of residual PVA is related to the % 
PVA solution used to stabilize the emulsion and the organic solvent used during particle 
preparation. Residual PVA can affect many physicochemical properties of the particles 
including drug release, zeta potential, encapsulation efficiency and surface hydrophobicity as
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well as cell uptake [217], Sahoo et al. (2002) found reduced cell uptake by human arterial 
smooth muscle cells of PLGA nanoparticles associated with increased residual PVA [217].
PLGA particle preparation techniques however involve mechanical, thermal and chemical 
stresses which could damage the drug being encapsulated [209]. DNA damage can be caused 
by sonication, homogenisation, high percentage PVA solutions, high interfacial surface tension 
at the oil water interface, acidic conditions during formulation due to the presence of PLGA and 
freeze drying [215]. Furthermore the amassing of oligomers due to degradation of DNA within 
the particles can produce an acidic environment leading to inactivation of the encapsulated DNA 
[215]. Various measures can be taken to minimize denaturation or inactivation of nucleic acids 
such as complexation with cationic agents to protect the nucleic acid or the addition of a 
buffering solution which can lower the deleterious effects of sonication and acidic environments 
[215].
4.1.3 siRNA-Microparticles
To date most studies have focused on the formulation of pDNA loaded polymeric particles but 
with an increased requirement for non-viral, biocompatible siRNA delivery systems these 
findings and formulations are being applied to siRNA polymer encapsulation and delivery. 
Double emulsion solvent evaporation is the most commonly used technique for siRNA 
microparticle preparations (Table 4.1) and produces solid particles with low encapsulation 
efficiencies. To overcome poor encapsulation and transfection efficiencies cationic reagents 
such as PEI [156, 218], DOTAP [219], chitosan and polyamines have been incorporated into 
formulations. Recently Lee et al took a more novel approach to PLGA siRNA particle 
formulation by the preparation of self-assembling siRNA-PLGA conjugate micelles [220]. siRNA 
was conjugated to PLGA via cleavable disulfide bonds at the 3’ end of siRNAs. These 
conjugate in aqueous solution spontaneously formed 20nm micelle structures which were then 
coated with linear PEI to form 30nm cationic particles.
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Table 4.1 Summary of PLGA delivery of siRNA
siRNA
Target
Method Particle
Diameter
EE % Effect Ref.
TNFa siRNA/PEI complexed
Double emulsion solvent evaporation
Lyophilisation
26 -32pm < 77% siRNA/PEI polyplex 
burst release
[156]
eGFP
Luciferase
DOTAP mixed with PLGA in 
chloroform
Double emulsion solvent evaporation 
Spray drying
207.7 -  
261.1 nm
Significant eGFP 
knockdown in H-1299 
cells
[219]
eGFP. Double emulsion solvent evaporation 
Spray drying
60% [221]
GFP siRNA conjugated to PLGA
Self-assembly followed by PEI 
coating
30nm - Successful knockdown 
of GFP
[220]
eGFP Double emulsion solvent evaporation 
Freeze dried
~250nm -70% Release profile shows 
initial burst followed by 
slow release. Optimised 
formulation parameters. 
siRNA functional after 
encapsulation
[222]
STAT3 siRNA complexed with PEI or PEI- 
StA
Double emulsion solvent evaporation 
Freeze dried
351/392nm
(w/PEI or 
PEI-StA)
26.31/43.98
%
(w/PEI or 
PEI-StA)
Three phase release 
profile with burst release 
within 24hrs, sustained 
release up to 6 
days.increased until 8 
days. Up to 77% 
reduction in pSTAT3 
compared to naked 
siRNA treated cells
[218]
TNFa siRNA/DOTAP complexes 
Single emulsion
709 nm -31% After 24 hours significant 
TNFa suppression in 
LPS activated 
macrophages
[223]
Luciferase siRNA/DOTAP complexes (also 
chitosan modified particles)
Emulsion solvent diffusion
Freeze dried
317nm 28.3% Chitosan modified 
nanospheres showed 
higher uptake and 
knockdown ability than 
unmodified PLGA 
nanospheres
[2241
VEGF siRNA complexed with arginine or 
PEI
Double emulsion solvent evaporation
35 -45 pm Arg:64.3%
PEI:80.3%
Sustained siRNA 
release for one month
Effect on tumour growth
[225]
EGFR Double emulsion deposition 10-20 pm [2261
119
4.1.4 Microparticles for Targeted Delivery to Alveolar Macrophages
Microparticles can be prepared over a wide range of sizes; larger sized microparticles are 
advantageous when targeting macrophages, as size is an important factor in cell uptake. It has 
been shown that particle size ranging from 1 to 10pm are preferentially internalised by antigen 
presenting cells (APCs) such as macrophages and dendritic cells which is an advantageous 
feature in DNA vaccine development [215]. Previously, uptake of PLGA microparticles ranging 
in size were assessed by us in primary alveolar macrophages and differentiated THP-1 cells 
and microparticles of 2.1 |jm in diameter showed the greatest cell uptake [198], The optimal 
mass median aerodynamic diameter (MMAD) of particles for efficient pulmonary delivery ranges 
from 1|jm to 5^m [153]. Consequently, PLGA microparticles loaded with siRNA can be 
bioengineered for both inhalation and alveolar macrophage targeting.
Previously it has been shown that gelatin coating can promote macrophage uptake possibly via 
opsonisation. Gelatin is a natural polymer and is derived from collagen [227]. It is widely used 
in various clinical applications and is noted for its safety in vivo. Similarly to PLGA, gelatin is 
biodegradable and can be used to load biomolecules for controlled release delivery to cells. 
The surface charge of gelatin is determined by the conditions used for extraction from collagen 
[227] and a change in zeta potential or surface charge can dramatically affect cell internalisation 
efficiency. Recently our group has shown the uptake of PLGA microparticles by differentiated 
THP-1 cells to be significantly (p < 0.05) enhanced by gelatin coating [198].
4.1.5 Chapter Aims
This chapter sets out to bioengineer microparticles specifically for siRNA delivery to alveolar 
macrophages.
• Development of a method for efficient siRNA encapsulation in PLGA microparticles of 
optimal size for macrophage uptake
• Assess macrophage cell uptake of PLGA microparticles loaded with siRNA
• Determine transfection efficiency using TNFa siRNA
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4.2 Materials
1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP), M.W. 698.542, Avanti Polar Lipids Inc. 
1x Saline
AllStars negative control siRNA, Qiagen 
Chloroform, Sigma Aldrich 
DCM, Sigma Aldrich 
DEPC, Sigma Aldrich
EasySep CD14 kit, StemCell Technologies
EasySep magnet, StemCell Technologies
Ethanol, Sigma Aldrich
FreeZone4.5, Labconco
Gelatin, Sigma Aldrich
HBSS, Invitrogen
Isopropanol, Sigma Aldrich
LightCycler 480 PCR system, Roche
LSM510 Meta laser scanning confocal microscope, Zeiss
Lymphoprep, Axis Shield
Malvern Mastersizer 2000, Malvern Instruments
Nanoseries Zetasizer, Malvern
Nucleofector® Device, Lonza
Nucleofector® Kit V for THP-1, Amaxa
Oligonucleotide primers, MWG Biotech
Poly(lactic-co-glycolic acid) (PLGA) 503, Boehringer Ingelheim
Quantitect Reverse Transcription kit, Qiagen
RPMI, BioSera
siGENOME Non-Targeting siRNA #2, Dharmacon
Silencer® Select Pre-designed siRNA, Ambion
siPORT™ NeoFXTM Transfection Reagent, Applied Biosystems
SYBRgreen master mix, Roche 
t-butanol, Sigma
Tescan Mira XMU Variable Pressure Field Emission Scanning Electron Microscope 
(VPFESEM), Tescan USA Inc. USA 
TRI Reagent, Sigma Aldrich 
Vectashield, Vector Laboratories
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4.3 Methods
4.3.1 siRNA
siGENOME Non-Targeting siRNA #2 (Dharmacon) and Silencer® Select Pre-designed TNFa 
siRNAs are described in 3.3.1. AHStars negative control siRNA (Qiagen) was modified with Alex 
Fluor 488 (fl-siRNA) and has no homology to any known mammalian gene. Silencer® Select 
Pre-designed siRNA were also targeted to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). siRNAs were reconstituted with nuclease-free water to a concentration of 50 or 
100mM.
4.3.2 Cell Culture
THP-1 cells were maintained as described in Chapter 3.
4.3.2.1 Isolation of Monocytes/Macrophages from peripheral blood
Primary blood monocytes were isolated using Ficoll-Paque™ Plus and MACS CD14 kit as 
described in 3.3.2.2 or Lymphoprep and EasySep CD14 kit. For EasySep CD14 purification 
primary monocytes were isolated from heparinized venous peripheral blood obtained from 
volunteers. Whole blood was collected from patients in Lithium-Heparin serum tubes. Blood 
was immediately transferred to 50ml tubes and mixed gently with an equal volume of 0.9% NaCI 
(1x saline). Diluted blood was then carefully layered over Lymphoprep in fresh 50ml tubes 
(volume ratio 2:1 blood: Lymphoprep) for density gradient centrifugation. Tubes were 
centrifuged at 800g for 10 minutes at room temperature with the brake off. Following 
centrifugation a distinct band of mononuclear cells is formed at the blood/lymphoprep interface 
(the buffy coat). The mononuclear cell layer was carefully aspirated using a pasture pipette and 
washed in HBSS (10 -  20ml). Cells were pelleted by centrifugation at 1500 rpm for 5 minutes 
with the brake on. Monocytes were purified using the EasySep Human CD14 Selection 
Cocktail. Briefly cell pellets were resuspended in 1ml EasySep recommended medium (PBS 
containing 2% FBS and 1 mM EDTA) and transferred to a polystyrene tube. EasySep positive 
selection cocktail 100pl per ml of cell suspension was added, mixed gently and incubated at 
room temperature for 15 minutes. Positive seclection cocktail consists of monoclonal antibodies 
bound in bispecific tetrameric antibody complexes (TAC) directed against CD14 and dextran in 
PBS. EasySep magnetic particles (magnetic dextran iron particles in water) were added to the 
cell suspension (50pl/ml of cells) and mixed followed by 10 minute incubation at room 
temperature. The cell suspension volume was brought up to 2.5ml with recommended medium 
and mixed. The tube was placed into the EasySep magnet and incubated for 5 minutes at room 
temperature. The magnet and tube were inverted in one continuous motion and held inverted 
for 2 seconds. The tube was removed from the magnet and cells (adhered to the tube sides) 
were resuspended in 2.5ml of recommended media and the washing step repeated twice more 
for a total of 3 washes. Finally cells were resuspended in 1ml of 10% RPMI and transferred to a
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polypropelene tube. Cells were counted, plated and maintained in RPMI 1640 containing 10% 
FBS in a 5% C02 atmosphere at 37°C.
4.3.3 Preparation of siRNA loaded Poly(lactic-co-glycolic acid) Microparticles
Microparticles containing fl-siRNA, GAPDH or TNF-a siRNA were prepared using a double 
emulsion (w1/o/w2). To improve encapsulation efficiency siRNA was condensed with a cationic 
lipid DOTAP at a N:P ratio of 4:1 (Table 2.4) using a HFDM method adapted from Wu et al. 
(2009) [228], HFDM was shown previously to produce lipid particles in the nanometer range 
with very high siRNA encapsulation efficiencies at N/P ratio 4 [228]. DOTAP and PEI have also 
been used in a number of studies to promote siRNA loading into PLGA partilces [156, 218, 219, 
223-225]. Naked siRNA and siRNA PEI complexes were also assessed but gave negligible 
siRNA encapsulation.
For a 50mg PLGA preparation, 100nmoles of siRNA was diluted in 200pl of DEPC-treated 
RNase-free water (the equivalent of 24.2 nmoles of phosphate). 96.8nmoles of DOTAP 
(67.62[jg) was dissolved in 200(jI of f-butanol. The siRNA solution was added dropwise to the 
lipid mixture, mixed and lyophilised overnight (Figure 4.3). 50mg of PLGA 503 (Boehringer 
Ingelheim) was dissolved in 1.75ml DCM (2.9% w/v) and vortexed. Lyophilised siRNA/DOTAP 
was resuspended in 50pl of RNase-free water and 1ml of the PLGA solution and vortexed 
vigorously. The remaining 750pl of PLGA solution was added and the mixture was manually 
probe sonicated for 30 seconds at an output level of 1 to form the primary (w/o) emulsion. The 
primary emulsion was added dropwise to a 5% (w/v) PVA solution (12.5ml) homogenizing over 
an ice-bath at 13,500 rpm (or level 3) to form a secondary or multiple w/o/w emulsion. This 
emulsion was added to 25 ml 1% (w/v) PVA and gently stirred for 4 hours or overnight at room 
temperature to allow DCM evaporation. Microparticles were recovered by centrifugation at 
5,000 rpm for 15 min at 4 °C, washed three times with water to remove residual PVA, 
resuspended in 1.5ml d dH20 and then lyophilized (Labconco, FreeZone 4.5). For gelatin 
coating, after centrifugation the final pellet was resuspended in gelatin solution (1 mg/ml gelatin 
Type A in deH20 to give a PLGA:Gelatin weight ratio of 1:3) and stirred gently for 4 hours. The 
coated particles were centrifuged at 5,000rpm for 15 min at 4 °C three times and washed with 
dH20  to remove excess gelatin. The final pellet was resuspended in 1.5ml dH20 and 
lyophilized.
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O O
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added to 1% PVA
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siRNA loaded 
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PLGA resuspended in 
1 mg/ml gelatin solution 
stirred for 4 hrs
Figure 4.3: Schematic of siRNA-microparticle preparation by double emulsion solvent 
evaporation method.
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4.3.4 Microparticle Characterisation
4.3.4.1 Particle Size
Microparticle size was determined by laser diffraction using a Malvern Mastersizer 2000 
(Malvern Instruments, UK). Lyophilized microparticles (5mg) were resuspended in 1 ml of dH20  
and sonicated. Particle sizes were recorded in triplicate for each batch of microparticles.
4.3.4.2 Zeta Potential of microparticles
Zeta potentials of microparticles were measured in disposable capillary cells using a nanoseries 
Zetasizer (Malvern) to determine surface charge. Lyophilized microparticles (5mg) were 
resuspended in 1 ml of dH20  and sonicated. Zeta potential for each batch was acquired five 
times and means were calculated.
4.3.4.3 Surface morphology by scanning electron microscopy (SEM)
Microparticle size and surface morphology was assessed by scanning electron microscopy 
(SEM) using a Tescan Mira XMU Variable Pressure Field Emission Scanning Electron 
Microscope (VPFESEM) (Tescan USA Inc. USA). Lyophilized particles were mounted onto 
aluminium stubs with double sided adhesive tape and coated in a vacuum with a thin layer of 
gold to impart electrically conductivity using a Polaron SC500 Gold Sputter Coater (Quotum 
technologies). The coated specimen was then examined under the microscope operated at an 
acceleration voltage of 5kV.
4.3.4.4 Encapsulation Efficiency
Lyophilised microparticles encapsulating siRNA (1mg) were dissolved in 50pl of chloroform. To 
this 50pl of nuclease free water was added and the mixture was vortexed for 15 minutes 
followed by centrifugation at 10000 rpm for 5 minutes. The upper aqueous layer was collected 
and the centrifugation step was repeated twice more after the addition of another 50jjI of TE 
buffer. Collected aqueous layers were pooled and the nucleic acid concentrations determined. 
siRNA quantification was estimated using a ribogreen assay (as described in 2.3.2.4) or in the 
case of fl-siRNA fluorescent intensities were measured using fluorescent spectroscopy at 
485nm and 520nm excitation and emission wavelengths respectively. Fl-siRNA concentration 
was determined using a prepared calibration curve.
4.3.4.5 Release Profile of siRNA
siRNA release from PLGA microparticles was assessed over 7 days at 37°C [229] and 
measured by RiboGreen assay. Lyophilised microparticles encapsulating siRNA (5mg) were 
suspended in 1ml TE buffer (pH 7.4) and incubated at 37° C under gentle shaking. At specific
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time points, the microparticle suspensions were centrifuged at 10000 rpm for 10 min. 
Supernatants were collected and stored at >80°C until analysis. Microparticle pellets were re­
suspended with 1ml fresh TE buffer and incubated at 37°C. siRNA in supernatants for each 
time point was determined using RiboGreen assay as described in 2.3.2.4. Cumulative siRNA 
release was calculated.
4.3.4.6 Integrity of encapsulated nucleic acids
siRNA integrity was evaluated by gel electrophoresis using a 20% polyacrylamide (19:1 
acrylamide:bisacrylamide) TBE gel as described in 2.3.2.2. Blue/orange 6x loading dye 
(Promega) was used to track gel migration. Nucleic acids were extracted from microparticle 
preparations by aqueous and solvent phase separation as described in 4.3.4.4. Extracted 
siRNA, stock siRNA and a siRNA marker were loaded and the gels were run in 1x TBE buffer at 
100V for 45 minutes followed by post-staining with GelStar for 30 minutes. Visualization was 
obtained by UV transillumination.
4.3.5 Functional Activity of encapsulated siRNA
TNFa siRNA was extracted from microparticle preparations by aqueous/solvent phase 
separation as described in 4.3.4.4. THP-1 cells (1x106) were electroporated with 50ng of 
unprocessed TNFa or 50ng of microparticle extracted TNFa siRNA using Nucleofector® Device 
(Lonza) and Nucleofector® Kit V for THP-1 (Amaxa). Briefly, 1x106 cells per replicate were 
centrifuged and resuspended in 100pl Nucleofector® Solution. For siRNA transfections, 50ng 
of unprocessed TNFa siRNA or extracted microparticle TNFa siRNA was added to the cell 
suspensions. Each cell suspension was transferred to a cuvette and the cuvette cap was 
closed. The cuvettes were placed into the Nucleofector® Cuvette Holder and programme V001 
selected. Cuvettes were removed from the device and 500pi of supplemented RPMI was 
added. Cell suspensions were transferred to 24 well plates and differentiated with the addition 
of 100nM PMA. After 21 and 45 hours cells were stimulated with 100ng/ml LPS for 3 hrs. 
Media was harvested 24 and 48 hours following electroporation and TNFa expression was 
determined by ELISA.
4.3.6 in  V itro  Uptake of siRNA-Microparticles
4.3.6.1 Confocal Microscopy
Primary monocytes were isolated and seeded at 1x105 cells/well in 8-well chamber slides. Cells 
were incubated with fresh media, fl-siRNA alone (28ng), fl-siRNA complexed with commercially 
available transfection reagent NeoFx, NeoFx alone, unloaded gelatin-coated and uncoated 
microparticles and fl-siRNA-loaded gelatin-coated and uncoated microparticles for 2 and 24 
hours. For NeoFx fl-siRNA complexation, 28ng of fl-siRNA was diluted in optiMEM up to 25pl 
while 1 pi NeoFx was diluted up to 25pl with optiMEM. Diluted siRNA and NeoFx were added
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together and mixed and incubated at room temperature for 10 minutes to allow complexation. 
Cells were washed with warmed PBS and stained with phalloidin-TRITC (45 minutes) and 
hoescht (5 minutes). Following a washing step, cells were mounted in Vectashield and 
visualised using a LSM510 Meta laser scanning confocal microscope (Zeiss, Germany).
4.3.6.2 Flow Cytometry
THP-1 cells were seeded at a density of 2x105 cells/well and differentiated in a 24-well plate. 
Differentiated THP-1 cells were incubated for 3 hrs with fl-siRNA alone, fl-siRNA-loaded 
microparticles, or fl-siRNA complexed with lipofectamine 2000. Cells were then washed with 
PBS, detached from wells, suspended in PBS and analyzed using Cell Quest Pro software.
4.3.6.3 High Content Cell Analysis
Primary monocytes were seeded in 96-well plates at a density of 1x105cells/ml. Cells were 
incubated with fresh media, fl-siRNA alone, fl-siRNA complexed with commercially available 
transfection reagent NeoFx, unloaded gelatin-coated and uncoated microparticles and fl-siRNA- 
loaded gelatin-coated and uncoated microparticles for 2 and 24 hours. Varying amounts of 
1 mg/ml microparticle preparations were added to the cells (50pl, 100pl and 250|jI). Cells were 
washed three times with warmed PBS and counterstained with phalloidin-TRITC and Hoescht. 
150|jl of PBS was added to each well and plates were stored at 4°C in the dark. HCA was 
carried out using INCELL 1000 analyser. Images were acquired in three channels with 
excitation/emission wavelengths 360/460nm, 480/535nm and 565/620nm and 5 fields per well. 
Images were analysed using INCELL analyser software as described in 3.3.4.2 with parameters 
adjusted accordingly.
4.3.7 Toxicity
THP-1 cells were seeded at 1x105 cells/ml in 96-well plates and incubated with microparticles or 
120jjM valinomycin (positive control) for 23.5 hours. Microparticles were suspended in RPMI at
1, 3 or 5mg/ml. 20 or 50pl of microparticle suspension was added to wells in triplicate and the 
final volume per well was brought up to 100jjI with supplemented media. The Cellomics 
Multiparameter Cytotoxicity assay was performed as described in 3.3.5.
4.3.8 Microparticle Mediated siRNA Knockdown in Macrophage Cell Models
4.3.8.1 Targeted Knockdown of GAPDH Expression in Primary Monocytes
Primary monocytes were seeded a t 2.5 - 5x105 cells per well in 24 well plates immediately 
following isolation and incubated overnight to allow adherence to the wells. Media was replaced 
with fresh supplemented RPMI. All transfections were performed in triplicate with 99ng siRNA 
per well. The commercially available transfection reagent NeoFx was used as a positive
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/transfection control. Briefly, 7.5pl of siRNA was brought up to 25pl with optiMEM while 
separately 1pl of NeoFX transfection reagent was brought up to 25pl with optiMEM and 
incubated at room temperature 10 minutes. Diluted siRNA and NeoFx were mixed and 
incubated room temperature for a further 10 minutes. The mixture was added dropwise to cells 
and plates were moved back and forth to mix. Microparticles empty or encapsulating non­
target, GAPDH targeted siRNA were suspended in media at a concentration dependent on 
encapsulation efficiency. 250pl of microparticle suspension was added to wells. After 48 hours 
cells were lysed for GAPDH gene expression analysis by real time PCR.
4.3.8.2 Targeted Knockdown of TNFa Expression in Differentiated THP-1 Cells
THP-1 cells were seeded 2*105 cells/well in a 96 well culture plate and differentiated. Cells 
were treated with an equal amount of siRNA complexed with lipofectamine 2000 or 
encapsulated in MPs for 3 hrs and media was replaced. Cells were stimulated with 100ng/ml 
LPS and supernatants were collected 24 and 48 hours post-transfection 3 hours following LPS 
stimulation. TNFa production was estimated by ELISA described in 3.3.6.3.
4.3.8.3 Targeted Knockdown of TNFa Expression in Primary Monocytes
Isolated primary monocytes were seeded at 3x104 cells per well in 96 well plates and incubated 
at 37°C 5% C02 overnight. Media was changed leaving adherent macrophages. siRNA 
transfections were mediated by a commercial transfection reagent Lipofectamine 2000 and 
microparticles. Non-target or three TNFa targeted siRNAs were diluted in serum free RPMI 
while 1pl of lipofectamine 2000 was diluted separately in serum free RPMI. Diluted siRNA and 
lipofectamine 2000 were mixed and incubated at room temperature for 20 minutes to allow 
complexation. siRNA lipofectamine 2000 complexes were added dropwise to wells in triplicate. 
Microparticles were suspended in serum-free RPMI (2 and 5mg/ml). Media was replaced with 
microparticle suspensions. 100pl of 2mg/ml empty and siRNA (non-target and TNFa targeted) 
encapsulating microparticles were added to wells in triplicate. 200pl of 5mg/ml TNFa siRNA 
encapsulating microparticles were also added to wells in triplicate. Cells were incubated with 
microparticles at 37°C for 2 -  3 hours and media was replaced with fresh supplemented RPMI. 
Cells were stimulated with 100ng/ml LPS for 3 hours prior to each media collection time point of 
48 and 72 hours. TNFa induction was determined by ELISA described in 3.3.6.3.
4.3.9 RNA Extractions
Total RNA was isolated from primary cells using TRI-reagent (Sigma-Aldrich) according to the 
manufacturer’s instructions. Following supernatant collection from transfected primary 
monocytes, 500jjI of TRI-reagent was added to each well of the 24 well plates and pipetted up 
and down to lyse cells and form a homogenate cell lysate. Cell lysates were transferred to 
microtubes and were allowed to stand at room temperature for 5 minutes. 100pl of chloroform 
was added to each sample and tubes were shaken vigorously. Following a 2 minute incubation
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at room temperature samples were centrifuged at 12,000xg for 15 minutes at 4°C. This results 
in phase separation with a lower red organic layer (protein), an interphase (DNA) and an upper 
aqueous layer (RNA). The upper layer was transferred to a fresh tube and 250pl of isopropanol 
was added and mixed. Samples were incubated at room temperature for 5 minutes and 
centrifuged at 12,000xg for 10 minutes at 4°C. Supernatants were discarded and the RNA 
pellet was washed by adding 500pl of 75% ethanol, vortexing and centrifuging at 12,000xg for 5 
minutes at 4°C. The supernatants were carefully removed so as not to disturb the RNA pellets. 
Samples were briefly allowed to air-dry and dissolved in 20pl 0.1% DEPC water. RNA yields 
and purity were determined spectrophotometrically using a NanoDrop8000. RNA samples were 
stored at -80°C.
4.3.10 cDNA Synthesis
Quantitect Reverse Transcription kit (Qiagen) was used to reverse transcribe 300ng of total 
RNA. RNA samples were thawed on ice. To eliminate genomic DNA (gDNA) 300ng of each 
sample template RNA was added to nuclease free reaction tubes. 2pl of gDNA wipeout buffer 
(7x) was added to each reaction and brought up to a final volume of 14pl with RNase-free 
water. Reaction tubes were incubated at 42°C for two minutes (PTC Thermocycler) and 
immediately placed on ice. To each reaction tube containing 300ng total RNA reverse- 
transcription reaction mixtures were added consisting of 1pl Quantiscript Reverse Transcriptase 
(RT), 4pl Quantiscript RT buffer and 1 jjl RT primer mix and incubated for 30 minutes at 42°C 
followed by 3 minutes at 95°C. cDNA samples were stored at -20°C until analysed by real time 
PCR.
4.3.11 Real time PCR
Quantitative PCR was preformed in 20 pi reactions containing 2 pi template cDNA, 2x SYBR 
green master mix (Roche) and 10 pmol of oligonucleotide primer (MWG Biotech). Reaction 
components were added to the wells of a white 96 well PCR plate (1pl reverse primer, 1pl 
forward primer, 10pl SYBR green and 6pl sterile water). Plates were sealed and centrifuged at 
2000rpm for 2 minutes. Primers used were GAPDH (NM_002046) (Forward Primer 
CATGAGAAGTATGACAACAGCCT, Reverse Primer AGTCCTTCCACGATACCAAAGT) or p- 
actin (F Oligo, 0.01scale 5'-GGACTTCGAGCAAGAGATGG-3\ R Oligo, 0.01scale 5'- 
AGGAAGGAAGGCTGGAAGAG-3’). Amplification was performed using a LightCycler 480 PCR 
system (Roche) set at 57°C for 55 cycles. Gene expression was calculated relative to p-actin 
expression giving an RQ value (2‘AACt, where CT is the threshold cycle).
4.3.12 Statistical Analysis
In general results are expressed as means ± SD. One way or two way ANOVA was used to test 
for differences between treatments with p-values < 0.05 considered significant, < 0.01 very 
significant and < 0.001 highly significant.
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4.4 Results
4.4.1 Characterisation of Microparticles
4.4.1.1 Size
Particle size is important to ensure particles were optimal for macrophage targeting and uptake, 
in the development of a drug delivery system especially for inhalation. 2.1pm PLGA 
microparticles were previously determined as optimal size for alveolar macrophage uptake 
[198]. Each microparticle was sized and mean diameters were found to be between 2 and 3.2 
|jm (Table 4.2), fitting into the size range for effective pulmonary delivery. Gelatin coating and 
siRNA/DOTAP complex encapsulation increased particle size.
Table 4.2: Microparticle Average sizes (mean ± SD)
PLGA Microparticle Average Size (dso pm)
Gelatin Coated Empty 3.209 ±0.126
Uncoated Empty 2.387 ± 0.034
Uncoated siRNA/DOTAP loaded 2.882 ± 0.416
4.4.1.2 Zeta Potential
Zeta potential is a measure of particle surface charge and has been associated with system 
stability and transfection efficiency. A colloidal system is stable when the zeta potential is within 
the -30 to +30mV range. Surface charge can also greatly affect cell internalisation. Overall 
zeta potentials of uncoated microparticles were negative and greater than -30mV (Table 4.3) 
while gelatin coating increased the charge to 11.2 mV a property that could effect cell uptake.
Table 4.3: Microparticle Zeta Potentials (mean ± SD)
PLGA Microparticle Zeta Potential (mV)
Gelatin coated Empty 11.2 ± 2.34
Empty -2.3 ±0.17
Uncoated siRNA/DOTAP loaded -26.1 ± 2.39
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4.4.1.3 Encapsulation Efficiency
To accurately assess nucleic acid dosing and concentrations the amount of siRNA 
encapsulated into the microparticles using DOTAP pre-condensation was determined. PLGA 
microparticle encapsulation efficiencies of siRNA on average were found to be 56.5 ± 12.9% for 
uncoated microparticles (Table 4.4). Encapsulation efficiencies confirmed the reproducibility 
and the versatility of this method for a range of siRNAs including non-target, GAPDH and TNFa 
targeted siRNA. However, gelatin-coated particles had much lower siRNA encapsulation 
efficiencies averaging 12.3 ± 7% perhaps due to the additional wash steps.
Table 4.4: Summary of % Encapsulation Efficiency of PLGA Microparticles (means ± SD) 
PLGA Microparticle Average Encapsulation Efficiency (%)
Empty 0
Gelatin Coated siRNA/DOTAP 12 3 ± 7
Uncoated siRNA/DOTAP 56 5 ± 12 9
4.4.1.4 Scanning Electron Microscopy (SEM)
SEM was used to examine morphology, size and particle size distributions of microparticles. 
SEM and laser diffraction established microparticle size to be with the optimal size range for 
successful pulmonary delivery and alveolar macrophage targeting. SEM also confirmed the 
homogeneity of microparticle size distribution showing smooth spherical particles (Figure 4.4).
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Figure 4.4: Microparticle morphology, particle size and particle size distribution was examined 
using SEM. (A) GAPDH loaded PLGA at 5.00 kx magnification and (B) fl-siRNA loaded PLGA 
microparticles at 8.33 kx magnification
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4.4.1.5 Microparticle siRNA Release
It has previously been reported that PLGA microparticles show a drug release profile that 
consists of an initial burst followed by slow release extending for days or months including 
PLGA particle release of siRNA [225], Microparticles encapsulating siRNA were incubated at 
37°C in pH 7.4 TE buffer and the amount of released siRNA determined after 0.5, 1 and 3 hours 
and 1, 2, 3, 5 and 7 days which was carried out by Dr. Awadh Yadav. An initial burst of siRNA 
release from PLGA microparticles was observed with 12.6 ± 1.2 % siRNA released by 3 hours 
followed by slow controlled release with 20.5 ±1.2 % released after 7 days (Figure 4.5). The 
extended siRNA release also shows the stability of the system at physiological conditions.
Time (hours)
Figure 4.5: Microparticle siRNA release profile. Microparticles encapsulating siRNA were
incubated at 37°C under gentle shaking at pH 7.4. Released siRNA was determined at 0.5, 1, 
3, 24, 48, 72, 120 and 168 (7 days) hours. Data is represented as means ± SD (n = 4)
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4.4.1.6 Nucleic Acid Integrity
The microparticle preparation procedure involves the use of stresses such as sonication, 
homogenisation and low temperatures increasing the possibility of degradation and functional 
loss to the loaded nucleic acids. To address this issue the integrity of loaded nucleic acids was 
assessed by gel electrophoresis. The presence of a single band of appropriate size showed no 
degradation or structural damage to extracted siRNA (Figure 4.6).
siRNA Marker siRNA stock Extracted siRNA
25bp 
21 bp
17bp
Figure 4.6: 20% polyacrylamide gel. The 20% polyacrylamide gel shows the siRNA marker 
(45ng), siRNA stock (1.1 pg) and microparticle extracted siRNA (18.5ng).
4.4.1.7 Functionality of Microparticle Encapsulated siRNA
Due to the stresses involved in microparticle preparation siRNA is susceptible to degradation. 
Gel electrophoresis showed single bands representing siRNA extracted from microparticles 
(Figure 4.6), however while this indicates intact siRNA it does not confirm functionality of the 
extracted siRNA. Therefore the ability of siRNA extracted from microparticles to mediate RNAi 
was compared to unprocessed siRNA in THP-1 cells and was carried out by Dr. Awadh Yadav 
(Figure 4.7). TNFa siRNA was extracted from microparticles and using nucleofection THP-1 
cells were transfected with TNFa siRNA. TNFa siRNA was most effective at mediating 
knockdown at 48 hours. Greater knockdown was observed by 50ng of unprocessed siRNA 
(61.6 ± 13% TNFa expression (p < 0.01)) but only marginal compared to extracted siRNA (77.4 
± 1% TNFa expression). Extracted siRNA also showed some functionality at 24 hours with 92 ± 
12% TNFa expression. Overall TNFa siRNA following the stresses of microparticle 
encapsulation remains largely functional.
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Figure 4.7: Functionality of microparticle encapsulated TNFa siRNA in THP-1 cells. TNFa 
siRNA was encapsulated in PLGA microparticles by the double emulsion evaporation method 
followed by lyophilisation. THP-1 cells were electroporated with 50ng of unprocessed TNFa 
siRNA (TNFa siRNA) or 50ng of TNFa siRNA extracted from microparticles (Ex TNFa siRNA). 
Cells were stimulated for 3 hours with LPS 24 and 48 hours following electroporation and TNFa 
expression determined. Data expressed as means ± SD (n = 3)
Statistical significance was determined by two-way ANOVA followed by Bonferroni Post hoc test 
(*p < 0.05, ** p < 0.01, *** p < 0.001) vs untransfected stimulated cells
4.4.2 Cell Uptake Studies
In order to achieve transfection, efficient uptake by cells of the microparticle delivery system is 
necessary. Microparticles were loaded with fl-siRNA for flow cytometric analysis and uptake 
determined by confocal laser scanning microscopy (CLSM) and HCA. Confocal microscopy, 
flow cytometry and HCA were used to determine internalisation and the extent of uptake 
respectively of a range of carrier systems into THP-1 cells and primary 
monocytes/macorphages.
4.4.2.11nternalisation by Differentiated THP-1 Cells
In order to quantify the percentage of differentiated THP-1 cells transfected fl-siRNA was 
quantified using flow cytometry by Dr. Awadh Yadav. The increase of fl-siRNA uptake was 
highly significant (p < 0.001) when loaded in uncoated microparticles compared to all other 
treatments including fl-siRNA dose and fl-siRNA transfected with Lipofectamine 2000 (Figure
4.8).
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Figure 4.8: Microparticle uptake by differentiated THP-1 cells assessed using flow cytometry. 
Cells were untreated or treated with, fl-siRNA alone, fl-siRNA/lipofectamine 2000 (Lipo- 
FIsiRNA), empty uncoated microparticles (MPs) or fl-siRNA loaded uncoated microparticles (Fl- 
siRNA-MPs). Data represented as means ± SD (n = 3). Statistical significance was determined 
by one-way ANOVA followed by Dunnett’s Post hoc test (*p < 0.05, ** p < 0.01, *** p < 0.001)
4.4.2.2 Internalisation by Primary Monocytes
Primary macrophages were treated with uncoated and coated fl-siRNA loaded microparticles 
and fl-siRNA/NeoFx as a positive control for 2 hours and 24 hours. CLSM and Z-stack analysis 
carried out by Katie Nolan and Warren Thomas confirmed microparticle uptake into the cells at 
24 hr for both gelatin-coated and uncoated microparticles (Figure 4.9). Coated and uncoated 
microparticle treatment showed increased fl-siRNA cell uptake at both time points in comparison 
to fl-siRNA alone and the positive control fl-siRNA/ NeoFx treatments. In addition cell loss was 
observed following 24 hour NeoFX treatments at concentrations recommended by the 
manufacturers.
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Figure 4.9: Confocal images of primary monocytes (A) untransfected or transfected with (B) 
fluorescently tagged siRNA (fl-siRNA, green) complexed with siPORT NeoFx, fl-siRNA 
encapsulated in (C) uncoated PLGA microparticles and (D) gelatin-coated PLGA microparticles. 
Z-stack analysis of (E) uncoated fl-siRNA loaded PLGA microparticle uptake in primary 
macrophages at 24 hours and (F) gelatin coated fl-siRNA loaded PLGA microparticle uptake in 
primary macrophages at 24 hours.
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Quantification of fl-siRNA loaded microparticles and fl-siRNA/NeoFx positive control uptake was 
determined using high content screening with corresponding treatment to confocal analysis at 2 
hr and 24 hr. Treatment at 24 hours with siRNA/NeoFx showed cell loss and the presence of 
cells without nuclei indicative of cytotoxicity as was observed by confocal uptake assessment. 
siPORT NeoFX siRNA complexes appeared more diffuse and not defined particles (Figure
4.1 OB). Hence, fl-siRNA/NeoFX complexes were not picked up in the particle count by the 
analysis software.
Uncoated and coated fl-siRNA loaded microparticle uptake at 50|jg, 100pg and 250jjg was 
significantly enhanced compared to untreated controls and cells transfected with the 
commercial transfection reagent NeoFx. Empty microparticles both coated and uncoated 
however showed slight autofluoresence. Uptake of 100pg and 250pg uncoated and 250pg 
gelatin coated fi-siRNA loaded microparticles was highly significant (p < 0.001) after 2 hours in 
comparison to empty uncoated and coated microparticles respectively (Figure 4.10E). Uptake 
of uncoated and gelatin coated fl-siRNA microparticles was greater at 2 hours than 24 hours 
most likely due to fl-siRNA release from microparticles. Confocal microscopy confirmed 
internalisation of microparticles (Figure 4.9).
Uncoated microparticles showed higher encapsulation efficiency of siRNA and greater uptake 
by primary macrophages than gelatin coated microparticles. siRNA leached from PLGA 
microparticles during the coating process leading to reduced siRNA encapsulation. Gelatin 
coating also added further complexity to manufacture, increasing the risk of contamination. 
Consequently all further studies were carried out using uncoated PLGA microparticles.
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Figure 4.10: High content cell of siRNA microparticle uptake by primary macrophages. Human 
monocytes were isolated and allowed to adhere to 96 well plates. Cells were transfected with 
empty microparticles (MP) or fluorescently tagged siRNA alone (AlexaFluor 488, green), 
complexed with NeoFx or encapsulated in uncoated or gelatin coated microparticles (siRNA- 
MP). Following 2 or 24 hour incubation cells were fixed and counterstained with phalloidin- 
TRITC (F-actin, red) and Hoecsht (nucleus, blue). Images were acquired at 10x using an 
INCELL 1000 showing (A) untreated cells, (B) cells transfected with fl-siRNA/NeoFX, (C) cells 
treated with uncoated FI-siRNA-MPs and (D) gelatin-coated siRNA-MPs after 2 hours. The 
number of fl-siRNA particles was counted per cell (E) using INCELL 1000. Data represented as 
mean ± SD (n = 3) Statistical significance was determined by two-way ANOVA followed by 
Bonferroni Post hoc test (*p < 0.05, ** p < 0.01, *** p < 0.001) vs empty microparticle 
counterparts
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4.4.3 Toxicity
Differentiated THP-1 cells were treated with PLGA microparticles empty or encapsulating siRNA 
at various concentrations for 24 hours in order to assess cell viability following microparticle 
treatment. As a positive control cells were treated with a toxic agent, valinomycin (120pM), 
while negative controls were left untreated and incubated in complete media. Cells were 
treated with two doses of 1 mg/ml empty or siRNA-microparticles (Figure 4.11 and 4.12).
To assess a dose response higher concentrations of 3mg/ml and 5mg/ml microparticles 
encapsulating TNFa were also used for comparison with later GAPDH transfections. In general 
transfections used 1 -  1.5mg/ml concentrations. Following 24 hour treatment cells were stained 
and fixed. Images (Figure 4.11) and quantitative analysis (Figure 4.12) were acquired using an 
INCELL 1000 cell analyser and cell loss, nuclear size and intensity, cell permeability, 
mitochondrial membrane potential and cytochrome c were determined.
Cell loss was significant following valinomycin treatment (Figure 4.11 and 4.12A) but not after 
microparticle treatment. Cell count however was variable within treatment groups and a loss 
although not significant was observed in the 100pg TNFa microparticle (100pl of 1 mg/ml) 
treatment group. Apoptosis is associated with chromatin condensation and consequently 
nuclear morphological changes were monitored i.e. size and intensity. Positive controls again 
showed significant changes compared to untreated healthy cells. Nuclear size was significantly 
decreased following valinomycin (p < 0.001) and 100pg NT microparticles (p < 0.05) treatment 
(Figure 4.12B). While total nuclear intensity was significantly increased by valinomycin (p < 
0.001) and 300pg and 500pg TNFa microparticles treatments (100|jl of 3mg/ml and 5mg/ml) 
(Figure 4.12C).
Cell permeability is linked with necrosis and was increased following valinomycin and all higher 
dose microparticle treatments with 100|jg TNFa microparticles significantly (p < 0.001) 
increasing permeability (Figure 4.12D). MMP decrease is associated with apoptosis and related 
to cytochrome c release. Valinomycin treatment decreased MMP as did 50pl of all 1 mg/ml 
microparticle treatments but not significantly. Increased MMP was found following the higher 
dose of all microparticles treatments (Figure 4.12E). In general cytochrome c levels did not 
deviate significantly from those of healthy cells except following 20pg and 100pg TNFa 
microparticle (1 mg/ml) treatment (p < 0.05) (Figure 4.12F).
Overall microparticles do not impair cell viability. At all concentrations there is no significant cell 
loss. Microparticles at the higher doses encapsulating siRNA caused changes in nuclear size. 
MMP and a small increase in cell permeability suggesting some toxicity induced through both 
apoptosis and necrosis. Additionally, the higher concentrations of TNFa microparticles 3mg/ml 
and 5mg/mi significantly increased nuclear intensity and MMP while cell loss was unaffected. 
The lower concentrations are therefore more suitable for in vitro transfection.
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Figure 4.11: High content cell assessment of toxicity in differentiated THP-1 cells induced by 
microparticles. Differentiated THP-1 cells were treated with either 20 or 100|jg empty 
microparticles (MP) or microparticles encapsulating non-target siRNA (NT MP). Negative 
controls were healthy cells incubated in complete media. Positive controls were treated with 
120pM valinomycin. Cells were treated for 24 hours, fixed and stained for nuclei (hoescht), cell 
permeability, mitochondrial membrane potential (MMP) and cytochrome c release. Images 
were acquired and analysed using an INCELL 1000.
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Figure 4.12: High content cell assessment of toxicity in differentiated THP-1 cells induced by 
PLGA microparticles. Differentiated THP-1 cells were treated with either 20pl B  or 10OpI ■  
of 1 mg/ml empty microparticles (MP) or microparticles encapsulating non-target siRNA (Non- 
Target MP) or TNFa targeted siRNA (TNFa MP). TNFa MP treatments were also at 3mg/ml 
and 5mg/ml. Positive controls were treated with 120pM valinomycin. Cells were treated for 24 
hours, fixed and stained. Images were acquired and analysed using an INCELL 1000. Cell loss, 
nuclear size and intensity, MMP, cytochrome c release were measured (A-F). Data represented 
as means ± SD. Statistical significance was determined by two-way ANOVA vs untreated 
controls (* p < 0.05, ** p < 0.01, *** p < 0.001)
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4.4.4 Microparticle siRNA Transfections
4.4.4.1 GAPDH Knockdown in Primary Monocytes
Initially knockdown of an endogenously expressed house keeping gene GAPDH was evaluated 
in isolated primary monocytes by qRT-PCR. Compared to non-target siRNA transfections 
NeoFX/GAPDH siRNA reduced GAPDH expression by 26.4 ± 36.3 % while an equivalent 
amount of GAPDH siRNA delivered via microparticles suppressed GAPDH expression by 31.1 ±
60.1 % (Figure 4.13). Microparticle GAPDH siRNA transfections also showed a dose 
dependent knockdown (data not shown). In order to acquire a sufficient amount of RNA for 
qRT-PCR analysis a large amount of cells were required and results between experiments were 
somewhat variable in the extent of knockdown. However, an optimised microparticle 
transfection method in primary monocytes was established.
Figure 4.13: Modulation of GAPDH expression in primary blood derived monocytes by GAPDH 
targeted siRNA delivered using siPort NeoFX transfection reagent and PLGA microparticles. 
Isolated primary monocytes were transfected with 99ng of GAPDH targeted siRNA delivered 
using (A) siPORT NeoFX commercial transfection reagent or (B) uncoated PLGA microparticles. 
Cells were transfected and harvested 48 hours later for qRT-PCR analysis. Data is represented 
as means ± SD (n = 3) normalised to non-target siRNA transfected counterparts.
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4.4A.2 TNFa Knockdown in LPS Stimulated THP-1 and Primary Monocyte Cells
Following knockdown of endogenously expressed GAPDH, microparticles were used for 
inflammatory gene knockdown in differentiated THP-1 cells. In LPS stimulated cells TNFa is 
greatly induced and therefore the need for high cell numbers to detect gene expression 
changes in this model is reduced offering a sensitive and potentially therapeutic target for 
knockdown. Also cytokine production can be determined by ELISA enabling sensitive detection 
of gene expression. Using another commericial transfection reagent LipoFectamine 2000 and 
siRNA-microparticles differentiated THP-1 cells were transfected with non-target and TNFa 
targeted siRNA. TNFa production was determined 3 hours following LPS stimulation at a 
number of time points following transfection. TNF-a expression was reduced by 44.8 ± 3.4 % 
and 39.6 ± 4.9 % after 48 and 72 hours respectively using microparticles. The commercial 
reagent Lipofectamine 2000 led to little or no knockdown (Figure 4.14). Lipofectamine 2000 
however caused TNFa induction in primary monocytes (Chapter 3 Figure 3.12).
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Figure 4.14: Modulation of TNF-a expression in LPS-stimulated differentiated THP-1 cells 
following transfection. Transfected cells were treated with empty microparticles (MP), non­
target or TNFa directed siRNA either complexed with commercial transfection reagent 
Lipofectamine™ 2000 (TNFaLipoFect) or encapsulated in microparticles (NT MP or TNFa MP). 
TNFa expression was determined by ELISA 48 and 72 hours post transfection following a 3 
hour LPS-stimuation. Data represented as means ± SD (n=2).
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Knockdown of TNFa in LPS stimulated primary monocytes was also assessed after 48 and 72 
hours. Monocytes were isolated from venous blood of 6 healthy donors and allowed to adhere 
to 96 well plates overnight. Cells were transfected with non-target or TNFa targeted siRNAs via 
Lipofectamine 2000 (data not shown) and PLGA microparticles. LipoFectamine 2000 mediated 
transfection decreased LPS stimulated TNFa expression by 52.8 and 49.7% at 48 and 72 hours 
respectively compared to untransfected stimulated cells. Levels of knockdown varied between 
donors as was observed in GAPDH transfections. However microparticles encapsulating TNFa 
siRNA on average decreased TNFa expression in LPS stimulated primary monocytes compared 
to non-target controls (Figure 4.15) at 48 and 72 hours. Knockdown was dose and time 
dependant with the 150pg dose significantly decreasing TNFa expression after 72hours (p < 
0.05).
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Figure 4.15: Modulation of TNFa expression by PLGA microparticles encapsulationg TNFa 
targeted siRNA in LPS stimulated primary monocytes. Primary blood derived monocytes from 6 
healthy donors were transfected with 100pg or 150|jg microparticles encapsulating non-target or 
TNFa targeted siRNA. After 48 and 72 hours TNFa expression was determined following a 3 
hour stimulation with 100ng/ml LPS. Data is represented as percentage mean of non-target 
siRNA transfected counterpart. Statistical significant was determined by one-way ANOVA vs 
non-target siRNA transfected counterparts (* p < 0.05) with Dunnett’s post hoc test
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4.5 Discussion
A method was developed for preparation of siRNA loaded gelatin coated and uncoated PLGA 
microparticles using the double emulsion solvent evaporation method. The central objectives 
were to achieve a high level of nucleic acid encapsulation into microparticles and to monitor the 
uptake of these loaded microparticles by macrophage cell lines and primary cells. 
Microparticles formulated were optimised for pulmonary delivery and alveolar macrophage 
targeting. Particle sizes were in the range of 2 -  3 pm an optimal size for pulmonary delivery 
and phagocytic uptake by alveolar macrophages. In addition uncoated microparticles showed 
negative surface charge most likely due to underivatised lactic and glycolic acid in PLGA 503. 
This characteristic could also promote uptake by macrophages.
Low encapsulation of nucleic acids by microparticles has previously been reported [230], 
Various strategies have been used to improve siRNA loading into PLGA particles including 
siRNA conjugation to PLGA [220] but pre-complexation of siRNA with cationic reagents 
including DOTAP [223, 224], PEI [156, 218, 225] and arginine [225] is the most common 
method used. Previously TNFa siRNA has been encapsulated in PLGA microparticles as 
siRNA/PEI polyplexes and in PLGA nanoparticles as siRNA/DOTAP lipoplexes achieving up to 
77% and 31% encapsulation efficiencies respectively [156, 223]. However in our hands PEI 
condensation of siRNA did not increase siRNA encapsulation over encapsulation of 
uncomplexed siRNA. DOTAP was instead complexed with siRNA using a method by Wu et al. 
(2009) with modifications. At N/P ratio of 4 siRNA/DOTAP lipid particles could be formed with 
high siRNA encapsulation (>90%) and a nanoscale size (<200nm) [228]. Loading of these 
siRNA lipid particles into PLGA microparticles achieved encapsulation efficiencies of 56.5 ± 
12.9%. During coating with gelatin however siRNA appeared to leach out of the particles 
reducing the encapsulation efficiency to 12.3 ± 7%. An encapsulation efficiency of PEI/siRNA 
complexes in PLGA microparticles was negligible but this may have been a method issue as 
found with liposome encapsulation efficiency determination. The siRNA quantification assay 
requires the siRNA to be accessible for binding of the reagent which may not be possible if it is 
still complexed. On the other hand the method used mixes the microparticle formulations in 
chloroform and water. Both DOTAP and PLGA separate into the organic phase while siRNA 
remains in the aqueous phase. It is less likely that siRNA is still complexed to DOTAP which is 
soluble in non-polar solvents such as chloroform and so siRNA can be detected. Therefore it is 
likely PEI/siRNA encapsulation results gave a false negative as this technique was unsuitable 
for the determination of encapsulation efficiency when PEI is the cationic condensing reagent.
Release of siRNA from uncoated microparticles at pH 7.4 and 37°C was monitored over 7 days. 
A release profile emmerged similar to that found by Lee et al. (2011) at pH 7.4, in a study which 
also evaluated siRNA release from polymeric microparticles at an acidic (phagosomal) pH. Lee 
et al. (2011) found at pH 5 almost complete siRNA release from particles at 48 hours with 50% 
after just 7 hours, showing the difference in particle stability and hence siRNA release for
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different pH environments. This indicates microparticles remain stable at physiological pH 7.4 
but upon entering an acidic intracellular environment the siRNA load will be released.
To visualise and confirm uptake of microparticles by macrophage cell models, particles were 
loaded with fluorescent siRNA. Confocal analysis of transfected differentiated THP-1 cells and 
primary macrophages with fl-siRNA loaded microparticles at 2 and 24 hours showed particle cell 
association and intracellular delivery was confirmed by Z-stack analysis. Commercial 
transfection reagent NeoFx complexed with fl-siRNA was used as a positive control however 
little uptake was observed at 2 hours and after 24 hours was cytotoxic which was represented 
by cell loss and the presence of cells with absent nuclei.
Quantification of cell uptake was determined by flow cytometry and HCA. Flow cytometry 
determined uptake of fl-siRNA by THP-1 cells to be significantly higher when encapsulated in 
microparticles. However, this method is not the most suitable for analysing differentiated 
monocytes as it requires cells to be in suspension and this is difficult to achieve once cells have 
differentiated into macrophages. HCA is a far more suitable technique for analysis of these 
adherent cells and was subsequently used for primary cell uptake assessment. HCA of primary 
macrophages transfected with fl-siRNA loaded microparticles for 2 and 24 hours showed 
significant enhancement of uptake of fl-siRNA in uncoated microparticles compared to fl-siRNA 
alone, complexed with NeoFx or encapsulated in coated particles. Furthermore images 
obtained again showed cell loss and the presence of cells without nuclei at 24 hours with fl- 
siRNA/NeoFx treatment.
Differentiated THP-1 cells were assessed for toxicity induced by a range of doses of empty and 
DOTAP/siRNA loaded uncoated microparticles by HCA. Cytotoxcity screens determined 
changes in total nuclear intensity, cell permeability, mitochondrial membrane potential and 
cytochrome C release of DOTAP/siRNA loaded microparticles particularly of DOTAP/TNFa 
loaded microparticles at 1 mg/ml. However there was no significant cell loss associated with 
microparticle treatment. Wilson et a/. (2010) evaluated cytotoxicity in macrophages treated with 
increasing doses of PLGA particles loaded with DOTAP/TNFa siRNA from 1 mg/ml up to 6mg/ml 
[223]. Toxicity assessed by MTT assay was not detected up to a dose of 5mg/ml [223]. 
Observed toxicity could be associated with the presence of the cationic lipid DOTAP and siRNA 
sequence. Synthetic siRNA can induce sequence specific immune responses which could be 
associated with presence of GU dinucleotides [231, 232]. Three siRNA sequences targeted at 
TNFa were pooled and used for in vitro studies. Two of these sequences contained two pairs 
GU nucleotides while the third contained one GU dinucleotide. The TNFa siRNA sequence 
therefore could have brought about the toxic effects determined following treatment with 
DOTAP/TNFa loaded microparticles.
Furthermore, a TH1/TH2 cytokine profile in response to 24 hour coated and uncoated 
microparticle treatment in differentiated THP-1 cells revealed no significant TH1 or TH1 cytokine 
induction (Lawlor et a/., unpublished). Levels of IL-1p and IL-8 were slightly increased above
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control untreated cells following microparticle treatment particularly with gelatin coated 
microparticle treatment. Additionally, PLGA microparticles particularly gelatin coated particles 
caused significant NFkB induction in differentiated THP-1 Blue cells (Lawlor et a/., unpublished). 
Although microparticles are not inert carriers, inflammatory cytokine induction is non-significant 
in differentiated THP-1 cells and most importantly the target cytokine TNFa is not affected by 
PLGA microparticle treatment.
Knockdown of an endogenous house keeping gene GAPDH was mediated via NeoFX 
transfection reagent and uncoated microparticles encapsulating GAPDH siRNA in primary 
monocytes. However gene suppression was variable and consequently not significant. 
Additonally high cell numbers were necessary to generate adequate cDNA for qRT-PCR 
analysis which can be an issue when using primary cells. Although ubiquitously expressed, the 
level of GAPDH mRNA in monocytes was low and consequently changes in expression were 
more challenging to decipher. Disease states are generally associated with abnormal gene 
expression such as elevated levels of TNFa in COPD patients [233]. Hence, targeted gene 
suppression of an inducible protein, TNFa, in response to an inflammatory stimulator, LPS, was 
a more suitable and valid approach to determine siRNA knockdown efficiency using 
macrophages. Differentiated THP-1 cells and adherent primary monocytes were stimulated with 
LPS to induce high levels of the target pro-inflammatory cytokine TNFa, a key mediator in the 
inflammatory response. Microparticle delivery of anti-inflammatory siRNA to inflammatory 
macrophage cell models showed significant knockdown after 48 and 72 hours (Figure 4.14). 
Previously significant TNFa knockdown in activated macrophages has been shown with similar 
particle formulations [223]. DOTAP/TNFa siRNA microparticles mediated almost 50% 
knockdown in stimulated differentiated THP-1 cells (Figure 4.14) while suppression levels were 
more variable in primary monocytes but none aimed at alveolar macrophages.
Lipofectamine 2000 was used as the positive control transfection reagent and showed no effect 
in differentiated THP-1 cells. However, in primary monocytes lipofectamine 2000 transfection 
with TNFa siRNA decreased TNFa expression in activated cells by 52.8 and 49.7% at 48 and 
72 hours respectively. In Figure 3.12 lipofectamine 2000 was shown to induce high levels of 
TNFa in LPS stimulated primary monocytes after 24 hours. It appears that lipofectamine 2000 
initially induces an inflammatory response in primary monocytes, not observed in THP-1 cells, 
but disappears by 48 hours. This emphasises that siRNA vectors are not always inert and the 
use of non-target siRNA as negative controls is essential to show the specificity of the target 
siRNA in cells that have undergone analogous processes.
PLGA is an FDA approved polymer. PLGA microparticles were bioengineered to efficiently 
encapsulate siRNA with a range of gene targets. These siRNA loaded microparticles also 
possessed beneficial physicochemical and biopharmaceutical properties such as 
biocompatibility, low cytotoxcity, low immunogenicity, sustained siRNA release at physiological 
pH and a size suitable for inhalation which is also optimal for targeting alveolar macrophages. 
Ultimately microparticles were used to knockdown TNFa expression in inflammatory
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macrophage cell models leading to significant TNFa gene suppression in primary monocytes. 
In conclusion, siRNA/DOTAP loaded microparticles as non -viral delivery vectors for siRNA in 
vitro are stable, biocompatible, non-toxic, non-immunogenic and efficient.
Key Findings
• Optimised method for maximal encapsulation of siRNA in PLGA microparticles
• Uncoated microparticles were optimal for macrophage uptake and delivery of siRNA
• Significant knockdown of TNFa in LPS stimulated primary cells via PLGA microparticles 
encapsulating TNFa targeted siRNA
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Chapter 5
Microparticles for Intracellular Delivery of shRNA Expressing 
Plasmids
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5.1 Introduction
Following on from the discovery of RNAi, siRNA was developed to specifically knockdown 
genes with high potency yet avoid innate immune activation initiated by dsRNA. However 
siRNA transfection is typically transient and efficiency can be low. Additionally synthesis is 
costly and delivery can be difficult. In 2002 Yu et af. first described using vectors to express 
siRNA and hairpin siRNA in the hopes of overcoming the aforementioned problems [234]. 
Herein, the microparticles developed in Chapter 4 were harnessed for short hairpin RNA 
(shRNA) delivery. shRNA is expressed, generally by a polymerase III promoter such as U6 
small nuclear RNA (U6) or human RNase P RNA H1 (H1) promoters, from a viral or non-viral 
DNA plasmid transfected into cells and consists of a base-paired stem and loop (Figure 5.1). 
shRNA utilizes miRNA machinery to be transported to the cytoplasm where it is processed to 
siRNA (Figure 5.2 and 5.3) and can mediate RNAi. Elucidation of the miRNA pathway has 
been greatly utilized in shRNA vector development for RNAi.
5.1.1 Short Hairpin RNA (shRNA) RNA Interference
There are three main approaches in the construction of shRNA vectors. The majority of shRNA 
constructs are synthesised by annealing complementary oligonucleotides but can also be 
assembled using a PCR method with hairpin containing primers or primer extension of hairpin 
templates [235]. For shRNA synthesis vectors containing an oligonucleotide for a shRNA 
sequence simply need to express a single strand of RNA (50 -  10Obp) specifically designed to 
fold back on itself with complimentary segments annealing and a mismatched segment forming 
a stem-loop (Figure 5.1). This requires a promoter, (generally a polymerase III promoter), 
followed by oligonucleotide sequences for the sense strand (at least 19 nt), loop ( 4 - 1 0  nt), 
anti-sense strand and lastly 4 - 6  terminating uracils [236].
Figure 5.1: Short hairpin RNA (shRNA). shRNA is initially expressed as single stranded RNA 
(ssRNA) in which complimentary segments anneal and a stem-loop formation arises. (Modified 
from [235])
Conventional shRNAs are expressed in this manner using a U6 promoter (and RNA polymerase 
III) and are transported via exp5 from the nucleus to the cytoplasm [237] where they are 
processed by dicer into a functional siRNA. However shRNA can also be designed to resemble 
pri-miRNA (using RNA polymerase II (pol II) or pol III promoters) and once in the cytoplasm 
enter the miRNA pathway. miRNA-like shRNA is transcribed by RNA polymerases (pol II) and
ssRNA transcript shRNA
Loop
complementary Stem
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processed to pre-shRNA in the nucleus by a complex containing the RNase III enzyme Drosha 
into shRNAs with 2 nt 3’ overhangs [238], Pre-shRNA is transported by the nuclear export 
factor exp5 to the cytoplasm where it is processed by another RNase III complex containing 
Dicer [238, 239]. The RNase III enzyme dicer binds to the 2nt 3’ overhang and cleaves the 
terminal loop leaving a 2nt 3’ overhang resulting in a double-stranded siRNA with 2nt 3’ 
overhangs [239], This siRNA product is then incorporated into RISC with Ago2 [238, 239] and 
can mediate sequence specific mRNA degradation as described in Chapter 1 (Figure 5.2).
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Figure 5.2: RNA interference mediated by shRNA or siRNA [239], shRNA is transcribed in the 
nucleus as an artificial pri-miRNA and processed by Drosha or as a shRNA structure. shRNA is 
exported to the nucleus by exportin 5 (Exp5) and processed by Dicer into a RNA duplex 
capable of mediated RNA interference. Synthetic siRNA is introduced into the cell cytoplasm 
where it enters the RISC complex mediating gene silencing.
5.1.2 Advantages and Problems of shRNA in RNA Interference
shRNA boasts many advantages over siRNA particularly in terms of long term gene 
suppression. As part of a plasmid or viral vector shRNA will be expressed by a cell once its 
vector has successfully inserted into the host cell genome and can be expressed for long 
periods of time. This is advantageous in the establishment of stable cell lines and for long term 
suppression of disease related genes. Also shRNA tends to be more potent than siRNA for 
mediating gene silencing [240, 241] and less susceptible to enzymatic degradation. 
Furthermore it is possible to deliver multiple shRNA sequences using for example polycistronic 
expression vectors [58, 242] or long hairpin RNAs (IhRNA) [243]. This is beneficial especially 
in the treatment of viral infections with high mutation rates such as human immunodeficiency 
virus (HIV) [243]. Also these shRNAs can target multiple regions of the same gene thereby
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decreasing overall shRNA dose requirements while maintaining gene suppression. Expression 
of several shRNA sequences by multiple promotors or vectors could lead to varied levels of 
expression of each shRNA which can be eliminated using polycistronic expression vectors. 
shRNA although long (>50bp) do not induce an interferon response.
shRNA expression vectors are also suitable for viral transfection which are very efficient delivery 
systems but as previously discussed can have immunogenic problems and vectors must be 
carefully designed to avoid the production of viral particles capable of replication. The necessity 
of genome insertion for shRNA production means that shRNA vectors must be delivered to the 
nucleus unlike siRNA which must only reach the cytoplasm to mediate RNAi. It has been 
estimated that as little as one in 1000 -  5000 cytosolic DNA plasmids penetrates the nuclear 
envelope and is transcribed [236, 244]. Additionally plasmids are much larger than siRNA 
(approximately 20bp siRNA compared to >2000bp DNA plasmid). This large size may hamper 
nucleocytoplasmic transport [244].
Unfortunately shRNA transfection is associated with similar side effects as that of siRNA 
(described in chapter 1) such as off-target effects and immune responses. In the case of 
shRNA these unwanted effects could be further amplified due to the extended expression of 
shRNA compared to siRNA. Pol III expressed shRNAs have been found to induce an interferon 
response [245]. However comparison studies of siRNA and a pol III expressed shRNA in vitro 
have found endogenously processed shRNA not to initiate an interferon response [246].
Moreover a major problem of shRNA vectors is over expression and consequently the possibility 
of over saturating intracellular miRNA machinery such as exp5, Dicer and RISC [245]. Several 
studies have found toxicity and morbidity due to this over expression [58]. Grimm et al. (2006) 
constructed a range of shRNA expressing vectors based on duplex-DNA-containing adeno- 
associated virus type 8 (AAV8) targeting luciferase, a1AT and four other genes in mice. 
Although targeted luciferase and a1AT gene suppression was maintained for over one month 
and one year respectively toxicity and morbidity were associated with a majority of the 49 
vectors assessed [247]. Toxicity was not accompanied by interferon response but was with 
high shRNA doses. Moreover competition studies with various shRNA vectors and over 
expression of exp5 showed an over saturation of miRNA machinery were linked to fatality in 
shRNA delivery [247]. shRNA as a therapy could be more suitable for retroviral transfections 
when the expression level will remain low and PLGA microparticles where shRNA release can 
be controlled. Over expression can also be overcome by designing shRNA that utilize RNA 
polymerase III (pol III) or pol II promoters and therefore will be processed similar to miRNA. 
Conventional shRNA use U6 or H1 promoters which express large quantities of shRNA 
whereas pol II promoters will express shRNA at a similar level to the endogenous miRNA [58]. 
Depending on the level of expression required shRNA vectors and their delivery systems need 
to be adjusted. It is also possible to design conditional expressing vectors [247].
152
5.1.3 shRNA Delivery
A wide range of delivery vectors both viral and non-viral based have been investigated for DNA 
and shRNA delivery (Figure 5.3). The need for vector systems has been driven by molecular 
biology and more recently drug delivery. These vectors must efficiently deliver their load, 
allowing lysosomal/endosomal escape of the nucleic acid as well as achieve delivery for their 
cargo to the nucleus. A major advantage of shRNA and DNA plasmid based therapeutics is 
their suitability for viral mediated delivery. Viral based vectors are very efficient delivery 
vehicles. However the down side is the associated oncogenicity and safety concerns. 
Consequently interest in non-viral delivery systems including the use of neutral or cationic 
polymer and lipid based nanoparticles as well as proteins and peptides has grown. Proteins 
used in gene delivery are usually viral proteins which can bind DNA and mediate nuclear 
transport while peptides include h¡stone and protamine derivatives [236]. Additionally bacteria 
can be used for shRNA vector delivery as shown in Figure 5.3. Transkingdom RNAi (tkRNA) 
involves the use of bacteria that have been altered to produce shRNA to infect cells and 
consequently lead to specific gene suppression. Alternatively, bacteria can be used simply to 
deliver shRNA expressing plasmids, a process known as bacteria mediated RNAi (bm-RNAi) 
[248],
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shRNA-encoding DNA SiRNA
Figure 5.3: Schematic representation of delivery strategies for shRNA and siRNA mediated 
RNA interference [248]. shRNA is expressed by specially designed vectors which can be 
delivered to cells via bacteria, viruses or synthetic particles. Once transcribed in the cytoplasm 
shRNA is processed by Dicer into siRNA. Synthetic siRNA duplexes can also be delivered 
directly to cells. Naked siRNA is often delivered in vivo but for enhanced delivery and protection 
from degradation siRNA can be encapsulated in micro- or nanoparticles or undergo chemical 
modification. siRNA will then complex with R ISC and direct sequence specific mRNA 
degradation.
5.1.3.1 Viral Vectors
The major advantage of viral vectors in gene delivery is their efficiency but this is for the most 
part outweighed by safety risks. Although the viral vectors used are modified to be replication- 
deficient (Figure 5.4) there are still some concerns associated with their use in patients [1] 
particularly oncogencity and immune activation. Also the need to produce large quantities of 
these vectors and their limitations in transgene loading capacity could be problematic. 
Adenoviruses (for example serotype 5 adenovirus (Ad5)), AAV, retroviruses (such as Moloney 
murine leuckemia virus (MoMLV) and lentiviruses) and Herpes Simplex virus are among the 
viral vectors being used in therapies today [1, 249].
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Adenoviruses (Adenoviridae Mastadenovirus) possess many advantageous attributes including 
the ability to transduce dividing and non-dividing cells [1, 250], produce high-titers of 
recombinant viruses and to package large transgenes [250]. Ad5 vectors do not integrate into 
host chromosomes avoiding potential oncogenecity. However, Ad5 vectors strongly activate a 
host immune response as was evidenced by the death of a clinical trial patient Jesse Gelsinger 
in 1999 due to an immune reaction following the administration of a modified Ad5 vector 
delivering the ornithine decarboxylase gene [1]. Other disadvantages of adenoviral vectors 
include long production time, pre-existing immunity and off-target cell transduction [250]. 
Despite this adenoviruses are the most commonly used shRNA viral vectors for in vitro use and 
are available commercially [251].
AAV (Parvoviridae Dependovirus) are non-pathogenic and not associated with any human 
disease. Furthermore long-term gene expression in a wide range of cells types has been seen 
in vivo by AAV transduction. AAV delivery of shRNA to specific cells or tissues is possible [251]. 
Similarly to adenoviruses AAV vectors can transduce off-target cells and pre-existing immunity 
can exist. These vectors also have a limited transgene capacity and only permit DNA-based 
material to be loaded [63] however up to 8  individual shRNA cassettes can be loaded [251]. 
Repeated administration of the same serotype of AAV in mice has shown gene expression to be 
decreased [252].
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Figure 5.4: Diagrammatic representation of non-replicating lentiviral vector transduction [58], 
The viral particles are constructed in a host cell line (such as human 293T cells). The host cells 
are transfected with various viral elements expressed on different plasmids including envelope 
expression cassette, packaging vector and transgene expression cassette (expressing shRNA). 
Target cells are infected with the lentivirus and the transgene integrated into the host genome. 
shRNA is expressed and enters the siRNA pathway. Only the transgene cassette is inserted 
into the host genome allowing shRNA expression but not replication of an infectious virus.
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Retroviruses such as MLV target dividing cells and can integrate into the chromosome of these 
cells resulting in stable and extended transfections [250]. Unfortunately this means limitations 
in target cell types and possible mutagenic events. Retroviruses were among the first used viral 
vectors for shRNA cassette delivery [251], Lentiviruses, unlike retroviruses such as MoMLV, 
can enter the nucleus of dividing, non-dividing and differentiated cells [58, 250] and generally 
integrate distally from promoters in introns which could reduce the possibility of oncogenicity 
[253]. Typically HIV-1 based vectors are used as HIV-1 replication is the most comprehensively 
characterised. Further safety precautions are taken when using HIV-1 including the removal of 
cis elements (essential for viral replication) from the packaging vector, deletion of accessory 
genes, dividing packaging genes into different plasmids and avoiding homology between the 
various plasmids [58]. These viruses are also very suitable for shRNA transfections (Figure 
5.4) however the side effects associated with siRNA such as immune activation and off-target 
effects are enhanced with the long-term expression of shRNA. Recent advances in this area 
stem from the development of specially engineered viral vectors that can avoid immune 
stimulation while retaining high efficiency as well as the development of viral-like particles [63, 
254] and bacteriophage vectors [63].
5.1.3.2 Non-Viral Polymer Based Delivery
Non-viral vectors have the added benefits of storage stability, scale up and enhanced quality 
control [255]. DNA delivery has been extensively explored while only in recent years is non- 
viral technology being applied to shRNA expressing vector delivery. shRNA expressing 
plasmids can be encapsulated in a wide variety of polymer based particles such as PEI [256- 
258], chitosan [259], PLL and PLGA for improved transfection efficiency. However compared to 
viral vectors these delivery systems tend to show low transfection and poor tissue penetration 
[236],
Each polymer type shows promise as well as associated problems for successful shRNA 
plasmid delivery. For instance, PEI has been used to prepare transferrin (Tf) coated 
nanoparticles for shRNA plasmid delivery for cancer therapies [257, 258]. Tf-PEI complexed 
with hypoxia-inducible factor-1 a (HIF-1a) expressing shRNA-vectors in mice delivering shRNA 
to target cells and reducing tumor growth [258] nevertheless PEI is not biodegradable and can 
cause necrotic and apoptotic toxicity [236]. On the other hand chitosan is biodegradable, 
biocompatible and of low immunogenicity and toxicity. Chitosan has also recently acted as a 
carrier for a cancer targeting shRNA expression vector in rhabomycosarcoma cells [259].
PLGA as discussed in chapter 4 is biocompatible and biodegradable polymer with low toxicity 
and immunogenicity. PLGA has also received approval for clinical use by the US FDA [260] 
though not for inhalation and biodegradable particles encapsulating DNA have entered clinical 
trials [261]. It has been extensively investigated for DNA delivery but only recently have shRNA 
expressing plasmids been incorporated into PLGA nanoparticles [249, 262]. Along with the 
biocompatibility advantages, PLGA particles also potentially protect DNA from degradation,
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allow sustained release and possible control over dosing. PLGA particle uptake is size 
dependent with larger microparticles phagocytosed by for example macrophages or target 
APCs (a feature advantageous for DNA vaccine delivery) [255] and smaller nanoparticles taken 
up via endocytosis. Particles cause swelling and rupture of endosomes and/or lysosomal 
compartments leading to their release into the cytoplasm. Cohen et al. (2000) monitored uptake 
of a fluorescently tagged pDNA and found PLGA nanoparticle encapsulated pDNA in the 
cytoplasm while released pDNA localised in the cytoplasm and around and in the nucleus [263] 
confirming the capability of nuclear delivery via these polymeric platforms.
5.1.4 shRNA Gene Targets
5.1.4.1 Interferon Regulatory Protein 3 (IRF3)
Interferon regulatory protein 3 (IRF3) is a transcription factor central in Type IIFN  transcriptional 
regulation which is key in the response to bacterial and viral infection. IRF3 is expressed 
constitutively in all cells and in its inactivated form is present in the cell cytoplasm [264], 
Activation of IRF3 can occur through various pathways. Briefly, following immune stimulation 
for example via TLRs (Figure 5.5) IRF3 is phosphorylated, dimerizes and translocates to the 
nucleus where it binds to its consensus sequence in target genes (such as the type I IFNs) and 
drives gene expression [264].
Figure 5.5: Interferon regulatory protein-3 (IRF3) activation via toll like receptor (TLR) activation 
[265].
IL-23 is a cytokine consisting of p19 and p40 subunits. It plays an important role in 
inflammation and auto-immunity and is highly expressed by macrophages. For this reason IL-
23 represents an important target in therapeutic development. Clinical trials are investigating
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monoclonal antibodies against IL23 for psoriasis, psoriatic arthritis and Crohn’s disease [266]. 
From studies carried out by Dr. Jefferies’ group, it is possible that IRF3 is involved in IL-23p19 
production. In order to decipher if the role played by IRF3 is central to IL-23p19 induction it will 
be knocked down and IL-23p19 secretion determined in monocytes stimulated with Poly l:C a 
TLR3 agonist.
5.1.4.2 Tripartite motif-containing 68 (TRIM68 or SS-56)
Tripartite motif-containing 6 8  (TRIM6 8  or SS-56) is an ubiquitin E3 ligase similar in structure to 
TRIM21 (Ro52) and a member of the superfamily of TRIM proteins [267]. It has been shown 
that TRIM6 8  is an auto-antigen in Systemic Lupus Erythematosus (SLE) and Sjôgren’s 
syndrome [268, 269] as well as playing a role in prostate cancer [270] however little is known of 
TRIM6 8  function. Unpublished data from Dr. Jefferies’ group have shown that TRIM68  activity 
is regulated by tyrosine phosphorylation and negatively regulates IFN(3 production a role that is 
blocked by TRIM6 8  tyrosine residue mutations. Additionally TRIM6 8  is highly expressed by 
natural killer (NK) cells. Association between NK cells and S LE  has been reported with SLE  
patients having a lower proportion of NKT cells [271] and NK cells producing high levels of 
IFNy [272].
As NK cells are altered in S L E  and could be involved in S LE  pathogenesis through IFN 
production TRIM6 8  may play a key role in this disease. The involvement of TRIM6 8  in NK cell 
TLR-responses and NK cell activity need to be elucidated. Consequently the knock down of 
TRIM68  in NK cells would allow the activation, cytokine release and activity of NK cells to be 
assessed in the absence of TRIM6 8 .
5.1.5 Chapter Aims
• To harness microparticle technology developed in chapter 4 for shRNA delivery to 
macrophages
• To optimise microparticle development and transfection with microparticles loaded 
green fluorescent protein (GFP) expressing plasmids
• To compare PLGA microparticle systems for macrophage transfection with commercial 
non-viral and lentiviral based transfections
• To assess targeted gene transfections using shRNA loaded microparticles
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5.2 Materials
10kb DNA ladder
10x Ultrapure TBE buffer, Invitrogen
30 % Acrylamide/Bisacrylamide (37.5:1) solution, Bio-Rad
Afl II restriction enzyme, New England Biolabs
Agarose, Sigma Aldrich
a-Lactose, Sigma Aldrich
Ammonium persulphate (AP), Sigma Aldrich
Ampicillin, Sigma Aldrich
Anti- a-actinin, Santa Cruz
Anti-IRF3 (polyclonal goat), Santa Cruz
Anti-TRIM6 8 , Sigma Aldrich
Aprotinin, Sigma Aldrich
BCA Protein Assay, Pierce
Black 96 well plates, Fisher scientific
Blue/orange 6 x loading dye, Promega
BSA, New England Biolabs
Cellstar flat-bottomed 96 well plates, Grenier
Chloroform, Fisher scientific
Competent DH5a cells, Invitrogen
DEPC-treated RNase DNase free water, Fisher
Dicholoromethane (DCM), Reagent grade, Fisher Scientific or Sigma Aldrich 
Dithiothreitol (DTT), Sigma Aldrich 
DMEM, BioSera 
EDTA, Amresco
EndoFree Plasmid Maxi Kit, Qiagen 
Ethidium bromide, Sigma Aldrich 
Foetal Bovine Serum, BioSera 
Freeze Drier FreeZone 4.5, Labconco 
Fuji SuperRXfilm, FujiFilm Ireland Ltd.
G:BOX, Syngene 
Glycerol 99.99%, Sigma Aldrich 
Hoescht, Sigma Aldrich 
Ika homogenizer, IKA
Immobilon Western HRP Substrate, Milli pore 
INCELL1000 Cell Analyser, GE Healthcare 
lodoacetamide, Sigma Aldrich 
Kanamycin, Sigma Aldrich 
LB broth, Sigma Aldrich 
LB-Agar, Sigma Aldrich 
Leupeptin, Sigma Aldrich
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Malvern Mastersizer 2000, Malvern Instruments 
Metafectene pro, Biontex 
Metafectene, Biontex 
Methanol, Sigma Aldrich
Mission® Interferon Regulatory Factor 3 (IRF3) shRNA Plasmid DNA, Sigma Aldrich
Mission® Non-Target Control Vector shRNA, Sigma Aldrich
Mission® Tripartite Motif-containing 6 8  (TRIM6 8 ) shRNA Plasmid DNA, Sigma Aldrich
MoFlo High Performance Cell Sorter, Dako
N,N,N\N'-Tetramethylethylenediamine (TEMED), Sigma Aldrich
NanodroplOOO, Thermo Scientific
Nanoseries Zetasizer, Malvern
NE Buffer 4, New England Biolabs
Nucleobond® Endotoxin Free Maxi Prep Kit, Machery-Nagel 
Paraformaldehyde, Sigma Aldrich 
pCDF1-MCS2-EF1-copGFP, System Biosciences, SBI 
pGIPz GFP
Phalloidin-FITC, Sigma Aldrich 
Phenylmethanesulfonyl fluoride (PMSF), Sigma Aldrich 
Phosphate Buffered Saline (PBS), BioSera and GIBCO (Invitrogen))
PLGA, Resomer RG503, 50:50, poly( lactide-co-glycolide), Boehringer Ingelheim 
pmaxGFP, AMAXA 
Polybrene, Millipore
polyethylene glycol (PEG) MW8000, Sigma Aldrich
Polyvinyl Alcohol (PVA), Mw 31,000 -  50,000, 87-89% hydrolyzed, Sigma Aldrich
Ponceau S Solution, Sigma Aldrich
Potassium Chloride (K C I), Sigma Aldrich
Potassium phosphate (KH2P04), Sigma Aldrich
Precast 1% Agarose Gel, Sigma Aldrich
Precision Plus Protein™ Dual Color Standard, Bio-Rad
Probe sonicator, Branson
Propan-2-ol (isopropanol), VWR International Ltd.
Quant-iT PicoGreen Assay, Invitrogen
Rotina 35 R centrifuge, Hettich
RPMI-1640 w/stable L-Glutamine, BioSera
Sodium Azide, Sigma Aldrich
Sodium Chloride, Sigma Aldrich
Sodium dodecylsulphate (SDS), Sigma Aldrich
Sodium Orthovanidate, Sigma Aldrich
Sodium phosphate dibasic (N a2PH 04), Sigma Aldrich
Tescan Mira XMU Variable Pressure Field Emission Scanning Electron Microscope 
(VPFESEM), Tescan USA Inc. USA.
Tris-acetate-EDTA (TAE), Sigma Aldrich
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Triton X-100, Sigma Aldrich 
Trizma Base, Sigma Aldrich 
Tween® 20, Sigma Aldrich 
Victor Wallac Multiplate Reader, Wallac
5.3 Methods
pmaxGFP is a 3486bp plasmid expressing copGFP (Evrogen) inserted into a pMCV1.4 
backbone (Mologen) (Figure 5.6A). copGFP gene is derived from copepod plankton (Panalina 
sp.). This plasmid contains 35 unique restriction sites and kanamycin resistance. pCDF1- 
MCS2-EF1-copGFP and pGIPz-GFP are lentiviral vectors expressing GFP with ampicillin (Amp) 
resistance and 6,771 bp and > 1 1 ,6 8 8 bp in size, respectively (Figure 5.6B and C). pCMV-VSV-G 
(6363bp) and pCMV-HIV1 lentiviral vectors are envelope and packaging plasmids respectively.
Mission® shRNA plasmid DNA express shRNA targeted to human IRF3 and TRIM6 8  (or SS-56) 
genes inserted into a pl_K0.1 vector backbone (Figure 5.7B). IRF3 is involved in interferon-a/p 
(IFNa/p) gene expression regulation. TRIM6 8  is an E3 ubiquitin ligase [270] as well as an auto­
antigen for S S  and S L E  [269]. Mission® non-target control vector was used as a negative 
control or “scrambled” sequence (Figure 5.7A). shRNA plasmids are both Amp and puromycin 
resistant for bacterial and mammalian selection respectively.
5.3.1 DNA and shRNA Plasmids
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Figure 5.6: G FP vector maps of (A) pmaxGFP, (B) pcdf1-mcs2-ef1-copGFP and (C) pGIPz 
(empty vector) plasmids.
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Figure 5.7: Mission® shRNA plasmid DNA. (A) Non-target shRNA vector and (B) pLKO.1 vector 
backbone and shRNA gene insert and expression. (Sigma Aldrich)
164
5.3.1.1 Plasmid Transformations
Plasmid vectors were transformed in competent DH5a cells. Briefly, 200pl of DH5a cells were 
added to 1fjl of plasmid stock and incubated on ice for 20 -  30 minutes. Controls contained no 
plasmid. The cells were heat shocked for 2 minutes at 43°C followed by cooling on ice for 1 -  2 
minutes. The cells were then transferred to 1ml of lysogeny broth (LB) at room temperature 
(RT) and shaken for 1 hour at 37°C. Kanamycin (pmaxGFP) and Amp agar plates were 
prepared with 35g/L of autoclaved LB-agar supplemented with 100|jg/ml of antibiotic. 50pl of 
cells were plated onto pre-warmed plates and incubated at 37°C for 15 -1 6  hours. Plates were 
then stored at 4°C.
5.3.1.2 Plasmid Maxi Preps
Single colonies were selected and grown in sterile LB broth (25mg/ml) containing antibiotic 
(1pg/ml) overnight shaken at 250 rpm at 37°C. Plasmids were isolated using maxi prep kits 
according to the manufacturer’s protocols. Concentration and DNA integrity was assessed by 
spectroscopy (NanoDrop) and gel electrophoresis. For gel electrophoresis pmaxGFP plasmid 
was linearised by digestion with Afl II restriction enzyme. The reaction mixture (50pl) contained 
BSA (5pl), NE Buffer 4 (5pl), pmaxGFP plasmid (0.5pg), TE buffer (32.02pl) and Afl II (0.5 
units). The control did not contain the restriction enzyme. Reaction mixtures were heated for 1 
hour at 37°C and 20 minutes at 65°C. DNA was analysed by gel electrophoresis (1 % agarose 
gel stained with ethidium bromide) tris-acetate-EDTA (TAE) for 40 minutes at 110V. 
Visualization was obtained by UV transillumination (Appendix).
5.3.2 Cell Culture
THP-1 cells were cultured and differentiated as described in 3.3.2. Human monocytes were 
isolated and maintained as described in 3.3.2.2 and 4.3.2.1. HEK-293T cells are a human 
embryonic kidney cell line and were maintained in dulbecco's modified eagle medium (DMEM) 
supplemented with 10% FBS, 0.1% Amphotericin B and 0.1% gentamicin. Natural killer 
(NK92MI) cells derived from peripheral blood mononuclear cells of a 50 year old Caucasian 
. male with rapidly progressive non-Hodgkins lymphoma were maintained in suspension in RPMI 
media supplemented with 10% FBS in a humidified atmosphere at 37°C and 5% C 0 2.
5.3.3 Preparation of pDNA and shRNA-loaded PLGA Microparticles
Microparticles containing pDNA or shRNA were prepared using a double emulsion (w1/o/w2) 
solvent evaporation method (Figure 5.8). pDNA was either encapsulated alone or complexed 
with DOTAP using the method described in 4.3.3 with an N/P ratio of 4 and 40pg of pDNA. 
50mg of PLGA 503 was dissolved in 1.75ml DCM (2.9% w/v) in a glass test tube and vortexed. 
A mixture of 30pl of pDNA-DOTAP complexes rehydrated in RNase free water or pDNA or 
shRNA with a nucleic acid concentration of at least 1 mg/ml and 32pl of dH20  containing 300mM
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lactose and 1mM EDTA was added to the PLGA solution and the mixture was manually probe 
sonicated with four pulses at an output level of 4 to form the primary w/o emulsion. The primary 
emulsion was added dropwise to a 5% (w/v) PVA solution containing 300mM lactose and 0.2M 
NaCI (12.5ml) homogenizing over an ice-bath at 13500 rpm (or level 3) to form a secondary or 
multiple w/o/w emulsion. This emulsion was added to 25ml 1% (w/v) PVA containing 300mM 
lactose and 0.2M NaCI and gently stirred for at least 4 hours at room temperature to allow DCM 
evaporation. Microparticles were recovered by centrifugation at 5,000rpm for 15 min at 4 °C, 
washed three times with water to remove residual PVA, resuspended in 1.5ml d dH20  and 
lyophilized for 18 hours.
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Figure 5.8. Schematic of pDNA or shRNA microparticle preparation by double emulsion solvent 
evaporation method.
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5.3.4 Microparticle Characterisation
5.3.4.1 Particle Size
Microparticle size was determined as described in 4.3.4.1.
5.3.4.2 Zeta Potential of microparticles
Zeta potentials of microparticles were measured as described in 4.3.4.2.
5.3.4.3 Surface morphology by scanning electron microscopy (SEM)
Microparticle size and surface morphology was assessed by SEM as described in 4.3.4.3.
5.3.4.4 Encapsulation Efficiency
Lyophilised pDNA or shRNA-loaded microparticles (1mg) were dissolved in 50pl of chloroform. 
To this 50|jl of nuclease free water was added and the mixture was vortexed for 15 minutes 
followed by centrifugation at 10000 rpm for 5 minutes. The upper aqueous layer was collected 
and the centrifugation step was repeated after the addition of another 50pl of TE buffer. 
Collected aqueous layers were pooled and the nucleic acid concentrations determined. pDNA 
and shRNA concentration was determined using a Quant-iT PicoGreen assay. This assay uses 
a fluorescent nucleic acid stain for double-stranded DNA (dsDNA) that allows detection of 
dsDNA at concentrations as low as 25pg/ml.
A standard curve was prepared using stock pDNA or shRNA diluted with TE buffer (200mM 
Tris-HCI, 20mM EDTA, pH 7.5) to give 0, 1 , 10, 100 and 1000ng/ml final concentration. 100pl 
of diluted pDNA or shRNA was added in triplicate to wells of a black 96 well plate. 5jjI of 
extracted nucleic acid was added in triplicate to wells. The volume per well was brought up to 
100pl. PicoGreen reagent was diluted 1 in 200 and 100pl was added per well. Fluorescence 
was detected at 485nm excitation and 535nm emission wavelengths using a Wallac multiplate 
reader. To correct for background fluorescence, readings of blank wells was subtracted from 
samples.
5.3.4.5 Integrity of Encapsulated Nucleic Acids
shRNA integrity was assessed by gel electrophoresis using a pre-cast 1% TBE-agarose gel with 
O.Spg/ml ethidium bromide. Blue/orange 6x loading dye (Promega) was used to track gel 
migration. shRNAs were extracted from microparticle preparations by aqueous and solvent 
phase separation as described in 5.3.4.4 50ng of stock and extracted shRNA were loaded per 
well and the gels were run in 1x TBE buffer at 100V for 1 hour. Visualization was obtained by 
UV transillumination (G:BOX, Syngene).
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5.3.5 Lipid Based DNA Transfection
5.3.5.1 Metafectene Transfection
THP-1 cells were seeded in 6  well plates and incubated overnight. 2[jg of pmaxGFP was added 
to serum free RPMI brought to a final volume of 700pl. 8 pl of metafectene or metafectene pro 
was added to 692|jl of serum free media and incubated at room temperature for 5 minutes. The 
diluted metafectene was added and gently mixed with the diluted DNA and incubated at RT for 
20 minutes. The mixture was added dropwise to the media covering the cells. The cells were 
incubated at 37°C for 24 hours and transfection was accessed by fluorescent microscopy and 
flow cytometry. Transfected cells were selected by fluorescence associated cell sorting (FACS).
5.3.5.2 Flow Cytometry and Fluorescence Associated Cell Sorting
THP - 1  cells transfected with pmaxGFP/metafectene and pmaxGFP/Metafectene Pro were 
pooled. Wash buffer (2ml) was added to pmaxGFP (1ml) and untransfected (500|jl) THP-1 cells 
and centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded. Cells were 
resuspended in 300pl of wash buffer and stored on ice. Flow cytometry determined transfection 
efficiency. Cells were maintained at 37°C for one week to increase cells numbers and sorted 
with a MoFlo High Performance Cell Sorter (Dako). Sorted cells were maintained at 37°C in 
1ml of fresh media supplement with 20% FBS.
5.3.6 Lentiviral Transfection
HEK-293T cells were seeded at 2.5x106/ml in 10cm culture dishes in a total of 10ml of DMEM 
supplemented with 10% FBS. After 24 hours the media was replaced with 9ml of fresh media 
and the cells were further incubated for 1 -  2  hours undér tissue culture conditions.
10pg of transfer plasmid (pGIPz-GFP), 3 pg of envelope plasmid (pCMV-VSV-G) and 6.5 pg of 
packaging plasmid (pCMV-HIV1 ) were diluted in sterile water to a final volume of 295pl. 55 pi of 
2 M calcium chloride (CaCI2) was added and mixed gently by pipetting. 350 pi of 2x H EPES (4- 
(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Buffered Saline (HeBS, pH 7.5 (280mM NaCI, 
10mM KCI, 1.5mM Na2H P04, 12mM D+Glucose and 50mM HEPES)) was added dropwise 
whilst bubbling the mixture and incubated at room temperature for 30 minutes. The mixture was 
added to the media covering cells dropwise. Cells were incubated for 4 hours at 37°C. The 
media was removed and the cells were washed once with warm PBS. The cells were shocked 
with 3ml per plate of 15% glycerol in PBS (v/v) for 60 seconds at 37°C. The glycerol was 
removed and the cells were washed twice with warm PBS. Fresh media was added and cells 
were incubated at 37°C for 24 hours.
The cells were washed once with PBS and 10ml of 20% FBS DMEM was added. Transfection 
was confirmed by fluorescent microscopy. A few hours later the media was replaced with 6 ml of
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20% RPMI and incubated overnight at 37°C. THP-1 cells were seeded in 6  well plates at 
2.5x105 cells in 3ml and incubated overnight.
The media was harvested off the transfected HEK-293T cells and replaced with 6 ml of fresh 
20% FBS RPMI. A few hours later the second media was collected. Harvested media was 
centrifuged at 1500rpm for 5 minutes and filtered (0.45|jm filter). Supernatants were transferred 
to sterile 50ml tubes and 1 volume of cold 1X PEG (MW8000, pH 7.2) solution was added. The 
solution was incubated at 4°C for at least 12 hours and then centrifuged at 1500xg for 30 
minutes. The supernatant was removed and residual PEG solution was spun down at 1500xg 
for 5 minutes. All trace of liquid was removed by pipette. The lentiviral pellet was resuspended 
in 1/10 or 1/100 of the original volume using cold sterile PBS.
THP-1 cell media was replaced with fresh media supplemented with 10% FBS. Polybrene 
(5[jg/ml) was added to each well. Concentrated lentiviral supernatant (0 -  200pl) was added 
dropwise to the wells, mixed and incubated at 35°C. After 24 hours the media was replaced
with fresh media and the cells were incubated for 48 hours at 35°C.
5.3.7 Microparticle mediated pDNA Transfection
5.3.7.1 Flow Cytometry
2x105 THP-1 cells were differentiated per well in 24 well plates. Microparticles were suspended 
in RPMI to give a final concentration of 1 mg/ml. Differentiated THP-1 cells were untreated or 
treated with 10Opg or 200pg empty microparticles, microparticles encapsulating pmaxGFP 
plasmid or pmaxGFP plasmid complexed with DOTAP at N/P ratio of 4 for 3 to 4 hours. 
Treatments were preformed in triplicate. Media was replaced by fresh media and cells were 
incubated for 24 hours. Cells were washed with warmed PBS and collected in 500jjI of PBS 
and centrifuged at 8000rpm in a microcentrifuge for 2 minutes. Supernatants were discarded 
and cells were resuspended in 500pl of PBS and analysed using a flow cytometer. Cells were 
divided into two populations based on fluorescence intensity and GFP expression determined 
from 5000 cells per replicate.
5.3.7.2 High Content Cell Analysis
THP-1 cells were differentiated at a density of 1x105 cells/ml in 96 well plates. Microparticles 
were resuspended at 1 mg/ml in RPMI. Cells treated with media alone, 20|jl (20pg) empty
microparticles or microparticles encapsulating pmaxGFP plasmid or pmaxGFP plasmid
complexed with DOTAP (N/P ratio 4) for 3 hours. GFP expression was monitored by 
fluorescent microscopy. 72 hours following microparticle treatment cells were fixed with 4% 
paraformaldehyde for 20 minutes at room temperature. Cells were washed with PBS three 
times and nuclei were stained with hoescht for 5 minutes at room temperature. PBS washes 
were repeated and 150|jl PBS was added to each well. Plates were stored at 4°C protected
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from the light until analysed. Images were acquired by an INCELL 1000 cell analyser at 10x 
magnification in 5 fields per well. G FP was detected at 480nm excitation and 535nm emission 
wavelengths and nuclei were detected at 360nm excitation and 460nm emission wavelengths.
Multi target analysis module was used with nuclei, cells and a reference inputted as objects to 
be measured and assigned wavelengths for nuclei, cells and green fluoresence respectively. 
Parameters for segmentation analysis were then inputted. Nuclei were identified using Top Hat. 
A minimum area was inputted based on the images required and sensitivity generally set to 
80%. Segmentation of cells was performed using the collar method. This sets up a ring-shaped 
region around the nucleus using an inputted average cell radius value assigning this region as 
the cell. The reference was detected in cells and cell intensity of the reference per cell above 
background fluorescence was used as the measure of GFP expression. Input values and 
sensitivity settings were adjusted for each experiment until all parameters were correctly 
assigned.
5.3.8 Microparticle mediated shRNA Transfection
5.3.8.1 shRNA Transfection
The functionality of microparticle encapsulated IRF3 and TRIM6 8  shRNA was assessed in 
isolated human monocytes and NK92MI cells respectively. IRF3 shRNA transfections were 
carried out by Siobhan Smith and TRIM6 8  shRNA transfections were carried out by Claire 
Wynne. Microparticles were suspended in media at 1 mg/ml and cells were either untreated or 
treated with empty microparticles or microparticles encapsulating scrambled, IRF3 or TRIM6 8 
shRNA for 24, 48 and 72 hours. As a positive control NK92MI cells were transfected with 
TRIM6 8 -FLAG. Protein expression was assessed by western blot analysis.
5.3.8.2 Western Blot Analysis
At each endpoint plates were spun down at 1600rpm for 5 minutes and supernatants removed. 
1 OOjjI of 1X sample loading buffer with protease inhibitors was added to the wells and cells were 
scraped and collected. Sample loading buffer contained 10% (v/v) glycerol, 2% (w/v) SDS, 
0.1% (w/v) Bromophenol blue, 5% (v/v) Tris HCI (1M, pH 6 .8 ) and 100mM DTT. The protease 
inhibitors phenylmethylsulfonyl fluoride (PMSF; 1mM), sodium orthovanadate (Na3V 0 4; 1mM) 
and potassium fluoride (KF; 1mM) were added to the sample loading buffer. Samples were 
then boiled for 5 minutes at 95°C followed by sonication for 15 seconds and centrifugation at 
13,000rpm for 5 minutes.
Ladders and samples (40^g) were loaded onto a stacking gel and electrophoresed on 8 % or 
1 2 % polyacrylamide Tris-HCI resolving gel (IRF3 and TRIM6 8  respectively) at 60mA in SD S  
running Tris-glycine buffer (25mM Tris, 92mM glycine and 0.1% SDS). Protein was transferred 
to PVDF membrane at 200mA for 1 hour in transfer buffer (25mM Tris, 192mM glycine and 20%
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(v/v) methanol). Membranes were rinsed in TBS-0.1% Tween and blocked for up to 5 hours at 
room temperature with blocking solution (5% milk in TBS-0.1% Tween). Membranes were then 
incubated with primary antibody, IRF3 goat polyclonal antibody (1:500), TRIM6 8  antibody or 
positive control actin primary antibodies at 4°C for 1-5 hours or overnight. Following incubation 
membranes underwent three 5 minutes washes in TBS-0.1% Tween. Membranes were 
incubated for 1-3 hours with HRP conjugated secondary antibody (anti-goat antibody 1:10000 
dilution for IRF3) followed by three 5 minute washes in TBS-0.1% Tween. Membranes were 
covered in EC L reagent and incubated for 1 minute in the dark followed by exposure to film in a 
cassette.
5.3.9 Statistical Analysis
In general results are expressed as means ± SD. One way or two way ANOVA was used to test 
for differences between treatments with p-values < 0.05 considered significant, < 0.01 very 
significant and < 0 .0 0 1  highly significant.
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5.4 Results
5.4.1 Plasmid Preparation
Various plasmids were transformed, replicated, isolated and purified with good yields. 
Spectrophotometry showed products with 260/280 ratio of about 1.8 and 260/230 ratio of 2.2 
indicating high purity. Yields ranged from 115 to 661 pg. Gel electrophoresis also confirmed 
purity as well as integrity (Appendix).
5.4.2 Characterisation of pGFP-loaded Microparticles
5.4.2.1 Size
The geometric sizes of the prepared microparticles were between 2 and 3pm (Table 5.1) fitting 
into the size range for effective pulmonary delivery. However, microparticles encapsulating 
GFP plasmid DNA complexed with DOTAP were greater than 6 pm.
Table 5.1: Average sizes of Microparticle Encapsulating DNA Plasmids (n = 3, ± SD)
Microparticle Average Size (dso pm)
Empty 2.387 ± 0.034
GFP 3.209 ±0.297
GFP-DOTAP 5.866 ± 1.293
5.4.2.2 Zeta Potential
Overall zeta potentials were negative. Empty particles had a surface charge of -2mV while 
following encapsulation of pDNA zeta potential decreased to greater than -37mV (Table 5.2).
Table 5.2: Zeta Potentials of Microparticle encapsulating plasmid DNA (n=3, ± SD)
Microparticle Zeta Potential (mV)
Empty -2.33 + 0.174
GFPpDNA -37.4 + 0.522
GFP pDNA-DOTAP -9.89 ± 0.514
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5.4.2.3 Encapsulation Efficiency
To accurately assess nucleic acid dosing and concentrations the amount of pDNA encapsulated 
into the microparticles was determined. Encapsulation efficiency of pDNA was >83%. 
Encapsulation efficiency of pDNA was decreased by 70% by pre-complexation of pDNA with 
DOTAP.
Table 5.3: Summary of % DNA Encapsulation Efficiency of PLGA Microparticles (n=5, ± 
SD)
Microparticle Average Encapsulation Efficiency (%)
Empty 0
GFPpDNA 83.33 ±10.90
GFPpDNA-DOTAP 13.26 ± 2.88
5.4.2.4 Scanning Electron Microscopy (SEM)
SEM was used to examine morphology, size and particle size distributions of microparticles. 
The electron micrographs also displayed the range of microparticle size distribution and showed 
smooth spherical empty particles (Figure 5.9A) and pDNA loaded particles (Figure 5.9B).
Figure 5.9. Morphology, particle size and particle size distribution of pDNA loaded 
microparticles was examined using SEM. (A) shows unloaded PLGA microparticles and (B) 
PLGA microparticles encapsulating pDNA at 5.00 kx magnification
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5.4.3 Metafectene GFP Plasmid Transfections
To determine a suitable GFP expression vector for microparticle pDNA transfections and to 
compare the efficiency of transfection by commercial reagents and microparticles THP-1 cells 
were transfected with a range of GFP plasmids using commercially available pDNA transfection 
reagents Metafectene and Metafectene Pro. THP-1 cells were transfected at a low efficiency 
with pmaxGFP. The efficiency assessed visually was improved using Metafectene Pro over 
Metafectene (Figure 5.10A and B). GFP could not be visualised by fluorescent microscopy in 
cells transfected with lentivectors. Flow cytometry of THP-1 cells transfected with pmaxGFP 
showed 43% transfection efficiency (Figure 5.10C). GFP positive THP-1 cells were collected by 
FACS. Low numbers of positive cells were collected (1x103 cells) from the pmaxGFP 
transfected cells. FACS showed less than 20% GFP positive cells in the transfected cell groups 
(Figure 5.10E) compared with the untransfected cells (Figure 5.10D). Sorted cells did not 
express GFP after one week.
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Figure 5.10: Bright field and fluorescent images of pmaxGFP THP - 1 transfection with 
Metafectene (A) and Metafectene Pro (B) after 24 hours. (C) Flow cytometry histogram of 
pmaxGFP transfected THP-1 cells. Fluorescent associated cell sorting (FACS) showing dot 
plots and histograms of (D) control untransfected THP-1 cells and (E) pmaxGFP transfected 
THP-1 cells.
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Lentiviruses are very well suited for stable transductions and have been used previously to 
stably transduce THP-1 cells [62, 273] and other monocytes [59, 61]. The viral particles are 
constructed in a host cell line (such as human 293T cells which can be easily transfected). The 
host cells are transfected with various viral elements expressed on different plasmids including 
envelope, packaging and transgene (for example a GFP gene) expression vectors. Target cells 
are infected or transduced with the viral particles and the GFP gene will be integrated into the 
host genome (Figure 5.11).
The transfection efficiency of the HEK-293T cells with the lentiviral plasmids was almost 100% 
as shown in Figure 5.11. Media was harvested from these cells and viral particles were 
concentrated with a PEG solution. Subsequent transfections with the concentrated viral 
particles yielded no expression of GFP in THP-1 cells.
5.4.4 Lentiviral Transfections
Figure 5.11: Bright light and fluorescent images of HEK-293T cells 48 hours after calcium 
phosphate transfection with pGIPZ-GFP, pCMV-VSV-G and pCMV-HlV- 1  at 40x (A) and 200x 
(B)
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5.4.5 Microparticle GFP Plasmid Transfections
5.4.5.1 Flow Cytometry
Differentiated THP-1 cells were transfected with pmaxGFP plasmid delivered by microparticles 
and assessed by flow cytometry and HCA. Through metafectene transfections pmaxGFP was 
chosen as the most suitable GFP plasmid. Although encapsulation efficiency by microparticles 
of pmaxGFP alone was significantly greater than pmaxGFP complexed with DOTAP, GFP  
expression was significantly enhanced after transfection by microparticles encapsulating 
pmaxGFP plasmid complexed with DOTAP. Flow cytometry carried out by Dr. Awadh Yadav 
showed a 69.6% increase in GFP positive cells (Figure 5.12) while HCA showed a 4-fold 
increase in GFP fluorescence intensity by the incorporation of DOTAP into formulations (Figure
5.13). It should also be noted that a significant level of fluorescence was detected by flow 
cytometry and HCA following treatment with empty PLGA microparticles suggesting the 
particles exhibit auto-fluorescent properties.
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Figure 5.12: Flow cytometry analysis of pmaxGFP-microparticle transfected differentiated THP- 
1 cells. Cells were treated with empty microparticles (MP), 100pg or 200jjg of 1 mg/ml 
microparticles encapsulating pmaxGFP plasmid DNA (pmaxGFP MP) or pmaxGFP complexed 
with DOTAP at N/P ratio of 4 (pmaxGFP/DOTAP MP).
Data represented as means ± SD (n = 2)
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5.4.5.2 High Content Cell Analysis
Differentiated THP-1 cells are resistant to trypsin treatment however some reagents such as 
accutase I [274] are recommended for detachment. Flow cytometry requires a high number of 
cells in suspension. The process of resuspending differentiated THP-1 cells can be stressful 
and cause cell damage. Additionally not all cells will detach successfully and consequent cell 
analysis may not be an accurate representation of the entire cell population. Therefore a 
method that avoids cell resuspension leaving cells in situ is preferable. HCA was used to 
assess copGFP expression in differentiated THP-1 cells (Figure 5.13). Cells could be imaged 
and analysed adhered to wells. Fewer cells are required and can be fixed or imaged live.
HCA showed a high level of fluorescence after treatment with empty microparticles (also 
observed by FACS analysis) suggesting microparticles autofluoresce at these wavelengths. 
GFP expression by microparticle transfected cells visually was not as intense or definite as 
observed in metafectene/GFP transfected cells. Expression appeared to be more diffuse in the 
pmaxGFP microparticle transfected cells but with a greater number of cells expressing GFP.
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Figure 5.13: High content cell analysis of GFP expression by differentiated THP-1 cells (A) 
untreated, treated with 20pg of (B) empty microparticles, (C) pmaxGFP encapsulated 
microparticles and (D) pmaxGFP-DOTAP encapsulated microparticles. Cells were fixed and 
stained with hoescht (nuclei; blue). (A-D) Images were acquired at 100x magnification and 
analysed for cell number (E) and GFP fluorescence intensity (F) (GFP fluorescence intensity 
was corrected for background fluorescence). Data expressed as means ± SD (n = 3)
Statistical differences were determined by one-way ANOVA with Bonferroni’s Post-hoc test. *p < 
0.05, ** p< 0.01 and *** p < 0.001
5.4.6 Characterisation of shRNA-loaded Microparticles
5.4.6.1 Size
The sizes of the prepared microparticles encapsulating shRNA plasmids were on average 
2.9pm (Table 5.4).
Table 5.4: Average sizes of Microparticle Encapsulating shRNA (n = 3, ± SD)
Microparticle Average Size (dso iJm)
Empty 2.91 ±0.036
Scrambled shRNA 2.853 ± 0.38
IRF3 shRNA 2.941 ±0.04
TRIM68 shRNA 2.936 ± 0.03
5.4.6.2 Zeta Potential
Zeta potentials were negative. Loaded particle zeta potentials ranged from -22 to
5.5).
Table 5.5: Zeta Potentials of Microparticles Encapsulating shRNA (n=3, ± SD)
Microparticle Zeta Potential (mV)
Empty -2.33 ±0.174
Scrambled shRNA -31.28 ±0.622
IRF3 shRNA -21.5 ±0.711
TRIM68 shRNA -31.9 ±0.663
5.4.6.3 Encapsulation Efficiency
Encapsulation efficiencies of shRNA plasmids were found to be >43% (Table 5.6). Stock 
concentrations of scrambled, IRF3 and TRIM68  shRNA were 0.863mg/ml, 1.217mg/ml and 
1.906mg/ml. For optimal encapsulation efficiency shRNA loading concentrations of at least 
1 mg/ml were required.
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Table 5.6: Summary of % shRNA Encapsulation Efficiency of Microparticles (n=5, ± SD)
Microparticle Average Encapsulation Efficiency (%)
Empty 0
Scrambled shRNA 42.68 ± 4.59
IRF3 shRNA 79.11 ±52.43
TRIM68 shRNA 62.91 ± 1.41
5.4.Ô.4 Scanning Electron Microscopy (SEM)
SEM assessing morphology and particle size showed smooth spherical particles of non- 
homogenous size distribution (Figure 5.14). Particles sizes concurred with laser diffraction 
data.
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Figure 5.14: Morphology, particle size and particle size distribution of pDNA loaded 
microparticles was examined using SEM. (A and B) show PLGA microparticles encapsulating 
scrambled shRNA and (C and D) PLGA microparticles encapsulating TRIM6 8  shRNA at 5.67, 
13.89, 9.35 and 5.36 kx magnification respectively.
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5.4.6.5 shRNA plasmid Integrity
Microparticle preparation involves stresses such as sonication, homogenisation, low 
temperatures and exposure to organic solvents increasing the possibility of damage and 
subsequently functional loss of the loaded nucleic acids [255, 275]. To address this issue the 
structural integrity of loaded nucleic acids was assessed by gel electrophoresis.
The presence of a single band of appropriate size would signify no degradation or structural 
damage to extracted pDNA and shRNA. Comparison of shRNA prior to and following 
microparticle encapsulation shows some degradation by the visualisation of a second band in 
each of the extracted shRNA samples (Figure 5.15). The second bands are of smaller size and 
appear to be the same size in each sample. The presence of strong bands representing the 
intact shRNA indicates the bulk of the shRNA has evaded degradation. Although shRNA 
extracted from microparticles appears to undergone some degradation this may not correspond 
to functional loss.
Stock shRNA Extracted shRNA
-------------------------------------------------------------------------- , |------------------------------------------------------------------------
Scrambled TRIM68 IRF3 Scrambled TRIM68 IRF3
Figure 5.15: 1% ethidium bromide agarose gel showing the supercoiled stock scrambled, 
TRIM6 8  and IRF3 shRNAs (Lanes 1 - 3 )  and scrambled, TRIM6 8  and IRF3 targeted shRNA 
extracted from microparticles (lane 4 - 6 ). 50ng of shRNA was loaded per well.
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5.4.7 Micrparticle Mediated IRF3 and TRIM68 shRNA Knockdown
IRF3 and TRIM6 8  expression was assessed in human monocytes and NK92NI cells 
respectively and was carried out by Siobhân Smith and Claire Wynne. Cells treated with 
microparticles encapsulating IRF3 and TRIM6 8  targeted shRNA showed knockdown of both 
genes at 48 and 72 hours (Figure 5.16A and 5.16B respectively). Endogenous control actin 
expression remained constant for each treatment.
A.
IRF3 MP
Untreated MP Scr MP 24 48 72
IRF3
actin
B.
TRIM68 MP
Untreated MP ScrMP 24h 48h 72h 68F
Figure 5.16: Western Blot analysis of IRF3 and TRIM68  knockdown by microparticles 
encapsulating shRNA. (A) shows IRF3 expression in isolated human monocytes treated with 
microparticles empty (MP) or encapsulating scrambled (scr) or IRF3 shRNA and (B) shows 
TRIM68  expression in NK92NI cells following treatment.
185
5.5 Discussion
DNA based therapeutics have been of great interest for the last three decades. The discovery 
that transfected DNA plasmids expressing antigens could activate specific humoral responses, 
lead to the development of DNA vaccines [276]. DNA vaccination or gene immunization is an 
intensely researched area and consequently improvements for therapeutic approaches mainly 
via DNA plasmid delivery are heavily investigated. Meanwhile over the last decade advances in 
RNAi and the understanding of endogenous RNAi pathways have brought about DNA vectors 
expressing shRNA as well as siRNA to mediate gene suppression with high potency and 
sustained effects. Similar approaches for delivery of pDNA and shRNA expressing vectors can 
be employed. Viral vectors show high efficiency but also severe safety risks. Non-viral vectors 
are wide ranging but the most successful and investigated are liposomes and polymers. One 
such polymer is PLGA boasting a good safety profile, biodegradability as well as FDA approval 
for use in humans. PLGA particles for DNA delivery have been studied extensively however to 
date very few studies have combined PLGA microparticles and shRNA expressing vectors.
Similar to siRNA microparticles, pDNA and shRNA encapsulating microparticles formulated 
were optimised for pulmonary delivery. PVA is the most commonly used emulsifier in PLGA  
microparticle formulation as it is associated with the formation of relatively small particles with 
uniform size distribution [216], pDNA microparticle sizes were in the range of 2 -  3 pm an 
optimal size for pulmonary delivery and phagocytic uptake by alveolar macrophages. In 
addition microparticles showed negative surface charge most likely due to underivatised lactic 
and glycolic acid in PLGA 503.
Low encapsulation of nucleic acids by microparticles has previously been reported [230]. In 
order to enhance encapsulation efficiency of pDNA/shRNA the osmotic balance during 
preparation was altered. 0.2M NaCI was added to the external aqueous phase (PVA solution) 
for osmotic balance [277] changing the tonicity of the solution. Various PGLA 503 
concentrations were initially examined and it was found increasing PLGA concentration 
improved encapsulation efficiencies of up 83%. This method however was not transferable to 
siRNA encapsulation perhaps due to its small size resulting in very low encapsulation efficiency. 
Conequently, siRNA was pre-complexed with the cationic lipid DOTAP. Optimal N:P ratios of 
4:1 were found for DOTAP:siRNA condensation and microparticle siRNA encapsulation. 
Conversely application of complexation of pDNA with DOTAP prior to microparticle 
encapsulation lead to decreased encapsulation compared to pRNA loaded alone. This did not 
however translate to a functional loss or decreased transfection efficiency as shown by 
microparticle mediated GFP transfections.
G FP transfections were initially performed using commercially available transfection reagents. 
Lentiviral vectors can integrate into the host cell genome more readily and give a high level of 
transfection [58]. However these vectors are very large in size and therefore difficult to deliver. 
Methods such as calcium phosphate transfection can be more effective but are not suitable for
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all cell types. pmaxGFP/metafectene successfully transfected THP-1 cells with a 43% efficiency 
while metafectene delivered GFP expressing viral vectors showed 0% transfection efficiency. 
An optimised calcium phosphate transfection was used to transfect HEK-293T cells with 
transfer, envelope and packaging lentiviral plasmids. The transfer plasmid expressed GFP and 
almost all cells expressed this protein after 48 hours with high levels (over 50%) after 24 hours. 
Despite this little or no viral particles were recovered and later infections of THP-1 cells yielded 
no GFP expressing cells. Lentiviral transfections are often used to establish stable cells lines 
as high efficiency can be achieved [61, 62, 273].
For microparticle GFP transfections pmaxGFP was selected. This allowed direct comparison 
between commercial reagent metafectene and microparticle transfection. Intensity of GFP  
expression was visually greater by metafectene transfection however the number of GFP  
expressing cells was lower (43% compared to 69.6% with microparticle treatment). GFP  
transfections could be used to develop a stable G FP THP-1 cell line as a reporter system for 
screening siRNA transfection. However, pmaxGFP does not contain a mammalian antibiotic 
selection marker.
Gel electrophoresis of shRNA before and after microparticle encapsulation gave an indication of 
the structural integrity of the plasmids. Intact unprocessed plasmids appeared as one clear 
band however those extracted from microparticles having undergone sonication, 
homogenisation and temperatures as low as -80°C bore two bands (Figure 5.15). Typically 
plasmids are represented by two bands in agarose gel electrophoresis one nicked circles and 
the other is supercoiled. These will not correspond to sizes of a DNA ladder only linear DNA will 
and therefore the ladder was omitted from the figure. Nicked circles can be faintly visualised 
above the strong bands in lanes 1 -  3 (Figure 5.15). The higher molecular weight band 
corresponded to the intact plasmid. The second band is unlikely to represent nicked circles as it 
has travelled further in the gel and are not present in the unprocessed shRNA. This lower 
molecular weight band is more likely to be plasmid fragments although the presence of only one 
band suggests all fragments to be of one size. For plasmid integrity damage multiple bands 
would be expected.
pmaxGFP microparticle transfections not only allowed formulation optimisation but also 
confirmed the prepared formulations facilitated transfection prior to shRNA transfections. 
Initially microparticles were prepared with uncomplexed shRNA and assessed in primary 
monocytes and NK92NI cells targeting IRF3 and TRIM6 8 . IRF3 knockdown was greatest after 
48 hours. Almost complete knockdown of TRIM6 8  was shown after 48 and 72 hours in NK92NI 
cells. This is due to slow release of the nucleic acid by the microparticles, a property that as 
has been repeatedly observed by in vitro release assays [278, 279].
Consequently the incorporation of DOTAP was not deemed necessary. Precomplexation also 
increases preparation time, reagent costs and potentially introduces DOTAP to cells. DOTAP 
has been widely associated with toxicity. Although gel electrophoresis suggests a high
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proportion of shRNA did not maintain its structural integrity knockdown studies have shown the 
system to work effectively with high potency. IRF3 and TRIM6 8  are important proteins in the 
study of immune signalling and auto-immune disease. It is planned for future work to further 
elucidate the roles and pathways these proteins are involved in particularly TRIM6 8  as little is 
known of its function.
shRNA expressing vectors can easily be designed and synthesised and offer the huge 
advantage of stock replenishment by replication in competent cells similar to plasmid DNA 
reducing the cost of synthesis. DNA is also less susceptible to degradation than siRNA and will 
have longer lasting knockdown with the possibility of stable selection making use of the 
mammalian selection marker. Additionally many manufacturers have pre-made shRNA 
targeting a wide range of genes readily available including shRNA targeting TNFa and many 
other pro-inflammatory genes. A possible direction for future work could focus on shRNA 
delivery for knockdown over siRNA. Here, we developed a potentially useful tool for delivery of 
shRNA to immune cells for molecular biology and in vivo. PLGA microparticles were harnessed 
for shRNA loading with good encapsulation efficiencies. Preparation and transfection methods 
were optimised using pGFP and transfection efficiencies compared with commercial non-viral 
transfection reagents and lentiviral transfections in macrophages. Microparticles mediated the 
most efficient transfection. The developed shRNA loaded microparticles also knocked down 
two target genes IRF3 and TRIM6 8  in immune cells.
Key Findings
• Achieved high encapsulation of pDNA and shRNA in microparticles
• Microparticles more efficiently transfected macrophage cells with GFP expressing 
pDNA than commercial transfection reagents and lentiviral transfection in macrophages
• shRNA loaded microparticles mediated efficient knockdown of targeted genes in vitro
188
Chapter 6
In Vivo Assessment of siRNA Delivery via Mannosylated Liposomes
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6.1 Introduction
RNAi could prove to be a powerful therapeutic tool for a wide range of diseases boasting 
superior specificity and potency over other forms of therapy. It shows promise to treat 
previously unbeatable or difficult to treat diseases and has the potential to be used 
prophylactically and therapeutically. However, RNAi therapy is still in its infancy. Clinical trials 
are ongoing for conditions including cancer, neovascular age-related macular degeneration 
(AMD) [280] and viral infections. Concerns over off-target effects, immunogenicity and toxicity 
remain due to the adverse effects witnessed during previous gene therapy trials [1], In addition 
due to its chemical nature as has been discussed previously in Chapter 1 it is necessary to 
encapsulate siRNA in a carrier vector such as a viral vector, liposome or microparticle for 
protection against nucleases and delivery efficiency. These delivery systems are not always 
inert and also may act differently in vivo than in vitro,
6.1.1 Pulmonary Delivery
Success of a therapeutic is greatly dependent on the target tissue, disease type and severity as 
well as the characteristics of the therapeutic agent. Pulmonary drug delivery presents many 
challenges such as the presence of mucus and other alveolar fluids [281]. Additionally, many 
chronic obstructive diseases such as C F  and asthma are associated with mucus hypersecretion 
and severe inflammation [281], Efficiency of delivery is important and dependent on a suitable 
drug, nanoparticle carrier and inhaler/nebuliser combination. The therapeutic system must 
reach the desired lung section and once there be protected from degradation or expulsion. 
Unfortunately nanoparticles can be captured by mucus mainly due to steric, hydrophobic or 
electrostatic interactions and removed from the lung by coughing [281]. Due to its specificity 
and potency of siRNA low doses can be used with inhalation offering the benefit of direct 
delivery to the target organ. Also specific cell targeting to alveolar macrophages allows off 
target effects to be minimized. Additionally alveolar macrophages are situated in the surfactant 
film and therefore more accessible to inhaled particles than endothelial cells due to the 
presence of the mucus layer barrier.
6.1.2 siRNA Therapy In Vivo
To date no siRNA based therapeutics has been approved as commercial products with all 
studies only reaching the clinical trial stage. However some success has been reported by 
Alnylam with an anti-RSV N gene siRNA, ALN-RSV01, reaching the Phase II clinical stage. 
Alnylam reports ALN-RSV01 to be safe and well tolerated with significant antiviral activity. A 
Phase Mb clinical trial is currently underway. Reports from animal studies have shown more 
success (Table 6.1). For instance, Bitko et al. (2005) showed very promising results using 
siRNA targeted at P proteins of both RSV and parainfluenza virus-3 (PIV-3) in infected mice 
[282] The Bitko group determined that intranasally administered siRNA alone or complexed 
with TranslT-TKO prior to RSV or PIV challenge inhibited viral proliferation, reduced infection
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and prevented disease. In addition, when administered after viral inoculation the siRNA had a 
curative effect [282],
Pulmonary drug delivery in humans generally involves the use of inhalers or nebulisers 
(Chapter 2). Prior to clinical testing, drug formulations must be assessed in suitable in vivo 
models to examine efficacy, toxicity and immunogenicity and siRNA therapies are no different. 
The most common routes for pulmonary drug administration particularly in rodents are 
intratracheal, intranasal and inhalation [283]. A recent study by Gutbier et al. (2010) compared 
intracheal, intranasal and intravenous administration of siRNA both naked and complexed with 
cationic liposomes in C57BL/6 mice [85]. Intratracheal instillation of fluorescently tagged naked 
siRNA was efficiently distributed throughout the lung while a higher dose was necessary to 
reach a similar level of siRNA delivery via the intranasal route with non-uniform distribution 
resulting. Although knockdown of E-cadherin was observed following intratracheal E-cadherin 
targeted naked siRNA administration, siRNA rapidly entered the systemic circulation and was 
detected in the kidneys. Interestingly siRNA cationic lipid (AtuFECTOI) lipoplexes caused an 
inflammatory response characterized by a leukocyte influx in the lungs following intratracheal 
administration however following intravenous administration, lipoplexes mediated significant 
targeted gene knockdown in lungs devoid of pulmonary inflammation.
In rodents intratracheal administration can offer many benefits over other routes of pulmonary 
administration due to their smaller anatomy such as increased dose reaching the smaller 
airways [284]. It can give more reproducible and higher deliverable dose than inhalation and 
improved pulmonary distribution compared to intranasal administration. Inhalation will lead to 
variable respired doses between animals which will depend on the animal model being used 
and may lead to exposure, for example of the eyes, to aerosolized drug formulations. Also 
stable and functional siRNA formulations for inhalation are complex to develop [283]. 
Intratracheal administration is invasive. It requires the animal to be anesthetized and 
formulations to be instilled via a tube surgically inserted between the tracheal rings or the 
endotracheal insertion of a tube through the mouth (without surgery and therefore less invasive) 
[283, 284]. Intratracheal administration works best for proof of concept work and due to its 
invasive nature it is not routinely used in humans and also does not require the assessment of 
aerosol droplet or particle size. Inhaled delivery in animals cannot be extrapolated to humans 
due to differences in anatomy and immunology.
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Table 6.1 Summary of non-viral siRNA delivery to the lungs in vivo via intratrachael 
administration
siRNA siRNA Dose Delivery
Target___________________ Carrier
Animal Model Effect Ref.
GRP78 50,100, 500mM Naked siRNA
eGFP
siGL3
p-catenin
35pg
“21 Mg
siGLO Green 3pg
SPARC
Ctgf
Cy3-tagged 9.3,/125|jg 
VE-Cadherin 50/250pg 
E-Cadherin
PEI
Naked siRNA
DharmaFect (lipid 
based transfection 
reagent)
naked, stabilized 
siRNA (AtuRNAi) 
Cationic liposomes
BALB/C mouse OVA 
induced asthma model
C57BL/6J- 
Tg(Bos/GFP)CaBa- 
BiiOUDcm mice
Pulmonary Fibrosis 
induced in C57BL/6N 
mice
Pulmonary Fibrosis 
induced in C57BL/6 
mice
C57BL/6 mice
Decreased GRP78 in lung [77] 
parenchyma, eosinophils in 
BAL and bronchial hyper- 
responsiveness in a dose 
dependent manner
Successful knockdown of [82]
target genes and non­
specific knockdown
Significant reduction in p- [78]
catenin expression and 
induced pulmonary fibrosis
siRNA detected in bronchi [83]
and bronchioles
Reduced collagen content in 
the lungs
Efficient distribution of [85]
siRNA in lung parenchyma
XCL1 
siGLO red
eGFP
p38
MAP kinase
GFP
Fas
Caspase-8
GFP
KC
MIP-2
5, 10, 15 pg 
~37pg
35pg
1,10, 50nmol 
(-0.75, 7.5, 37.5 
mg/kg)
Naked C57BL/6 mice
100|jg
75pg
Cationic liposomes Athymic nu/nu mice
PEI
Naked siRNA
Cholesterol
Peptides
Naked siRNA
Naked siRNA
C57BL/6 Tg(CAG- 
EGFP)10sb/J mice
BALB/c mice
Significant knockdown of [79]
XCL1 gene
Longer siRNA retention in [84]
the lungs compared to 
systemic delivery
42% decrease in eGFP [80]
expression
Acute 30 -45% p38 [285]
MAPkinase knockdown 
extended by cholesterol 
conjugation
C57BL/6- GFP expression decreased. [81]
TgN(ACTbEGFP)10sb Fas and Caspase-8 
mice expression significantly
C3H/HeN mice reduced.
C57BL/6-TgN and 
C3H/HeN mice
Lung GFP expression 
suppressed. Lung KC and 
MIP-2 expression 
significantly decreased in a 
hemorrhage/sepsis mouse 
model
[286]
6.1.3 LPS Mouse Models
For proof of concept of anti-inflammatory siRNA in the lung the establishment of an 
inflammatory animal model was required. Therein we used a LPS mouse model. LPS is an 
endotoxin of the outer membrane on gram-negative bacteria [287] that is used in the 
establishment of a variety of animal models including sepsis, acute lung injury (ALI) and acute 
respiratory distress syndrome (ARD) [288]. LP S is most commonly derived from different 
serotypes of E. coli and consists of a hydrophobic lipid (lipid A) and a hydrophilic polysaccharide
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which is composed of a core region and an O-specific chain [287], LP S structure is mainly 
serotype dependent with some being more suitable than others in the establishment of an 
inflammatory model for instance LPS from rough E.coli colonies tend to be more pyrogenic
[289]. LP S can be administered systemically (as a model of sepsis) or directly to the lungs via 
inhalation, intranasal or intratracheal administration to produce models for lung inflammation
[290]. Mice such as C57BL/6 are frequently used [291], In general animal models such as 
mice [289, 290] and dogs [288] are not as sensitive to LP S and doses necessary to achieve an 
adequate inflammatory response are usually quite high (mg/kg in some mouse strains). An 
inflammatory lung model is used to model respiratory diseases such as COPD and asthma to 
carry out early pre-clinical testing of novel therapeutics.
Once administered LP S can induce acute inflammation via the induction of TLR-4 and CD14 
signalling cascades which involve MyD88  and the activation of the mitogen-activated protein 
kinase (MAPK) signalling cascade. This in turn leads to cytokine secretion and 
bronchoconstriction as well as chemokine production and neutrophil infiltration as p38 MAPK is 
pivotal in TNFa transcription regulation and chemotaxis of neutrophils [292], Jeyaseelan et al. 
(2004) generated a temporal gene expression profile of the inflamed mouse lung. C57BL/6 
mice received aerosolised 0.3mg/ml LP S and the transcriptional profile from 1 to 24 hours was 
determined using an oligonucleotide microarray. 71 inflammatory related genes were up- 
regulated with maximal expression levels at 2 hours [293].
In the normal healthy lung, residential macrophages are present in the interstitium and the 
alveoli within the pulmonary surfactant film which is produced by type II alveolar epithelial cells 
(Figure 6.1A). If activated for example by LPS or other inhaled pathogens or toxins pro- 
inflammatory cytokines such as TNFa [291] or IL-1 and chemokines including keratinocyte- 
derived chemokine (KC or chemokine (C-X-C motif) ligand 1 (CXCL1)) and macrophage 
inflammatory protein-2 (MIP-2) [290] are released. In response further chemokines are 
produced by respiratory epithelial cells subsequently leading to neutrophil migration and 
infiltration [291] into the interstitium and alveolar space (Figure 6.1B). Neutrophils are the first 
cells recruited during an inflammatory response [294] the process of which is illustrated in 
Figure 6 .1  B. Neutrophils are a type of polymorphonuclear cells which can neutralise LPS by the 
release of antimicrobial cationic proteins that bind to the endotoxin rendering it inactive or 
degrade it (and lipid A) enzymatically [287]. If the inflammatory response persists, or is 
substantial, damage to the epithelium can occur which is characterised by an influx of protein 
rich fluid along with other macromolecules into the alveolar space [294]. The central role played 
by TNFa in the inflammatory response makes it an attractive target for anti-inflammatory siRNA 
therapies.
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Figure 6.1: Structure of the alveolus under normal and inflammatory conditions [294].
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6.1.4 Mannoslyated Liposomes In vivo
As has been previously discussed cationic lipids are most commonly used for non-viral siRNA 
delivery both in vitro and in vivo. This is due to both the high encapsulation and transfection 
efficiencies associated with nucleic acid cationic lipid formulations. Toxicity is a problem 
(Chapter 3) and the use of neutral or negatively charged lipids which avoid this toxic effect but 
lack the high encapsulation and transfection rates of cationic counterparts are becoming more 
attractive. Macrophages are the first line of defense against inhaled toxins and pathogens due 
to their location in the lungs [295]. These monocyte-derived phagocytes are situated within the 
pulmonary surfactant film in the interstitium and the alveoli. The MR is highly expressed by this 
cell type and has been studied widely for macrophage drug targeting by the mannosylation of 
carriers with ligands including alkyl mannosides [174], palmitoyl mannose [296], Cholesten-5- 
yloxy-/V-(4-((1 -imino-2-a-thioglycosy lethyl)amino)butyl)formamide (Mann-C4-Chol) [130, 165, 
193, 194, 297], Mann-His-C4-Chol [194], Man2DOG [131], 4-aminophenyl-a-D-
mannopyranoside [133, 190] and manntriose (Man3)-DPPE [134, 135, 191] in liposome 
formulations or by liposome coating with p-aminophenyl-a-D-mannopyranoside [132].
Delivery using mannosylated liposomes of anti-inflammatory agents such as dex [130] and 
NFkB decoy as well as anti-cancer agents CpG oligonucleotides and DNA [195] targeting 
macrophages and DCs have been extensively explored by Hasida and colleagues. 
Intratracheally administered Man-C4-Chol liposomes were shown to be preferentially taken up 
by alveolar macrophages in rats which was mediated via MR endocytosis as revealed by 
inhibition studies [115]. These liposomes were also reasonably stable in lung microenvironment 
with increased levels of uptake and hence targeting associated with higher degrees of 
mannosylation [115]. Wijagkanalan etal. (2008) showed dex encapsulated in neutral Mann-C4- 
Chol liposomes was localised in alveolar macrophages and undetectable systemically following 
intratrachael instillation in Wistar rats whereas systemic distribution of free drug was detected 
within 30 minutes [130], In addition co-administration of LPS and mannosylated liposomes 
containing dex showed significantly enhanced anti-inflammatory effects including suppression of 
the inflammatory cytokines TNFa, IL-1(3 and CINC1 (rat homolog to murine KC) in BAL and lung 
tissue as well as decreased neutrophil infiltration and myeloperoxidase (MPO) activity in lungs 
via mannoyslated liposome delivery of dex compared to co-administration of dex alone or dex in 
non-man nosy lated liposomes. This effect was blocked in the presence of an excess of man nan 
(a MR competitive ligand).
To date the literature indicates that mannosylated liposomes have not been used for siRNA 
delivery but a few studies have assessed DNA [194] and oligonucleotide delivery [297, 298]. A 
NFkB decoy encapsulated in a cationic mannosylated liposome however has successfully 
decreased inflammation in a rat LPS-induced lung inflammatory model following intratracheal 
instillation [298]. This is an oligonucleotide with a sequence analogous to the binding site of the 
transcription factor NFkB and therefore competes for NFkB binding and modulates NFkB 
related gene expression. More recently Singodia et al. (2011) compared the delivery capability
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of mannosylated liposomes and liposomes coated with another MR ligand sulfated-N- 
acetylgalactosamine (4-S04GalNAc) carrying Amphotericin B. Male wistar rats received 
liposomes by IV administration and a significant enhancement of drug localisation in spleen and 
liver cells in coated liposome treated groups compared to uncoated liposomes was observed 
[296].
Overall mannosylated liposomes in vivo have been shown to specifically target macrophages, 
deliver their drug load efficiently and be safe and well tolerated [190]. Although as of yet siRNA 
delivery via mannosylated liposomes has not been published. Zhao et aL (2008) are currently 
investigating chemically modified siRNAs for MR targeting [299]. This group has synthesised 
mannosylated oligoribonucleotides with the intention of further investigation into mannosylated 
siRNA synthesis. Recently mannosylated pegylated PEIs were synthesised and complexed 
with siRNA to mediate knockdown of luciferase and hypoxanthine-guanine phosphoribosyl 
transferase (HGPT) in RAW264.7 cells with up to 42 and 62% knockdown respectively [300].
6.1.5 Chapter Aims
This chapter set out to assess the efficacy, immunogenicity and toxicity of mannosylated 
liposomes as siRNA delivery systems in a mouse model.
• To assess mannosylated liposome uptake and cytotoxicity in a murine macrophage cell 
line
• To determine suitable siRNA sequences for TNFa knockdown in vitro
• To assess immunogenic and therapeutic effects of empty and siRNA loaded 
mannosylated liposomes in vivo
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6.2 Materials
20 GA I.V. Catheter, BD Insyte
24 GA I.V. Catheter, BD Insyte
ABTS Chromogen/Substrate Solution for ELISA, Invitrogen 
Biolegend Mouse TNFa ELISA MAX™ Deluxe set 
Bovine serum albumin (BSA), Sigma Aldrich 
Cellomics Multiparameter Cytotoxicity kit 3, Thermo Scientific 
DPX, Sigma Aldrich
Duoset Mouse CXCL1/KC Immunoassay, R & D Systems
Duoset Mouse CXCL2/MIP-2 Immunoassay, R & D Systems
Duoset Mouse IL-1p Immunoassay, R & D Systems
Eosin Y, Dye content -99%, MW 647.89, Sigma Aldrich
Formaldehyde 38% Solution, GPR, BDH
Hematoxylin Solution, Harris Modified, Sigma Aldrich
Heparin Sodium Preservative Free, 1000 units in 1ml, Wockhardt®
HistoChoice® Clearing Agent, Sigma Aldrich 
INCELL 1000 Analyser, GE Healthcare 
Ketaset
LPS from E.coli 055:B5, Sigma Aldrich
Magnesium Sulphate, Sigma Aldrich
Magnum T microscope with Si 3000 camera, CETI
Mouse Intubation Platform, Penn Century
Paraformaldehyde, Sigma Aldrich
PBS tablets, GIBCO
Potassium Bicarbonate, Sigma Aldrich
Pro-lab Diagnostics Immersion Oil (R.l. 1.517)
RNAIater Solution, Ambion 
Shandon Cytospin 2
Shandon double cytoslide, microscope slides for Shandon Cytospin (coated), Thermo Scientific
Shandon Filter Cards Thick (white), Thermo Scientific
siGENOME Non-Targeting siRNA#2, MW 13,400 g/mol, Dharmacon
Silencer® Select Pre-designed In Vivo Ready siRNA, MW 13,400 g/mol, Ambion,
Silencer® Select Pre-designed siRNA TNFa Targeting, MW 13,400 g/mol, Ambion 
Small Animal Laryngoscope, Model LS-2, Penn Century 
Speedy DIFF, Clin-Tech Ltd.
Synergy HT Multi-Mode Microplate Reader, Bio-Tek 
Tween-20, Sigma Aldrich
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6.3 Methods
6.3.1 siRNA
siGENOME Non-Targeting siRNA #2 (Dharmacon) is described in 3.3.1. Three Silencer®  
Select Pre-designed siRNA sequences (sequence 1 (mTNFa 1; siRNA ID # s75248) sense 5’- 
GCCGAUUUGCUAUCUCAUAtt-3’ and anti-sense 5’-U AUGAGAU AGCAAAUCGGCtg-3’,
sequence 2 (mTNFa 2; siRNA ID # s75250) sense 5’-CAAUCUGCCCAAGUACUUAtt-3’ and 
antisense 5’-UAAGUACUUGGGCAGAUUGac-3’ and sequence 3 (mTNFa 3; siRNA ID # 
S202295) sense 5’-CGUCGUAGCAAACCACCAAtt-3’ and anti-sense 5’- 
UUGGUGGUUUGCUACGACGtg-3’ targeted to murine TNFa. Silencer®  Select Pre-designed 
In Vivo Ready siRNA (sequence 1) is targeted to murine TNFa and negative control #1 has no 
significant rat, mouse or human gene sequence similarities. In vivo ready siRNA have 
undergone extra purification in the manufacturing process. siRNAs for in vitro studies were 
reconstituted with provided ambion nuclease-free water to a concentration of 20pM. In vivo 
ready siRNAs were reconstituted with nuclease-free water to a concentration of 500pM.
6.3.2 Cell Culture
RAW 264.7 cells an Abelson murine leukemia virus transformed macrophage cell line derived 
from ascites of a male BALB/c mouse were maintained in RPMI 1640 supplemented with 10% 
heat inactivated FBS from passage 2 -  12 in a humidified atmosphere at 37°C and 5% C 0 2.
6.3.3 Animals
Female C57BL/6 mice were purchased from Harlan Laboratories UK and housed in the 
Biological Resource Unit (BRU) at Queen’s University Belfast. Mice were maintained in a 
specific pathogen free unit with 1 0  mice per cage and permitted water and food ad libitum. 
Experiments were performed using 20g mice between 8 and 12 weeks in accordance with 
Animals (Scientific Procedures) Act 1986 and local ethics approval.
6.3.4 In Vitro Mannose Receptor (CD206) Expression
RAW 264.7 cells were seeded at 5x104 cells/ml in 96 well plates and incubated overnight. 
Cells were treated as described in 3.3.3.
6.3.5 In Vitro Uptake Studies by High Content Cell Analysis
RAW 264.7 cells were seeded at a density of 5x104 cells/ml in 96-well plates and incubated at
37°C overnight 200nm anionic, neutral and mannosylated liposomes at 0, 100, 200 and 300
pM were incubated with unstimulated or LP S stimulated cells for 2 hours at 4°C or 37°C. Cells 
were washed three times with warmed PBS and fixed with 4% paraformaldehyde for 20 minutes
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and counterstained with phalloidin-FITC and Hoescht. 150pl of PBS was added to each well 
and plates were stored at 4°C in the dark. HCA was carried out using INCELL 1000 analyser as 
described in 3.3.42. Images were acquired in three channels, 5 fields per well and analysed 
using INCELL analyser software with parameters shown in Table 6.2.
Table 6.2 Representative High Content Cell Analysis Uptake Assay Parameters
Parameters Wavelength
(Ex/Em wavelengths, nm)
Analysis Settings Sensitivity
Nucleus 360/460 Top Hat; min. area 39.6 pm" 70%
Cell Top Hat; min. area 93.2 pm' 93%
Liposomes 535/600 Organelle; In Cell 
Scales: 10
Min. 0.2 pm (3 pixels) - Max. 2.26 pm (7 pixels)
30%
6.3.6 in Vitro Toxicity
Cellomics® Multiparameter Cytotoxicty 3 kit and an INCELL 1000 analyser were used to 
determine toxicity in RAW 264.7 cells following liposome treatment. Liposomes were prepared 
as described in 2.3.3. RAW 264.7 cells were seeded at 5x104 cells/ml in a flat-blottomed 96- 
well plate (CellStar, Grenier) and incubated overnight at 37°C and 5% C 0 2. Media was 
replaced with fresh RPMI and cells were treated with liposomes at concentrations of 0 , 10 0  or 
300|jM in triplicate and incubated at 37°C for 23.5 hours. Cells were also treated with 
valinomycin (120pM) for 23.5 hours as a positive control. Staining and analysis was carried out 
as described in 3.3.5. Cell loss, nuclear area, nuclear intensity, cytochrome c release, 
mitochondrial membrane potential and cell permeability were determined using INCELL  
analysis software using multiparameter target analysis and the settings in Table 6.3.
Table 6.3 Representative High Content Cell Analysis Toxicity Assay Parameters 
Parameters Wavelength Analysis Settings
(Ex/Em wavelengths, nm)
360/460 Region growing; min. area 42.02 pm2
Collar; 6.75 pm
480/535 Reference; In Cell
535/600 Reference; In Cell
620/700 Reference; In Cell
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6.3.7 siRNA Transfection of RAW 264.7 cells
Transfection of RAW 264.7 cells was carried out using HiPerFect transfection reagent as per 
the manufacturer’s recommendations. RAW 264.7 cells were seeded at 2x105 cells per well of 
a 24 well plate in 100|jl of complete medium and incubated at 37°C until transfection. 
Transfections were performed in triplicate with untreated, HiPerFect transfection reagent and 
non-target siRNA/HiPerFect complexes as controls. Non-target and TNFa siRNAs were diluted 
separately to 375ng in 100}jl of serum free RPMI (per well). 6 pl of HiPerFect transfection 
reagent was added to the diluted siRNA and vortexed. The mixtures were incubated for 10 
minutes at room temperature to allow complexation and then added drop wise to the cells. 
Plates were gently swirled and incubated at 37°C for 6  hours. Media was replaced and cells 
were incubated overnight. 24, 48 and 72 hours following transfection cells were stimulated with 
100ng/ml LPS for 3 hrs. Bright field images were acquired 24 and 48 hours post-transfection at 
10x and 40x magnification prior to LPS stimulation. Supernatants were collected. Mouse TNFa 
ELISAs were preformed to determine TNFa expression as described in 3.3.6.3.
6.3.8 Acute In Vivo Study
6.3.8.1 In Vivo Liposome Preparation
Mannosylated liposomes were prepared using DOPC, cholesterol and Mann-C6 -Chol 
(70:22.5:7.5 molar ratio) by dehydration rehydration as described in 2.3.3 with modification. 
Liposome components were dissolved in Folch in sterile autoclaved glassware and solvents 
were evaporated using a rotary evaporator. Briefly, for 1ml liposome preparations 600pg of in 
vivo ready siRNA was diluted in RNase free sterile water and mixed with 548.5pg PEI dissolved 
in RNase free sterile water (N/P ratio 7). in vivo ready siRNA and PEI were allowed to complex 
at room temperature for 20 minutes in a sterile environment. RNase free water was not DEPC  
treated. The thin lipid film was rehydrated with siRNA/PEI complexes brought up to 1ml with 
sterile PBS and agitated. Final liposome concentration was 2.5 times more concentrated than 
in vitro preparations with a final concentration of 17mg/ml. Rehydrated lipid suspensions were 
stored at 4°C overnight and extruded using an Avanti mini extruder and 400nm pore 
polycarbonate filters. Size and zeta potential was determined as described in 2.3.4.1.
6.3.8.2 Endotrachael Intubation
Mice received 1 0 0 pl of intraperionteal (I.P.) administered recovery anaesthetic (2 ml Ketaset, 
9.2ml Saline and 2ml Rhompin) and were returned to their home cage until anaesthetic took 
effect. A tail or toe pinch was used to assess the depth of anaesthesia. Anaesthetised mice 
were positioned supine on an inclined mouse intubation platform suspended from front incisors 
(Figure 6.2A). The tongue was extended and moved to one side using forceps. A small animal 
laryngoscope was used to illuminate the vocal cords, epiglottis and opening to the trachea as 
well as to hold the tongue in place (Figure 6.2B). The needle tip from a 24-gauge IV catheter
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(similar to Figure 6.2C) was cut and placed back into the flexible tubing of the catheter to 
provide rigidity during intubation. The blunted catheter was carefully inserted between the vocal 
chords and into the trachea and the needle was quickly removed from the catheter and liquid 
formulations administered.
A.
Figure 6.2: In vivo endotracheal intubation and BAL collection components. (A) Penn Century 
Mouse Intubation Platform, (B) Penn Century small animal laryngoscope (LS-2) and (C) 20 
gauge catheter including syringe (BD Insyte). Mice are suspended by front incisors from part 1 
and immobilised (parts 2 and 3).
2 0 1
6.3.8.3 Intratrachael siRNA/Liposome Administration
Prior to endotrachael intubation, saline, LPS, siRNA or liposomes (50pl) were loaded into 1ml 
syringes such that an air pocket (2 0 0 |jl in volume) remained behind the leading liquid load. 
Following endotrachael intubation of mice and the removal of the needle from the catheter a 1 ml 
syringe loaded with saline, 30pg NT or TNFa targeted siRNA or mannosylated liposomes empty 
or loaded with 30|jg siRNA complexes (NT or TNFa targeted) was securely attached to the 
catheter and the plunger depressed expelling the 50pl of liquid followed by a volume of air. The 
catheter was immediately removed and mice were placed on their sides on a heated mat and 
then moved to a room with constant temperature set at 37°C for 24 hours with access to food 
and water ad libitum. 24 hours following the initial treatment mice underwent intratracheal 
administration of either 50|jl saline or 0.4mg/ml LP S (from E.Coli 055: B5) by the same 
procedure. After 3 hours mice were administered 100pl ketaset (100mg/ml) by IP injection for 
terminal anaesthesia. A set of control mice were administered 2% Evan’s Blue to confirm the 
accuracy of lung delivery.
6.3.8.4 in Vivo Tissue Harvesting
Mice were administered 1 OOjjI IP injection of ketaset and placed in their cages until anaesthesia 
took effect. A tail or toe pinch was used to assess depth of anaesthesia. Once mice were 
anaesthetised and pain free the thoracic cavity was opened to expose the heart. Blood was 
collected directly from the heart using a 23 gauge needle and 1ml syringe pre-washed with 
heparin. Blood was stored on ice and centrifuged at 13,000rpm for 15 minutes at 4°C. 
Supernatant (plasma) was collected and stored at -80°C.
The lungs and heart were excised en bloc. One bronchus was clamped to allow BAL collection 
from one side of the lungs only. 2 0 0 fjl of saline was added to one side of the lung through the 
trachea using a 20 gauge catheter with the needle removed (Figure 6.2C) and a 1ml syringe. 
Saline was collected and a further 200pl of fresh saline was added. This procedure was 
repeated until the lung had been washed with 1 ml of saline. The remaining lobes were 
collected for PCR and histological analysis in 1ml of RNase later and 1ml 4% paraformaldehyde 
respectively.
6.3.8.5 Bronchoalveolar Lavage (BAL) Differential Cell Count
BAL was collected from mouse lungs and centrifuged at 1xg for 10 minutes at 4°C. 
Supernatants were collected as BALF and stored at -80°C. Cell pellets were resuspended in 
1ml of red cell lysis buffer and centrifuged at 1xg for 10 minutes at 4°C. Supernatants were 
discarded and cell pellets resuspended in 10Q|J| of saline. 10pl of cell suspension was mixed 
with 90pl of trypan blue and total cell counts taken using a haemocytometer. 90pl of cell 
suspension was spun for 5 minutes at 500rpm onto Shandon coated microscope slides using 
Shandon filter cards and Shandon cytospin 2. Cells were fixed and stained using Speedy-Diff
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cell stain kit. Briefly, slides were immersed for a few seconds in speedy-diff fixative (coloured 
methanol) five times then immersed for a few seconds in Speedy-Diff A (buffered Eosin Y) at 
least 5 times followed by blotting and washing in PBS and finally immersed in Speedy-Diff B 
(buffered azur/methylene blue) at least 5 times, blotted and washed. Slides were allowed to dry 
and differential cell counts were obtained using a CETI light microscope at 100x magnification 
under oil immersion. Macrophages and neutrophils were counted in 5 random fields and total 
differential cell counts calculated.
6.3.9 In Vivo Cytokine Expression
6.3.9.1 Enzyme Linked Immunosorbant Assay
TNFa, IL-1 (3, KC and MIP-2 (or CXCL2) levels were determined in BALF by ELISA. TNFa  
ELISAs were carried out as described in 3.3.6.3. IL-p, CXCL1/KC and CLXCL2/MIP-2 were 
performed according to the manufacturer’s protocol with some modifications. Briefly, 96 well 
ELISA plates were coated overnight at room temperature with 100pl per well capture antibody 
(rat anti-mouse IL-1 p, KC or MIP-2) diluted in PBS to 4pg/ml (IL-1P) or 2pg/ml (KC and MIP-2). 
Capture antibody was aspirated and plates were washed 3 times with wash buffer (PBS with 
0.05% Tween-20) and blotted with absorbent paper. Plates were blocked with 300[jI of assay 
diluent (1% BSA in PBS) for 1 hour with shaking. Standard curves were prepared using 
provided IL-1 p, KC and MIP-2 standards and assay diluent from 0 up to 500 or 1000 pg/ml. 
Washing and blotting was repeated. 100pl of diluted standards and BALF samples were added 
to the wells, plates were sealed and incubated at room temperature for 2  hours with shaking. 
Plates were washed 4 times and blotted. IL-10, KC or MIP-2 biotinylated goat anti-mouse 
detection antibodies (1 0 0 pl) were added to each well at working concentrations of 2.5pg/ml, 
200ng/ml and 75ng/ml in assay diluent respectively. Plates were sealed and shaken at room 
temperature for 2 hours. Washing and blotting steps were repeated and 1 00(jl of streptavidin 
conjugated to horse radish peroxidise (strep-HRP) diluted 1 in 200 in assay diluent was added 
to the wells for 20 minutes with shaking at room temperature out of direct light. Strep-HRP was 
aspirated and plates were washed and blotted. 100pl of ABTS substrate solution was added to 
each well and plates were incubated at room temperature in the dark unsealed until a green 
colour developed (1 5 -3 0  minutes). Absorbance was measured at 405nm using a Synergy HT 
Multi-Mode Microplate reader and Gen5™ software.
6.3.9.2 Mouse TH1/TH2 9-plex Assay
The MesoScale Discovery multiplex assay is described in 3.3.7.2. Mouse TH1/TH2 9-plex 
assay simultaneously detects IFNy, IL-1p, IL-2, IL-4, IL-5, KC, IL-10, total IL-12 and TNFa key 
effectors in the TH1/TH2 inflammatory response. Capture antibodies for all analytes are rat 
monoclonal antibodies except the IL-1 p capture antibody which is a mouse monoclonal 
antibody. Briefly, 25pl of provided Diluent 4 was added to each well and the plate was sealed 
and incubated at room temperature for 30mins. A 4-fold serial dilution of mouse TH1/TH2 9-
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Plex Calibrator (1 |jg/ml to 2.4pg/ml) was prepared in Diluent 4 (for plasma calibration) or 1% 
BSA in PBS (for BALF calibration). BALF samples were mixed with 1% BSA to reduce protein 
adherence to the microtubes. Standards, plasma and BALF (25pl) were added in duplicate to 
wells and the plate was sealed and incubated over night at 4°C. The plate was washed 3 times 
with PBS-T followed by the addition of 25pl of 1X detection antibody solution (50X stock diluted 
in Diluent 5 containing either rat or goat monoclonal antibodies to each analyte). The plate was 
resealed and vigorously shaken at room temperature for 2 hours. Washing 3 times in PBS-T  
was repeated. 150pl of 2X Read Buffer T (4X Read Buffer T diluted in deH2G) was added to 
each well and the plate was immediately analysed on a SECTO R  Imager Read buffer provides 
a suitable chemical environment for electrochemiluminescence. Standard curves were 
produced and concentrations of analytes for each sample determined using the MSD 
DISCOVERY W ORKBENCH® software.
6.3.9.3 Histopathology
Fixed lung tissue was embedded in paraffin and sections mounted onto slides. Paraffin was 
removed by immersing slides in HistoChoice® Clearing Agent for at least 30 minutes. Tissue 
sections were hydrated by immersing for a few seconds in 100% ethanol followed by 90%, 70% 
and 50% ethanol and finally dH20. After hydration sections were stained with haematoxylin for 
15 minutes followed by rinsing in dH20. Sections were differentiated in 1 % acid alcohol to 
remove excess haematoxylin by immersing for a few seconds in 50% ethanol, then 70% ethanol 
followed by acid alcohol (1% concentrated hydrochloric acid in 70% ethanol (v/v)). Sections 
were then immersed in 70% ethanol followed by rinsing in dH20. Sections were immersed in 
alkaline ammonia water (0 .2 % potassium bicarbonate and 2 % magnesium sulphate) and rinsed 
by running under tap water for 10 minutes. Following rinsing sections were stained with eosin 
(5 minutes) and then immersed for a few seconds in dH20. Sections were then dehydrated by 
immersing for a few seconds in 50%, then 70%, 90% and finally 100% ethanol followed by a 
short immersion in HistoChoice® Clearing Agent. Coverslips were mounted onto slides with 
DPX mounting medium. Lung sections were examined by a pathologist Dr Joseph Cassidy for 
inflammation by light microscopy with up to 4 mice per treatment group. The degree of 
neutrophil-rich inflammation was scored as -  (absent), +/- (very mild), + (mild) or ++ (moderate). 
Scores were then assigned per treatment group. Photomicrographs were acquired for each 
“score” using a Nikon Eclipse E600 microscope.
6.3.10 Statistics
Data was analysed using one or two-way ANOVA. If any statistically significant difference was 
found, post hoc comparisons were performed using Bonferroni’s test. Data was deemed 
significant when p < 0.05 and expressed as group means with standard errors.
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6.4 Results
Mouse macrophage RAW 264.7 cells were assessed for MR expression by 
immunofluorescence similarly to differentiated THP-1 cells in chapter 3. RAW 264.7 cells were 
fixed and stained for MR expression with primary MR antibody and secondary Alexa Fluor-488, 
nucleus (hoescht; blue) and F-Actin (phalloidin-TRITC; red). Representative images are shown 
in Figure 6.3 and show ubiquitous MR expression by RAW 264.7 cells.
6.4.1 Mannose Receptor Mediated Mannosylated Liposome Uptake in RAW 264.7 cells
Figure 6.3: High content cell analysis of mannose receptor expression by RAW264.7 cells. 
Cells were fixed and stained for mannose receptor expression with primary mannose receptor 
antibody (1pg/ml) and secondary Alexa Fluor-488 (1/1000 dilution), nucleus (hoescht; blue) and 
F-Actin (phalloidin-TRITC; red). Images were acquired by an INCELL 1000 analyser (A) shows 
cells incubated without primary mannose receptor or secondary antibodies, (B) shows cells 
incubated without primary mannose receptor antibody only and (C) shows cells stained using 
primary mannose receptor antibody and 1/1000 AlexFluor488 secondary antibody.
Uptake of rhodamine labelled anionic, neutral and mannosylated liposomes was determined by 
HCA in order to assess the impact of liposome composition on uptake into RAW 264.7 cells and 
to compare this uptake with human differentiated THP-1 cells. Liposome uptake of DOPS, 
DOPC and mannosylated (7.5% MC2C, MC4C, MC6 C) liposomes was assessed at 0, 100, 200 
and 300pM concentrations after 2 hours and showed highly significant uptake (p < 0.001) of 
DOPS liposomes at all concentrations and MC6 C liposomes at 300pM (Figure 6.4). This is in 
accordance with uptake assessment in human differentiated THP-1 cells.
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Figure 6.4: Assessment of liposome uptake by RAW 264.7 cells by high content cell analysis. 
RAW 264.7 cells were incubated with 0, 100, 200 or 300pM rhodamine (red) tagged anionic 
(DOPS), neutral (DOPC) or mannosylated (MC2C, MC4C or MC6 C) liposomes for 2 hours at 
37°C, fixed and counterstained with hoescht (nucleus; blue) and phalloidin-FITC (F-Actin; 
green). Images were acquired using an INCELL 1000 cell analyser in 5 fields per well. Images 
show (A) untreated cells, cells treated with (B) DOPS, (C) DOPC, (D) MC2C, (E) MC4C and (F) 
MC6 C liposomes at 200pM for 2 hours. All images were analysed and liposomes per cell 
counted (G).
Statistical significance was determined by a two-way ANOVA.
* p < 0.05, ** p < 0.01, *** p < 0.001 vs. DOPC treated counterparts (Bonferrioni’s test)
Data represented as means ± SD (n = 6 )
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Uptake of 0, 100, 200 and 300pM liposomes was also assessed by HCA at 4°C, with the lower 
temperature impeding uptake in all but DOPS and DOPC treated cells. This suggests an active 
uptake process is involved in mannosylated liposome uptake. Mannosylated liposome uptake is 
receptor mediated and co-incubation with MR ligands such as mannan has been previously 
shown to inhibit mannosylated liposome uptake [115, 130]. MC2C liposomes showed the most 
significant decrease (p < 0.001) in uptake due to the low temperature (Figure 6.5D).
To develop liposome formulations for delivery to the lung the liposomes must be capable of 
aersolisation. Uptake of liposomes at 100, 200 and 300pM pre- and post-nebulisation via an 
AeroNeb Pro nebuliser was measured by HCA (Figure 6 .6 ) in order to determine the impact of 
nebulisation on cell interaction. Overall there was a decrease in uptake following nebulisation. 
MC6 C liposomes showed significant reduction in liposome association following 100 and 200pM 
treatments (p < 0.05) (Figure 6 .6 D). Mannosylated liposome stability may have been affected 
during nebulisation resulting in decreased uptake by RAW 264.7 cells.
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Figure 6.5: High content cell analysis of liposome uptake by RAW 264.7 cells at 4 and 37°C. 
RAW 264.7 cells were treated with 0, 100, 200 or 300pM of fluorescently tagged liposomes and 
incubated at either 4°C or 37°C for 2 hours, fixed and counterstained. HCA was used to acquire 
images in 3 channels and 5 fields per well. (A) shows untreated cells, (B) cells treated with 
100pM MC2C liposomes and incubated for 2 hours at 4°C and (C) 37°C and (D) uptake of 
lOOpM liposomes.
Statistical significance determined by two-way ANOVA with Bonferrini’s post-hoc tests. * p < 
0.05, ** p < 0.01 and *** p < 0.0001 
Data represented as means ± SD (n = 6 )
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Figure 6 .6 : High content cell analysis of liposome uptake into RAW 264.7 cells pre- and post- 
nebulisation. Fluorescently labelled lipsomes were nebulised by an AeroNeb Pro nebuliser. 
Pre-nebulised and post-nebulised liposomes were incubated at 37°C for 2 hours with RAW 
264.7 cells followed by fixation and staining of nuclei (hoescht; blue) and cells (phalloidin-FITC; 
green). Images (A) were acquired in 5 fields per well and analysed by an INCELL 1000 cell 
analyser for uptake of (B) DOPS, (C) DOPC and (D) MC6 C liposomes ( B 1 0 0  pM, ■ §  
200pM and ^■300pM ) Statistical differences were determined by two-way ANOVA with 
Bonferrini’s post-hoc test (* p < 0.05, ** p < 0.01) vs. un-nebulised liposome treated 
counterparts. Data represented as means ± SD (n = 3)
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6.4.2 In vitro Assessment of Liposome Toxicity
A major limitation of in vivo drug delivery is toxicity. A novel method for predicting in vivo airway 
toxicology was used combining HCA and cellomics cytotoxicity kits. RAW 264.7 cells were 
treated for 24 hours with liposome DOPS, DOPC, MC2C, MC4C and MC6 C preparations and 
compared to untreated cells (negative control) and cells treated with DOTAP liposomes or 
120pM valinomycin (positive controls). Cell viability, permeability, nuclear intensity, nuclear size 
and mitochondrial membrane potential were measured using a Cellomics multiparameter 
cytotoxicity kit and HCA. All preparations were found to be non-toxic at both 100 and 300pM 
concentrations except 300pM DOTAP and DOPS treatments (Figures 6.7 -  6.10).
In all cases positive control valinomycin showed high levels of toxicity (Figure 6.7) compared to 
untreated healthy cells validating this method for assessing toxicity. Significant toxic effects 
were also observed in the liposome positive control preparation consisting of 50% DOTAP. Due 
to toxicity cell count decreased, nuclei condensed reducing nuclear size and increasing the 
fluorescent intensity detected, cells became more permeable and mitochondrial membrane 
potential decreased. DOPS (at 100|jM only) and all concentrations of DOPC (neutral) and 
mannosylated liposomes showed levels of cell viability consistent with untreated negative 
control cells. Toxicity induced by liposomes was assessed at two different concentrations 
100pM (Figure 6 .8 ) and 300pM (Figure 6.9) as concentrations required for in vitro transfection 
are within this range. Cells were stained for nuclei, permeability and MMP and images acquired 
(Figure 6.7 -  6.9). ■ Images clearly show differences in cell number between 300pM DOTAP and 
DOPS liposome treatments (Figure 6.9) and healthy control cells (Figure 6.7).
Images were analysed using INCELL 1000 multi-target analysis mode of 5 fields per well. Cell 
loss, nuclear size, total nuclear intensity, cell permeability and MMP measurements per 
treatment were determined (Figure 6.10). In comparison to healthy untreated RAW 264.7 cells 
substantial cell loss was observed following treatment with 120pM valinomycin (positive 
control), 100pM and 300pM DOTAP liposomes and most significantly 300pM DOPS liposomes 
(p < 0.001). Only marginal decrease in cell viability was observed following neutral and 
mannosylated liposome treatments at both concentrations (Figure 6.10A). Hallmarks of 
apoptosis and necrosis include chromatin condensation and increased cell permeability or 
leakiness respectively. Additionally, MMP collapse is a mark of apoptosis and related to 
cytochrome c release.
Chromatin condensation was detected by a decrease in nuclear size and increase in total 
nuclear intensity. Valinomycin (p < 0.05) and 300pM DOPS liposome treatments showed 
similar nuclear shrinkage while DOTAP liposomes at both concentrations also decreased 
nuclear size but not to the same extent (Figure 6.10B). 100pM DOPS liposomes and DOPC 
and mannosylated liposomes at 100pM and 300|jM showed nuclear sizes equivalent to healthy 
cells (Figure 6.10B). Total nuclear intensity was also increased by positive control treatment
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valinomycin (p < 0.001) and DOTAP liposomes while cell nuclear intensities remained at healthy 
levels following all other liposome treatments at both concentrations (Figure 6.10C).
Necrosis can lead to cells becoming leaky and therefore the permeability of RAW 264.7 cells 
was assessed. Increased uptake of a fluorescent (Ex/Em 480/535nm) dye indicated an 
increase in permeability as demonstrated by the positive control valinomycin (Figure 6.10D). 
DOTAP liposomes at both concentrations also caused RAW 264.7 cells to become more 
permeable with 300|jM DOTAP liposome treatment resulting in greater cell permeability than 
valinomycin. Again all other liposome treatments at both concentrations showed levels 
equivalent to untreated healthy control cells. This included DOPS liposomes of 300pM which by 
other parameters showed to induce substantial decrease in cell viability perhaps indicating 
induction of apoptosis as opposed to necrosis. MMP collapse associated with apoptosis was 
observed following treatment with positive control valinomycin, DOTAP and DOPS liposomes at 
300|j M. All other liposome treatments including DOPC and mannosylated liposomes at both 
concentrations and DOTAP and DOPS liposomes at 100pM maintained healthy cell MMPs. 
Overall this indicated apoptotic and necrotic cell death induced by 120pM valinomycin, DOTAP 
liposomes at both concentrations but more significantly at the higher 300pM concentration and 
apoptosis following 24 hour treatment with 300pM DOPS liposomes. DOPC (neutral) and 
mannosylated liposomes showed no significant changes in cell health compared to untreated 
negative control RAW 264.7 cells.
Nuclei Cell Permeability MMP
Figure 6.7: High content cell assessment of liposome associated cytotoxicity in RAW 264.7 
cells. Fluorescent images were acquired by an INCELL 1000 analyser in 3 channels and show 
control treatments with cells treated with complete media as a negative control or 1 2 0 |jM 
valinomycin as a positive control.
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Figure 6 .8 : High content cell assessment of liposome associated cytotoxicity in RAW 264.7 
cells. Fluorescent images were acquired in 3 channels by an INCELL 1000 analyser and show 
cells treated with 100pM liposomes in complete media for 24 hours.
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Figure 6.9: High content cell assessment of liposome associated cytotoxicity in RAW 264.7 
cells. Fluorescent images were acquired in 3 channels by an IN CELL 1000 analyser and show 
cells treated with 300(JM liposomes in complete media for 24 hours.
213
Cell loss Nuclear size
A. 500-
■o
0» 400-
IP
a  300-
3
O 200-
Ü
o 100«
T ota I Nuclear Intensity D.
$ ^ V V V V V C
Cell Permeability
150- 1000- *** ***
E.
Mitochondrial Membrane Potential
400-1
^ ^ V V V V V °
Figure 6.10: High content cell assessment of liposome toxicity in RAW 264.7 cells. RAW 
264.7 cells were treated with complete media alone (negative control), 120pM valinomycin 
(positive control) or liposomes at L —J  lOOpM or IH E I 300jjM for 24 hours at 37°C. Cells were 
stained for nuclei (hoescht; blue), cell permeability (green) and mitochondrial membrane 
potential (MMP; red). Images were acquired and analysed using an INCELL 1000. Cell loss, 
nuclear size, nuclear intensity, cell permeability and MMP were measured (A - E). Data 
presented as means ± SD (n = 6 ). Statistical significance was determined by a two-way 
ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. healthy untreated groups (Bonferrioni’s test)
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6.4.3 In vitro Toxicity Assessment of siRNA Encapsulating Liposomes
Toxicity associated with siRNA loaded liposomes was also assessed in RAW 264.7 cells prior to 
formulation of liposomes for in vivo transfection. siRNA was complexed with cationic reagents 
DOTAP, PEI and protamine each being associated with toxicity [301-304] to improve siRNA 
encapsulation efficiency. Consequently cytotoxicity of siRNA complex loaded liposomes was 
also monitored as complexation can dramatically affect the physicochemical properties of a 
formulation. RAW 264.7 cells were untreated (negative control) or treated with 120pM 
valinomycin (positive control) or liposomes at 300pM for 24 hours at 37°C. DOPS, DOPC and 
mannosylated liposomes were either empty or encapsulated non-target siRNA complexed with 
DOTAP (N/P 4), protamine (weight ratio 4) or 25kDa PEI (N/P 7). DOTAP liposomes were also 
used as a cationic liposome control. Cells were stained for nuclei, cell permeability and MMP. 
Images were acquired of controls (Figure 6.7), DOPS liposomes (Figure 6.11), DOPC  
liposomes (Figure 6.12) and mannosylated liposomes (Figure 6.13) and analysed using an 
INCELL 1000. Cell loss, nuclear size, nuclear intensity, MMP and cell permeability were 
determined (Figure 6.14)
300pM DOPS liposomes showed high levels of toxicity with almost complete cell loss. Cell loss 
was greater than that of the positive control 120|j M valinomycin and cationic DOTAP liposomes. 
Additionally an increase in nuclear size and drop in mitochondrial membrane potential was 
observed corresponding to a toxic event. The encapsulation of siRNA/DOTAP, 
siRNA/protamine and siRNA/PEI complexes in DOPS liposomes lessened the degree of toxicity 
compared to empty DOPS liposomes however DOPS liposomes encapsulating siRNA/PEI 
complexes exhibited cell loss almost equivalent to DOTAP liposome treatment (Figure 6.11 and
6.14).
Neutral DOPC liposomes showed little toxicity, although a small decrease in mitochrondrial 
membrane potential was found (Figure 6.12 and 6.14). Additionally a small proportion of cell 
loss was detected following 24 hour treatment with DOPC liposomes encapsulating 
siRNA/DOTAP and siRNA/PEI complexes and a decrease in nuclear size following DOPC 
siRNA/protamine liposomes. Toxic effects were however minimal following DOPC liposome 
treatment whether empty or encapsulating siRNA complexes.
Overall mannosylated (MC6C) liposomes show similar toxicity profiles to the neutral DOPC 
liposomes (Figure 6.13 and 6.14). Some cell loss was observed with mannosylated liposomes 
encapsulating siRNA/protamine and siRNA/PEI complexes with a marginally higher cell loss 
using protamine as the complexing reagent. This cell loss however is similar to that found in 
neutral liposome formulation counterparts. Minimal changes are found in nuclear size and 
intensity with a minor decrease in mitochondrial membrane potential following treatment with 
siRNA/protamine complex loaded mannosylated liposomes.
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DOPS Liposomes
Figure 6.11: High content cell assessment of toxicity in RAW 264.7 cells induced by DOPS 
liposomes encapsulating siRNA complexes. RAW 264.7 cells were treated with 300pM empty 
DOPS liposomes or DOPS liposomes encapsulating siRNA complexed with DOTAP (N/P 4), 
protamine (weight ratio 4) or PEI (N/P 7) for 24 hours. Cells were stained for nuclei (hoescht), 
cell permeability and mitochondrial membrane potential (MMP). Images were acquired and 
analysed using an INCELL 1000.
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Figure 6.12: High content cell assessment of toxicity in RAW 264.7 cells induced by DOPC 
liposomes encapsulating siRNA complexes. RAW 264.7 cells were treated with 300pM empty 
DOPC liposomes or DOPC liposomes encapsulating siRNA complexed with DOTAP (N/P 4), 
protamine (weight ratio 4) or PEI (N/P 7) for 24 hours at 37°C. Cells were stained for nuclei 
(hoescht), cell permeability and mitochondrial membrane potential (MMP). Images were 
acquired and analysed using an INCELL 1000 at 100x magnification.
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Figure 6.13: High content cell assessment of toxicity in RAW 264.7 cells induced by
mannosylated (MC6 C) liposomes encapsulating siRNA complexes. RAW 264.7 cells were 
treated with 300pM empty MC6 C liposomes or MC6 C liposomes encapsulating siRNA 
complexed with DOTAP (N/P 4), protamine (weight ratio 4) or PEI (N/P 7) for 24 hours at 37°C. 
Cells were stained for nuclei (hoescht), cell permeability and mitochondrial membrane potential 
(MMP). Images were acquired and analysed using an INCELL 1000 at 100x magnification.
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Figure 6.14: High content cell assessment of liposome toxicity in RAW 264.7 cells. RAW 
264.7 cells were untreated (negative control), 120pM valinomycin (positive control) or liposomes 
at 300pM for 24 hours at 37°C. Liposomes were either empty or encapsulated non-target siRNA 
complexed with DOTAP (N/P 4), protamine (weight ratio 4) or 25kDa PEI (N/P 7). Cells were 
stained for nuclei (hoescht), cell permeability and mitochondrial membrane potential (MMP). 
Images were acquired and analysed using an INCELL 1000. Cell loss, nuclear size, nuclear 
intensity, cell permeability and MMP were measured (A - E). Data presented as means ± SD (n 
= 3). Statistical significance was determined by one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 
0.001 vs. healthy untreated groups (Dunnetts test)
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6.4.4 TNFa siRNA Sequence Comparisons
Prior to in vivo studies knockdown of TNFa was assessed in vitro using three commercially 
available siRNA sequences targeted to mouse TNFa in order to determine the optimal 
sequence for in vivo use. Transfections were carried out using HiPerFect transfection reagent 
in mouse RAW 264.7 cells which is suitable for macrophage transfection with protocols 
optimised for RAW 264.7 cell siRNA transfections. Initially knockdown was assessed 24, 48 
and 72 hours post-transfection however an effect was only detected after 24 hours (Figure 
6.15). TNFal and TNFa2 sequences lead to knockdown of TNFa expression after 24hours 
whilst TNFa3 siRNA enhanced TNFa secretion following LPS stimulation. Subsequent induced 
TNFa expression was determined 24 hours post-transfection.
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Figure 6.15: In vitro modulation of TNFa expression in RAW 264.7 cells using HiPerFect 
transfection reagent and three TNFa targeted siRNA sequences. RAW 264.7 cells were 
transfected with 375ng of non-target siRNA or one of three TNFa targeted siRNAs (TNFal, 
TNFa2 or TNFa3). 24, 48 and 72 hours post-transfection cells were stimulated with 100ng/ml 
LPS for 3 hours and TNFa expression determined. Expression is represented as % of non­
target siRNA transfected controls. Data is represented as means ± SD (n = 3)
HiPerFect mediated transfection of RAW264.7 cells was determined at 24 hours. Cells were 
stimulated with LPS for 3 hours and TNFa expression measured. As was previously seen in 
Figure 6.15 TN Fal and TNFa2 siRNAs decreased TNFa induction while TNFa3 increased 
TNFa expression. TNFa expression was decreased to 34 ± 32.8% and 52.7 ± 55.6% following 
HiPerFect mediated transfection of TN Fal and TNFa2 siRNA respectively compared to non­
target siRNA transfected cells (Figure 6.16). TNFa expression by cells transfected with TNFa3 
siRNA was increased 2-fold compared to non-target siRNA transfected controls. This validates 
TN Fal siRNA together with a 24 hour transfection optimal for subsequent in vivo transfections.
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Figure 6.16: In vitro modulation of TNFa expression in RAW 264.7 cells using HiPerFect 
transfection reagent and three TNFa targeted siRNA sequences. RAW 264.7 cells were 
transfected with 375ng of non-target siRNA or one of three TNFa targeted siRNAs (TNFal, 
TNFa2 or TNFa3). 24 hours post-transfection cells were stimulated with 100ng/ml LPS for 3 
hours and TNFa expression determined. Expression is represented as % of non-target (NT) 
siRNA transfected controls.
Data is represented as means ± SD (n = 6 ).
Statistical significance was determined by unpaired students t-test. * p < 0.05 vs. NT siRNA 
transfected control
6.4.5 In Vivo Testing of siRNA Liposomes
6.4.5.1 Size and Zeta Potential of siRNA Mannosylated (MC6C) Liposomes
Each batch of liposomes for in vivo use was characterised to ensure reproducibility. 
Mannosylated liposomes for in vivo administration showed post-extrusion diameter sizes of 
280.4 ± 62 nm, 214.4 ± 3 nm and 188 ± 4 nm for empty, NT siRNA and TNFa siRNA 
encapsulating liposomes respectively (Table 6.4). Zeta potentials for siRNA complex 
encapsulating liposomes were less than empty liposomes. Overall zeta potentials were very 
positive and less than +65mV (Table 6.4). Prior to extrusion zeta potentials were above 
+70mV.
Table 6.4 In Vivo Mannosylated liposome sizes and zeta potentials (Means ± SD)
Liposome Size (d.nm) PDI Zeta Potential (mV)
Empty Mannosylated Liposomes 280.4 ± 62 0.304 64.1 ± 3
Non-target siRNA/PEI Mannosylated Liposomes 214.4 ± 3 0.244 58.9 ± 2
TNFa siRNA/PEI Mannosylated Liposomes 188 ± 4 0.166 56 ± 1
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6.4.5.2 Validation of In Vivo Pulmonary Administration
Evan’s blue is frequently used to measure vascular permeability for example across the blood 
brain barrier and in the lungs but also to determine the accuracy of delivery [286]. Initially, 2% 
Evan’s blue dye was used to establish the effectiveness of the intratracheal method used in 
delivery of liquid formulations to the lungs prior to immunogenicity and knockdown studies. This 
showed a good distribution of the dye throughout the lungs and confirmed delivery to the lungs 
via the trachea as opposed to the stomach via the oesophagus. Intratracheal administration is 
a difficult procedure and therefore it was important for the technique to be as accurate and 
reproducible as possible before siRNA experiments were carried out. Mice were instilled with 
saline, siRNA or liposomes and after 24 hours received saline or LPS via the trachea followed 3 
hours later by euthanasia. For day two saline treated groups’ immunogenicity screens to naked 
siRNA and mannosylated liposomes were acquired. Although this was only an acute study, 
weights of mice were closely monitored and treatments did not cause any observable changes 
in animal health.
6.4.6 In Vivo Mannosylated Liposome Transfection
6.4.6.1 Bronchoalveolar Lavage (BAL)
Mice received saline, siRNA or siRNA/liposomes by intratracheal administration followed by 
LPS after 24 hours. BAL was collected 3 hours following LPS instillation and BAL cells were 
counted and identified. Differences in total ceil counts per treatment group were non-significant. 
In general LPS increased the number of BAL cells compared to saline however mannosylated 
liposomes both empty and encapsulating NT siRNA showed higher cell counts without LPS than 
with LPS treatment. Although a decrease in cell number was observed in NT siRNA and all 
mannosylated liposome treated groups particularly mice treated with mannosylated liposomes 
encapsulating TNFa siRNA (37.5 ± 1 3  (104) cells/ml) compared to saline/LPS treated controls 
(63.3 ± 49 (104) cells/ml). Additionally a decrease in cell number was observed following 
treatment with liposomes encapsulating TNFa siRNA compared to naked TNFa siRNA in LPS  
treated groups.
Neutrophils and macrophages were the only cell types identified in BAL (Figure 6.17). 
Macrophages were the predominant cell type identified and were found in abundance even in 
saline controls. Neutrophil presence was highest in groups receiving saline followed by LPS  
with low numbers counted in all other treatment groups. Treatment with liposomes 
encapsulating TNFa siRNA showed reduced levels of macrophages compared to naked and 
liposome encapsulated NT siRNA and naked TNFa siRNA treated groups. Furthermore 
neutrophil presence was lower following mannoyslated liposome encapsulated TNFa siRNA 
administration compared to naked TNFa siRNA.
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Figure 6.17: Bronchoalveolar lavage (BAL) cell differentiation from LPS stimulated mice. Total 
BAL cell counts were taken from saline and LPS (Day 2) treated groups using a 
haemocytometer (A). BAL cells were fixed in methanol and stained with Eosin Y and 
azur/methylene blue. Bright field images were acquired at 20x from C57BL/6 mice treated for 
24 hours (Day 1) with (B) saline, (C) non-target (NT) siRNA, (D) TNFa targeted siRNA, (E) 
empty mannosylated liposomes, (F) mannosylated liposomes encapsulating NT/PEI complexes 
and (G) mannosylated liposomes encapsulating TNFa/PEI complexes (N/P ratio 7) followed by 
3 hour (Day 2) LP S treatment. Macrophages and neutrophils were identified and counted (H).
6.4.6.2 TNFa knockdown and Cytokine Expression
Following siRNA or mannosylated liposome treatment mice were also treated with LPS. This 
was to stimulate an inflammatory response in the lung and assess the effectiveness of TNFa 
targeted siRNA to specifically suppress TNFa expression. In addition a comparision between 
the effectiveness of naked TNFa siRNA to liposome encapsulated siRNA could be made. To 
date there have been very few in vivo studies delivering siRNA to the lungs (Table 6.1 shows in 
vivo studies to date using intratracheal administration). Doses of siRNA have ranged from
1.33pg to 665pg via intratracheal administration. Our study was limited by the maximum 
tolerable volume that could be administered which was 50pl. Liposomes prepared in chapter 3 
for in vitro experiments encapsulated a maximum of 1pM siRNA or almost 0.7pg per pi of 
liposome formulation. A starting dose of 30pg was selected as a similar dose had been used 
most frequently in previous studies. For these in vivo studies liposomes were prepared 2.5 
times more concentrated than for in vitro studies in order to compensate for a higher siRNA 
loading. Additionally liposome preparations this concentrated had been administered previously 
in vivo.
Mice received either saline, siRNA or liposomes (day 1) and 24 hours later LPS for 3 hours (day 
2) intratracheally. BALF cytokine levels were variable within treatment groups but similar 
between groups. siRNA naked or encapsulated in mannosylated liposomes was targeted to the 
pro-inflammatory cytokine TNFa with controls of non-target siRNA. TNFa expression levels 
were decreased following administration of naked TNFa siRNA and all liposome treatments 
most notably TNFa siRNA loaded mannosylated liposomes (Figure 6.18A). The decrease in 
expression was not significant due to a large variability with the treatment groups. It should be 
noted that the longer the time between preparation of liposomes and administration the less 
effective the formulation was in lowering TNFa protein levels. Figure 6.18E shows the 
percentage knockdown of TNFa in the various treatment groups with TNFa siRNA and 
mannosylated liposomes encapsulating TNFa siRNA yielding the most apparent TNFa 
knockdown.
The secretion of other major markers of inflammation including IL-1 p, KC and MIP-2 not 
targeted by siRNA were measured in BALF (Figure 6.18). IL-1 p induction was lessened 
following siRNA and mannosylated liposome administration compared to the control saline 
treatment (Figure 6.18B). Empty liposomes and liposomes encapsulating TNFa siRNA/PEI 
complexes showed a marginally higher IL-1 p level than other siRNA and liposome treated 
groups.
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Figure 6.18: Bronchoalveolar lavage (BAL) cytokine expression in mice following 3 hour LPS  
treatment. C57 mice received saline, non-target siRNA (NT siRNA), TNFa targeting siRNA, 
empty mannoslyated liposomes or mannosylated liposomes encapsulating either NT siRNA or 
TNFa siRNA complexed with PEI (N/P 7) via intratracheal administration. After 24 hours 
0.4mg/ml LPS was intratracheally administered for 3 hours and BAL was collected. 
Proinflammatory cytokine expression was determined of TNFa (A), IL-ip  (B), KC (C) and MIP-2 
(D). The percentage of TNFa knockdown was determined (F).
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6.4.6.3 Histopathology
Haemotoxylin and eosin stained lung sections from C57 mice were semi-quantitatively scored 
as shown in Table 6.5 and Figure 6.19. Mice received LP S via intrachael administration 
following 24 hour treatment with saline, siRNA or siRNA mannosylated liposomes. 
Histopathology showed the degree of inflammation through structural changes such as cell 
infiltration and blood vessel leakage. The effect of TNFa targeted siRNA on overall LP S  
induced lung inflammation could therefore be evaluated. Mild neutrophil-rich inflammation was 
observed following LPS administration with saline control showing an absence of inflammation 
and mannosylated liposomes encapsulating non-target siRNA complexed with PEI exhibiting 
very mild inflammation.
Table 6.5 Histopathology Semi-quantitative scores
Treatment Group Degree of Neutrophil-
Day 1 (24hrs) Day 2 (3hrs) rich Inflammation
Saline Saline -
Saline LPS +
Non-target siRNA LPS +
TNFa siRNA LPS +
Non-target siRNA/PEI Mannosylated Liposomes LPS -/+
TNFa siRNA/PEI Mannosylated Liposomes LPS +
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Figure 6.19: Photomicrographs representative of pulmonary histolopathology semi-quantitative 
scoring of neutrophil-rich inflammation. Haemotoxylin and eosin stained lung sections from 
saline, siRNA and mannoyslated liposome treated mice were scored based on the degree of 
neutrophil-rich inflammation observed (- absent, -/+ very mild, + mild and ++ moderate). Images 
were acquired at 40x, 200x and 600x magnification.
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6.4.7 Effect of Mannosylated Liposomes on Immune Responses in the Lung
6.4.7.1 Bronchoalveolar Lavage (BAL) cells
BAL cells were counted and total cell counts per ml calculated (Figure 6.20E) from mice treated 
for 24 hours with saline, saline followed by LPS (3 hours), non-target siRNA, TNFa siRNA, 
empty mannosylated (MC6 C) liposomes, liposomes encapsulating non-target siRNA/PEI 
complexes and mannosylated liposomes encapsulating TNFa siRNA/PEI complexes. A marked 
increase in cell number was found following empty mannosylated liposome treatment. This 
increase was far greater than 24 hour saline followed by a 3 hour LPS treatment (the positive 
control).
The majority of BAL cells identified were macrophages (Figure 6.20A). A notable increase in 
macrophage presence was found following 24 hour treatment with empty mannosylated 
liposomes (Figure 6.20B). Neutrophils were also present mainly following LPS treatment and 
treatment with empty mannosylated liposomes.
Treatment groups of 30pg siRNA alone were n = 1 for some analysis methods and therefore a 
more accurate representation of the immunological response would require an increase in the n 
number. Liposome treatments were in general n = 2 -3 however for total cell count of the empty 
liposome treated group a lot of debris was collected in BALF from one animal. It was difficult to 
distinguish cells accurately and therefore data for this sample was omitted. Additionally a 
number of cell differential slides did not stain optimally and cells were not easily identifiable 
which reduced n numbers for these counts in some groups.
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Figure 6.20: Bronchoalveolar lavage (BAL) cell differentiation collected from siRNA and 
liposome treated mice. Total BAL cell counts were taken using a haemocytometer (E). BAL 
cells were fixed in methanol and stained with Eosin Y and azur/methylene blue. Representative 
bright field images were acquired at 20x from C57 mice treated for 24 hours with (A) saline, (B) 
saline followed by 3 hour LPS treatment and (C) empty mannosylated liposomes. Macrophages 
and neutrophils were identified and counted (D).
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6.4.7.2. Local and Systemic TH1/TH2 Response to siRNA and Mannosylated Liposomes
A range of cytokines and chemokines involved in TH1 and TH2 immune responses were 
detected by a multi-spot ultrasensitive assay in mouse BALF and plasma. Mice were 
intratrachaelly instilled with saline, non-target siRNA, TNFa targeted siRNA, empty 
mannosylated (MC6 C) liposomes, non-targeted siRNA/PEI complexes encapsulated in 
mannosylated liposomes or TNFa siRNA/PEI complexes encapsulated in mannosylated 
liposomes and sacrificed 24 hours later. A summary of treatments and TH1/TH2 responses are 
shown in Table 6 .6 . LP S  was intratrachea I ly administered for 3 hours to show an acute 
TH1/TH2 response. Figure 6.21 shows the cytokine profiles in BALF and plasma following 
saline treatment for 24hour followed either by saline or LPS for 3hrs. Following saline 
administration cytokine concentrations are very low with BALF and plasma KC and IL-12 having 
the highest expression levels. LP S induced TNFa production in BALF but not in plasma 
therefore validating the animal model. KC, IL-10 and IL-12 expression was increased in BALF 
and plasma following the 3 hour LP S challenge. These immune mediators are mainly produced 
by macrophages.
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Figure 6 .2 1 : TH1/TH2 response in mice following saline and/or LPS intratracheal instillation. 
Saline was administered for 24 hours followed by saline or LPS for 3 hours. BALF and plasma 
cytokine profiles were determined using a Th1/Th2 cytokine 9-plex multi spot assay.
Data represented as means ± SD (n = 3)
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An acute 3 hour LP S challenge to the lungs produced a balanced Th1/Th2 response with all 
measured cytokines induced in the lung when compared to saline alone. The negative control 
saline treated groups set the baseline or normal lung cytokine levels and allow the effect of 
treatments on cytokine levels to be established. IFNy, IL-2 and IL-5 were not increased 
systemically. However, as blood was stored on ice haemolysis occurred and therefore lipids 
present in the plasma samples due to haemolysis could interfere with the assay. Additionally, 
only siRNA alone and liposomes encapsulating TNFa siRNA treatment groups were n = 1 for 
Th1/Th1 immunogenic studies. Proteins particularly in BALF can adhere to labware and so 
MSD recommend adding a carrier protein such as BSA upon sample collection to reduce any 
protein loss. A carrier protein had not been added until immediately prior to analysis by the 
MSD multispot assay.
Non-target (NT) siRNA caused IFNy induction in the lung while increasing levels of IFNy, IL-4, 
IL-5 and IL-10 in the plasma (Table 6 .6  and Figure 6.22). This shows a predominantly Th2 
response systemically. TNFa siRNA on the other hand showed no effect on cytokine levels in 
BALF or plasma. Empty mannosylated liposomes delivered to the lungs induced all measured 
cytokines in the lungs after 24 hours however systemic expression was unaltered when 
compared to saline negative control. Mannosylated liposomes encapsulating NT siRNA/PEI 
complexes showed a similar response to NT siRNA inducing lung IFNy, IL-4 and IL-5 and 
systemic IFNy, IL-4 and IL-10. Induction of IL-5 was confined to the lung when NT siRNA was 
encapsulated in the mannosylated liposome. TNFa siRNA encapsulated in liposomes also 
showed a similar induction profile to TNFa alone whereby little or no Th1/Th2 response was 
detected. Only a moderate increase in lung IL-4 was measured. Both naked TNFa siRNA and 
TNFa siRNA/PEI complexes encapsulated in mannosylated liposomes showed no induction of 
lung IFNy while NT siRNA and empty or NT siRNA loaded mannosylated liposomes showed 
increased IFNy production compared to negative saline controls.
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Table 6.6: Summary of TH1/TH2 Response in Mice Following Saline, siRNA and Mannosylated Liposome Administration (Data represented as means ± SD)
Treatment TH1 TH2
Day 1 (24hrs) Day 2 (3hrs) TNFa IL-1P IL-2 IL-12 IFNy KC IL-4 IL-5 IL-10
Saline Saline BALF 1.8 ± 2.2 4.0 ± 3 .3 0.7 ± 1.5 13.9 ± 1.3 0 ± 0 39.5 ± 44.5 0.0 ±0.1 1.0 ± 0 .9 3.4 ± 3.6
Plasma 1.3 ± 1 .4 7.3 ± 1.6 15.5 ± 6 .6 511.1 ± 232.2 5.4 ± 2 .8 87.4 ±65.1 7.3 ± 4.3 12.6 ± 3 .5 36.8 ± 10.7
Saline LPS BALF 1775.9 ±1179.9 17.9 ± 9 .6 8.5 ± 6.2 90.9 ± 40.6 1.0 ± 0 .8 1240.8 ±627.1 1.3 ± 1.0 2.6± 1.3 734.5 ± 5 28 .6
Plasma 34.5 ± 1.0 16.2 ± 5 .4 19.8 ±3.1 4056.2 ±2456.3 9.9 ± 8 .9 2323.9 ± 895.6 22.1 ± 13.2 15.9 ± 5 .5 239.9 ± 34.8
NT siRNA Saline BALF 0.3 ± 0 .3 5.1 ± 1.1 0.7 ± 1 .0 21.8 ± 4.6 0.2 ±0.1 6.7 ± 1 .0 0.1 ± 0 .2 1.2 ± 1.7 0 ± 0
Plasma 1.3 ± 1 .8 4.3 ± 2.2 18.3 ± 2 .5 465.1 ± 3 7 .5 52.3 ±8.1 59.6 ± 7.4 86.1 ± 14.6 27.8 ± 2.6 182.9 ± 11.7
TNFa SiRNA Saline BALF 5.6 ± 2 ,9 2.0 ± 0 .8 0.5 ± 0 .7 21.48 ± 0 .6 0 ± 0 15.0 ± 0 .3 0 ± 0 1.0 ± 0 .2 5.4 ± 7 .7
Plasma 0 ± 0 5.0 ± 0 .6 15.7 ± 7 .6 440.5 ± 13.7 1.9 ±2.1 268.8 ± 0.4 5.1 ± 0 .2 7.8 ± 0 .6 46.2 ± 2 .5
Empty MC6C 
Liposomes Saline BALF 198.3 ±212.6 11.2 ± 1.0 3.6 ± 2 .3 48.4 ± 20.3 1.1 ± 0 .6 427.1 ± 4 81 .4 1.4 ± 0.5 2 7  ±2.1 100.4 ± 112.5
Plasma 2.7 ± 2 .2 5.8 ± 0.7 14.4 ± 6 .2 290.7 ± 1 02 .6 3.7± 0.9 109.1 ± 109.9 5.0 ± 2 .2 9.7 ± 3.2 37.2 ± 1 0 .2
NT siRNA 
Liposome Saline BALF 0.8 ± 1 .2 1 .4±  1.2 1.0 ± 1.9 17.7 ± 4 .4 0.8 ± 0 .7 2.7 ± 1 .4 0.3 ± 0 .6 2.6 ± 0 .3 1.9 ± 1.6
Plasma 3.7 ± 2 .7 4.2 ± 1.9 13.6 ± 4 .4 460.5 ± 9.6 17.0 ± 18.1 65.1 ± 2 4 .8 34.0 ± 34.3 15.5 ± 7 .9 93.1 ± 7 2 .8
TNFa siRNA 
Liposome Saline BALF 0.8 ± 0 .5 1.9 ±0.1 0 ± 0 12.2 ± 0 .5 0 ± 0 8.1 ± 1 .2 0.5 ± 0 .7 0.4 ± 0.2 0 ± 0
Plasma 2.2 ± 3 .2 3.1 ± 1 .2 14.0 ± 7 .5 462.4 ± 33.7 6.0 ± 1.9 71.6 ± 0 .0 7.7 ± 2 .0 10.9 ± 1 .0 45.3 ± 3 .8
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Figure 6.22: TH1/TH2 response in mice following saline, siRNA or mannosylated liposomes by 
intratracheal instillation. Saline, non-target (NT) siRNA, TNFa targeted siRNA, mannoslyated 
liposomes empty or encapsulating NT or TNFa siRNA complexed with PEI were administered 
for 24 hours. As a positive control a saline group were challenged with intratracheal 
administered LPS for 3 hours. BALF and plasma TNFa, IL-1(B and IL-2 were determined using a 
Th1/Th2 cytokine 9-plex multi spot assay. Data represented as means ± SD (n = 1 -  4). 
Continued.
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Figure 6.22: Continued. TH1/TH2 response in mice following saline, siRNA or mannosylated 
liposomes by intratracheal instillation. Saline, non-target (NT) siRNA, TNFa targeted siRNA, 
mannoslyated liposomes empty or encapsulating NT or TNFa siRNA complexed with PEI were 
administered for 24 hours. As a positive control a saline group were challenged with 
intratracheal administered LPS for 3 hours. BALF and plasma IL-12, IFN-y and KC were 
determined using a Th1/Th2 cytokine 9-plex multi spot assay. Data represented as means ± 
SD (n = 1 -  4). Continued.
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Figure 6.22: Continued. TH1/TH2 response in mice following saline, siRNA or mannosylated 
liposomes by intratracheal instillation. Saline, non-target (NT) siRNA, TNFa targeted siRNA, 
mannoslyated liposomes empty or encapsulating NT or TNFa siRNA complexed with PEI were 
administered for 24 hours. As a positive control a saline group were challenged with 
intratracheal administered LP S for 3 hours. BALF and plasma IL-4, IL-5 and IL-10 were 
determined using a Th1/Th2 cytokine 9-plex multi spot assay. Data represented as means ± 
SD (n = 1 -4 ).
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6.4.7.3 Histopathology following siRNA and Mannosylated Liposome Administration
Haemotoxylin and eosin stained lung sections from C57 mice intratracheally administered 
saline, siRNA or mannosylated liposomes were semi-quantitatively scored as shown in Table 
6.7. The most apparent feature of inflammation was the presence of infiltrating neutrophils. An 
absent or very mild response was observed in this acute study to NT siRNA and mannosylated 
liposomes encapsulating siRNA/PEI complexes. Mild neutrophil-rich inflammation was found 
following 24 hour treatment with TNFa siRNA and also in groups treated with saline followed by 
an acute 3 hour LPS treatment. Empty mannosylated liposomes showed the greatest degree of 
inflammation scoring as moderate (++). In addition inflammatory features such as pavementing 
of neutrophils and the presence of neutrophils in the interstitium were observed following 24 
hour empty liposome treatment.
Table 6.7: Histopathology Semi-quantitative scores
Treatment Group Degree of Neutrophil-rich Inflammation
Saline
Saline + LPS (3hrs)
Non-target siRNA 
TNFa siRNA
Empty Mannosylated Liposomes 
Non-target siRNA/PEI Mannosylated Liposomes 
TNFa siRNA/PEI Mannosylated Liposomes
-/+
-/+
++
+
+
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6.5 Discussion
Through the use of inhalable biocompatible nanoparticles siRNA therapies for conditions 
including COPD, asthma and C F  can be developed. Inhalable therapies offer an opportunity to 
delivery a drug directly to the target organ and thereby improve delivery, efficiency and avoid 
off-target effects. siRNA targeting pro-inflammatory mediators such as TNFa encapsulated in 
non-immungenic biocompatible targeted liposomes are one such therapeutic approach. TNFa 
siRNA has never been delivered directly to the lungs and therein we harnessed mannosylated 
liposomes for the first time to target alveolar macrophages.
The MR is highly expressed by macrophages and its expression has been measured by 
western blot analysis, immunocytochemistry, flow cytometry [305, 306], immunoprécipitation 
and PCR [307]. In a recent study by Kraus et al. (2010) MR expression of BV-2 cells, a mouse 
microglial cell line, was determined by high content screening [308]. Immunofluoresence 
confirmed MR expression by RAW 264.7 cells. Uptake of anionic, neutral and mannosylated 
liposomes also showed a similar pattern to that determined in differentiated THP-1 cells 
(chapter 3) but nebulised liposomes were also assessed. Comparison in uptake of liposomes 
pre- and post-nebulisation by a vibrating-mesh nebuliser (AeroNeb) revealed a significant 
decrease in uptake of mannosylated (MC6 C) liposomes at 100 and 200pM post-nebulisation. 
This suggests these targeted systems may be less stable following nébulisation.
Propidium iodide and MTT assays are generally used to assess toxicity or cell viability in vitro. 
More recently high throughput screening techniques have been used to measure these effects 
in vitro whilst providing more detailed information on the effects of drugs or particles as well as 
images. Cellomics mulitparameter cytotoxicity assay allows the measurement of 7 parameters 
of cell death simultaneously. Before in vivo studies the most suitable, that is the least toxic, 
liposome formulation was determined. Cell loss, size and intensity of nuclei, cell permeability 
and mitochondrial membrane potentials in RAW 264.7 cells could be measured. Cytochrome c 
detection was determined using a mouse monoclonal cytochrome c primary antibody and 
DyLight™ 649 conjugated goat anti-mouse IgG secondary antibody and did not successfully 
bind under the conditions used.
Both DOPS and mannosylated liposomes were prepared as the targeting carriers to 
macrophages with DOPC liposomes as the neutral controls. On the whole, DOPS liposomes at 
high concentrations exhibited high levels of toxicity. These high concentrations would be 
necessary for transfection both in vitro and in vivo. The majority of the parameters measured 
were at an equivalent level to the positive toxic controls (valinomycin and DOTAP liposomes 
[93, 178, 179]). Valinomycin is a highly toxic potassium ionophor. DOTAP is a cationic lipid 
frequently used in the formulation of liposomes and lipoplexes for transfection. Although it is a 
more convenient lipid for transfection with high transfection efficiency it has been shown to 
interact with proteoglycans on the cell surface leading to toxicity as has been discussed in 
chapter 3. Consequently mannosylated liposomes were considered more suitable for in vivo
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use. Mannosylated liposomes at both concentrations showed non-significant toxic effects. 
Liposomes composed with Mann-C6 -Chol were the most biocompatible. Therefore, toxicity was 
assessed of MC6 C liposomes empty or encapsulating siRNA. Some toxic effects were seen but 
were only minor. These effects were generally highest with siRNA complexed with protamine 
followed by PEI and the least pronounced effects seen when siRNA/DOTAP complexes were 
assessed. siRNA/DOTAP complexes were the least reproducible complexes with variability in 
size, zeta potential and most importantly encapsulation efficiency (Chapter 2). Also in vitro 
experiments indicated when siRNA/protamine and siRNA/PEI complexes were added to 
liposome formulations they improved transfection efficiency. Hence mannosylated (MC6 C) 
liposomes encapsulating siRNA/PEI complexes were deemed the most suitable formulation for 
in vivo studies.
Additionally, Mann-C4-Chol containing liposomes, having positive zeta potentials [297], have 
previously been shown to be well tolerated in vivo [115]. Zeta potentials of in vivo MC6 C  
liposomes encapsulating siRNA and empty ranged from 56 to 64 mV. This surface charge 
decreased from over +65mV following extrusion possibly due to neutral lipids masking or 
enveloping the positively charged siRNA/PEI complexes. PEI may also offer other advantages 
in siRNA delivery. PEI perhaps acts as a “proton sponge” [309] and can be protonated to a 
higher degree at lower pH. Thus within endosomes or lysosomes PEI will buffer the lower 
environmental pH causing osmotic swelling, possible lysosome rupture and release of the 
complex into the cell cytoplasm. Consequently PEI could assist in cytoplasmic delivery of 
siRNA while also protecting siRNA from lysosomal degradation. Toxic effects associated with 
this polymer is also most likely masked by liposome encapsulation.
A range of commercially available siRNAs against TNFa were compared using HiPerFect 
transfection reagent which is optimised for macrophage transfection. Transfections with these 
sequences revealed TN Fal and TNFa2 to knockdown TNFa expression while TNFa3 enhanced 
TNFa expression particularly when compared to non-target siRNA transfected controls. TN Fal 
siRNA was the most potent inhibitor of TNFa expression in RAW 264.7 cells and therefore was 
used for in vivo mannosylated liposome formulations encapsulating TNFa siRNA/PEI 
complexes. It has previously been shown that synthetic siRNA can induce a sequence 
dependent immune response [310]. Sioud et al. (2005) assessed 32 different siRNA 
sequences, 8 of which targeted TNFa [311]. One particular siRNA sequence targeting mouse 
TNFa induced high levels of TNFa and IL-6  in adherent PBMCs. Sequence homology between 
immune stimulating siRNAs was not significant but the presence of GU dinucleotides appeared 
to be involved in immune activation [311]. GU dinucleotides occur once in TNFa2 and twice in 
TNFa3 but not in TN Fal. This could explain the differences in TNFa expression between the 
three sequences.
It was not known whether LPS would interact with the liposome preparations and due to this 
and volume per dose constraints it was decided to administer siRNA or liposomes and LPS  
separately. It has previously been shown that intracellularly siRNA degrades after 24 hours.
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Also recovery time for the mice was necessary from anaesthetic and the procedure itself, thus a 
recovery time of 24 hours was chosen. This allowed another 50|jI liquid dose (either saline or 
LPS) to be safely administered and well tolerated. siRNA could then be delivered intracellularly 
prior to LP S challenge. Since the induction of a cytokine TNFa was to be determined, mice 
were sacrificed 3 hours following LP S administration. Lefort et al. (2001) showed a dose 
dependent increase in BALF TNFa concentration in C56BL/6 mice treated with aeroso/ised LP S  
(£  coli 055:B5) after 3 hours. TNFa was undetected in BALF after 24 hours [291]. A temporal 
transcriptional profile from C57BL/6 mouse lung post-treatment with aerosolised LPS (E. coli 
0111:B4) from 1 to 24 hours was generated in a study by Jeyaseelan et al. (2004). TNFa 
expression was 53.3-fold greater than controls 2 hours following LPS treatment and with only a 
2-fold increase at 24 hours [293]. Therefore this time point maximises the amount of cytokines 
present in the BALF.
Although not significant, TNFa expression was marginally decreased in groups administered 
with TNFa siRNA and mannosylated liposomes encapsulating TNFa siRNA. The more freshly 
prepared the liposomes the more effective the siRNA was, as formulations administered over a 
week following preparation had little or no effect on TNFa expression compared to saline/LPS 
treated controls. This suggests degradation of siRNA over time and that preparations must be 
used immediately. Assessment of further doses was planned however time constraints did not 
permit this. Other pro-inflammatory cytokines and chemokines were elevated due to LPS  
stimulation of TLR-4 but were more variable with little difference between groups. This was a 
preliminary study and could be extensively optimised in terms of time points, dosing and 
formulation. Many of the in vitro liposome knockdown studies were carried out in parallel to the 
in vivo work but early experiments indicated 24 hour liposome treatment followed by a 3 hour 
LP S stimulation was optimal. It should also be noted that liposomes were targeted to alveolar 
macrophages but although the predominant mediators of inflammation these are not the only 
cell type present. Endothelial cells present would also be involved in the inflammatory response 
boosting cytokine and chemokine levels.
In vivo NT siRNA treatment in non-LPS challenged mice was associated with a low presence of 
neutrophils and histology revealed inflammation equivalent to the negative control group in the 
BAL while IFNy was induced in the lung and IFNy, IL-4, IL-5 and IL-10 were increased in the 
plasma. Additionally total BAL cell counts were on par with negative controls. This shows an 
absence of immunological response in the lung with a systemic mainly Th2 response. TNFa  
siRNA on the other hand showed little cytokine response in the lung or systemically but 
histology revealed mild inflammation. Additionally total BAL cell counts were similar to negative 
controls and neutrophils were not present. It has been postulated that synthetic siRNA could be 
recognised within the endosomes by TLR-7 and T LR -8 and thus elicit a sequence dependent 
immune response [310, 311].
A large increase in total BAL cell count was found following treatments with mannosylated 
liposomes particularly empty liposomes. Empty liposome treatments also lead to neutrophil
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infiltration into alveolar spaces as indicated by the presence of neutrophils in BAL almost 
equivalent to acute LPS challenge. Liposome presence also induced a wide range of cytokines 
in the lung including TNFa, IFNy, IL-12, KC, IL-10, IL-2, IL-4, IL-5 and IL-10 but not 
systemically. This effect was induced by empty liposomes but not by liposomes encapsulating 
siRNA which only altered IFNy, IL-4 and IL-5 in the lung. Liposome encapsulation of NT 
siRNA/PEI complexes also increased systemic levels of IFNy, IL-4 and IL-10. Histological 
analysis revealed neutrophil rich inflammation following liposome treatments scored as 
moderate and mild following empty liposome and siRNA encapsulating liposome treatments 
respectively. Overall this shows empty mannosylated liposomes inducing an inflammatory 
response after 24 hours similar to that of an acute LPS challenge. This response involved the 
recruitment of neutrophils and the upregulation of all immune mediators measured but was 
localised in the lung. Liposomes encapsulating siRNA caused a far lesser degree of 
inflammation but an effect was detected in the plasma. Interestingly groups administered NT 
siRNA and liposomes encapsulating NT siRNA showed increased plasma levels of the same 
immune mediators (IFNy, IL-4 and IL-10) but NT siRNA unencapsulated induced these 
mediators to a much greater extent.
In vitro screening of a range of liposomes and TNFa targeted siRNA sequences for toxicity and 
efficacy respectively were used to optimise formulations for in vivo transfection. In vitro 
liposomes showed low toxicity at 100 and 300|jM with DOPS (300}jM) the exception. 
Mannosylated liposomes containing Mann-C6 -Chol were developed for in vivo administration. 
This shows the first time Mann-C6 -Chol containing liposomes have been administered in vivo 
and siRNA has been incorporated into mannosylated liposomes. Although toxicity in RAW
264.7 cells was negligible following 24 hour empty mannosylated liposome treatment in vivo an 
immune response was elicited in the lung only. Loaded liposomes did not have such an 
exaggerated effect. Additionally, siRNA induction of systemic immune mediators was reduced 
following liposome encapsulation. Previously liposomes have been shown to maintain localised 
effects of drugs following pulmonary administration and avoid systemic or off-target effects 
[154]. Although a clear knockdown of TNFa was not observed following administration of naked 
TNFa siRNA or mannoslyated liposomes encapsulating TNFa siRNA a decrease in TNFa 
expression was observed in these treatment groups particularly following the administration of 
freshly prepared liposomes. In general the mannosylated liposomes prepared are non-toxic 
and well tolerated.
Key Findings
v
• Optimal liposome formulation and TNFa siRNA sequence determined in vitro
• TNFa knockdown was observed in the mouse lung following naked and mannosylated 
liposome encapsulated TNFa siRNA treatment in LPS challenged mice
• Mannosylated liposomes induced an immune response in vivo but were well tolerated 
and effects were localised to the lung
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Chapter 7 
Discussion
7.1 General Discussion and Conclusions
Macrophages play a key role in inflammatory lung diseases such as COPD, asthma and C F  and 
consequently represent an important therapeutic target. To date the majority of clinical 
therapies provide relief from the immediate symptoms associated with these diseases with no 
long term or curative therapies available. Gene therapy could open a new avenue in the 
treatment of inflammatory lung disease. RNAi via siRNA can provide potent and specific 
targeting of inflammatory genes but requires biocompatible and safe delivery vectors [223, 312]. 
Viral vectors for gene therapies have been harnessed for RNA delivery producing high 
transfection efficiencies [312], However, serious side-effects have ensued following viral-based 
transfection including immunogenicity and oncogenicity [249, 253, 312] calling for alternative 
vector systems for delivery. Non-viral vectors such as liposomes and polymeric systems are 
widely investigated for this purpose and can be modified to enable RNA targeting, slow RNA 
release and improved stability in vivo. The combination of RNAi with biocompatible, targeted 
delivery systems offers the potential to develop potent, gene and cell specific therapeutic 
agents.
In this thesis, a range of non-viral vectors for targeted siRNA delivery to alveolar macrophages 
were developed and compared including anionic and mannosylated liposomes and uncoated 
and gelatin-coated PLGA microparticles. These vector systems were developed to avoid the 
use of cationic lipids and polymers for intracellular delivery which can induce cytotoxicity. 
Anionic liposomes were composed of DOPS (a synthetic phosphatidylserine) and mannosylated 
liposomes incorporated mannosylated cholesterols into their bilayer in order to target 
macrophage SR  and MRs. Uptake of PLGA microparticles by macrophages is optimal when the 
microparticles are manufactured in the size range 2 -  3pm in diameter [313] and has a 
hydrophobic surface which is readily opsonised [314]. Methods were developed to effectively 
encapsulate siRNA into liposome and microparticle formulations. siRNA liposomal and 
polymeric carrier systems were evaluated based on physicochemical properties and in vitro cell 
uptake, toxicity, immunogenicity and knockdown efficiency in macrophage cell models. 
Mannosylated siRNA liposomes were further developed for in vivo testing of both siRNA 
efficacy by direct delivery to the mouse lungs; liposomes induced local and systemic 
immunogenic effects. There is a growing need to deliver shRNA to monocytes and 
macrophages for research purposes and also as a potential means of eliciting therapeutic RNAi 
for clinical applications and the PLGA microparticle platforms were harnessed for delivery of 
shRNA.
Encapsulation methods were optimised for siRNA loading into anionic and mannosylated 
liposomes and PLGA microparticles. Both systems are generally associated with poor 
encapsulation efficiencies therefore siRNA encapsulation presents a considerable challenge. 
Cationic lipids are conventionally used for gene delivery because of their efficiency in 
encapsulation of nucleic acids and transfection of cells in vitro. Unfortunately cationic lipids 
such as DOTAP can be cytotoxic and lipoplex formulations are not as effective in vivo [92].
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Several studies have encapsulated siRNA into anionic and neutral liposomes using a number of 
techniques such as freeze dried lipid matrix [94], pre-condensation of siRNA [96, 98] and 
repeated freeze thaw cycles [99, 105]. Pre-condensation of siRNA with cationic reagents, such 
as PEI and octa-arginine, has achieved encapsulation efficiencies of >80% in non-cationic 
liposomes [98]. Another challenge lay in the determination of encapsulation efficiency 
particularly when siRNA was condensed prior to encapsulation and in fact many published 
studies omit siRNA encapsulation efficiency determinations. Methods described in the literature 
used ribogreen or fluorescence assays to detect free siRNA removed by centrifugation or 
following liposome disruption by detergents [105, 169]. Using these techniques it was found 
that >95% siRNA was encapsulated in the prepared DOPS and mannosylated liposomes but 
this did not take into account the siRNA complexed with the cationic complexing agent which is 
undetectable by the quantitation method used. Similarly pre-condensation of siRNA has 
previously been used as a strategy for improved siRNA loading into PLGA particles with 
encapsulation efficiencies up to 80% and 32% with PEI and DOTAP respectively [156, 218, 
219]. Percentage encapsulation efficiencies using DOTAP/siRNA complexes was better than 
reported in the literature with 56.5 ± 12.9% while siRNA appeared to leach out of the 
microparticles during the gelatin coating process reducing the encapsulation efficiency to 12.3 ± 
7%.
Liposomes and microparticles were developed for both anatomical and cellular targeting to 
alveolar macrophages, i.e. they were designed for inhalation and cell targeting. Nébulisation of 
liposomes has been assessed with a variety of nebulisers including air jet, ultrasonic and 
vibrating mesh technologies and cargos such as DNA, proteins and peptides [119, 140-145, 
148], Although anionic liposomes have previously been aerosolised [119, 121], mannosylated 
liposomes and siRNA loaded liposomes have not been evaluated following nébulisation. 
Liposome formulations were nebulised using an air jet (PARI) or vibrating mesh (AeroNeb) 
nebuliser coupled with a glass twin impinger and characterised by size, zeta potential, 
deposition pattern and in vitro macrophage uptake. The AeroNeb device was more efficient 
than the air jet PARI device for all liposome formulations although there were differences in 
deposition patterns in a TSI between anionic, neutral and mannosylated liposomes. 
Furthermore, mannosylated liposomes showed a dramatic fall in zeta potential from positive to 
negative following nébulisation particularly those reaching TSI Stage B. Uptake of nebulised 
mannosylated liposomes was also significantly decreased in comparison to pre-nebulised 
liposomes, together suggesting an unstable system and possible damage to the mannose 
coating of the liposomes during nébulisation. Studies have been published using the PARI 
[140, 146] and AeroNeb [146, 147, 315-317] devices for liposome nébulisation. Gaspar et a/. 
(2 0 1 0 ) compared the size, zeta-potential and drug retention of a range of liposome preparations 
encapsulating a fluorescent model compound calcein following nébulisation by an AeroNeb 
nebuliser [315], Size and surface charge of liposomes remained relatively stable post- 
nebulisation however nebulised liposomes were collected directly and not impinged so direct 
comparisons with our results cannot be made. Similarly other studies reported minimal change 
in liposome properties post-nebulisation however the presence of PEG on the liposome surface
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resulted in decreased stability [316, 317]. Elhissi et al. (2007) nebulised liposome formulations 
into a TSI using a PARI LC Plus air-jet and a customised AeroNeb Pro nebuliser and observed 
nébulisation by the AeroNeb device was less disruptive to liposomes, completed nebulization in 
a much shorter time and lead to a greater mass output rate than the PARI nebulizer [146]. 
Although following size reduction to 400nm by extrusion liposomes were less stable post- 
nebulisation most likely due to the reduced liposome lammellarity [146].
Microparticles mean geometric diameters were -2pm, an ideal size for deep lung deposition. 
PLGA microparticles are generally prepared as dry powder systems and therefore particle size 
is critical for efficient pulmonary delivery [9] whereas liposomes are typically in suspension 
which can be delivered via nébulisation in which droplet size is the important factor. For 
efficient alveolar deposition an aerodynamic diameter, which depends on geometric size and 
particle density, of 1 -  5pm is optimal [7]. Work from our lab has determined MMAD of 2.25pm 
for these PLGA microparticles using an Anderson cascade impactor [278],
Cell targeting was determined In vitro in a human macrophage cell model, differentiated THP-1 
cells, monocytes/macrophages isolated from peripheral donor blood and mouse macrophages, 
RAW 264.7 cells. THP-1 cells are a monocytic cell line that can be differentiated by phorbol 
esters into macrophage like cells which express both SR s and MRs upon differentiation [318, 
319]. Uptake assays were developed using HCA technology which combines imaging with 
quantification and gives a more precise measure of uptake than methods such as flow 
cytometry with liposomes or microparticles counted per cell [154, 198], Uptake of liposomes in 
differentiated THP-1 cells corresponded with levels determined in RAW 264.7 cells confirming 
DOPS and MC6 C liposomes as the leading delivery platforms. Kawakami et al. (1998) 
compared DNA/liposome complex transfection efficiency using galactosylated liposomes 
prepared with Gal-C2-Chol, Gal-C4-Chol and Gal-C6 -Chol [173], Similarly, the liposome 
incorporating the derivative with longer spacer length mediated the greatest gene transfer, most 
likely, associated with higher MR recognition [173] as previously spacer length of liposome 
surface ligands has been shown to be important in receptor binding [320, 321].
Both liposome and PLGA based systems successfully delivered siRNA for mediation of gene 
suppression in vitro. Transfection was more successful in primary monocytes/macrophages 
derived from peripheral blood than differentiated THP-1 cells, the macrophage-like cell line. 
THP-1 cells are notoriously difficult to transfect with approaches including viral transfection and 
nucleofection the most frequently used to date [274]. Non-viral methods for transfection, mainly 
nucleofection, with differentiation of THP-1 cells have been associated with a loss in cell viability 
and function [274]. At the concentrations required for our delivery systems (MPs and 
liposomes) to effect efficient knockdown toxicity was not evident. However the efficiency of 
transfection was variable between experiments particularly with isolated human blood 
monocytes/macrophages which could be due to donor dependent variation. Anti-TNFa siRNA 
complexed with either PEI or protamine and encapsulated in DOPS and MC6 C liposomes 
showed the most efficient knockdown of TNFa expression in LP S stimulated cells.
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Mannoyslated liposomes have previously been used to deliver DNA and oligodeoxynucleotides 
(ODNs) but not siRNA [116], so this is the first proof of principle for this application. Similarly 
DOPS liposomes have not previously been used for siRNA delivery. PLGA nanoparticles and 
microparticles have previously been used for TNFa siRNA delivery [156, 223] but not for 
pulmonary use. Microparticles have also been used for pDNA transfection [215] which led to 
the development of shRNA loaded PLGA microparticles. shRNA microparticles were used to 
effectively knockdown expression of target genes IRF3 and TRIM68  in PBMCs and NK92NI 
cells respectively. This emphasised the versatility of this gene delivery platform.
MC6 C liposomes were further tested for preliminary in vivo studies in a mouse inflammatory 
lung model. Pulmonary delivery of Mann-C6 -Chol composed liposomes or anti-TNFa siRNA 
has not previously been reported in the literature. MC6 C  liposomes encapsulating PEI/anti- 
TNFa siRNA complexes were selected based on in vitro uptake and toxicity screens in mouse 
RAW 264.7 macrophage cells and knockdown and immune screens in human macrophage cell 
models. In vitro cell uptake screens strongly indicated DOPS and MC6 C liposomes as 
forerunners for siRNA delivery with both systems achieving highly significant uptake by mouse 
and human macrophages. DOPS liposomes mediated significant knockdown of TNFa in LPS  
stimulated cells in vitro but also showed significant cytotoxicity. On the other hand MC6 C  
liposomes knocked down TNFa but not significantly and did not induce significant toxicity in 
RAW 264.7 cells. In vivo, although not significant anti-TNFa siRNA decreased TNFa levels in 
BALF following a LPS challenge. Howard et al. (2009) achieved 44.3% knockdown of TNFa in 
peritoneal macrophages following I.P. administration of chitosan/TNFa siRNA nanoparticles 
compared to chitosan/control siRNA nanoparticle treatment in C57BL/6J mice [322]. It should 
also be noted that our liposomes were targeted to alveolar macrophages the predominant 
mediators of inflammation; however, these are not the only cell type present. Epithelial cells 
present would also be involved in the inflammatory response boosting cytokine and chemokine 
levels. Furthermore, Howard et al. (2009) harvested peritoneal macrophages from mice shortly 
after I.P. nanoparticle administration and cultured the cells ex vivo for 24 and 48 hours before 
determining TNFa expression [322].
In order to determine any adverse effects induced by these carrier systems, toxicity and 
immune screens were established. Anionic, neutral and mannosylated liposome in vitro toxicity 
and immune effects were compared to cationic DOTAP liposomes. Overall, treatment with 
DOTAP liposomes lead to highly significant levels of cell toxicity and induced the pro- 
inflammatory cytokine IL-1 p in macrophage cells. Previously, DOTAP has been shown to cause 
high levels of toxicity in macrophages along with down regulation of TNFa and nitric oxide (NO) 
[93, 199, 200]. Moreover cationic liposomes can induce apoptosis in macrophages [178-181, 
323], In comparison, DOPS, DOPC and mannosylated liposomes tended to cause minimal or 
no toxic effects. However, anionic DOPS liposomes showed significant concentration 
dependent toxicity, particularly at 300|jM following 24 hour treatment of RAW 264.7 cells. In 
differentiated THP- 1  cells DOPS liposomes also caused significant activation of NFkB and 
induction of pro-inflammatory cytokines including IL-1 (5, IL-8 and TNFa. This targeting strategy
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harnesses the endogenous processes of macrophages to recognise phosphatidylserine (PS) 
exposed on apoptotic cells followed by their phagocytosis. Kurosaka et al. (1998) found that 
differentiated THP-1 cells and monocyte-derived macrophages produced pro-inflammatory 
cytokines most notably IL-8 following exposure to apoptotic cells which were deemed apoptotic 
by size and PS exposure [324]. Perhaps DOPS therefore triggers a pro-inflammatory response 
in macrophages by a similar mechanism to PS of apoptotic cells. Uncoated PLGA  
microparticles exhibited some signs of toxicity in differentiated THP-1 cells but did not induce 
significant cell loss. PLGA microparticles also induced IL-1(3 and IL-8 and NFkB activation in 
differentiated THP-1 cells most significantly with gelatin coating.
Cell toxicity and immunogenic effects caused by neutral and mannosylated liposomes were far 
less significant than cationic and anionic liposomes. Mannosylated liposomes in vitro did 
produce a slight anti-inflammatory effect compared to untargeted DOPC liposomes that was 
concentration and linker dependent. Mannosylated liposomes significantly reduced NFkB 
activity and marginally decreased IL-8 , IFNy and TNFa production in differentiated THP-1 cells. 
Longer mannosylated cholesterol spacers reduced NFkB activity more significantly along with 
enhancing cell uptake. The longer the linker length the greater the availability of mannose to 
interact with the macrophage MR and thus cause MR activation and enhance mannosylated 
liposome uptake. Previously, MR activation has been shown to induce immunosuppression and 
NFkB inhibition in vitro [188, 189], Nonetheless, significant induction of IL-13 (p < 0.05) was 
observed. IL-13 has been linked to asthma and COPD pathogenesis; macrophages being the 
predominant cellular source [325]. However, IL-13 inhibits the production of pro-inflammatory 
mediators such as RO S and prostaglandins in monocytes and macrophages possibly due to 
NFkB suppression while having the opposite effect on many other inflammatory cells [325]. 
Hence, mannosylated liposomes appear to activate MRs on macrophages to suppress NFkB 
activation and inflammation.
Conversely, empty MC6 C liposomes in vivo strongly induced an inflammatory response in the 
mouse lung which was significantly dampened following encapsulation of PEI/siRNA 
complexes. Empty mannosylated liposomes after 24 hours increased neutrophil and 
macrophage presence in BALF as well as induction of a wide range of cytokines and chemokine 
most notably TNFa, IL-1 p, KC, IL-4, IL-5 and IFNy. Histopathology also revealed neutrophil-rich 
inflammation. Again it has to be highlighted that macrophages are not the only cell type present 
and although an inflammatory response was observed it may not be representative of the 
macrophage response but due to off-target effects. Cytokine and chemokine levels have been 
determined in rat lungs following administration of dex encapsulated in mannosylated liposomes 
[130]. However this study focused on the anti-inflammatory effects of dex and liposome 
encapsulated dex and did not examine the effects of the empty liposomes [130].
Liposome encapsulation of proteins and nucleic acids such as rSLPI and siGLO siRNA for in 
vivo pulmonary delivery has been reported to induce local effects while avoiding systemic 
effects and increasing lung retention [84, 154]. Cytokine and chemokine induction was detected
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following NT naked or liposome encapsulated siRNA and empty MC6 C liposomes in BALF. 
Synthetic siRNA within the endosomes may be recognised by TLR-7 and TLR -8 and induce a 
sequence dependent immune response [310, 311]. Mannosylated liposome encapsulation of 
NT siRNA reduced systemic immune mediator induction such as IFNy and no systemic effects 
induced by empty MC6 C were detected. Therefore intratracheal I ly administered mannosylated 
liposomes act locally with minimal systemic effects.
When comparing the two technologies described herein as potential platforms for clinical 
treatment a number of issues aside from those described above need to be considered 
including their stability and scalability. Microparticle formulations could sustain functional siRNA 
for longer periods than liposomes. DOPS mediated TNFa knockdown was very significant (p < 
0.01) at 24 and 48 hours while MC6 C liposomes mediated TNFa suppression 48 hours 
following transfection only. Microparticles on the other hand reduced TNFa expression after 48 
and 72 hours. Previous studies have achieved TNFa knockdown ranging from 27 to 70% [102, 
204] delivered via anionic liposomes with knockdown observed 24 to 96 hours following 
transfection [102] in LP S stimulated macrophages. Microparticles could be freeze dried, stored 
as powders and resuspended when required. Liposome formulations however had to be used 
as soon as possible to avoid loss of siRNA function.
7.2 Future Work
This project has explored many aspects of siRNA delivery to the lungs with the intention of 
developing safer more efficient carrier systems for targeting siRNA to alveolar macrophages in 
the lungs in vivo. Mannosylated liposomes represent promising siRNA carriers for therapeutic 
roles but a disadvantage is the poor siRNA stability over extended periods. Liposomes can be 
successfully lyophilised to improve long term storage stability but numerous variables are 
involved for optimisation including choice of lyoprotectant, methods of lyophilisation and 
liposome characteristics [326].
At a cellular level there are still many areas to be investigated such as an understanding of the 
uptake mechanisms and intracellular trafficking of the various carriers. Liposome and siRNA 
intracellular fate could be monitored over time using microscopy techniques [279]. Other 
inflammatory gene targets such as IL-1[3 and IL-6  [327] could be investigated and it is also 
possible to target multiple genes [282] potentially even within the same carrier system.
in vivo studies described were only preliminary and therefore require further optimisation 
including most importantly comprehensive dose-response studies. PCR analysis of the tissue 
would give a clearer understanding of the inflammatory response of the entire lung and give a 
more detailed and quantitative result than histopathological scoring provides. This would help 
distinguish the effects of siRNA/liposome treatments on alveolar macrophages and the lung 
epithelial cells and infiltrating neutrophils. It would also be interesting to isolate alveolar 
macrophages and assess knockdown as well as examine different time points and doses.
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Additionally the use of fluorescently labelled siRNA and/or liposomes could be used to assess 
uptake and biodistribution within the lung tissue. As another leading siRNA carrier platform an 
obvious next step is the in vivo delivery of siRNA-microparticles and this is currently underway. 
The inflammatory lung model used represented an acute inflammatory response however a 
more appropriate model of chronic inflammatory lung disease such as models established with 
ovalbumin (OVA) or bleomycin [328] could be used to look at the ability of these systems to 
mediate gene silencing and/or affect inflammation long term [229, 322].
7.3 Conclusion
The major aim of this project was to develop non-toxic efficient vectors for siRNA delivery to 
alveolar macrophages and to mediate an anti-inflammatory effect via RNAi. A range of non- 
viral siRNA carriers were assessed for biocompatibility and ability to mediate gene silencing in 
alveolar macrophages under inflammatory conditions. Methods were developed to maximise 
siRNA encapsulation in targeted liposomes and microparticles and screen these carriers for 
uptake, toxicity and immunogenicity. HCA screening methods were developed to compare the 
siRNA carriers in human and mouse macrophage cells and hence determine optimal 
formulations for macrophage gene knockdown. High levels of knockdown via siRNA and shRNA 
delivery by microparticles were achieved with significant concentration- and time-dependent 
knockdown seen in a range of cell types for a number of cargoes. These platforms were 
capable of high RNA loading and prolonged RNA interference using both shRNA and siRNA, 
demonstrating the versatility of microparticles as both a research tool and a potential 
therapeutic carrier. Anionic DOPS liposomes induced very significant TNFa knockdown in 
monocytes/macrophages from human peripheral blood but at certain concentrations initiated a 
pro-inflammatory response and cell death in macrophages. Mannosylated liposomes showed 
optimal uptake, toxicity and immunogenic profiles with extended spacer length in vitro. 
Additonally, known anti-inflammatory effects of MR activation were observed in macrophage 
cells following mannosylated liposome treatment. MC6 C  liposomes also mediated successful 
TNFa knockdown in vitro and in vivo and the siRNA-MC6 C liposomes were well tolerated in 
C57BL/6 mice. Therefore, a number of platforms for RNA delivery to macrophage cells were 
developed that offer an effective method of delivering RNA for research and therapeutic 
applications.
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Chapter 8 
Appendix
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8.1 Mannosylated Cholesterol Characterisation
Wavenumber cm-1
Figure 8.1: Infra-Red spectra of (A) Mann-C2-Chol, (B) Mann-C4-Chol and (C) Mann-C6 -Chol
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Figure 8.2: Nuclear Magnetic Resonance (NMR) spectra of (A) Mann-C2-Chol, (B) Mann-C4 - 
Chol and (C) Mann-C6 -Chol
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Figure 8.3: Mass spectrometry spectra of (A) Mann-C2-Chol, (B) Mann-C4-Chol and (C) Mann- 
C 6 -Chol
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8.2 Liposome Characterisation
Cholesterol (jig )
Figure 8.4: Representative cholesterol assay standard curve
Phospholipid C (|ig)
Figure 8.5: Representative phospholipid assay standard curve
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A Size Distribution by intensity
Size (d.nm)
Size Distribution by Intensity
Size (d.nm)
Figure 8 .6 : Size distribution by intensity before and after extrusion of DOPS:Chol 7:3
liposomes. Average size before extrusion was 1579 nm (PDI 0.776) and after extrusion was 
148.4nm (PDI 0.096).
Table 8.1: Liposome Stability
WeekO Week 1 Week 3 Week 4
Average Average Average Average
Liposome Size Size Size Size
(nm) PDI (nm) PDI (nm) PDI (nm) PDI
DOPS 148.6 0.115 153.7 0.088 157.2 0 . 1 2 2 151.2 0.103
DSPC 186.4 0.289 170.0 0.151 168.2 0.138 168.6 0.147
DOTAP 135.8 0.060 164.1 0.086 174.1 0.088 179.7 0.107
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8.3 Supplemental siRNA Data
Figure 8.7: Representative Ribogreen Assay standard curve
Table 8.2: NanoDrop siRNA limits of detection
Dilution Concentration Detected STDEV FROM
(ng/pl) Concentration (ng/pl) THEORETICAL 260/280
266 265 ± 3.7 0.70 2 .1
10 0 101.4 ±2.5 0.98 2 .1
50 46.8 ± 0.2 2.24 2 .2
25 22.3 ±0.9 1 .8 6 2 .1
12.5 10.4 ±1 1.51 2 .1
6.25 5.3 ± 1.2 0.71 1.7
3.125 1.5 ±0.6 1.18 1 .8
2 0.5 ± 0.4 1.09 1 . 2
1 -0.3 ±0.2 0.93 1.5
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8.4.1 siRNA Cell Uptake Via a Commericial Tranfection Reagent
8.4 Supplemental In Vitro Liposome Data
Figure 8 .8 : Fluorescent microscopy images (20x) of differentiated THP-1 cells treated as follows 
(A) media (control), (B) Dharmafect 2 transfection reagent only, (C) siGLO/Dharmafected 2 
incubated for 1 hour, (D) siGLO/Dharmafected 2  incubated for 2  hours, (E) 
siGLO/Dharmafected 2  incubated for 3 hours and (F) siGLO/Dharmafected 2 incubated for 4 
hours. siGLO is a fluorescently tagged siRNA (red). Cells were counter stained with Hoescht 
(blue; nuclei) and phalloidin-FITC (green; F-Actin).
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8.4.2 Mannoyslated Liposome Mediated TNFa Knockdown in Differentiated THP-1 Cells
15CH
Figure 8.9: TNFa knockdown in differentiated THP-1 cells via 7.5% MC4C mannosylated 
liposomes (incorporating 10% DOTAP into the formulation) (n = 2)
8.4.3 Liposome Induced Toxicity
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Figure 8.10: Toxicity screening determined by high content cell analysis. Differentiated THP-1 
cells were treated with either (A) media alone (negative control) or (B) 120pM valinomycin 
(positive control). Cells were treated for 24 hours, fixed and stained for nuclei (hoescht; blue), 
cell permeability (green), mitochondrial membrane potential (MMP; red), and cytochrome c 
(cytochrome c antibody). Fused images were acquired using an INCELL 1000 (GE Healthcare).
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Figure 8.11: Liposome toxicity screening determined by high content cell analysis. 
Differentiated THP-1 cells were treated with 100pM (A) DOTAP, (B) DOPS, (C) DOPC, (D) 
MC2C, (E) MC4C and (F) MC6 C liposomes for 24 hours, fixed and stained for nuclei (hoescht; 
blue), cell permeability (green), mitochondrial membrane potential (MMP; red), and cytochrome 
c (cytochrome c antibody). Fused images were acquired using an INCELL 1000 (GE 
Healthcare).
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8.5 Supplemental In Vitro siRNA-Microparticle Toxicity Data
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Figure 8.12: Microparticle toxicity screening determined by high content cell analysis. 
Differentiated THP-1 cells were treated with either 20 or 100pg empty microparticles (MP) or 
microparticles encapsulating non-target siRNA (NT MP). Cells were treated for 24 hours, fixed 
and stained for nuclei (hoescht; blue), cell permeability (green), mitochondrial membrane 
potential (MMP; red), and cytochrome c (cytochrome c antibody). Fused images were acquired 
using an INCELL 1000 (GE Healthcare), (controls Figure 8.10)
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8.6 Supplemental In Vitro shRNA-Microparticle Data
kb Ladder Afl II Control
Figure 8.13: DNA digest of pmaxGFP with Afl II restriction enzyme.
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Figure 8.14: Representative shRNA standard curve by Quant iT picogreen assay
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